INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112001, 'Gadobenic acid', 'Tamoxifen', 'Moderate', 'Gadobenate dimeglumine may compete with other substrates of the canalicular multispecific organic anion transporter, also known as cMOAT or MRP2, which is an endogenous transporter protein that works in coordination with the conjugation process to facilitate drug excretion. In solid tumor cells, overexpression of MRP2 confers resistance to a wide variety of anticancer chemotherapeutic agents. Substrates of MRP2 include anthracyclines, protease inhibitors, taxanes, vinca alkaloids, cisplatin, etoposide, methotrexate, and tamoxifen. Theoretically, competition for MRP2 transport may interfere with the clearance of these drugs and/or gadobenate dimeglumine.', 'DDInter', 'Caution is advised during concomitant use of gadobenate dimeglumine and other substrates of MRP2. Patients should be monitored for potentially increased pharmacologic effects of gadobenate dimeglumine as well as the coadministered drug(s).', 'Excretion', 'Caution is advised during concomitant use of gadobenate dimeglumine and other substrates of MRP2.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112132/', '[1] "Product Information. Multihance (gadobenate dimeglumine)." Bracco Diagnostics Inc, Princeton, NJ.[2] Huisman MT, Smit JW, Crommentuyn KM, et al. "Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs." AIDS 16 (2002): 2295-2301', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, More', 'Gadoversetamide, Gadobutrol, Gadofosveset trisodium, Gadopentetic acid, Gadoxetic acid, Gadoteric acid, Gadodiamide, Gadoteridol, Ferumoxsil', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112002, 'Galantamine', 'Tamoxifen', 'Moderate', 'Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.', 'DDInter', 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.', 'Synergism', 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112133/', '[1] "Product Information. Razadyne (galantamine)." Johnson and Johnson Medical Inc, Arlington, TX.[2] "Product Information. Exelon (rivastigmine)" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Aricept (donepezil)." Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 'Ginkgo biloba, Aducanumab', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Flutamide, Enzalutamide, Bicalutamide, Nilutamide, Apalutamide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112003, 'Gatifloxacin', 'Tamoxifen', 'Major', 'Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112134/', '[1] Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001): 23[2] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003): 292-303[5] Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002): 455-64[6] "Product Information. Tequin (gatifloxacin)" Bristol-Myers Squibb, Princeton, NJ.[7] Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004): 1091-124[8] Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72[9] Dale KM, Lertsburapa K, Kluger J, White CM "Moxifloxacin and torsade de pointes." Ann Pharmacother 41 (2007): 336-40[10] Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002): 861-3[11] Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003): 2317-20[12] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[13] Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001): 361-2[14] Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF "Effects of three fluoroquinolones on QT analysis after standard treatment courses." Ann Noninvasive Electrocardiol 11 (2006): 52-6[15] Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000): 658-66[16] Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19[17] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[18] Falagas ME, Rafailidis PI, Rosmarakis ES "Arrhythmias associated with fluoroquinolone therapy." Int J Antimicrob Agents 29 (2007): 374-9[19] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.[20] White CM, Grant EM, Quintiliani R "Moxifloxacin does increase the corrected QT interval." Clin Infect Dis 33 (2001): 1441-2[21] Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002): 269-77[22] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[23] Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001): 1468-72[24] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001): 46-7[25] Cerner Multum, Inc. "Australian Product Information." O 0[26] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6[27] "Product Information. Tequin (gatifloxacin)" Bristol-Myers Squibb, Princeton, NJ.[28] Wallace AW, Victory JM, Amsden GW "Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers." J Clin Pharmacol 43 (2003): 92-6', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Rifamycin, Kanamycin, Ampicillin, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112004, 'Gemifloxacin', 'Tamoxifen', 'Moderate', 'Certain quinolones, including gemifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if gemifloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation may increase with increasing plasma concentrations of gemifloxacin, the recommended dosage should not be exceeded, especially in patients with renal or hepatic impairment.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if gemifloxacin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112135/', '[1] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001): 46-7[2] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[3] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[4] Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19[5] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112005, 'Gilteritinib', 'Tamoxifen', 'Moderate', 'Gilteritinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution and clinical monitoring are recommended if gilteritinib is used in combination with other drugs that can prolong the QT interval. Patients should have electrocardiograms (ECGs) performed prior to initiation of treatment with gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended if gilteritinib is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112136/', '[1] "Product Information. Xospata (gilteritinib)." Astellas Pharma US, Inc, Deerfield, IL.', 'Anastrozole, Fulvestrant, Exemestane, Letrozole', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112006, 'Givosiran', 'Tamoxifen', 'Major', 'Chronic coadministration of potent or moderate CYP450 2D6 inhibitors including certain antidepressants may reduce the effectiveness of tamoxifen. The proposed mechanism is inhibition of tamoxifen bioactivation via CYP450 2D6 to endoxifen (4-hydroxy-N-desmethyltamoxifen), the active metabolite that may be responsible for much of tamoxifen''s antiestrogenic activity.', 'DDInter', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline. If an antidepressant is required during treatment with tamoxifen, agents such as desvenlafaxine, fluvoxamine, milnacipran, levomilnacipran, mirtazapine, and venlafaxine may be considered, since they have mild to no effects on CYP450 2D6. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients.', 'Metabolism', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112137/', '[1] Goetz MP, Rae JM, Suman VJ, et al. "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes." J Clin Oncol 23 (2005): 9312-8[2] Schroth W, Antoniadou L, Fritz P, et al. "Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes." J Clin Oncol 25 (2007): 5187-93[3] Stearns V, Johnson MD, Rae JM, et al. "Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 95 (2003): 1758-64[4] Desta Z, Flockhart DA "Germline pharmacogenetics of tamoxifen response: have we learned enough?" J Clin Oncol 25 (2007): 5147-9[5] Jordan VC, Collins MM, Rowsby L, Prestwich G "A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity." J Endocrinol 75 (1977): 305-16[6] Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M "Drug interactions and pharmacogenomics in the treatment of breast cancer and depression." Am J Psychiatry 165 (2008): 1251-5[7] Jin Y, Desta Z, Stearns V, et al. "CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment." J Natl Cancer Inst 97 (2005): 30-9[8] Lash TL, Pedersen L, Cronin-Fenton D, et al "Tamoxifen''s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram." Br J Cancer 99 (2008): 616-21[9] Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S "Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer." Breast Cancer Res 9 (2007): R7[10] Ponzone R, Biglia N, Sismondi P "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883-4; author reply 884-5[11] Johnson MD, Zuo H, Lee KH, et al. "Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen." Breast Cancer Res Treat 85 (2004): 151-9[12] McCaffrey P "Genetics and drug interactions affect tamoxifen metabolism." Lancet Oncol 6 (2005): 72[13] Coller JK, Krebsfaenger N, Klein K, et al. "The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver." Br J Clin Pharmacol 54 (2002): 157-167[14] Young D "Genetics examined in tamoxifen''s effectiveness: recurrence warning urged for labeling." Am J Health Syst Pharm 63 (2006): 2286, 2296[15] Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A "Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition." J Clin Pharmacol 44 (2004): 861-5[16] Dehal SS, Kupfer D "CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver." Cancer Res 57 (1997): 3402-6[17] Rochat B "Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance : focus on tamoxifen, Paclitaxel and imatinib metabolism." Clin Pharmacokinet 44 (2005): 349-66[18] Bonanni B, Macis D, Maisonneuve P, et al. "Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial." J Clin Oncol 24 (2006): 3708-9[19] Borgna JL, Rochefort H "Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues." J Biol Chem 256 (1981): 859-68[20] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5[21] Desta Z, Ward BA, Soukhova NV, Flockhart DA "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6." J Pharmacol Exp Ther (2004):[22] Brauch H, Murdter TE, Eichelbaum M, Schwab M "Pharmacogenomics of tamoxifen therapy." Clin Chem 55 (2009): 1770-82[23] Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM "Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4''-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen." Drug Metab Dispos 30 (2002): 869-74[24] Goetz MP, Kamal A, Ames MM "Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response." Clin Pharmacol Ther (2007):[25] Wegman P, Vainikka L, Stal O, et al "Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients." Breast Cancer Res 7 (2005): R284-90[26] Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883; author reply 884-5[27] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51[28] Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J "Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer." J Clin Oncol 25 (2007): 3837-45[29] Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H "Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer." Clin Cancer Res 15 (2009): 15-21[30] Goetz MP, Loprinzi CL "A hot flash on tamoxifen metabolism." J Natl Cancer Inst 95 (2003): 1734-5[31] Gaston C, Kolesar J "Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer." Clin Adv Hematol Oncol 6 (2008): 825-33[32] Borges S, Desta Z, Li L, et al. "Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment." Clin Pharmacol Ther 80 (2006): 61-74[33] Jordan VC "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance." Breast Cancer Res Treat 2 (1982): 123-38[34] Aubert RE, Stanek EJ, Yao J, et al "Increased risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Available from: URL: https://www.medcoresearch.com/community/oncology/tamoxifen." ([2009 May 30]):[35] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Bicalutamide, Degarelix, More', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112007, 'Glasdegib', 'Tamoxifen', 'Moderate', 'Glasdegib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of glasdegib with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have electrocardiograms (ECGs) performed prior to initiation of treatment with glasdegib, approximately one week after initiation, and then once monthly for the next two months, although patients with risk factors may require more frequent and ongoing ECG monitoring.', 'Synergism', 'Coadministration of glasdegib with other drugs that can prolong the QT interval should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112138/', '[1] "Product Information. Daurismo (glasdegib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Daurismo (glasdegib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 'Anastrozole, Fulvestrant, Exemestane, Letrozole', 'Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112008, 'Glycerol phenylbutyrate', 'Tamoxifen', 'Moderate', 'Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates. The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.', 'DDInter', 'Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.', 'Metabolism', 'Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112139/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Ravicti (glycerol phenylbutyrate)." Hyperion Therapeutics Inc, South San Francisco, CA.', 'Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, More', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112009, 'Goserelin', 'Tamoxifen', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112140/', '[1] "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] "Product Information. Zoladex (goserelin)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.[5] "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc, Deerfield, IL.[7] "Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals, New York, NY.[8] "Product Information. Plenaxis (abarelix)." Praecis Pharmaceuticals Inc, Waltham, MA.', 'Megestrol acetate, Ethinylestradiol, Diethylstilbestrol', 'Darolutamide, Aminoglutethimide, Abarelix, Enzalutamide, Relugolix, Degarelix, Nilutamide, Apalutamide, Abiraterone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112010, 'Granisetron', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112141/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant', 'Scopolamine, Nabilone, Dronabinol', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112011, 'Grepafloxacin', 'Tamoxifen', 'Major', 'Grepafloxacin can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112142/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[4] Thomas M, Maconochie JG, Fletcher E "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol 41 (1996): 77-81[5] Lode H, Vogel F, Elies W "Grepafloxacin: A review of its safety profile based on clinical trials and postmarketing surveillance." Clin Ther 21 (1999): 61-74[6] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[7] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112012, 'Griseofulvin', 'Tamoxifen', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112143/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Ciclopirox, Econazole, Flucytosine, Tioconazole, Chlorphenesin', 'Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, Abiraterone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112013, 'Halofantrine', 'Tamoxifen', 'Major', 'Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses. QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112144/', '[1] "Product Information. Lariam (mefloquine)." Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Halfan (halofantrine)." GlaxoSmithKline, Philadelphia, PA.[4] Nosten F, ter Kuile FO, Luxemburger C, et al "Cardiac effects of antimalarial treatment with halofantrine." Lancet 341 (1993): 1054-6[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] "Sudden death in a traveler following halofantrine administration--Togo, 2000." MMWR Morb Mortal Wkly Rep 50 (2001): 169-70, 179[7] Giao PT, de Vries PJ "Pharmacokinetic interactions of antimalarial agents." Clin Pharmacokinet 40 (2001): 343-73[8] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[9] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7[10] Giao PT, de Vries PJ "Pharmacokinetic interactions of antimalarial agents." Clin Pharmacokinet 40 (2001): 343-73[11] "Product Information. Halfan (halofantrine)." GlaxoSmithKline, Philadelphia, PA.[12] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7[13] Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C "Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine." Clin Pharmacol Ther 72 (2002): 514-23', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112014, 'Haloperidol', 'Tamoxifen', 'Major', 'Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Haloperidol treatment alone has been associated with a number of reported cases of torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with haloperidol. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.', 'DDInter', 'Caution is recommended if haloperidol is used in combination with other drugs that can prolong the QT interval, particularly when administered intravenously or at higher than recommended dosages.', 'Synergism', 'Caution is recommended if haloperidol is used in combination with other drugs that can prolong the QT interval, particularly when administered intravenously or at higher than recommended dosages.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112145/', '[1] Huyse F, van Schijndel RS "Haloperidol and cardiac arrest." Lancet 2 (1988): 568-9[2] "Product Information. Haldol (haloperidol)." McNeil Pharmaceutical, Raritan, NJ.[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] O''Brien JM, Rockwood RP, Suh KI "Haloperidol-induced torsade de pointes." Ann Pharmacother 33 (1999): 1046-9[7] Wilt JL, Minnema AM, Johnson RF, Rosenblum AM "Torsade de pointes associated with the use of intravenous haloperidol." Ann Intern Med 119 (1993): 391-4[8] Hatta K, Takahashi T, Nakamura H, Yamashiro H, Asukai N, Matsuzaki I, Yonezawa Y "The association between intravenous haloperidol and prolonged QT interval." J Clin Psychopharmacol 21 (2001): 257-61[9] Metzger E, Friedman R "Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill." J Clin Psychopharmacol 13 (1993): 128-32[10] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[11] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[12] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112015, 'Halothane', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112146/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, Etomidate, Ketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112016, 'Histrelin', 'Tamoxifen', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112147/', '[1] "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] "Product Information. Zoladex (goserelin)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.[5] "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc, Deerfield, IL.[7] "Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals, New York, NY.[8] "Product Information. Plenaxis (abarelix)." Praecis Pharmaceuticals Inc, Waltham, MA.', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, Degarelix, More', 'Megestrol acetate, Ethinylestradiol, Diethylstilbestrol', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112017, 'Hydroxychloroquine', 'Tamoxifen', 'Major', 'Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Because COVID-19 may disproportionately affect the elderly and individuals with preexisting heart disease, and cardiac complications such as myocarditis and cardiomyopathy as well as organ failure may occur in patients with severe COVID-19, it appears likely that hospitalized patients with COVID-19 may represent a particularly susceptible and high-risk population, and other, less critically ill patients may not have the same arrhythmic risk.', 'DDInter', 'Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.g., QTc >=500 msec) or congenital long QT syndrome. Close monitoring of QTc interval, electrolyte levels, and renal and hepatic function is recommended if concomitant use is required and benefits are anticipated to outweigh the risks. Electrolyte abnormalities should be corrected prior to initiating treatment with chloroquine or hydroxychloroquine. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Because chloroquine and hydroxychloroquine are eliminated slowly from the body, the potential for drug interactions should be observed for a prolonged period following their discontinuation.', 'Synergism', 'Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112148/', '[1] Mercuro NJ, Yen CF, Shim DJ, et.al "Risk of QT interval prolongation associated with the use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)" JAMA Cardiol May 1:e201834 (2020): epub ahead of print[2] "Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine)." Prasco Laboratories, Cincinnati, OH.[3] US Food and Drug Administration "FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF HYDROXYCHLOROQUINE SULFATE SUPPLIED FROM THE STRATEGIC NATIONAL STOCKPILE FOR TREATMENT OF COVID-19 IN CERTAIN HOSPITALIZED PATIENTS. Available from: URL: https://www.fda.gov/media/" ({2020, Apr 27]):[4] "Product Information. Plaquenil (R). (hydroxychloroquine)." Sanofi Winthrop Pharmaceuticals, New York, NY.[5] "Product Information. Chloroquine Phosphate (chloroquine)." West-Ward Pharmaceutical Corporation, Eatontown, NJ.[6] Bessiere F, Roccia H, Deliniere A, et.al "Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit." JAMA Cardiol May 1 (2020): epub ahead of print[7] National Institutes of Health (NIH) "Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available from: URL: https://covid19treatmentguidelines.nih.gov/" ([2020, Apr 21]):[8] Sacher F, Fauchier L, Boveda S, et.al "Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection." Arch Cardiovasc Dis Apr 24 (2020): epub ahead of print[9] Kapoor A, Pandurangi U, Arora V, et.al "Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society." Indian Pacing Electorphysiol J Apr 8 (2020): epub ahead of print[10] Borba MGS, Val FFA, Sampaio VS, et.al "Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 1 (SARS-CoV-2) infection: A randomized clinical trial." JAMA Netw Open Apr 1 (2020): epub ahead of print[11] Sapp JL, Alqarawi W, MacIntyre CJ, et.al "Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: A statement from the Canadian Heart Rhythm Society." Can J Cardiol Apr 8 (2020): epub ahead of print[12] Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ "Chloroquine for SARS-CoV-2: Implications of its unique pharmacokinetic and safety properties." Clin Pharmacokinet Ar 18 (2020): epub ahead of print[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] Javelot H, El-Hage W, Meyer G, Becker G, Michel B, Hingray C "COVID-19 and (hydroxy)chloroquine-azithromycin combination: should we take the risk for our patients?" Br J Clin Pharmacol Apr 29 (2020): epub ahead of print[15] US Food and Drug Administration "Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication - FDA Cautions Against Use Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems. Available from: URL: https://www.fda.gov/safety/medical-product-" ([2020, Apr 24]):[16] Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ "Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)" Mayo Clin Proc Apr 7 (2020): epub ahead of print[17] Roden DM, Harrington RA, Poppas A, Russo AM "Considerations for drug interactions on QTc in exploratory COVID-19 (Coroanvirus disease 2019) treatment." Heart Rhythm Apr 14 (2020): epub ahead of print[18] mitra RL, Greenstein SA, Epstein lm "An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin; Possible benefits of intravenous lidocaine." HeartRythm Case Rep Apr 1 (2020): epub ahead of print[19] US Food and Drug Administration "FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF CHLOROQUINE PHOSPHATE SUPPLIED FROM THE STRATEGIC NATIONAL STOCKPILE FOR TREATMENT OF COVID-19 IN CERTAIN HOSPITALIZED PATIENTS. Available from: URL: https://www.fda.gov/media/13653" ([2020, Apr 27]):[20] Saleh M, Gabriels J, ChangD, et.al "The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection." Circ Arrhythm Electrophysiol Apr 29 (2020): epub ahead of print[21] Bonow RO, Hernandez AF, Turakhia M "Hydroxychloroquine, coronavirus disease 2019, and QT prolongation." JAMA Cardiol May 1 (2020): epub ahead of print[22] Cerner Multum, Inc. "Australian Product Information." O 0', 'Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112018, 'Hydroxyzine', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112149/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Clobazam, Meprobamate, Halazepam, Clorazepic acid, Chlordiazepoxide', 'Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112019, 'Ibutilide', 'Tamoxifen', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112150/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Corvert (ibutilide)." Pharmacia and Upjohn, Kalamazoo, MI.[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 'Moricizine, Tocainide, Bretylium, Mexiletine', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112020, 'Idarubicin', 'Tamoxifen', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.', 'DDInter', 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.', 'Absorption', 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112151/', '[1] "Product Information. Daunoxome (daunorubicin liposomal)." Nexstar Pharmaceuticals Inc, Boulder, CO.[2] "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.[3] "Multum Information Services, Inc. Expert Review Panel"[4] "Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Dactinomycin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112021, 'Idelalisib', 'Tamoxifen', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', 'DDInter', 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112152/', '[1] "Product Information. Zydelig (idelalisib)." Gilead Sciences, Foster City, CA.[2] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 'Anastrozole, Fulvestrant, Relugolix, Degarelix, Exemestane', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112022, 'Iloperidone', 'Tamoxifen', 'Major', 'Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged. Persistent QTc measurements exceeding 500 msec will require suspension of iloperidone therapy and immediate action to correct any concomitant risk factors before resuming treatment.', 'Synergism', 'Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112153/', '[1] "Product Information. Exforge HCT (amlodipine/hydrochlorothiazide/valsartan)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112023, 'Imatinib', 'Tamoxifen', 'Moderate', 'Coadministration with imatinib may increase the plasma concentrations of drugs that are substrates of CYP450 2C9, 2D6 and/or 3A4. The mechanism is decreased clearance due to inhibition of these isoenzymes by imatinib.', 'DDInter', 'Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever imatinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112154/', '[1] "Product Information. Gleevec (imatinib mesylate)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Gleevec (imatinib mesylate)." Novartis Pharmaceuticals, East Hanover, NJ.', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 'Anastrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Abiraterone, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112024, 'Imipramine', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112155/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine', 'Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112025, 'Indacaterol', 'Tamoxifen', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112156/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112026, 'Inotuzumab ozogamicin', 'Tamoxifen', 'Moderate', 'Inotuzumab ozogamicin may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of inotuzumab ozogamicin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use cannot be avoided or if inotuzumab ozogamicin is used in patients with other risk factors for QT prolongation. The manufacturer suggests obtaining electrocardiograms and serum electrolytes at baseline and regularly during treatment.', 'Synergism', 'Coadministration of inotuzumab ozogamicin with other drugs that can prolong the QT interval should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112157/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Besponsa (inotuzumab ozogamicin)." Wyeth Laboratories, Philadelphia, PA.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112027, 'Interferon beta-1a', 'Tamoxifen', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', 'DDInter', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112158/', '[1] "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA.[2] "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.[3] "Product Information. Rebif (interferon beta-1a)." Serono Laboratories Inc, Norwell, MA.[4] "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.', 'Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Sargramostim, Histamine, Pegademase, Pegfilgrastim, More', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Degarelix, Apalutamide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112028, 'Interferon beta-1b', 'Tamoxifen', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', 'DDInter', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112159/', '[1] "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA.[2] "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.[3] "Product Information. Rebif (interferon beta-1a)." Serono Laboratories Inc, Norwell, MA.[4] "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.', 'Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Sargramostim, Histamine, Pegademase, Pegfilgrastim, More', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Degarelix, Apalutamide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112029, 'Isavuconazonium', 'Tamoxifen', 'Moderate', 'Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.', 'DDInter', 'Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112160/', '[1] "Product Information. Cresemba (isavuconazonium)." Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 'Anastrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Abiraterone, Exemestane', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112030, 'Isoetharine', 'Tamoxifen', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112161/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112031, 'Isoprenaline', 'Tamoxifen', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112162/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112032, 'Itraconazole', 'Tamoxifen', 'Moderate', 'Coadministration with itraconazole may significantly increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by itraconazole.', 'DDInter', 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever itraconazole is added to or withdrawn from therapy. Some authorities recommend avoiding concomitant use of nevirapine from 2 weeks before and during treatment with itraconazole.', 'Metabolism', 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112163/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Kaukonen KM, Olkkola KT, Neuvonen PJ "Itraconazole increases plasma concentrations of quinidine." Clin Pharmacol Ther 62 (1997): 510-7[3] Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44[4] Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH "Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor." Drug Metab Dispos 24 (1996): 307-14[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[7] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[8] Gillies J, Hung KA, Fitzsimons E, Soutar R "Severe vincristine toxicity in combination with itraconazole." Clin Lab Haematol 20 (1998): 123-4[9] Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ "Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite." Eur J Clin Pharmacol 52 (1997): 403-6[10] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[13] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[14] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[15] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[16] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[17] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[18] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[19] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 'Anastrozole, Fulvestrant, Letrozole, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, Exemestane', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112033, 'Ivabradine', 'Tamoxifen', 'Major', 'Due to its bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased when ivabradine is used with drugs that prolong the QT interval.', 'DDInter', 'Coadministration of ivabradine with drugs that can prolong the QT interval should generally be avoided. Caution and cardiac monitoring are recommended if concomitant use is required.', 'Synergism', 'Coadministration of ivabradine with drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112164/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Corlanor (ivabradine)." Amgen USA, Thousand Oaks, CA.[3] Mittal SR "Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine." J Assoc Physicians India 62 (2014): 426-7[4] "Product Information. Corlanor (ivabradine)." Amgen USA, Thousand Oaks, CA.[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Exemestane', 'Regadenoson, Alprostadil, Ubidecarenone, Felodipine, Nebivolol, Bisoprolol', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112034, 'Tamoxifen', 'Ivosidenib', 'Major', 'Ivosidenib can cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of ivosidenib with other drugs that can prolong the QT interval should generally be avoided. Otherwise, close monitoring of electrocardiograms and electrolytes is recommended. If QT prolongation occurs during treatment, withhold and/or reduce dose in accordance with the product labeling. Ivosidenib should be permanently discontinued in patients who develop QT prolongation with signs or symptoms of life-threatening arrhythmia.', 'Synergism', 'Coadministration of ivosidenib with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112165/', '[1] "Product Information. Tibsovo (ivosidenib)." Agios Pharmaceuticals, Cambridge, MA.[2] "Product Information. Tibsovo (ivosidenib)." Agios Pharmaceuticals, Cambridge, MA.[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Anastrozole, Fulvestrant, Aminoglutethimide, Letrozole', 'Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112035, 'Tamoxifen', 'Ketoconazole', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112166/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Trichlormethiazide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112036, 'Tamoxifen', 'Lapatinib', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112167/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Exemestane, Fulvestrant', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112037, 'Tamoxifen', 'Larotrectinib', 'Moderate', 'Coadministration with larotrectinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.', 'DDInter', 'Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever larotrectinib is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects. Some authorities recommend avoiding concomitant use of larotrectinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.', 'Metabolism', 'Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112168/', '[1] "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT.', 'Anastrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Exemestane', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112038, 'Tamoxifen', 'Lefamulin', 'Major', 'Lefamulin may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of lefamulin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have electrocardiograms (ECGs) and electrolyte levels assessed during treatment as appropriate based on individual risk factors. The recommended dosage and infusion rate of lefamulin should not be exceeded, as the magnitude of QT prolongation may increase with increasing concentrations of the drug or increasing the rate of infusion.', 'Synergism', 'Coadministration of lefamulin with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112169/', '[1] "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.', 'Anastrozole, Fulvestrant', 'Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112039, 'Tamoxifen', 'Leflunomide', 'Major', 'The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.', 'DDInter', 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide''s active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112170/', '[1] EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions. Available from URL: http://www.eudra.org/emea.html." ([1999 Sept 2]):[2] "Product Information. Arava (leflunomide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Degarelix, Apalutamide, Exemestane', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112040, 'Tamoxifen', 'Lemborexant', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112171/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Anastrozole, Fulvestrant, Letrozole, Abarelix, Flutamide, Degarelix, Nilutamide, Abiraterone, Exemestane', 'Suvorexant, Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112041, 'Tamoxifen', 'Lenalidomide', 'Major', 'Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of lenalidomide. Deep vein thrombosis (DVT) and pulmonary embolism (PE) have been observed at significantly increased rates when lenalidomide was coadministered with dexamethasone for the treatment of multiple myeloma.', 'DDInter', 'Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body. It is not known whether prophylactic anticoagulation or antiplatelet therapy may lessen the risk of venous thromboembolic events. The decision to take prophylactic measures should be done carefully after a thorough assessment of underlying risk factors. If a thromboembolic event occurs during therapy with lenalidomide, treatment must be discontinued and standard anticoagulation therapy initiated. Once anticoagulation is stabilized and complications of the thromboembolic event under control, lenalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks. Anticoagulation therapy should be continued during the remaining course of lenalidomide treatment.', 'Synergism', 'Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112172/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] "Product Information. Revlimid (lenalidomide)." Celgene Corporation, Summit, NJ.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] "Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.[6] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Darolutamide, Anastrozole, Letrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112042, 'Tamoxifen', 'Lenvatinib', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112173/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112043, 'Tamoxifen', 'Letermovir', 'Moderate', 'Coadministration with letermovir may increase the plasma concentrations of drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or organic anion transporting polypeptide protein (OATP) 1B1 and 1B3. Letermovir has been shown to be a reversible inhibitor of CYP450 2C8 in vitro, although its effect on CYP450 2C8 substrates has not been evaluated clinically. Letermovir is also a time-dependent inhibitor and inducer of CYP450 3A4 in vitro.', 'DDInter', 'Caution is advised when letermovir is used concurrently with drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or OATP 1B1 and 1B3, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever letermovir is added to or withdrawn from therapy. Moreover, clinicians should be aware that the magnitude of CYP450 3A- and OATP1B1/3-mediated drug interactions with coadministered drugs may be different when letermovir is used with cyclosporine. The combined effect of the two drugs on CYP450 3A4 may be similar to that of a strong CYP450 3A4 inhibitor, hence clinicians should refer to the prescribing information for dosing recommendations of the CYP450 3A4 substrate with a strong CYP450 3A4 inhibitor. Similarly, letermovir and cyclosporine may demonstrate some additive effects on OATP1B1 inhibition, although cyclosporine by itself is already a strong OATP1B1/3 inhibitor.', 'Metabolism', 'Caution is advised when letermovir is used concurrently with drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or OATP 1B1 and 1B3, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112174/', '[1] "Product Information. Prevymis (letermovir)." Merck & Company Inc, Whitehouse Station, NJ.', 'Anastrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, Abiraterone, Exemestane', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Telaprevir, Velpatasvir, Dolutegravir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112044, 'Tamoxifen', 'Levosalbutamol', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112175/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112045, 'Tamoxifen', 'Levofloxacin', 'Moderate', 'Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112176/', '[1] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002): 455-64[5] Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES "Arrhythmias associated with fluoroquinolone therapy." Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones." Br Med J 322 (2001): 46-7[12] "Product Information. Floxin (ofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B "Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?" South Med J 99 (2006): 52-6[14] Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG "QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine." Ann Pharmacother 39 (2005): 543-6[16] Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[20] Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[25] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin, Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112046, 'Tamoxifen', 'Levacetylmethadol', 'Major', 'Levomethadyl acetate may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. High dosages of levomethadyl acetate alone have been associated with QT interval prolongation and torsade de pointes.', 'DDInter', 'Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112177/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.[3] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[4] Krantz MJ, Mehler PS "Synthetic opioids and QT prolongation." Arch Intern Med 163 (2003): 1615; author reply 1615[5] Deamer RL, Wilson DR, Clark DS, Prichard JG "Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM)." J Addict Dis 20 (2001): 7-14[6] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Exemestane', 'Diamorphine, Acamprosate, Disulfiram, Nalmefene, Nicotine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112047, 'Tamoxifen', 'Lisdexamfetamine', 'Moderate', 'Limited data suggests the lisdexamfetamine may rarely prolong the QT interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including ventricular tachycardia, torsade de pointes, and sudden death.', 'DDInter', 'Caution is recommended whenever lisdexamfetamine is used concomitantly with other agents known to cause QT prolongation. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended whenever lisdexamfetamine is used concomitantly with other agents known to cause QT prolongation.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112178/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[7] Jiao X, Velez S, Ringstad J, Eyma V, Miller D, Bleiberg M "Myocardial infarction associated with Adderall XR and alcohol use in a young man." J Am Board Fam Med 22 (2009): 197-201', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Amphetamine, Pemoline, Metamfetamine, Solriamfetol, Caffeine, Dexmethylphenidate, Dextroamphetamine, Citicoline', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112048, 'Tamoxifen', 'Lithium carbonate', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112179/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112049, 'Tamoxifen', 'Lofexidine', 'Moderate', 'Lofexidine has been associated with asymptomatic prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Coadministration of lofexidine with other agents with hypotensive effects may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution is recommended if lofexidine is used in combination with other drugs that can prolong the QT interval. Periodic monitoring with on-treatment electrocardiograms and serum electrolytes (magnesium, potassium) should be considered. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if lofexidine is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112180/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Lucemyra (lofexidine)." US WorldMeds LLC, Louisville , KY.[4] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[7] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Diamorphine, Acamprosate, Disulfiram, Nalmefene, Nicotine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112050, 'Tamoxifen', 'Lomefloxacin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112181/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Rifamycin, Kanamycin, Ampicillin, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112051, 'Tamoxifen', 'Lomitapide', 'Major', 'Coadministration of lomitapide with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Lomitapide can cause elevations in serum transaminases and hepatic steatosis. Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with lomitapide, although the long-term consequences are unknown.', 'DDInter', 'Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with lomitapide should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking lomitapide not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112182/', '[1] "Product Information. Juxtapid (lomitapide)." Aegerion Pharmaceuticals Inc, Cambridge, MA.[2] "Product Information. Juxtapid (lomitapide)." Aegerion Pharmaceuticals Inc, Cambridge, MA.', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Degarelix, Apalutamide, Exemestane', 'Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, Colestipol, Bempedoic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112052, 'Tamoxifen', 'Lonafarnib', 'Moderate', 'Coadministration with lonafarnib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Lonafarnib is a potent CYP450 3A time-dependent and mechanism-based inhibitor in vitro.', 'DDInter', 'Caution is advised when lonafarnib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lonafarnib is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects. The prescribing information recommends avoiding concomitant use of lonafarnib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges when possible. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.', 'Metabolism', 'Caution is advised when lonafarnib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112183/', '[1] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.[2] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 'Anastrozole, Fulvestrant, Abarelix, Flutamide, Degarelix, Nilutamide, Exemestane', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112053, 'Tamoxifen', 'Lorlatinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112184/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Anastrozole, Fulvestrant, Abarelix, Flutamide, Degarelix, Nilutamide, Aminoglutethimide', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112054, 'Tamoxifen', 'Lusutrombopag', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of lusutrombopag, which is a substrate of both efflux transporter proteins.', 'DDInter', 'Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors. Pharmacologic response to lusutrombopag should be monitored more closely following initiation, discontinuation, or change of dosage of the concomitant P-gp or BCRP inhibitor.', 'Distribution', 'Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112185/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):', 'Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, More', 'Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112055, 'Tamoxifen', 'Macimorelin', 'Major', 'Macimorelin can cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of macimorelin with other drugs that can prolong the QT interval should generally be avoided. A sufficient washout period following discontinuation of these drugs is recommended prior to macimorelin administration. Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of macimorelin with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112186/', '[1] "Product Information. Macrilen (macimorelin)." Aeterna Zentaris, Charleston, SC.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] "Product Information. Macrilen (macimorelin)." Aeterna Zentaris, Charleston, SC.', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Exemestane', 'Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Methacholine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112056, 'Tamoxifen', 'Maprotiline', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112187/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112057, 'Tamoxifen', 'Maraviroc', 'Moderate', 'Coadministration with inhibitors of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may increase the plasma concentrations of maraviroc, which is a substrate of both.', 'DDInter', 'Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein. Dosage adjustment for maraviroc may be necessary if an interaction is suspected.', 'Metabolism', 'Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112188/', '[1] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 'Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Abiraterone, Exemestane', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Telaprevir, Velpatasvir, Dolutegravir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112058, 'Tamoxifen', 'Medroxyprogesterone acetate', 'Minor', 'Limited data suggest that concomitant administration of medroxyprogesterone may reduce N-demethylation of tamoxifen, but that overall metabolism remains unchanged. The mechanism and the clinical significance of this interaction are unknown.', 'DDInter', '-', 'Others', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112189/', '[1] Reid AD, Horobin JM, Newman EL, Preece PE "Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients." Breast Cancer Res Treat 22 (1992): 153-6[2] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Desogestrel, Dienogest, Estetrol, More', 'Darolutamide, Fulvestrant, Toremifene, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Abiraterone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112059, 'Tamoxifen', 'Mefloquine', 'Moderate', 'Mefloquine is a myocardial depressant and can cause ECG abnormalities. Theoretically, coadministration with other agents that can affect cardiac conduction (e.g., antiarrhythmic agents, beta blockers, calcium channel blockers, certain antihistamines, tricyclic antidepressants, phenothiazines, some neuroleptics) may result in additive effects and increased risk of ventricular arrhythmias including ventricular tachycardia and torsade de pointes.', 'DDInter', 'Caution and clinical monitoring are recommended if mefloquine is used in combination with other drugs that can prolong the QT interval or otherwise affect cardiac conduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes or other arrhythmia such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended if mefloquine is used in combination with other drugs that can prolong the QT interval or otherwise affect cardiac conduction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112190/', '[1] "Product Information. Lariam (mefloquine)." Roche Laboratories, Nutley, NJ.[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] "Product Information. Lariam (mefloquine)." Roche Laboratories, Nutley, NJ.[6] Schmidt LE, Dalhoff K "Food-drug interactions." Drugs 62 (2002): 1481-502[7] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[8] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[10] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Anastrozole, Fulvestrant, Exemestane, Letrozole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112060, 'Tamoxifen', 'Methylphenobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112191/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, Abiraterone', 'Tiagabine, Ethotoin, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Mephenytoin, Perampanel, Zonisamide, Eslicarbazepine, Phensuximide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112061, 'Tamoxifen', 'Mesoridazine', 'Major', 'Mesoridazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Mesoridazine overdosage has been associated with ventricular arrhythmias and death. The extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s). In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with mesoridazine. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.', 'DDInter', 'Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112192/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Serentil (mesoridazine)" Boehringer-Ingelheim, Ridgefield, CT.[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112062, 'Tamoxifen', 'Orciprenaline', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112193/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate, Ephedrine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112063, 'Tamoxifen', 'Methotrimeprazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112194/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112064, 'Tamoxifen', 'Metronidazole', 'Minor', 'Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112195/', '[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F "QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone." Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983): 509-15[3] "Product Information. Benznidazole (benznidazole)." Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR "Do ethanol and metronidazole interact to produce a disulfiram-like reaction?." Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ "An unexpected adverse drug effect." J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985): 292-3[7] "Product Information. Flagyl (metronidazole)." Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP "Lack of disulfiram-like reaction with metronidazole and ethanol." Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO "Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole." Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[12] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darolutamide, Anastrozole, Aminoglutethimide', 'Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Tinidazole, Quinacrine, Secnidazole, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112065, 'Tamoxifen', 'Midostaurin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112196/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Exemestane, Letrozole', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112066, 'Tamoxifen', 'Mifepristone', 'Major', 'Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing''s syndrome, coadministration with other drugs that can prolong the QT interval should generally be avoided. Caution is recommended if no alternatives exist and concomitant use is required. Serum potassium should be assessed prior to starting mifepristone and 1 to 2 weeks following initiation of therapy or an increase in dosage, and periodically as needed. Hypokalemia must be corrected prior to initiation of mifepristone. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heart rhythm.', 'Synergism', 'When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing''s syndrome, coadministration with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112197/', '[1] "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated, Menlo Park, CA.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated, Menlo Park, CA.[6] "Product Information. Mifeprex (mifepristone)" Danco Laboratories, New York, NY.[7] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[8] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[10] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darolutamide, Anastrozole, Exemestane, Fulvestrant', 'Ulipristal, Prasterone, Danazol, Bazedoxifene', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112067, 'Tamoxifen', 'Mipomersen', 'Major', 'Coadministration of mipomersen with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Mipomersen can cause elevations in serum transaminases and hepatic steatosis.', 'DDInter', 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, lomitapide, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Mipomersen has not been studied with other LDL-lowering agents that can also increase hepatic fat, thus concomitant use is not recommended. Patients treated with mipomersen should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112198/', '[1] "Product Information. Kynamro (mipomersen)." Genzyme Corporation, Cambridge, MA.[2] "Product Information. Kynamro (mipomersen)." Genzyme Corporation, Cambridge, MA.', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Degarelix, Apalutamide, Exemestane', 'Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, Colestipol, Bempedoic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112068, 'Tamoxifen', 'Mirabegron', 'Major', 'Chronic coadministration of potent or moderate CYP450 2D6 inhibitors including certain antidepressants may reduce the effectiveness of tamoxifen. The proposed mechanism is inhibition of tamoxifen bioactivation via CYP450 2D6 to endoxifen (4-hydroxy-N-desmethyltamoxifen), the active metabolite that may be responsible for much of tamoxifen''s antiestrogenic activity.', 'DDInter', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline. If an antidepressant is required during treatment with tamoxifen, agents such as desvenlafaxine, fluvoxamine, milnacipran, levomilnacipran, mirtazapine, and venlafaxine may be considered, since they have mild to no effects on CYP450 2D6. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients.', 'Metabolism', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112199/', '[1] Goetz MP, Rae JM, Suman VJ, et al. "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes." J Clin Oncol 23 (2005): 9312-8[2] Schroth W, Antoniadou L, Fritz P, et al. "Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes." J Clin Oncol 25 (2007): 5187-93[3] Stearns V, Johnson MD, Rae JM, et al. "Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 95 (2003): 1758-64[4] Desta Z, Flockhart DA "Germline pharmacogenetics of tamoxifen response: have we learned enough?" J Clin Oncol 25 (2007): 5147-9[5] Jordan VC, Collins MM, Rowsby L, Prestwich G "A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity." J Endocrinol 75 (1977): 305-16[6] Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M "Drug interactions and pharmacogenomics in the treatment of breast cancer and depression." Am J Psychiatry 165 (2008): 1251-5[7] Jin Y, Desta Z, Stearns V, et al. "CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment." J Natl Cancer Inst 97 (2005): 30-9[8] Lash TL, Pedersen L, Cronin-Fenton D, et al "Tamoxifen''s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram." Br J Cancer 99 (2008): 616-21[9] Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S "Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer." Breast Cancer Res 9 (2007): R7[10] Ponzone R, Biglia N, Sismondi P "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883-4; author reply 884-5[11] Johnson MD, Zuo H, Lee KH, et al. "Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen." Breast Cancer Res Treat 85 (2004): 151-9[12] McCaffrey P "Genetics and drug interactions affect tamoxifen metabolism." Lancet Oncol 6 (2005): 72[13] Coller JK, Krebsfaenger N, Klein K, et al. "The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver." Br J Clin Pharmacol 54 (2002): 157-167[14] Young D "Genetics examined in tamoxifen''s effectiveness: recurrence warning urged for labeling." Am J Health Syst Pharm 63 (2006): 2286, 2296[15] Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A "Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition." J Clin Pharmacol 44 (2004): 861-5[16] Dehal SS, Kupfer D "CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver." Cancer Res 57 (1997): 3402-6[17] Rochat B "Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance : focus on tamoxifen, Paclitaxel and imatinib metabolism." Clin Pharmacokinet 44 (2005): 349-66[18] Bonanni B, Macis D, Maisonneuve P, et al. "Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial." J Clin Oncol 24 (2006): 3708-9[19] Borgna JL, Rochefort H "Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues." J Biol Chem 256 (1981): 859-68[20] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5[21] Desta Z, Ward BA, Soukhova NV, Flockhart DA "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6." J Pharmacol Exp Ther (2004):[22] Brauch H, Murdter TE, Eichelbaum M, Schwab M "Pharmacogenomics of tamoxifen therapy." Clin Chem 55 (2009): 1770-82[23] Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM "Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4''-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen." Drug Metab Dispos 30 (2002): 869-74[24] Goetz MP, Kamal A, Ames MM "Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response." Clin Pharmacol Ther (2007):[25] Wegman P, Vainikka L, Stal O, et al "Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients." Breast Cancer Res 7 (2005): R284-90[26] Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883; author reply 884-5[27] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51[28] Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J "Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer." J Clin Oncol 25 (2007): 3837-45[29] Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H "Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer." Clin Cancer Res 15 (2009): 15-21[30] Goetz MP, Loprinzi CL "A hot flash on tamoxifen metabolism." J Natl Cancer Inst 95 (2003): 1734-5[31] Gaston C, Kolesar J "Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer." Clin Adv Hematol Oncol 6 (2008): 825-33[32] Borges S, Desta Z, Li L, et al. "Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment." Clin Pharmacol Ther 80 (2006): 61-74[33] Jordan VC "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance." Breast Cancer Res Treat 2 (1982): 123-38[34] Aubert RE, Stanek EJ, Yao J, et al "Increased risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Available from: URL: https://www.medcoresearch.com/community/oncology/tamoxifen." ([2009 May 30]):[35] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Abiraterone, Exemestane', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Sildenafil, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112069, 'Tamoxifen', 'Mirtazapine', 'Moderate', 'Available data suggest that mirtazapine may cause mild prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if mirtazapine is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if mirtazapine is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112200/', '[1] "Product Information. Remeron (mirtazapine)." Organon, West Orange, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine', 'Fulvestrant', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112070, 'Tamoxifen', 'Mitomycin', 'Moderate', 'Tamoxifen significantly increases the risk of microangiopathic hemolytic uremic syndrome (HUS) associated with mitomycin C. HUS can be fatal in up to 50% of affected patients. The mechanism of this interaction is not known, but may involve a combination of subclinical endothelial damage induced by mitomycin C and a thrombotic effect on platelets caused by tamoxifen.', 'DDInter', 'Some experts advise that tamoxifen should be avoided during or immediately after mitomycin C therapy unless the patient is carefully monitored with frequent and regular CBCs as well as serum BUN and creatinine measurements.', 'Synergism', 'Some experts advise that tamoxifen should be avoided during or immediately after mitomycin C therapy unless the patient is carefully monitored with frequent and regular CBCs as well as serum BUN and creatinine measurements.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112201/', '[1] Ellis PA, Luckitt J, Treleaven J, Smith IE "Haemolytic uraemic syndrome in a patient with lung cancer: further evidence for a toxic interaction between mitomycin-C and tamoxifen." Clin Oncol (R Coll Radiol) 8 (1996): 42-3[2] O''Brien ME, Casey S, Treleaven J, Powles TJ "Use of erythropoietin in the management of the haemolytic uraemic syndrome induced by mitomycin C/tamoxifen." Eur J Cancer 30a (1994): 894-5[3] Montes A, Powles TJ, O''Brien ME, Ashley SE, Luckit J, Treleaven J "A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome." Eur J Cancer 29a (1993): 1854-7[4] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Dactinomycin', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, Degarelix, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112071, 'Tamoxifen', 'Mitotane', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112202/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More', 'Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112072, 'Tamoxifen', 'Mitoxantrone', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of mitoxantrone, which is a substrate of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor.', 'DDInter', 'Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.', 'Others', 'Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112203/', '[1] "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.[2] "Multum Information Services, Inc. Expert Review Panel"[3] "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.[4] "Multum Information Services, Inc. Expert Review Panel"[5] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 'Anastrozole, Fulvestrant, Toremifene, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide', 'Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Dactinomycin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112073, 'Tamoxifen', 'Modafinil', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112204/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Anastrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, Abiraterone', 'Amphetamine, Pemoline, Metamfetamine, Solriamfetol, Caffeine, Dexmethylphenidate, Dextroamphetamine, Citicoline', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112074, 'Tamoxifen', 'Montelukast', 'Moderate', 'Coadministration with inhibitors of CYP450 2C8 and/or 2C9 may increase the plasma concentrations of montelukast, which is metabolized by these isoenzymes in addition to CYP450 3A4. When montelukast was administered with the potent CYP450 2C8/2C9 inhibitor gemfibrozil, montelukast systemic exposure (AUC) increased by 4.4-fold.', 'DDInter', 'According to the product labeling, no dosage adjustment of montelukast is required when used in combination with gemfibrozil. However, it may be advisable to monitor patients for potentially increased adverse effects during coadministration with gemfibrozil or other CYP450 2C8/2C9 inhibitors.', 'Metabolism', 'According to the product labeling, no dosage adjustment of montelukast is required when used in combination with gemfibrozil.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112205/', '[1] Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT "Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast." Clin Pharmacol Ther (2010):[2] "Product Information. Singulair (montelukast)." Merck & Co, Inc, West Point, PA.[3] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 'Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, More', 'Darolutamide, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112075, 'Tamoxifen', 'Moxifloxacin', 'Major', 'Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112206/', '[1] Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001): 23[2] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003): 292-303[5] Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002): 455-64[6] "Product Information. Tequin (gatifloxacin)" Bristol-Myers Squibb, Princeton, NJ.[7] Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004): 1091-124[8] Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72[9] Dale KM, Lertsburapa K, Kluger J, White CM "Moxifloxacin and torsade de pointes." Ann Pharmacother 41 (2007): 336-40[10] Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002): 861-3[11] Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003): 2317-20[12] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[13] Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001): 361-2[14] Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF "Effects of three fluoroquinolones on QT analysis after standard treatment courses." Ann Noninvasive Electrocardiol 11 (2006): 52-6[15] Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000): 658-66[16] Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19[17] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[18] Falagas ME, Rafailidis PI, Rosmarakis ES "Arrhythmias associated with fluoroquinolone therapy." Int J Antimicrob Agents 29 (2007): 374-9[19] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.[20] White CM, Grant EM, Quintiliani R "Moxifloxacin does increase the corrected QT interval." Clin Infect Dis 33 (2001): 1441-2[21] Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002): 269-77[22] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[23] Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001): 1468-72[24] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001): 46-7[25] Cerner Multum, Inc. "Australian Product Information." O 0[26] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6[27] "Product Information. Tequin (gatifloxacin)" Bristol-Myers Squibb, Princeton, NJ.[28] Wallace AW, Victory JM, Amsden GW "Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers." J Clin Pharmacol 43 (2003): 92-6', 'Rifamycin, Kanamycin, Ampicillin, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112076, 'Tamoxifen', 'Nafcillin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112207/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More', 'Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, Abiraterone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112077, 'Tamoxifen', 'Naloxegol', 'Minor', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or weak inhibitors of CYP450 3A4 may increase the plasma concentrations of naloxegol, which is a substrate of both the efflux transporter and the isoenzyme.', 'DDInter', '-', 'Metabolism, Absorption', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112208/', '[1] "Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] "Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 'Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Exemestane', 'Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112078, 'Tamoxifen', 'Naltrexone', 'Moderate', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.', 'DDInter', 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.', 'Synergism', 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112209/', '[1] "Product Information. ReVia (naltrexone)." DuPont Pharmaceuticals, Wilmington, DE.', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Degarelix, Apalutamide, Exemestane', 'Oxymorphone, Tapentadol, Meperidine, Butorphanol, Hydromorphone, Dezocine, Opium, Pentazocine, Nalbuphine, Dihydrocodeine, Naloxone, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112079, 'Tamoxifen', 'Nateglinide', 'Moderate', 'Coadministration with inhibitors of CYP450 2C9 may increase the plasma concentrations of nateglinide, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Because the antidiabetic effect of nateglinide is dose- and concentration-dependent, close monitoring for the development of hypoglycemia is recommended during coadministration with CYP450 2C9 inhibitors. Patients should regularly monitor their blood sugar and learn how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation. The dosage of nateglinide may require adjustment if an interaction is suspected. Likewise, patients should be observed for potential loss of glycemic control following discontinuation of the CYP450 2C9 inhibitor, and the nateglinide dosage adjusted as necessary.', 'Metabolism', 'Because the antidiabetic effect of nateglinide is dose- and concentration-dependent, close monitoring for the development of hypoglycemia is recommended during coadministration with CYP450 2C9 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112210/', '[1] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[2] Sabia H, Sunkara G, Ligueros-Saylan M, et al. "Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects." Eur J Clin Pharmacol (2004):[3] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[4] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[7] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[8] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[12] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 'Darolutamide, Anastrozole, Letrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Abiraterone, Exemestane', 'Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112080, 'Tamoxifen', 'Nefazodone', 'Moderate', 'Coadministration with nefazodone may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by nefazodone.', 'DDInter', 'Caution is advised if nefazodone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. A lower initial dosage, as well as clinical and laboratory monitoring, may be appropriate for some drugs.', 'Metabolism', 'Caution is advised if nefazodone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112211/', '[1] "Product Information. Serzone (nefazodone)." Bristol-Myers Squibb, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Apalutamide, Exemestane', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112081, 'Tamoxifen', 'Nelfinavir', 'Moderate', 'Coadministration with nelfinavir may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by nelfinavir.', 'DDInter', 'Caution is advised if nelfinavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever nelfinavir is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if nelfinavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112212/', '[1] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Telaprevir, Velpatasvir, Dolutegravir, More', 'Anastrozole, Fulvestrant, Letrozole, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112082, 'Tamoxifen', 'Nevirapine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112213/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Telaprevir, Velpatasvir, Dolutegravir, More', 'Anastrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112083, 'Tamoxifen', 'Nilotinib', 'Major', 'Nilotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of nilotinib with other drugs that can prolong the QT interval should generally be avoided. Should treatment with other QT-prolonging drugs be required, the manufacturer recommends that nilotinib therapy be withheld temporarily. Caution and clinical monitoring are recommended if concomitant use is unavoidable. Patients should have frequent ECGs and be monitored for arrhythmias when QT interval is prolonged.', 'Synergism', 'Coadministration of nilotinib with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112214/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals, East Hanover, NJ.[5] "Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals, East Hanover, NJ.[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Anastrozole, Exemestane, Fulvestrant', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112084, 'Tamoxifen', 'Nilutamide', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112215/', '[1] "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] "Product Information. Zoladex (goserelin)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.[5] "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc, Deerfield, IL.[7] "Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals, New York, NY.[8] "Product Information. Plenaxis (abarelix)." Praecis Pharmaceuticals Inc, Waltham, MA.', 'Tamoxifen', 'Darolutamide, Anastrozole, Letrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112085, 'Tamoxifen', 'Nitisinone', 'Moderate', 'Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.', 'DDInter', 'If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.g., celecoxib, tolbutamide) or CYP450 2C9 substrates with a narrow therapeutic index (e.g., phenytoin, warfarin), the dosage of the drug metabolized by CYP450 2C9 should be reduced by one-half and additional dosage adjustments made as needed to maintain therapeutic drug concentrations. Clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with CYP450 2C9 substrates. Refer to individual substrate prescribing information for additional dosing recommendations.', 'Metabolism', 'If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112216/', '[1] "Product Information. Orfadin (nitisinone)." Orphan Pharmaceuticals USA, Inc, Nashville, TN.[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[5] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[29] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[35] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More', 'Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112086, 'Tamoxifen', 'Norfloxacin', 'Moderate', 'Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112217/', '[1] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002): 455-64[5] Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES "Arrhythmias associated with fluoroquinolone therapy." Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones." Br Med J 322 (2001): 46-7[12] "Product Information. Floxin (ofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B "Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?" South Med J 99 (2006): 52-6[14] Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG "QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine." Ann Pharmacother 39 (2005): 543-6[16] Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[20] Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[25] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Netilmicin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112087, 'Tamoxifen', 'Nortriptyline', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112218/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine', 'Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112088, 'Tamoxifen', 'Ofloxacin', 'Moderate', 'Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112219/', '[1] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002): 455-64[5] Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES "Arrhythmias associated with fluoroquinolone therapy." Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones." Br Med J 322 (2001): 46-7[12] "Product Information. Floxin (ofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B "Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?" South Med J 99 (2006): 52-6[14] Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG "QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine." Ann Pharmacother 39 (2005): 543-6[16] Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[20] Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[25] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Anastrozole, Aminoglutethimide', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin, Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112089, 'Tamoxifen', 'Olanzapine', 'Moderate', 'It is uncertain whether olanzapine causes clinically significant prolongation of the QT interval.', 'DDInter', 'Some authorities recommend caution when olanzapine is used with drugs that are known to cause QT prolongation.', 'Synergism', 'Some authorities recommend caution when olanzapine is used with drugs that are known to cause QT prolongation.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112220/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[4] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[5] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[6] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[7] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[8] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[9] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[10] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[11] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[12] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[16] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[17] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[19] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Darolutamide, Anastrozole, Fulvestrant, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112090, 'Tamoxifen', 'Olaparib', 'Moderate', 'Coadministration with olaparib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 1A2 and/or 2B6. The proposed mechanism, based on in vitro data, is increased clearance due to olaparib-mediated induction of CYP450 1A2 and/or 2B6.', 'DDInter', 'Caution is advised if olaparib is used concomitantly with drugs that are substrates of CYP450 1A2 and/or 2B6. Pharmacologic response and serum levels should be monitored more closely whenever olaparib is added to or withdrawn from therapy with these drugs. Dosage adjustments may be required if an interaction is suspected.', 'Metabolism', 'Caution is advised if olaparib is used concomitantly with drugs that are substrates of CYP450 1A2 and/or 2B6.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112221/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[4] "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[8] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[10] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Bicalutamide, Degarelix, Nilutamide, Abiraterone, Exemestane', 'Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112091, 'Tamoxifen', 'Oliceridine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112222/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Exemestane', 'Oxymorphone, Tapentadol, Meperidine, Butorphanol, Hydromorphone, Dezocine, Opium, Pentazocine, Nalbuphine, Dihydrocodeine, Naloxone, Codeine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112092, 'Tamoxifen', 'Olodaterol', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112223/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112093, 'Tamoxifen', 'Omacetaxine mepesuccinate', 'Moderate', 'The use of omacetaxine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Omacetaxine alone may cause severe myelosuppression, neutropenia, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other hematotoxic therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', 'DDInter', 'Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms such as fever, chills, shortness of breath, fatigue, and any unusual bleeding or bruising.', 'Synergism', 'Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112224/', '[1] "Product Information. Synribo (omacetaxine)." Teva Pharmaceuticals USA, North Wales, PA.', 'Darolutamide, Anastrozole, Aminoglutethimide, Abarelix, Enzalutamide, Relugolix, Bicalutamide, Degarelix, Apalutamide, Abiraterone', 'Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112094, 'Tamoxifen', 'Ondansetron', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112225/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Aminoglutethimide', 'Scopolamine, Nabilone, Dronabinol', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112095, 'Tamoxifen', 'Osilodrostat', 'Moderate', 'Osilodrostat can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if osilodrostat is used in combination with other drugs that can prolong the QT interval. An electrocardiogram and serum electrolyte levels should be obtained prior to initiating osilodrostat therapy and periodically thereafter. Correct hypokalemia and/or hypomagnesemia before starting treatment and as indicated during treatment, as they may be risk factors for ventricular arrhythmias.', 'Synergism', 'Caution is recommended if osilodrostat is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112226/', '[1] "Product Information. Isturisa (osilodrostat)." Recordati Rare Diseases Inc, Lebanon, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Anastrozole, Exemestane, Fulvestrant', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112096, 'Tamoxifen', 'Osimertinib', 'Major', 'Osimertinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if osimertinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting osimertinib therapy and periodically during treatment.', 'Synergism', 'Caution is recommended if osimertinib is used in combination with other drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112227/', '[1] "Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Anastrozole, Fulvestrant, Exemestane, Letrozole', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112097, 'Tamoxifen', 'Ospemifene', 'Moderate', 'The concurrent use of ospemifene with estrogens or other estrogen agonists/antagonists has not been evaluated. Safety and efficacy of this combination are unknown.', 'DDInter', 'Due to the lack of clinical data, concomitant use of ospemifene with estrogens or other estrogen agonists/antagonists is not recommended.', 'Others', 'Due to the lack of clinical data, concomitant use of ospemifene with estrogens or other estrogen agonists/antagonists is not recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112228/', '[1] "Product Information. Osphena (ospemifene)." Shionogi USA Inc, Florham Park, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.[4] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[5] "Product Information. Osphena (ospemifene)." Shionogi USA Inc, Florham Park, NJ.', 'Darolutamide, Anastrozole, Letrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, More', 'Ulipristal, Prasterone, Danazol, Bazedoxifene', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112098, 'Tamoxifen', 'Oxaliplatin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112229/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112099, 'Tamoxifen', 'Oxcarbazepine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112230/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, Abiraterone', 'Tiagabine, Ethotoin, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Mephenytoin, Perampanel, Zonisamide, Eslicarbazepine, Phensuximide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112100, 'Tamoxifen', 'Oxytocin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112231/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Methylergometrine, Ergometrine, Dinoprostone, Terlipressin, Desmopressin', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112101, 'Tamoxifen', 'Ozanimod', 'Major', 'Due to the risk of bradycardia and atrioventricular (AV) block, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of ozanimod treatment in patients receiving drugs that prolong the QT interval.', 'DDInter', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.', 'Synergism', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112232/', '[1] "Product Information. Zeposia (ozanimod)." Celgene Corporation, Summit, NJ.[2] "Product Information. Zeposia (ozanimod)." Celgene Corporation, Summit, NJ.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112102, 'Tamoxifen', 'Paliperidone', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112233/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112103, 'Tamoxifen', 'Palonosetron', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112234/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Scopolamine, Nabilone, Dronabinol', 'Anastrozole, Aminoglutethimide, Exemestane, Letrozole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112104, 'Tamoxifen', 'Panobinostat', 'Major', 'Chronic coadministration of potent or moderate CYP450 2D6 inhibitors including certain antidepressants may reduce the effectiveness of tamoxifen. The proposed mechanism is inhibition of tamoxifen bioactivation via CYP450 2D6 to endoxifen (4-hydroxy-N-desmethyltamoxifen), the active metabolite that may be responsible for much of tamoxifen''s antiestrogenic activity.', 'DDInter', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline. If an antidepressant is required during treatment with tamoxifen, agents such as desvenlafaxine, fluvoxamine, milnacipran, levomilnacipran, mirtazapine, and venlafaxine may be considered, since they have mild to no effects on CYP450 2D6. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients.', 'Metabolism', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112235/', '[1] Goetz MP, Rae JM, Suman VJ, et al. "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes." J Clin Oncol 23 (2005): 9312-8[2] Schroth W, Antoniadou L, Fritz P, et al. "Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes." J Clin Oncol 25 (2007): 5187-93[3] Stearns V, Johnson MD, Rae JM, et al. "Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 95 (2003): 1758-64[4] Desta Z, Flockhart DA "Germline pharmacogenetics of tamoxifen response: have we learned enough?" J Clin Oncol 25 (2007): 5147-9[5] Jordan VC, Collins MM, Rowsby L, Prestwich G "A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity." J Endocrinol 75 (1977): 305-16[6] Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M "Drug interactions and pharmacogenomics in the treatment of breast cancer and depression." Am J Psychiatry 165 (2008): 1251-5[7] Jin Y, Desta Z, Stearns V, et al. "CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment." J Natl Cancer Inst 97 (2005): 30-9[8] Lash TL, Pedersen L, Cronin-Fenton D, et al "Tamoxifen''s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram." Br J Cancer 99 (2008): 616-21[9] Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S "Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer." Breast Cancer Res 9 (2007): R7[10] Ponzone R, Biglia N, Sismondi P "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883-4; author reply 884-5[11] Johnson MD, Zuo H, Lee KH, et al. "Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen." Breast Cancer Res Treat 85 (2004): 151-9[12] McCaffrey P "Genetics and drug interactions affect tamoxifen metabolism." Lancet Oncol 6 (2005): 72[13] Coller JK, Krebsfaenger N, Klein K, et al. "The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver." Br J Clin Pharmacol 54 (2002): 157-167[14] Young D "Genetics examined in tamoxifen''s effectiveness: recurrence warning urged for labeling." Am J Health Syst Pharm 63 (2006): 2286, 2296[15] Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A "Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition." J Clin Pharmacol 44 (2004): 861-5[16] Dehal SS, Kupfer D "CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver." Cancer Res 57 (1997): 3402-6[17] Rochat B "Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance : focus on tamoxifen, Paclitaxel and imatinib metabolism." Clin Pharmacokinet 44 (2005): 349-66[18] Bonanni B, Macis D, Maisonneuve P, et al. "Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial." J Clin Oncol 24 (2006): 3708-9[19] Borgna JL, Rochefort H "Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues." J Biol Chem 256 (1981): 859-68[20] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5[21] Desta Z, Ward BA, Soukhova NV, Flockhart DA "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6." J Pharmacol Exp Ther (2004):[22] Brauch H, Murdter TE, Eichelbaum M, Schwab M "Pharmacogenomics of tamoxifen therapy." Clin Chem 55 (2009): 1770-82[23] Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM "Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4''-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen." Drug Metab Dispos 30 (2002): 869-74[24] Goetz MP, Kamal A, Ames MM "Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response." Clin Pharmacol Ther (2007):[25] Wegman P, Vainikka L, Stal O, et al "Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients." Breast Cancer Res 7 (2005): R284-90[26] Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883; author reply 884-5[27] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51[28] Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J "Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer." J Clin Oncol 25 (2007): 3837-45[29] Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H "Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer." Clin Cancer Res 15 (2009): 15-21[30] Goetz MP, Loprinzi CL "A hot flash on tamoxifen metabolism." J Natl Cancer Inst 95 (2003): 1734-5[31] Gaston C, Kolesar J "Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer." Clin Adv Hematol Oncol 6 (2008): 825-33[32] Borges S, Desta Z, Li L, et al. "Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment." Clin Pharmacol Ther 80 (2006): 61-74[33] Jordan VC "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance." Breast Cancer Res Treat 2 (1982): 123-38[34] Aubert RE, Stanek EJ, Yao J, et al "Increased risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Available from: URL: https://www.medcoresearch.com/community/oncology/tamoxifen." ([2009 May 30]):[35] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Exemestane', 'Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112105, 'Tamoxifen', 'Papaverine', 'Major', 'Intracoronary administration of papaverine has been associated with QT interval prolongation and torsade de pointes (TdP) arrhythmia. The risk may theoretically increase in patients receiving concomitant medications that can also prolong the QT interval or cause bradycardia. The precise mechanism of papaverine-induced ventricular tachyarrhythmias has not been delineated, but may involve inhibition of potassium currents and prolongation of the action potential duration.', 'DDInter', 'Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.', 'Synergism', 'Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112236/', '[1] Vrolix M, Piessens J, De Geest H "Torsades de pointes after intracoronary papaverine." Eur Heart J 12 (1991): 273-6[2] Jain A, Jenkins MG "Intracoronary electrocardiogram during torsade des pointes secondary to intracoronary papaverine." Cathet Cardiovasc Diagn 18 (1989): 255-7[3] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31[4] Talman CL, Winniford MD, Rossen JD, Simonetti I, Kienzle MG, Marcus ML "Polymorphous ventricular tachycardia: a side effect of intracoronary papaverine." J Am Coll Cardiol 15 (1990): 275-8[5] Kern MJ, Deligonul U, Serota H, Gudipati C, Buckingham T "Ventricular arrhythmia due to intracoronary papaverine: analysis of QT intervals and coronary vasodilatory reserve." Cathet Cardiovasc Diagn 19 (1990): 229-36[6] Nakayama M, Tanaka N, Sakoda K, et.al "Papaverine-induced polymorphic ventricular tachycardia during coronary flow reserve study of patients with moderate coronary artery disease." Circ J 79 (2015): 530-6[7] Inoue T, Asahi S, Takayanagi K, Morooka S, Takabatake Y "QT prolongation and possibility of ventricular arrhythmias after intracoronary papaverine." Cardiology 84 (1994): 9-13[8] Nakayama M, Saito A, Kitazawa H, et.al "Papaverine-induced polymorphic ventricular tachycardia in relation to QTU and giant T-U waves in four cases." Intern Med 51 (2012): 351-6', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Sildenafil, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112106, 'Tamoxifen', 'Paroxetine', 'Major', 'Chronic coadministration of potent or moderate CYP450 2D6 inhibitors including certain antidepressants may reduce the effectiveness of tamoxifen. The proposed mechanism is inhibition of tamoxifen bioactivation via CYP450 2D6 to endoxifen (4-hydroxy-N-desmethyltamoxifen), the active metabolite that may be responsible for much of tamoxifen''s antiestrogenic activity.', 'DDInter', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline. If an antidepressant is required during treatment with tamoxifen, agents such as desvenlafaxine, fluvoxamine, milnacipran, levomilnacipran, mirtazapine, and venlafaxine may be considered, since they have mild to no effects on CYP450 2D6. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients.', 'Metabolism', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112237/', '[1] Goetz MP, Rae JM, Suman VJ, et al. "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes." J Clin Oncol 23 (2005): 9312-8[2] Schroth W, Antoniadou L, Fritz P, et al. "Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes." J Clin Oncol 25 (2007): 5187-93[3] Stearns V, Johnson MD, Rae JM, et al. "Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 95 (2003): 1758-64[4] Desta Z, Flockhart DA "Germline pharmacogenetics of tamoxifen response: have we learned enough?" J Clin Oncol 25 (2007): 5147-9[5] Jordan VC, Collins MM, Rowsby L, Prestwich G "A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity." J Endocrinol 75 (1977): 305-16[6] Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M "Drug interactions and pharmacogenomics in the treatment of breast cancer and depression." Am J Psychiatry 165 (2008): 1251-5[7] Jin Y, Desta Z, Stearns V, et al. "CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment." J Natl Cancer Inst 97 (2005): 30-9[8] Lash TL, Pedersen L, Cronin-Fenton D, et al "Tamoxifen''s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram." Br J Cancer 99 (2008): 616-21[9] Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S "Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer." Breast Cancer Res 9 (2007): R7[10] Ponzone R, Biglia N, Sismondi P "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883-4; author reply 884-5[11] Johnson MD, Zuo H, Lee KH, et al. "Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen." Breast Cancer Res Treat 85 (2004): 151-9[12] McCaffrey P "Genetics and drug interactions affect tamoxifen metabolism." Lancet Oncol 6 (2005): 72[13] Coller JK, Krebsfaenger N, Klein K, et al. "The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver." Br J Clin Pharmacol 54 (2002): 157-167[14] Young D "Genetics examined in tamoxifen''s effectiveness: recurrence warning urged for labeling." Am J Health Syst Pharm 63 (2006): 2286, 2296[15] Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A "Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition." J Clin Pharmacol 44 (2004): 861-5[16] Dehal SS, Kupfer D "CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver." Cancer Res 57 (1997): 3402-6[17] Rochat B "Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance : focus on tamoxifen, Paclitaxel and imatinib metabolism." Clin Pharmacokinet 44 (2005): 349-66[18] Bonanni B, Macis D, Maisonneuve P, et al. "Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial." J Clin Oncol 24 (2006): 3708-9[19] Borgna JL, Rochefort H "Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues." J Biol Chem 256 (1981): 859-68[20] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5[21] Desta Z, Ward BA, Soukhova NV, Flockhart DA "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6." J Pharmacol Exp Ther (2004):[22] Brauch H, Murdter TE, Eichelbaum M, Schwab M "Pharmacogenomics of tamoxifen therapy." Clin Chem 55 (2009): 1770-82[23] Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM "Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4''-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen." Drug Metab Dispos 30 (2002): 869-74[24] Goetz MP, Kamal A, Ames MM "Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response." Clin Pharmacol Ther (2007):[25] Wegman P, Vainikka L, Stal O, et al "Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients." Breast Cancer Res 7 (2005): R284-90[26] Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883; author reply 884-5[27] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51[28] Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J "Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer." J Clin Oncol 25 (2007): 3837-45[29] Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H "Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer." Clin Cancer Res 15 (2009): 15-21[30] Goetz MP, Loprinzi CL "A hot flash on tamoxifen metabolism." J Natl Cancer Inst 95 (2003): 1734-5[31] Gaston C, Kolesar J "Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer." Clin Adv Hematol Oncol 6 (2008): 825-33[32] Borges S, Desta Z, Li L, et al. "Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment." Clin Pharmacol Ther 80 (2006): 61-74[33] Jordan VC "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance." Breast Cancer Res Treat 2 (1982): 123-38[34] Aubert RE, Stanek EJ, Yao J, et al "Increased risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Available from: URL: https://www.medcoresearch.com/community/oncology/tamoxifen." ([2009 May 30]):[35] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Darolutamide, Aminoglutethimide, Toremifene, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Apalutamide', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112107, 'Tamoxifen', 'Pasireotide', 'Major', 'Pasireotide can cause bradycardia and QT prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if pasireotide is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting pasireotide therapy and periodically during treatment in accordance with the product labeling. Hypokalemia and hypomagnesemia must be corrected prior to pasireotide administration.', 'Synergism', 'Caution is recommended if pasireotide is used in combination with other drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112238/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals, East Hanover, NJ.[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[6] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Norethisterone, Nafarelin, Octreotide, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112108, 'Tamoxifen', 'Pazopanib', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112239/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Exemestane, Letrozole', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112109, 'Tamoxifen', 'Pegaspargase', 'Moderate', 'Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.', 'DDInter', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112240/', '[1] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub[4] Cerner Multum, Inc "ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp." O 0 (2015):[5] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[6] Christ TN, Stock W, Knoebel RW "Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen." J Oncol Pharm Pract 24 (2018): 299-308[7] Lu G, Karur V, Herrington JD, Walker MG "Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine" Proc (Bayl Univ Med Cent) 29 (2016): 46-7[8] Jenkins R, Perlin E "Severe hepatotoxicity from Escherichia coli L-asparaginase." J Natl Med Assoc 79 (1987): 775-9[9] "Product Information. Asparlas (calaspargase pegol)." Servier, Boston, MA.[10] Burke PW, Aldoss I, Lunning MA, et.al "High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles." Blood 122 (2013): 2671[11] "Product Information. Erwinaze (asparaginase Erwinia chrysanthemi)." EUSA Pharma, Newtown, PA.[12] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[13] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4', 'Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Degarelix, Apalutamide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112110, 'Tamoxifen', 'Peginterferon beta-1a', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', 'DDInter', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112241/', '[1] "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA.[2] "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.[3] "Product Information. Rebif (interferon beta-1a)." Serono Laboratories Inc, Norwell, MA.[4] "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Degarelix, Apalutamide, Exemestane', 'Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Sargramostim, Histamine, Pegademase, Pegfilgrastim, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112111, 'Tamoxifen', 'Pentobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112242/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Suvorexant, Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, More', 'Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, Abiraterone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112112, 'Tamoxifen', 'Perflutren', 'Moderate', 'Perflutren lipid microsphere suspension (Definity) has been reported to cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if perflutren lipid microsphere suspension is used in combination with other drugs that can prolong the QT interval. Please refer to the prescribing information for these drugs for more information. No data are available regarding the effect of perflutren protein-type A microsphere suspension (Optison) on the QT interval of the electrocardiogram.', 'Synergism', 'Caution is recommended if perflutren lipid microsphere suspension is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112243/', '[1] "Product Information. Definity (perflutren)." Lantheus Medical Imaging Inc, North Billerica, MA.[2] "Product Information. Optison (perflutren)." Mallinckrodt Medical Inc, St. Louis, MO.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112113, 'Tamoxifen', 'Perphenazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112244/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112114, 'Tamoxifen', 'Pexidartinib', 'Major', 'Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases.', 'DDInter', 'The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The use of pexidartinib with other potentially hepatotoxic agents should be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112245/', '[1] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.[2] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.', 'Anastrozole, Fulvestrant, Letrozole, Abarelix, Degarelix, Aminoglutethimide', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112115, 'Tamoxifen', 'Phenylbutazone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112246/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, Abiraterone', 'Fenoprofen, Ketorolac, Glucosamine, Oxaprozin, Chondroitin sulfate, Flurbiprofen, Esomeprazole, Tolmetin, Meclofenamic acid, Mefenamic acid, Tolazoline, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112116, 'Tamoxifen', 'Phenytoin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112247/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Tiagabine, Ethotoin, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Mephenytoin, Perampanel, Zonisamide, Eslicarbazepine, Phensuximide, More', 'Fulvestrant, Letrozole, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112117, 'Tamoxifen', 'Pimavanserin', 'Moderate', 'Pimavanserin may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of pimavanserin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged.', 'Synergism', 'Coadministration of pimavanserin with other drugs that can prolong the QT interval should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112248/', '[1] "Product Information. Nuplazid (pimavanserin)." Accelis Pharma, East Windsor, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Exemestane', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112118, 'Tamoxifen', 'Pimozide', 'Major', 'Pimozide can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with pimozide. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.', 'DDInter', 'Coadministration of pimozide with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of pimozide with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112249/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Orap Tablets (pimozide)." Gate Pharmaceuticals, Sellersville, PA.[3] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[4] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[5] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[6] "Product Information. Orap Tablets (pimozide)." Gate Pharmaceuticals, Sellersville, PA.[7] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[8] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[10] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112119, 'Tamoxifen', 'Pitolisant', 'Moderate', 'Limited data suggest that pitolisant may produce mild to moderate QT interval prolongation (10 to 13 milliseconds) at doses 3 to 6 times the standard therapeutic dose. Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Concomitant use of pitolisant with other agents associated with QT interval prolongation should generally be avoided. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Concomitant use of pitolisant with other agents associated with QT interval prolongation should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112250/', '[1] "Product Information. Wakix (pitolisant)." Harmony Biosciences, LLC, Plymouth Meeting, PA.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Ingrezza (valbenazine)." Neurocrine Biosciences, Inc., San Diego, CA.', 'Darolutamide, Anastrozole, Fulvestrant, Aminoglutethimide, Abiraterone, Exemestane', 'Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112120, 'Tamoxifen', 'Pomalidomide', 'Major', 'Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of pomalidomide. Deep venous thrombosis (DVT) and pulmonary embolism (PE) occur in patients with multiple myeloma treated with pomalidomide.', 'DDInter', 'Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving pomalidomide. Prophylactic antithrombotic measures should be considered after assessing underlying risk factors such as health history and concomitant medications. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.', 'Synergism', 'Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving pomalidomide.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112251/', '[1] "Product Information. Pomalyst (pomalidomide)." QLT Phototherapeutics Inc, Vancouver, AZ.[2] "Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.[3] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[4] "Product Information. Pomalyst (pomalidomide)." QLT Phototherapeutics Inc, Vancouver, AZ.', 'Darolutamide, Anastrozole, Letrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112121, 'Tamoxifen', 'Posaconazole', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112252/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112122, 'Tamoxifen', 'Prasugrel', 'Minor', 'Coadministration with prasugrel may alter the metabolism of drugs that are substrates of CYP450 2B6. Prasugrel is a weak inhibitor of the isoenzyme.This change is not considered clinically significant. Therefore, prasugrel is not anticipated to have a significant effect on the pharmacokinetics of drugs that are primarily metabolized by CYP450 2B6 such as cyclophosphamide, efavirenz, halothane, nevirapine, propofol, selegiline, and tamoxifen.', 'DDInter', '-', 'Metabolism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112253/', '[1] "Product Information. Effient (prasugrel)." Lilly, Eli and Company, Indianapolis, IN.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Ito D, Amano T, Sato H, Fukuuchi Y "Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson''s disease." J Neurol 248 (2001): 533-4[4] McGrath PJ, Stewart JW, Quitkin FM "A possible L-deprenyl induced hypertensive reaction." J Clin Psychopharmacol 9 (1989): 310-1[5] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[6] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[7] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[8] "Product Information. Emsam (selegiline)." Bristol-Myers Squibb, Princeton, NJ.[9] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[10] "Product Information. Eldepryl (selegiline)." Somerset Pharmaceuticals Inc, Tampa, FL.[11] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[12] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[13] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[14] Lefebvre H, Noblet C, Morre N, Wolf LM "Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline." Clin Endocrinol (Oxf) 42 (1995): 95-8', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, More', 'Ticagrelor, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Desirudin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112123, 'Tamoxifen', 'Primaquine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112254/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112124, 'Tamoxifen', 'Primidone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112255/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide', 'Suvorexant, Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112125, 'Tamoxifen', 'Probucol', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112256/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, Colestipol, Bempedoic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112126, 'Tamoxifen', 'Procainamide', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112257/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Yamreudeewong W, DeBisschop M, Martin L, Lower D "Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs." Drug Saf 26 (2003): 421-38[3] "Product Information. Norpace (disopyramide)." Searle, Skokie, IL.[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] "Product Information. Betapace (sotalol)." Berlex, Richmond, CA.[6] "Product Information. Procan SR (procainamide)." Parke-Davis, Morris Plains, NJ.[7] Maxa JL, Hebeler RF, Adeeko MA "Torsades de pointes following concurrent amiodarone and levofloxacin therapy." Proc (Bayl Univ Med Cent) 19 (2006): 345-6[8] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[9] "Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[10] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[11] "Product Information. Vascor (bepridil)." McNeil Pharmaceutical, Raritan, NJ.[12] "Product Information. Quiniglute (quinidine)." Berlex, Richmond, CA.[13] Trujillo TC, Nolan PE "Antiarrhythmic agents - Drug interactions of clinical significance." Drug Safety 23 (2000): 509-32[14] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[15] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[16] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[17] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[18] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[19] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[20] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[21] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[22] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[25] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[26] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[27] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[28] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[29] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[30] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[31] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[32] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[33] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[34] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[35] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[36] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[37] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[38] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[39] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[40] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[41] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[42] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[43] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[44] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[45] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Moricizine, Tocainide, Bretylium, Mexiletine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112127, 'Tamoxifen', 'Promazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112258/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112128, 'Tamoxifen', 'Propafenone', 'Major', 'Chronic coadministration of potent or moderate CYP450 2D6 inhibitors including certain antidepressants may reduce the effectiveness of tamoxifen. The proposed mechanism is inhibition of tamoxifen bioactivation via CYP450 2D6 to endoxifen (4-hydroxy-N-desmethyltamoxifen), the active metabolite that may be responsible for much of tamoxifen''s antiestrogenic activity.', 'DDInter', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline. If an antidepressant is required during treatment with tamoxifen, agents such as desvenlafaxine, fluvoxamine, milnacipran, levomilnacipran, mirtazapine, and venlafaxine may be considered, since they have mild to no effects on CYP450 2D6. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients.', 'Metabolism', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112259/', '[1] Goetz MP, Rae JM, Suman VJ, et al. "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes." J Clin Oncol 23 (2005): 9312-8[2] Schroth W, Antoniadou L, Fritz P, et al. "Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes." J Clin Oncol 25 (2007): 5187-93[3] Stearns V, Johnson MD, Rae JM, et al. "Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 95 (2003): 1758-64[4] Desta Z, Flockhart DA "Germline pharmacogenetics of tamoxifen response: have we learned enough?" J Clin Oncol 25 (2007): 5147-9[5] Jordan VC, Collins MM, Rowsby L, Prestwich G "A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity." J Endocrinol 75 (1977): 305-16[6] Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M "Drug interactions and pharmacogenomics in the treatment of breast cancer and depression." Am J Psychiatry 165 (2008): 1251-5[7] Jin Y, Desta Z, Stearns V, et al. "CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment." J Natl Cancer Inst 97 (2005): 30-9[8] Lash TL, Pedersen L, Cronin-Fenton D, et al "Tamoxifen''s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram." Br J Cancer 99 (2008): 616-21[9] Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S "Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer." Breast Cancer Res 9 (2007): R7[10] Ponzone R, Biglia N, Sismondi P "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883-4; author reply 884-5[11] Johnson MD, Zuo H, Lee KH, et al. "Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen." Breast Cancer Res Treat 85 (2004): 151-9[12] McCaffrey P "Genetics and drug interactions affect tamoxifen metabolism." Lancet Oncol 6 (2005): 72[13] Coller JK, Krebsfaenger N, Klein K, et al. "The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver." Br J Clin Pharmacol 54 (2002): 157-167[14] Young D "Genetics examined in tamoxifen''s effectiveness: recurrence warning urged for labeling." Am J Health Syst Pharm 63 (2006): 2286, 2296[15] Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A "Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition." J Clin Pharmacol 44 (2004): 861-5[16] Dehal SS, Kupfer D "CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver." Cancer Res 57 (1997): 3402-6[17] Rochat B "Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance : focus on tamoxifen, Paclitaxel and imatinib metabolism." Clin Pharmacokinet 44 (2005): 349-66[18] Bonanni B, Macis D, Maisonneuve P, et al. "Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial." J Clin Oncol 24 (2006): 3708-9[19] Borgna JL, Rochefort H "Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues." J Biol Chem 256 (1981): 859-68[20] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5[21] Desta Z, Ward BA, Soukhova NV, Flockhart DA "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6." J Pharmacol Exp Ther (2004):[22] Brauch H, Murdter TE, Eichelbaum M, Schwab M "Pharmacogenomics of tamoxifen therapy." Clin Chem 55 (2009): 1770-82[23] Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM "Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4''-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen." Drug Metab Dispos 30 (2002): 869-74[24] Goetz MP, Kamal A, Ames MM "Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response." Clin Pharmacol Ther (2007):[25] Wegman P, Vainikka L, Stal O, et al "Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients." Breast Cancer Res 7 (2005): R284-90[26] Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883; author reply 884-5[27] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51[28] Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J "Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer." J Clin Oncol 25 (2007): 3837-45[29] Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H "Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer." Clin Cancer Res 15 (2009): 15-21[30] Goetz MP, Loprinzi CL "A hot flash on tamoxifen metabolism." J Natl Cancer Inst 95 (2003): 1734-5[31] Gaston C, Kolesar J "Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer." Clin Adv Hematol Oncol 6 (2008): 825-33[32] Borges S, Desta Z, Li L, et al. "Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment." Clin Pharmacol Ther 80 (2006): 61-74[33] Jordan VC "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance." Breast Cancer Res Treat 2 (1982): 123-38[34] Aubert RE, Stanek EJ, Yao J, et al "Increased risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Available from: URL: https://www.medcoresearch.com/community/oncology/tamoxifen." ([2009 May 30]):[35] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Moricizine, Tocainide, Bretylium, Mexiletine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112129, 'Tamoxifen', 'Protriptyline', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112260/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112130, 'Tamoxifen', 'Quetiapine', 'Moderate', 'There is some concern that quetiapine may have additive cardiovascular effects in combination with other drugs that are known to prolong the QT interval of the electrocardiogram.', 'DDInter', 'Coadministration of quetiapine with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. In addition, if combination therapy with agents with anticholinergic properties is required, caution is advised, particularly in the elderly and those with underlying organic brain disease.', 'Synergism', 'Coadministration of quetiapine with other drugs that can prolong the QT interval should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112261/', '[1] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[2] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] Vieweg WV "New generation antipsychotic drugs and QTc interval prolongation." Prim Care Companion J Clin Psychiatry 5 (2003): 205-15[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Vieweg WV, Schneider RK, Wood MA "Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine." Acta Psychiatr Scand 112 (2005): 318-22[9] Sala M, Vicentini A, Brambilla P, et al. "QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy." Ann Gen Psychiatry 4 (2005): 1[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[13] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Exemestane, Fulvestrant, Letrozole', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112131, 'Tamoxifen', 'Quinidine', 'Major', 'Chronic coadministration of potent or moderate CYP450 2D6 inhibitors including certain antidepressants may reduce the effectiveness of tamoxifen. The proposed mechanism is inhibition of tamoxifen bioactivation via CYP450 2D6 to endoxifen (4-hydroxy-N-desmethyltamoxifen), the active metabolite that may be responsible for much of tamoxifen''s antiestrogenic activity.', 'DDInter', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline. If an antidepressant is required during treatment with tamoxifen, agents such as desvenlafaxine, fluvoxamine, milnacipran, levomilnacipran, mirtazapine, and venlafaxine may be considered, since they have mild to no effects on CYP450 2D6. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients.', 'Metabolism', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112262/', '[1] Goetz MP, Rae JM, Suman VJ, et al. "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes." J Clin Oncol 23 (2005): 9312-8[2] Schroth W, Antoniadou L, Fritz P, et al. "Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes." J Clin Oncol 25 (2007): 5187-93[3] Stearns V, Johnson MD, Rae JM, et al. "Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 95 (2003): 1758-64[4] Desta Z, Flockhart DA "Germline pharmacogenetics of tamoxifen response: have we learned enough?" J Clin Oncol 25 (2007): 5147-9[5] Jordan VC, Collins MM, Rowsby L, Prestwich G "A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity." J Endocrinol 75 (1977): 305-16[6] Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M "Drug interactions and pharmacogenomics in the treatment of breast cancer and depression." Am J Psychiatry 165 (2008): 1251-5[7] Jin Y, Desta Z, Stearns V, et al. "CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment." J Natl Cancer Inst 97 (2005): 30-9[8] Lash TL, Pedersen L, Cronin-Fenton D, et al "Tamoxifen''s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram." Br J Cancer 99 (2008): 616-21[9] Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S "Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer." Breast Cancer Res 9 (2007): R7[10] Ponzone R, Biglia N, Sismondi P "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883-4; author reply 884-5[11] Johnson MD, Zuo H, Lee KH, et al. "Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen." Breast Cancer Res Treat 85 (2004): 151-9[12] McCaffrey P "Genetics and drug interactions affect tamoxifen metabolism." Lancet Oncol 6 (2005): 72[13] Coller JK, Krebsfaenger N, Klein K, et al. "The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver." Br J Clin Pharmacol 54 (2002): 157-167[14] Young D "Genetics examined in tamoxifen''s effectiveness: recurrence warning urged for labeling." Am J Health Syst Pharm 63 (2006): 2286, 2296[15] Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A "Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition." J Clin Pharmacol 44 (2004): 861-5[16] Dehal SS, Kupfer D "CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver." Cancer Res 57 (1997): 3402-6[17] Rochat B "Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance : focus on tamoxifen, Paclitaxel and imatinib metabolism." Clin Pharmacokinet 44 (2005): 349-66[18] Bonanni B, Macis D, Maisonneuve P, et al. "Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial." J Clin Oncol 24 (2006): 3708-9[19] Borgna JL, Rochefort H "Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues." J Biol Chem 256 (1981): 859-68[20] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5[21] Desta Z, Ward BA, Soukhova NV, Flockhart DA "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6." J Pharmacol Exp Ther (2004):[22] Brauch H, Murdter TE, Eichelbaum M, Schwab M "Pharmacogenomics of tamoxifen therapy." Clin Chem 55 (2009): 1770-82[23] Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM "Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4''-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen." Drug Metab Dispos 30 (2002): 869-74[24] Goetz MP, Kamal A, Ames MM "Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response." Clin Pharmacol Ther (2007):[25] Wegman P, Vainikka L, Stal O, et al "Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients." Breast Cancer Res 7 (2005): R284-90[26] Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883; author reply 884-5[27] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51[28] Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J "Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer." J Clin Oncol 25 (2007): 3837-45[29] Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H "Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer." Clin Cancer Res 15 (2009): 15-21[30] Goetz MP, Loprinzi CL "A hot flash on tamoxifen metabolism." J Natl Cancer Inst 95 (2003): 1734-5[31] Gaston C, Kolesar J "Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer." Clin Adv Hematol Oncol 6 (2008): 825-33[32] Borges S, Desta Z, Li L, et al. "Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment." Clin Pharmacol Ther 80 (2006): 61-74[33] Jordan VC "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance." Breast Cancer Res Treat 2 (1982): 123-38[34] Aubert RE, Stanek EJ, Yao J, et al "Increased risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Available from: URL: https://www.medcoresearch.com/community/oncology/tamoxifen." ([2009 May 30]):[35] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Darolutamide, Exemestane, Aminoglutethimide, Fulvestrant', 'Moricizine, Tocainide, Bretylium, Mexiletine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112132, 'Tamoxifen', 'Quinine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112263/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Anastrozole, Fulvestrant, Exemestane, Letrozole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112133, 'Tamoxifen', 'Ranolazine', 'Major', 'Chronic coadministration of potent or moderate CYP450 2D6 inhibitors including certain antidepressants may reduce the effectiveness of tamoxifen. The proposed mechanism is inhibition of tamoxifen bioactivation via CYP450 2D6 to endoxifen (4-hydroxy-N-desmethyltamoxifen), the active metabolite that may be responsible for much of tamoxifen''s antiestrogenic activity.', 'DDInter', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline. If an antidepressant is required during treatment with tamoxifen, agents such as desvenlafaxine, fluvoxamine, milnacipran, levomilnacipran, mirtazapine, and venlafaxine may be considered, since they have mild to no effects on CYP450 2D6. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients.', 'Metabolism', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112264/', '[1] Goetz MP, Rae JM, Suman VJ, et al. "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes." J Clin Oncol 23 (2005): 9312-8[2] Schroth W, Antoniadou L, Fritz P, et al. "Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes." J Clin Oncol 25 (2007): 5187-93[3] Stearns V, Johnson MD, Rae JM, et al. "Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 95 (2003): 1758-64[4] Desta Z, Flockhart DA "Germline pharmacogenetics of tamoxifen response: have we learned enough?" J Clin Oncol 25 (2007): 5147-9[5] Jordan VC, Collins MM, Rowsby L, Prestwich G "A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity." J Endocrinol 75 (1977): 305-16[6] Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M "Drug interactions and pharmacogenomics in the treatment of breast cancer and depression." Am J Psychiatry 165 (2008): 1251-5[7] Jin Y, Desta Z, Stearns V, et al. "CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment." J Natl Cancer Inst 97 (2005): 30-9[8] Lash TL, Pedersen L, Cronin-Fenton D, et al "Tamoxifen''s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram." Br J Cancer 99 (2008): 616-21[9] Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S "Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer." Breast Cancer Res 9 (2007): R7[10] Ponzone R, Biglia N, Sismondi P "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883-4; author reply 884-5[11] Johnson MD, Zuo H, Lee KH, et al. "Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen." Breast Cancer Res Treat 85 (2004): 151-9[12] McCaffrey P "Genetics and drug interactions affect tamoxifen metabolism." Lancet Oncol 6 (2005): 72[13] Coller JK, Krebsfaenger N, Klein K, et al. "The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver." Br J Clin Pharmacol 54 (2002): 157-167[14] Young D "Genetics examined in tamoxifen''s effectiveness: recurrence warning urged for labeling." Am J Health Syst Pharm 63 (2006): 2286, 2296[15] Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A "Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition." J Clin Pharmacol 44 (2004): 861-5[16] Dehal SS, Kupfer D "CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver." Cancer Res 57 (1997): 3402-6[17] Rochat B "Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance : focus on tamoxifen, Paclitaxel and imatinib metabolism." Clin Pharmacokinet 44 (2005): 349-66[18] Bonanni B, Macis D, Maisonneuve P, et al. "Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial." J Clin Oncol 24 (2006): 3708-9[19] Borgna JL, Rochefort H "Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues." J Biol Chem 256 (1981): 859-68[20] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5[21] Desta Z, Ward BA, Soukhova NV, Flockhart DA "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6." J Pharmacol Exp Ther (2004):[22] Brauch H, Murdter TE, Eichelbaum M, Schwab M "Pharmacogenomics of tamoxifen therapy." Clin Chem 55 (2009): 1770-82[23] Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM "Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4''-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen." Drug Metab Dispos 30 (2002): 869-74[24] Goetz MP, Kamal A, Ames MM "Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response." Clin Pharmacol Ther (2007):[25] Wegman P, Vainikka L, Stal O, et al "Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients." Breast Cancer Res 7 (2005): R284-90[26] Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883; author reply 884-5[27] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51[28] Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J "Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer." J Clin Oncol 25 (2007): 3837-45[29] Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H "Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer." Clin Cancer Res 15 (2009): 15-21[30] Goetz MP, Loprinzi CL "A hot flash on tamoxifen metabolism." J Natl Cancer Inst 95 (2003): 1734-5[31] Gaston C, Kolesar J "Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer." Clin Adv Hematol Oncol 6 (2008): 825-33[32] Borges S, Desta Z, Li L, et al. "Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment." Clin Pharmacol Ther 80 (2006): 61-74[33] Jordan VC "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance." Breast Cancer Res Treat 2 (1982): 123-38[34] Aubert RE, Stanek EJ, Yao J, et al "Increased risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Available from: URL: https://www.medcoresearch.com/community/oncology/tamoxifen." ([2009 May 30]):[35] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Regadenoson, Alprostadil, Ubidecarenone', 'Anastrozole, Fulvestrant, Exemestane, Letrozole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112134, 'Tamoxifen', 'Relugolix', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112265/', '[1] "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] "Product Information. Zoladex (goserelin)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.[5] "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc, Deerfield, IL.[7] "Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals, New York, NY.[8] "Product Information. Plenaxis (abarelix)." Praecis Pharmaceuticals Inc, Waltham, MA.', 'Darolutamide, Anastrozole, Letrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Abiraterone, Exemestane', 'Norethisterone, Nafarelin, Octreotide, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin, Tamoxifen', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112135, 'Tamoxifen', 'Remdesivir', 'Moderate', 'Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from investigational use and clinical studies suggest that remdesivir may be associated with hepatotoxic effects.', 'DDInter', 'Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible. Liver function should be evaluated prior to starting remdesivir and monitored during treatment as clinically appropriate. Remdesivir should not be initiated in patients with ALT greater than or equal to 5 times the upper limit of normal (ULN) at baseline. Likewise, remdesivir should be discontinued immediately if ALT increases to 5 times ULN or greater during treatment (may be restarted when ALT falls below 5 times ULN), or if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.', 'Synergism', 'Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112266/', '[1] Gilead Sciences, Inc "About Remdesivir. Available from: URL: https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir." ([2020]):[2] US Food and Drug Administration "Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM) Available from: URL: https://www.fda.gov/media/137566/download." ([2020, May 1]]):[3] European Medicines Agency "Summary on compassionate use. Remdesivir Gilead. Available from: URL: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf." ([2020 Apr 03]):[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Relugolix, Degarelix, Aminoglutethimide, Exemestane', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Telaprevir, Velpatasvir, Dolutegravir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112136, 'Tamoxifen', 'Ribociclib', 'Major', 'Ribociclib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Coadministration with ribociclib may increase the plasma concentrations and pharmacologic effects of drugs that are substrates of CYP450 3A4. The proposed mechanism is decreased clearance due to ribociclib-mediated inhibition of CYP450 3A4 metabolism.', 'DDInter', 'Coadministration of ribociclib with other drugs that can prolong the QT interval and are substrates of CYP450 3A4, particularly those with a narrow therapeutic range, should generally be avoided. Since the magnitude of QT prolongation may increase with increasing plasma concentrations of these drugs, caution and close clinical monitoring are recommended if concomitant use with these drugs is unavoidable. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ribociclib is added to or withdrawn from therapy.', 'Metabolism, Synergism', 'Coadministration of ribociclib with other drugs that can prolong the QT interval and are substrates of CYP450 3A4, particularly those with a narrow therapeutic range, should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112267/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[4] Abbas R, Hug BA, Leister C, Sonnichsen D "A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects." Int J Cancer 131 (2012): Epub[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] "Product Information. Uroxatral (alfuzosin)." sanofi-aventis , Bridgewater, NJ.[7] "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.[8] "Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.[9] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[10] "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.', 'Abarelix, Anastrozole, Exemestane, Fulvestrant', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112137, 'Tamoxifen', 'Rifampicin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112268/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112138, 'Tamoxifen', 'Rifapentine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112269/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112139, 'Tamoxifen', 'Riociguat', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 or moderate to potent inhibitors of P-glycoprotein (P-gp) or breast cancer resistant protein (BCRP) may increase the plasma concentrations of riociguat, which is partially metabolized by CYP450 3A and also a substrate of the P-gp and BCRP efflux transporters. Increased levels of riociguat may increase the risk for hypotension.', 'DDInter', 'Caution is advised when riociguat is prescribed with potent CYP450 3A4 inhibitors or moderate to potent P-gp or BCRP inhibitors. Patients should be monitored for signs and symptoms of hypotension, and the dosage of riociguat adjusted if necessary.', 'Metabolism', 'Caution is advised when riociguat is prescribed with potent CYP450 3A4 inhibitors or moderate to potent P-gp or BCRP inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112270/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc, West Haven, CT.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc, West Haven, CT.', 'Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Abiraterone, Exemestane', 'Ambrisentan, Macitentan, Metyrosine, Tadalafil', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112140, 'Tamoxifen', 'Ripretinib', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of ripretinib and its active metabolite, DP-5439. In vitro studies indicate that ripretinib and DP-5439 are substrates of the P-gp efflux transporter.', 'DDInter', 'Until more information is available, caution is recommended when ripretinib is used concomitantly with drugs that are inhibitors of P-gp. Clinical and laboratory monitoring should be considered whenever a P-gp inhibitor is added to or withdrawn from therapy with ripretinib, and the dosage adjusted as necessary. Patients should be monitored for development of adverse effects such as nausea, vomiting, constipation, diarrhea, alopecia, arthralgia, myalgia, hypertension, cardiac dysfunction, and palmar-plantar erythrodysesthesia.', 'Absorption', 'Until more information is available, caution is recommended when ripretinib is used concomitantly with drugs that are inhibitors of P-gp.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112271/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Qinlock (ripretinib)." Deciphera Pharmaceuticals, Waltham, MA.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Qinlock (ripretinib)." Deciphera Pharmaceuticals, Waltham, MA.[5] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.[6] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[7] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[11] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[12] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[13] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[14] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[15] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[16] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[17] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[18] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[19] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[20] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[21] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[22] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[23] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[25] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[27] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[28] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[29] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[30] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[31] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[32] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[33] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[34] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[35] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[36] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[37] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31', 'Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Exemestane', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112141, 'Tamoxifen', 'Ritodrine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112272/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Bremelanotide, Flibanserin, Cabergoline', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112142, 'Tamoxifen', 'Rivastigmine', 'Moderate', 'Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.', 'DDInter', 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.', 'Synergism', 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112273/', '[1] "Product Information. Razadyne (galantamine)." Johnson and Johnson Medical Inc, Arlington, TX.[2] "Product Information. Exelon (rivastigmine)" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Aricept (donepezil)." Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Flutamide, Enzalutamide, Bicalutamide, Nilutamide, Apalutamide, Abiraterone, Exemestane', 'Ginkgo biloba, Aducanumab', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112143, 'Tamoxifen', 'Rolapitant', 'Major', 'Chronic coadministration of potent or moderate CYP450 2D6 inhibitors including certain antidepressants may reduce the effectiveness of tamoxifen. The proposed mechanism is inhibition of tamoxifen bioactivation via CYP450 2D6 to endoxifen (4-hydroxy-N-desmethyltamoxifen), the active metabolite that may be responsible for much of tamoxifen''s antiestrogenic activity.', 'DDInter', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline. If an antidepressant is required during treatment with tamoxifen, agents such as desvenlafaxine, fluvoxamine, milnacipran, levomilnacipran, mirtazapine, and venlafaxine may be considered, since they have mild to no effects on CYP450 2D6. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients.', 'Metabolism', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112274/', '[1] Goetz MP, Rae JM, Suman VJ, et al. "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes." J Clin Oncol 23 (2005): 9312-8[2] Schroth W, Antoniadou L, Fritz P, et al. "Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes." J Clin Oncol 25 (2007): 5187-93[3] Stearns V, Johnson MD, Rae JM, et al. "Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 95 (2003): 1758-64[4] Desta Z, Flockhart DA "Germline pharmacogenetics of tamoxifen response: have we learned enough?" J Clin Oncol 25 (2007): 5147-9[5] Jordan VC, Collins MM, Rowsby L, Prestwich G "A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity." J Endocrinol 75 (1977): 305-16[6] Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M "Drug interactions and pharmacogenomics in the treatment of breast cancer and depression." Am J Psychiatry 165 (2008): 1251-5[7] Jin Y, Desta Z, Stearns V, et al. "CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment." J Natl Cancer Inst 97 (2005): 30-9[8] Lash TL, Pedersen L, Cronin-Fenton D, et al "Tamoxifen''s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram." Br J Cancer 99 (2008): 616-21[9] Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S "Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer." Breast Cancer Res 9 (2007): R7[10] Ponzone R, Biglia N, Sismondi P "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883-4; author reply 884-5[11] Johnson MD, Zuo H, Lee KH, et al. "Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen." Breast Cancer Res Treat 85 (2004): 151-9[12] McCaffrey P "Genetics and drug interactions affect tamoxifen metabolism." Lancet Oncol 6 (2005): 72[13] Coller JK, Krebsfaenger N, Klein K, et al. "The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver." Br J Clin Pharmacol 54 (2002): 157-167[14] Young D "Genetics examined in tamoxifen''s effectiveness: recurrence warning urged for labeling." Am J Health Syst Pharm 63 (2006): 2286, 2296[15] Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A "Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition." J Clin Pharmacol 44 (2004): 861-5[16] Dehal SS, Kupfer D "CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver." Cancer Res 57 (1997): 3402-6[17] Rochat B "Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance : focus on tamoxifen, Paclitaxel and imatinib metabolism." Clin Pharmacokinet 44 (2005): 349-66[18] Bonanni B, Macis D, Maisonneuve P, et al. "Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial." J Clin Oncol 24 (2006): 3708-9[19] Borgna JL, Rochefort H "Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues." J Biol Chem 256 (1981): 859-68[20] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5[21] Desta Z, Ward BA, Soukhova NV, Flockhart DA "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6." J Pharmacol Exp Ther (2004):[22] Brauch H, Murdter TE, Eichelbaum M, Schwab M "Pharmacogenomics of tamoxifen therapy." Clin Chem 55 (2009): 1770-82[23] Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM "Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4''-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen." Drug Metab Dispos 30 (2002): 869-74[24] Goetz MP, Kamal A, Ames MM "Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response." Clin Pharmacol Ther (2007):[25] Wegman P, Vainikka L, Stal O, et al "Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients." Breast Cancer Res 7 (2005): R284-90[26] Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883; author reply 884-5[27] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51[28] Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J "Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer." J Clin Oncol 25 (2007): 3837-45[29] Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H "Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer." Clin Cancer Res 15 (2009): 15-21[30] Goetz MP, Loprinzi CL "A hot flash on tamoxifen metabolism." J Natl Cancer Inst 95 (2003): 1734-5[31] Gaston C, Kolesar J "Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer." Clin Adv Hematol Oncol 6 (2008): 825-33[32] Borges S, Desta Z, Li L, et al. "Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment." Clin Pharmacol Ther 80 (2006): 61-74[33] Jordan VC "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance." Breast Cancer Res Treat 2 (1982): 123-38[34] Aubert RE, Stanek EJ, Yao J, et al "Increased risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Available from: URL: https://www.medcoresearch.com/community/oncology/tamoxifen." ([2009 May 30]):[35] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Abiraterone, Exemestane', 'Scopolamine, Nabilone, Dronabinol', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112144, 'Tamoxifen', 'Romidepsin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112275/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112145, 'Tamoxifen', 'Rucaparib', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112276/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant', 'Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112146, 'Tamoxifen', 'Salmeterol', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112277/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darolutamide, Anastrozole, Fulvestrant, Aminoglutethimide, Exemestane', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112147, 'Tamoxifen', 'Saquinavir', 'Major', 'Saquinavir in combination with ritonavir may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of ritonavir-boosted saquinavir with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of ritonavir-boosted saquinavir with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112278/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Invirase (saquinavir)." Roche Laboratories, Nutley, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] FDA. U.S. Food and Drug Administration "FDA drug safety communication: Ongoing safety review of Invirase (saquinavir) and possible association with abnormal heart rhythms. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm201221.h" ([2010 Feb 23]):[5] Biondi L "Health Canada endorsed important safety information on Invirase (saquinavir mesylate). Available from: URL: http://hc-sc.gc.ca/dhp-mps/alt_formats/pdf/medeff/advisories-avis/prof/2010/invirase_hpc-cps-eng.pdf." ([2010 Apr 14]):[6] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686[7] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[9] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[10] Cerner Multum, Inc. "Australian Product Information." O 0[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[13] Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, Krahenbuhl S "Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man." Br J Clin Pharmacol 45 (1998): 355-9[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] "Product Information. Invirase (saquinavir)." Roche Laboratories, Nutley, NJ.', 'Anastrozole, Fulvestrant, Exemestane, Letrozole', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Telaprevir, Velpatasvir, Dolutegravir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112148, 'Tamoxifen', 'Secobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112279/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Suvorexant, Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, More', 'Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, Abiraterone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112149, 'Tamoxifen', 'Selpercatinib', 'Major', 'Selpercatinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if selpercatinib is used in combination with other drugs that can prolong the QT interval. An electrocardiogram and serum electrolyte levels should be obtained prior to initiating selpercatinib therapy and periodically during treatment as appropriate based on individual risk factors including diarrhea. Correct hypokalemia, hypomagnesemia, and/or hypocalcemia before starting treatment and during treatment, as they may be risk factors for ventricular arrhythmias.', 'Synergism', 'Caution is recommended if selpercatinib is used in combination with other drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112280/', '[1] "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company, Indianapolis, IN.[2] "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company, Indianapolis, IN.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Anastrozole, Exemestane, Fulvestrant', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112150, 'Tamoxifen', 'Sertraline', 'Major', 'Chronic coadministration of potent or moderate CYP450 2D6 inhibitors including certain antidepressants may reduce the effectiveness of tamoxifen. The proposed mechanism is inhibition of tamoxifen bioactivation via CYP450 2D6 to endoxifen (4-hydroxy-N-desmethyltamoxifen), the active metabolite that may be responsible for much of tamoxifen''s antiestrogenic activity.', 'DDInter', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline. If an antidepressant is required during treatment with tamoxifen, agents such as desvenlafaxine, fluvoxamine, milnacipran, levomilnacipran, mirtazapine, and venlafaxine may be considered, since they have mild to no effects on CYP450 2D6. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients.', 'Metabolism', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112281/', '[1] Goetz MP, Rae JM, Suman VJ, et al. "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes." J Clin Oncol 23 (2005): 9312-8[2] Schroth W, Antoniadou L, Fritz P, et al. "Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes." J Clin Oncol 25 (2007): 5187-93[3] Stearns V, Johnson MD, Rae JM, et al. "Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 95 (2003): 1758-64[4] Desta Z, Flockhart DA "Germline pharmacogenetics of tamoxifen response: have we learned enough?" J Clin Oncol 25 (2007): 5147-9[5] Jordan VC, Collins MM, Rowsby L, Prestwich G "A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity." J Endocrinol 75 (1977): 305-16[6] Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M "Drug interactions and pharmacogenomics in the treatment of breast cancer and depression." Am J Psychiatry 165 (2008): 1251-5[7] Jin Y, Desta Z, Stearns V, et al. "CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment." J Natl Cancer Inst 97 (2005): 30-9[8] Lash TL, Pedersen L, Cronin-Fenton D, et al "Tamoxifen''s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram." Br J Cancer 99 (2008): 616-21[9] Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S "Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer." Breast Cancer Res 9 (2007): R7[10] Ponzone R, Biglia N, Sismondi P "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883-4; author reply 884-5[11] Johnson MD, Zuo H, Lee KH, et al. "Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen." Breast Cancer Res Treat 85 (2004): 151-9[12] McCaffrey P "Genetics and drug interactions affect tamoxifen metabolism." Lancet Oncol 6 (2005): 72[13] Coller JK, Krebsfaenger N, Klein K, et al. "The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver." Br J Clin Pharmacol 54 (2002): 157-167[14] Young D "Genetics examined in tamoxifen''s effectiveness: recurrence warning urged for labeling." Am J Health Syst Pharm 63 (2006): 2286, 2296[15] Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A "Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition." J Clin Pharmacol 44 (2004): 861-5[16] Dehal SS, Kupfer D "CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver." Cancer Res 57 (1997): 3402-6[17] Rochat B "Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance : focus on tamoxifen, Paclitaxel and imatinib metabolism." Clin Pharmacokinet 44 (2005): 349-66[18] Bonanni B, Macis D, Maisonneuve P, et al. "Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial." J Clin Oncol 24 (2006): 3708-9[19] Borgna JL, Rochefort H "Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues." J Biol Chem 256 (1981): 859-68[20] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5[21] Desta Z, Ward BA, Soukhova NV, Flockhart DA "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6." J Pharmacol Exp Ther (2004):[22] Brauch H, Murdter TE, Eichelbaum M, Schwab M "Pharmacogenomics of tamoxifen therapy." Clin Chem 55 (2009): 1770-82[23] Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM "Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4''-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen." Drug Metab Dispos 30 (2002): 869-74[24] Goetz MP, Kamal A, Ames MM "Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response." Clin Pharmacol Ther (2007):[25] Wegman P, Vainikka L, Stal O, et al "Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients." Breast Cancer Res 7 (2005): R284-90[26] Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883; author reply 884-5[27] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51[28] Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J "Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer." J Clin Oncol 25 (2007): 3837-45[29] Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H "Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer." Clin Cancer Res 15 (2009): 15-21[30] Goetz MP, Loprinzi CL "A hot flash on tamoxifen metabolism." J Natl Cancer Inst 95 (2003): 1734-5[31] Gaston C, Kolesar J "Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer." Clin Adv Hematol Oncol 6 (2008): 825-33[32] Borges S, Desta Z, Li L, et al. "Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment." Clin Pharmacol Ther 80 (2006): 61-74[33] Jordan VC "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance." Breast Cancer Res Treat 2 (1982): 123-38[34] Aubert RE, Stanek EJ, Yao J, et al "Increased risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Available from: URL: https://www.medcoresearch.com/community/oncology/tamoxifen." ([2009 May 30]):[35] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Aminoglutethimide', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112151, 'Tamoxifen', 'Sevoflurane', 'Moderate', 'Sevoflurane may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if sevoflurane is used in combination with other drugs that can prolong the QT interval. The patient''s cardiovascular status and serum electrolytes should be closely monitored.', 'Synergism', 'Caution is recommended if sevoflurane is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112282/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Ultane (sevoflurane)." Abbott Pharmaceutical, Abbott Park, IL.[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[6] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, Etomidate, Ketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112152, 'Tamoxifen', 'Siponimod', 'Major', 'Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of siponimod treatment in patients receiving drugs that prolong the QT interval.', 'DDInter', 'Siponimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with siponimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.', 'Synergism', 'Siponimod has not been studied in patients receiving drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112283/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Mayzent (siponimod)." Novartis Pharmaceuticals, East Hanover, NJ.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112153, 'Tamoxifen', 'Sirolimus', 'Moderate', 'Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.', 'DDInter', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112284/', '[1] "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.[2] "Product Information. Rapamune (sirolimus)" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.', 'Darolutamide, Anastrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Abiraterone', 'Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112154, 'Tamoxifen', 'Solifenacin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112285/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Exemestane, Letrozole', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Sildenafil, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112155, 'Tamoxifen', 'Somapacitan', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112286/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112156, 'Tamoxifen', 'Somatrem', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112287/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112157, 'Tamoxifen', 'Somatotropin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112288/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112158, 'Tamoxifen', 'Sorafenib', 'Moderate', 'Sorafenib has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if sorafenib is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting sorafenib therapy and periodically during treatment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if sorafenib is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112289/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] "Product Information. Nexavar (sorafenib)." Bayer Pharmaceutical Inc, West Haven, CT.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[6] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[7] "Product Information. Nexavar (sorafenib)." Bayer Pharmaceutical Inc, West Haven, CT.', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 'Anastrozole, Exemestane, Fulvestrant', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112159, 'Tamoxifen', 'Sotalol', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112290/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Yamreudeewong W, DeBisschop M, Martin L, Lower D "Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs." Drug Saf 26 (2003): 421-38[3] "Product Information. Norpace (disopyramide)." Searle, Skokie, IL.[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] "Product Information. Betapace (sotalol)." Berlex, Richmond, CA.[6] "Product Information. Procan SR (procainamide)." Parke-Davis, Morris Plains, NJ.[7] Maxa JL, Hebeler RF, Adeeko MA "Torsades de pointes following concurrent amiodarone and levofloxacin therapy." Proc (Bayl Univ Med Cent) 19 (2006): 345-6[8] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[9] "Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[10] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[11] "Product Information. Vascor (bepridil)." McNeil Pharmaceutical, Raritan, NJ.[12] "Product Information. Quiniglute (quinidine)." Berlex, Richmond, CA.[13] Trujillo TC, Nolan PE "Antiarrhythmic agents - Drug interactions of clinical significance." Drug Safety 23 (2000): 509-32[14] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[15] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[16] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[17] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[18] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[19] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[20] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[21] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[22] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[25] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[26] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[27] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[28] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[29] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[30] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[31] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[32] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[33] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[34] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[35] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[36] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[37] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[38] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[39] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[40] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[41] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[42] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[43] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[44] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[45] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 'Nadolol, Labetalol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Bisoprolol, Carteolol, Pindolol, Nadolol, Labetalol, More', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112160, 'Tamoxifen', 'Sparfloxacin', 'Major', 'Sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112291/', '[1] Thomas M, Maconochie JG, Fletcher E "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol 41 (1996): 77-81[2] Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996): 161-7[3] Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996): 350-1[4] Lipsky BA, Dorr MB, Magner DJ, Talbot GH "Safety profile of sparfloxacin, a new fluoroquinolone antibiotic." Clin Ther 21 (1999): 148-59[5] Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72[6] Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004): 1091-124[7] Zix JA, GeerdesFenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[8] Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002): 455-64[9] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[10] Falagas ME, Rafailidis PI, Rosmarakis ES "Arrhythmias associated with fluoroquinolone therapy." Int J Antimicrob Agents 29 (2007): 374-9[11] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[12] Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003): 2317-20[13] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[14] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001): 46-7[15] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6[16] Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996): 499-503[17] Cerner Multum, Inc. "Australian Product Information." O 0[18] Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19[19] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[20] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[21] Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002): 269-77', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112161, 'Tamoxifen', 'St. John''s Wort', 'Moderate', 'Coadministration with St. John''s wort may alter the pharmacokinetics of antineoplastic agents that are substrates of the CYP450 3A4 isoenzyme (e.g., abiraterone, bexarotene, bortezomib, busulfan, cyclophosphamide, dasatinib, docetaxel, doxorubicin, etoposide, exemestane, ifosfamide, imatinib, irinotecan, letrozole, paclitaxel, sorafenib, sunitinib, tamoxifen, temsirolimus, teniposide, thiotepa, toremifene, tretinoin, vandetanib, vinca alkaloids). The mechanism is induction of CYP450 3A4 metabolism by constituents of St. John''s wort, which is expected to reduce the systemic levels and pharmacologic effects of many of these agents. In contrast, some agents such as cyclophosphamide and ifosfamide are prodrugs that are converted to active metabolites by CYP450 3A4, thus pharmacologic effects may be enhanced by St. John''s wort.', 'DDInter', 'Until more information is available, the use of St. John''s wort should probably be avoided before and during the entire course of chemotherapy. It is not known how much time should elapse between the discontinuation of St. John''s wort and initiation of chemotherapy. Patients should be advised to consult with their caregivers before using any herbal or alternative medicines.', 'Metabolism', 'Until more information is available, the use of St.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112292/', '[1] Sparreboom A, Cox MC, Acharya MR, Figg WD "Herbal remedies in the United States: potential adverse interactions with anticancer agents." J Clin Oncol 22 (2004): 2489-503[2] Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH "St John''s Wort: Effect on CYP3A4 activity." Clin Pharmacol Ther 67 (2000): 451-7[3] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112162, 'Tamoxifen', 'Stiripentol', 'Major', 'Chronic coadministration of potent or moderate CYP450 2D6 inhibitors including certain antidepressants may reduce the effectiveness of tamoxifen. The proposed mechanism is inhibition of tamoxifen bioactivation via CYP450 2D6 to endoxifen (4-hydroxy-N-desmethyltamoxifen), the active metabolite that may be responsible for much of tamoxifen''s antiestrogenic activity.', 'DDInter', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline. If an antidepressant is required during treatment with tamoxifen, agents such as desvenlafaxine, fluvoxamine, milnacipran, levomilnacipran, mirtazapine, and venlafaxine may be considered, since they have mild to no effects on CYP450 2D6. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients.', 'Metabolism', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112293/', '[1] Goetz MP, Rae JM, Suman VJ, et al. "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes." J Clin Oncol 23 (2005): 9312-8[2] Schroth W, Antoniadou L, Fritz P, et al. "Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes." J Clin Oncol 25 (2007): 5187-93[3] Stearns V, Johnson MD, Rae JM, et al. "Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 95 (2003): 1758-64[4] Desta Z, Flockhart DA "Germline pharmacogenetics of tamoxifen response: have we learned enough?" J Clin Oncol 25 (2007): 5147-9[5] Jordan VC, Collins MM, Rowsby L, Prestwich G "A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity." J Endocrinol 75 (1977): 305-16[6] Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M "Drug interactions and pharmacogenomics in the treatment of breast cancer and depression." Am J Psychiatry 165 (2008): 1251-5[7] Jin Y, Desta Z, Stearns V, et al. "CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment." J Natl Cancer Inst 97 (2005): 30-9[8] Lash TL, Pedersen L, Cronin-Fenton D, et al "Tamoxifen''s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram." Br J Cancer 99 (2008): 616-21[9] Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S "Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer." Breast Cancer Res 9 (2007): R7[10] Ponzone R, Biglia N, Sismondi P "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883-4; author reply 884-5[11] Johnson MD, Zuo H, Lee KH, et al. "Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen." Breast Cancer Res Treat 85 (2004): 151-9[12] McCaffrey P "Genetics and drug interactions affect tamoxifen metabolism." Lancet Oncol 6 (2005): 72[13] Coller JK, Krebsfaenger N, Klein K, et al. "The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver." Br J Clin Pharmacol 54 (2002): 157-167[14] Young D "Genetics examined in tamoxifen''s effectiveness: recurrence warning urged for labeling." Am J Health Syst Pharm 63 (2006): 2286, 2296[15] Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A "Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition." J Clin Pharmacol 44 (2004): 861-5[16] Dehal SS, Kupfer D "CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver." Cancer Res 57 (1997): 3402-6[17] Rochat B "Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance : focus on tamoxifen, Paclitaxel and imatinib metabolism." Clin Pharmacokinet 44 (2005): 349-66[18] Bonanni B, Macis D, Maisonneuve P, et al. "Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial." J Clin Oncol 24 (2006): 3708-9[19] Borgna JL, Rochefort H "Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues." J Biol Chem 256 (1981): 859-68[20] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5[21] Desta Z, Ward BA, Soukhova NV, Flockhart DA "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6." J Pharmacol Exp Ther (2004):[22] Brauch H, Murdter TE, Eichelbaum M, Schwab M "Pharmacogenomics of tamoxifen therapy." Clin Chem 55 (2009): 1770-82[23] Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM "Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4''-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen." Drug Metab Dispos 30 (2002): 869-74[24] Goetz MP, Kamal A, Ames MM "Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response." Clin Pharmacol Ther (2007):[25] Wegman P, Vainikka L, Stal O, et al "Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients." Breast Cancer Res 7 (2005): R284-90[26] Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883; author reply 884-5[27] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51[28] Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J "Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer." J Clin Oncol 25 (2007): 3837-45[29] Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H "Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer." Clin Cancer Res 15 (2009): 15-21[30] Goetz MP, Loprinzi CL "A hot flash on tamoxifen metabolism." J Natl Cancer Inst 95 (2003): 1734-5[31] Gaston C, Kolesar J "Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer." Clin Adv Hematol Oncol 6 (2008): 825-33[32] Borges S, Desta Z, Li L, et al. "Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment." Clin Pharmacol Ther 80 (2006): 61-74[33] Jordan VC "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance." Breast Cancer Res Treat 2 (1982): 123-38[34] Aubert RE, Stanek EJ, Yao J, et al "Increased risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Available from: URL: https://www.medcoresearch.com/community/oncology/tamoxifen." ([2009 May 30]):[35] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Anastrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Exemestane', 'Tiagabine, Ethotoin, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Mephenytoin, Perampanel, Zonisamide, Eslicarbazepine, Phensuximide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112163, 'Tamoxifen', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112294/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112164, 'Tamoxifen', 'Sulfinpyrazone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112295/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, Abiraterone', 'Lesinurad, Febuxostat, Pegloticase, Rasburicase, Probenecid', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112165, 'Sunitinib', 'Tamoxifen', 'Moderate', 'Sunitinib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if sunitinib is used in combination with other drugs that can prolong the QT interval. Periodic monitoring with on-treatment electrocardiograms and serum electrolytes (magnesium, potassium) should be considered. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if sunitinib is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112296/', '[1] "Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] "Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 'Anastrozole, Fulvestrant, Exemestane, Letrozole', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112166, 'Tamoxifen', 'Tacrine', 'Moderate', 'Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.', 'DDInter', 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.', 'Synergism', 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112297/', '[1] "Product Information. Razadyne (galantamine)." Johnson and Johnson Medical Inc, Arlington, TX.[2] "Product Information. Exelon (rivastigmine)" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Aricept (donepezil)." Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 'Ginkgo biloba, Aducanumab', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Flutamide, Enzalutamide, Bicalutamide, Nilutamide, Apalutamide, Abiraterone, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112167, 'Tamoxifen', 'Tacrolimus', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112298/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant', 'Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112168, 'Tamoxifen', 'Talazoparib', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of talazoparib, which has been shown in vitro to be a substrate of both efflux membrane transporters.', 'DDInter', 'No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil. However, patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and dosage adjustments made or treatment withheld as needed in accordance with the product labeling.', 'Distribution', 'No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112299/', '[1] "Product Information. Talzenna (talazoparib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 'Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, Degarelix, More', 'Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112169, 'Tazemetostat', 'Tamoxifen', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112300/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Anastrozole, Fulvestrant, Letrozole, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Abiraterone', 'Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112170, 'Telavancin', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112301/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112171, 'Telithromycin', 'Tamoxifen', 'Moderate', 'Telithromycin has the potential to prolong the QT interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if telithromycin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation may increase with increasing plasma concentrations of telithromycin, the recommended dosage should not be exceeded, particularly in patients with renal or hepatic impairment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if telithromycin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112302/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] "Product Information. Ketek (telithromycin)." Aventis Pharmaceuticals, Bridgewater, NJ.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Demolis JL, Vacheron F, Cardus S, Funck-Brentano C "Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects." Clin Pharmacol Ther 73 (2003): 242-52[5] European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products "European Public Assessment Report Ketek (telithromycin) (Rev. 2) Available from: URL: http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm." ([2001]):[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[8] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Anastrozole, Exemestane, Fulvestrant', 'Lincomycin, Troleandomycin, Dirithromycin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112172, 'Telotristat ethyl', 'Tamoxifen', 'Moderate', 'Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.', 'DDInter', 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112303/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.', 'Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112173, 'Temsirolimus', 'Tamoxifen', 'Moderate', 'Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.', 'DDInter', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112304/', '[1] "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.[2] "Product Information. Rapamune (sirolimus)" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.', 'Darolutamide, Anastrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Abiraterone', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112174, 'Terbinafine', 'Tamoxifen', 'Major', 'Chronic coadministration of potent or moderate CYP450 2D6 inhibitors including certain antidepressants may reduce the effectiveness of tamoxifen. The proposed mechanism is inhibition of tamoxifen bioactivation via CYP450 2D6 to endoxifen (4-hydroxy-N-desmethyltamoxifen), the active metabolite that may be responsible for much of tamoxifen''s antiestrogenic activity.', 'DDInter', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline. If an antidepressant is required during treatment with tamoxifen, agents such as desvenlafaxine, fluvoxamine, milnacipran, levomilnacipran, mirtazapine, and venlafaxine may be considered, since they have mild to no effects on CYP450 2D6. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients.', 'Metabolism', 'Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112305/', '[1] Goetz MP, Rae JM, Suman VJ, et al. "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes." J Clin Oncol 23 (2005): 9312-8[2] Schroth W, Antoniadou L, Fritz P, et al. "Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes." J Clin Oncol 25 (2007): 5187-93[3] Stearns V, Johnson MD, Rae JM, et al. "Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 95 (2003): 1758-64[4] Desta Z, Flockhart DA "Germline pharmacogenetics of tamoxifen response: have we learned enough?" J Clin Oncol 25 (2007): 5147-9[5] Jordan VC, Collins MM, Rowsby L, Prestwich G "A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity." J Endocrinol 75 (1977): 305-16[6] Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M "Drug interactions and pharmacogenomics in the treatment of breast cancer and depression." Am J Psychiatry 165 (2008): 1251-5[7] Jin Y, Desta Z, Stearns V, et al. "CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment." J Natl Cancer Inst 97 (2005): 30-9[8] Lash TL, Pedersen L, Cronin-Fenton D, et al "Tamoxifen''s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram." Br J Cancer 99 (2008): 616-21[9] Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S "Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer." Breast Cancer Res 9 (2007): R7[10] Ponzone R, Biglia N, Sismondi P "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883-4; author reply 884-5[11] Johnson MD, Zuo H, Lee KH, et al. "Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen." Breast Cancer Res Treat 85 (2004): 151-9[12] McCaffrey P "Genetics and drug interactions affect tamoxifen metabolism." Lancet Oncol 6 (2005): 72[13] Coller JK, Krebsfaenger N, Klein K, et al. "The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver." Br J Clin Pharmacol 54 (2002): 157-167[14] Young D "Genetics examined in tamoxifen''s effectiveness: recurrence warning urged for labeling." Am J Health Syst Pharm 63 (2006): 2286, 2296[15] Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A "Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition." J Clin Pharmacol 44 (2004): 861-5[16] Dehal SS, Kupfer D "CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver." Cancer Res 57 (1997): 3402-6[17] Rochat B "Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance : focus on tamoxifen, Paclitaxel and imatinib metabolism." Clin Pharmacokinet 44 (2005): 349-66[18] Bonanni B, Macis D, Maisonneuve P, et al. "Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial." J Clin Oncol 24 (2006): 3708-9[19] Borgna JL, Rochefort H "Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues." J Biol Chem 256 (1981): 859-68[20] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5[21] Desta Z, Ward BA, Soukhova NV, Flockhart DA "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6." J Pharmacol Exp Ther (2004):[22] Brauch H, Murdter TE, Eichelbaum M, Schwab M "Pharmacogenomics of tamoxifen therapy." Clin Chem 55 (2009): 1770-82[23] Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM "Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4''-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen." Drug Metab Dispos 30 (2002): 869-74[24] Goetz MP, Kamal A, Ames MM "Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response." Clin Pharmacol Ther (2007):[25] Wegman P, Vainikka L, Stal O, et al "Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients." Breast Cancer Res 7 (2005): R284-90[26] Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883; author reply 884-5[27] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51[28] Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J "Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer." J Clin Oncol 25 (2007): 3837-45[29] Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H "Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer." Clin Cancer Res 15 (2009): 15-21[30] Goetz MP, Loprinzi CL "A hot flash on tamoxifen metabolism." J Natl Cancer Inst 95 (2003): 1734-5[31] Gaston C, Kolesar J "Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer." Clin Adv Hematol Oncol 6 (2008): 825-33[32] Borges S, Desta Z, Li L, et al. "Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment." Clin Pharmacol Ther 80 (2006): 61-74[33] Jordan VC "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance." Breast Cancer Res Treat 2 (1982): 123-38[34] Aubert RE, Stanek EJ, Yao J, et al "Increased risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Available from: URL: https://www.medcoresearch.com/community/oncology/tamoxifen." ([2009 May 30]):[35] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, More', 'Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Ciclopirox, Econazole, Flucytosine, Tioconazole, Chlorphenesin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112175, 'Terbutaline', 'Tamoxifen', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112306/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Ephedrine, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112176, 'Terfenadine', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112307/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112177, 'Teriflunomide', 'Tamoxifen', 'Major', 'The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.', 'DDInter', 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide''s active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112308/', '[1] EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions. Available from URL: http://www.eudra.org/emea.html." ([1999 Sept 2]):[2] "Product Information. Arava (leflunomide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 'Anastrozole, Fulvestrant, Toremifene, Letrozole, Abarelix, Relugolix, Degarelix, Aminoglutethimide, Exemestane', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112178, 'Tetrabenazine', 'Tamoxifen', 'Moderate', 'Tetrabenazine may cause modest prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of tetrabenazine with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of tetrabenazine with other drugs that can prolong the QT interval should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112309/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] "Product Information. Xenazine (tetrabenazine)." Prestwick Pharmaceuticals Inc, Washington DC, VA.[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[11] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112179, 'Thalidomide', 'Tamoxifen', 'Major', 'Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, oestrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of thalidomide. When used in multiple myeloma, there is an increased risk of venous thromboembolism such as deep venous thrombosis and pulmonary embolism. This risk increases significantly when thalidomide is combined with standard chemotherapeutic agents and/or steroids.', 'DDInter', 'Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving thalidomide with standard chemotherapeutic agents and/or steroids. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body. Prophylaxis with anticoagulants such as low-molecular weight heparins or warfarin may be appropriate, but the decision to take thromboprophylactic measures should be made after careful assessment of underlying risk factors. If a thromboembolic event occurs during therapy with thalidomide, treatment must be discontinued and standard anticoagulation therapy initiated. Once anticoagulation is stabilized and complications of the thromboembolic event under control, thalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks. Anticoagulation therapy should be continued during the remaining course of thalidomide treatment.', 'Synergism', 'Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving thalidomide with standard chemotherapeutic agents and/or steroids.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112310/', '[1] "Product Information. Thalomid (thalidomide)." Celgene Corporation, Warren, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.[4] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[5] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darolutamide, Aminoglutethimide, Fulvestrant', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112180, 'Tioguanine', 'Tamoxifen', 'Moderate', 'The concomitant or sequential use of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with thioguanine. A high risk of liver toxicity characterized by vascular endothelial damage has been reported with long-term continuous use of thioguanine, particularly in children receiving the drug as part of maintenance therapy for acute lymphoblastic leukemia and in other conditions associated with continuous use.', 'DDInter', 'The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Baseline and regular monitoring of hepatic function is recommended. Thioguanine therapy should be discontinued if there is evidence of toxic hepatitis or biliary stasis, as reversal of signs and symptoms of liver toxicity have been reported upon withdrawal. Early indications of liver toxicity are signs associated with portal hypertension such as thrombocytopenia out of proportion with neutropenia and splenomegaly. Elevations of liver enzymes have also been reported, but do not always occur.', 'Synergism', 'The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112311/', '[1] "Product Information. Aubagio (teriflunomide)." Genzyme Corporation, Cambridge, MA.[2] "Product Information. Tabloid (thioguanine)." Prasco Laboratories, Cincinnati, OH.', 'Pemetrexed, Mercaptopurine, Cladribine, Trifluridine, Floxuridine, Nelarabine, Cytarabine, Pralatrexate, Decitabine, Azacitidine', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Degarelix, Apalutamide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112181, 'Thioridazine', 'Tamoxifen', 'Major', 'Thioridazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with thioridazine. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.', 'DDInter', 'Coadministration of thioridazine with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of thioridazine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112312/', '[1] "Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Liberatore MA, Robinson DS "Torsade de pointes: a mechanism for sudden death associated with neuroleptic drug therapy?" J Clin Psychopharmacol 4 (1984): 143-6[4] Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969): 135-8[5] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[8] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[9] Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SHL "Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans." Clin Pharmacol Ther 60 (1996): 543-53[10] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[13] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[14] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[15] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[16] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[17] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[18] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[19] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[20] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[21] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[22] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[23] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[24] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[25] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[26] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112182, 'Tizanidine', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112313/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Baclofen, Chlorzoxazone, Methocarbamol, Chlormezanone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112183, 'Toremifene', 'Tamoxifen', 'Major', 'Toremifene has the potential to prolong the QT interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of toremifene with other drugs that can prolong the QT interval should generally be avoided. If treatment with other QT-prolonging drugs is required, interruption of toremifene therapy should be considered. Caution and clinical monitoring are recommended if concomitant use is unavoidable. In patients at increased risk, electrocardiograms (ECGs) are recommended at baseline and as clinically indicated. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of toremifene with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112314/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] "Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.[10] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Tamoxifen', 'Darolutamide, Anastrozole, Fulvestrant, Toremifene, Letrozole, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112184, 'Torasemide', 'Tamoxifen', 'Moderate', 'Coadministration with inhibitors of CYP450 2C9 may increase the plasma concentrations of torsemide. The interaction has not been evaluated in pharmacokinetic studies; however, torsemide has been shown to undergo metabolism by CYP450 2C9.', 'DDInter', 'Caution is advised when torsemide is prescribed with CYP450 2C9 inhibitors. Patients should be monitored for potentially increased adverse effects such as dehydration, hypotension, electrolyte imbalances, hyperglycemia, tinnitus, and hearing loss.', 'Metabolism', 'Caution is advised when torsemide is prescribed with CYP450 2C9 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112315/', '[1] Vormfelde SV, Engelhardt S, Zirk A, et al. "CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide." Clin Pharmacol Ther 76 (2004): 557-66[2] Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJ "Human hepatic cytochrome p450 2c9 catalyzes the rate-limiting pathway of torsemide metabolism." J Pharmacol Exp Ther 272 (1995): 1076-81[3] "Product Information. Demedex (torsemide)." Boehringer Mannheim, Gaithersburg, MD.[4] Miners JO, Birkett DJ "Cytochrome P4502C9: an enzyme of major importance in human drug metabolism." Br J Clin Pharmacol 45 (1998): 525-38[5] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 'Etacrynic acid, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', 'Darolutamide, Anastrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112185, 'Trabectedin', 'Tamoxifen', 'Moderate', 'Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'DDInter', 'The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.', 'Synergism', 'The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112316/', '[1] "Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals, Titusville, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Relugolix, Degarelix, Exemestane', 'Cabazitaxel, Vinblastine, Topotecan, Teniposide, Irinotecan', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112186, 'Triclabendazole', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112317/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Praziquantel, Oxamniquine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112187, 'Trifluoperazine', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112318/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112188, 'Triflupromazine', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112319/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112189, 'Alimemazine', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112320/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112190, 'Trimipramine', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112321/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112191, 'Triptorelin', 'Tamoxifen', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112322/', '[1] "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] "Product Information. Zoladex (goserelin)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.[5] "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc, Deerfield, IL.[7] "Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals, New York, NY.[8] "Product Information. Plenaxis (abarelix)." Praecis Pharmaceuticals Inc, Waltham, MA.', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, Degarelix, More', 'Megestrol acetate, Ethinylestradiol, Diethylstilbestrol', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112192, 'Troglitazone', 'Tamoxifen', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112323/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More', 'Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, Abiraterone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112193, 'Tucatinib', 'Tamoxifen', 'Moderate', 'Coadministration with tucatinib may increase the plasma concentrations of CYP450 3A4 substrates. The mechanism involves tucatinib-mediated inhibition of CYP450 3A isoenzymes.', 'DDInter', 'Caution is advised when tucatinib is used concomitantly with drugs that undergo metabolism by CYP450 3A4. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever tucatinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when tucatinib is used concomitantly with drugs that undergo metabolism by CYP450 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112324/', '[1] "Product Information. Tukysa (tucatinib)." Seattle Genetics Inc, Bothell, WA.', 'Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Exemestane', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112194, 'Ubrogepant', 'Tamoxifen', 'Moderate', 'Coadministration with breast cancer resistance protein (BCRP) and/or P-glycoprotein (P-gp) only inhibitors may increase the exposure of ubrogepant, which is a substrate of these transporters.', 'DDInter', 'The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors. If needed, a second 50 mg dose of ubrogepant may be administered at least 2 hours after the initial dose.', 'Distribution', 'The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112325/', '[1] "Product Information. Ubrelvy (ubrogepant)." Allergan Inc, Irvine, CA.[2] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.[3] "Product Information. Ubrelvy (ubrogepant)." Allergan Inc, Irvine, CA.', 'Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Exemestane', 'Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Ergotamine, Naratriptan, Galcanezumab, Zolmitriptan, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112195, 'Valbenazine', 'Tamoxifen', 'Moderate', 'Valbenazine may cause modest prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Central nervous system (CNS)-depressant effects may be additively or synergistically increased in patients taking valbenazine with certain other drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'Caution and clinical monitoring are recommended if concomitant use of valbenazine with other drugs that can prolong the QT interval is required. Valbenazine is not recommended for use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. In patients with other risk factors for QT prolongation, the QT interval should be assessed before increasing the dose of valbenazine. The manufacturer recommends that valbenazine dosage be reduced to 40 mg once daily in patients on concomitant therapy with a strong CYP450 3A4 inhibitor (e.g., itraconazole, ketoconazole, clarithromycin). Valbenazine dose reduction should also be considered in patients on concurrent therapy with a strong CYP450 2D6 inhibitor (e.g., paroxetine, fluoxetine, quinidine), or in patients who are poor metabolizers of CYP450 2D6.', 'Synergism', 'Caution and clinical monitoring are recommended if concomitant use of valbenazine with other drugs that can prolong the QT interval is required.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112326/', '[1] "Product Information. Ingrezza (valbenazine)." Neurocrine Biosciences, Inc., San Diego, CA.[2] "Product Information. Ingrezza (valbenazine)." Neurocrine Biosciences, Inc., San Diego, CA.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112196, 'Vandetanib', 'Tamoxifen', 'Major', 'Vandetanib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of vandetanib with other drugs that can prolong the QT interval should generally be avoided. Should treatment with other QT-prolonging drugs be required, the manufacturer recommends more frequent monitoring of the ECG as well as serum potassium, magnesium, and calcium levels.', 'Synergism', 'Coadministration of vandetanib with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112327/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[6] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112197, 'Vardenafil', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112328/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Sildenafil, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112198, 'Vasopressin', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112329/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112199, 'Vemurafenib', 'Tamoxifen', 'Major', 'Vemurafenib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of vemurafenib with other drugs that can prolong the QT interval is not recommended. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting vemurafenib therapy and after dose modification.', 'Synergism', 'Coadministration of vemurafenib with other drugs that can prolong the QT interval is not recommended.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112330/', '[1] "Product Information. Zelboraf (vemurafenib)." Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[6] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Anastrozole, Fulvestrant, Letrozole', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Trichlormethiazide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112200, 'Venetoclax', 'Tamoxifen', 'Major', 'Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter.', 'DDInter', 'Concomitant use of venetoclax with P-gp inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%. The dosage used prior to initiating the P-gp inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.', 'Absorption', 'Concomitant use of venetoclax with P-gp inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112331/', '[1] "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.[5] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 'Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Degarelix, Nilutamide, Exemestane', 'Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112201, 'Venlafaxine', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112332/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine', 'Aminoglutethimide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112202, 'Vigabatrin', 'Tamoxifen', 'Major', 'Theoretical concerns exist that oculotoxic effects of vigabatrin may be additive with those of other drugs that are associated with serious adverse ophthalmic effects. Vigabatrin causes permanent bilateral concentric visual field constriction in 30% or more of patients, with severity ranging from mild to severe. Vigabatrin can also damage the central retina and decrease visual acuity. The onset of vision loss is unpredictable, occurring within weeks of starting treatment to months or even years later. The risk of vision loss increases with increasing dose and cumulative exposure, although there is no dose or exposure known to be risk-free. It is possible that vision loss can worsen even after discontinuation of vigabatrin.', 'DDInter', 'Vigabatrin should generally not be used with other drugs associated with serious adverse ophthalmic effects such as retinopathy or glaucoma unless the benefits clearly outweigh the risks. These drugs may include amiodarone, deferoxamine, ethambutol, quinine derivatives, tamoxifen, and long-term corticosteroids. Vision testing at baseline (no later than 4 weeks after starting vigabatrin) and at least every 3 months during therapy is required for adults. Vision testing is also required about 3 to 6 months after the discontinuation of vigabatrin therapy. Due to the risk of irreversible vision loss, vigabatrin should be withdrawn from patients who fail to show substantial clinical benefit within 3 months of initiation, or sooner if treatment failure becomes obvious. The patient''s response and continued need for vigabatrin should be periodically reassessed. The lowest dosage and shortest duration of treatment consistent with clinical objectives should be employed.', 'Synergism', 'Vigabatrin should generally not be used with other drugs associated with serious adverse ophthalmic effects such as retinopathy or glaucoma unless the benefits clearly outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112333/', '[1] "Product Information. Sabril (vigabatrin)." Lundbeck Inc, Deerfield, IL.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, More', 'Tiagabine, Ethotoin, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Mephenytoin, Perampanel, Zonisamide, Eslicarbazepine, Phensuximide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112203, 'Vismodegib', 'Tamoxifen', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein may increase the plasma concentrations of vismodegib, which has been shown in vitro to be a substrate of the efflux transporter. The potential for increased pharmacologic effects of vismodegib, including adverse effects such as muscle spasm, alopecia, dysgeusia/ageusia, weight loss, fatigue, nausea, vomiting, diarrhea, decreased appetite, constipation and arthralgia, should be considered.', 'DDInter', 'Caution is advised if vismodegib is used in combination with P-glycoprotein inhibitors.', 'Others', 'Caution is advised if vismodegib is used in combination with P-glycoprotein inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112334/', '[1] "Product Information. Erivedge (vismodegib)." Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):', 'Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, More', 'Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112204, 'Voriconazole', 'Tamoxifen', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112335/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Anastrozole, Fulvestrant, Exemestane, Letrozole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112205, 'Warfarin', 'Tamoxifen', 'Major', 'Tamoxifen may enhance the hypoprothrombinemic effects of warfarin and other similar anticoagulants. The mechanism of interaction has not been established. Significant increases in prothrombin time or INR as well as severe and fatal bleeding complications have been reported. In some cases, a substantial reduction in anticoagulant dose was required.', 'DDInter', 'The use of tamoxifen is considered contraindicated in women who require concomitant coumarin-type anticoagulants or in women with a history of deep vein thrombosis or pulmonary embolus. Where such coadministration exists, careful monitoring of the INR is recommended.', 'Synergism', 'The use of tamoxifen is considered contraindicated in women who require concomitant coumarin-type anticoagulants or in women with a history of deep vein thrombosis or pulmonary embolus.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112336/', '[1] "Product Information. Nolvadex (tamoxifen)." Zeneca Pharmaceuticals, Wilmington, DE.[2] Ritchie LD, Grant SM "Tamoxifen-warfarin interaction: the Aberdeen hospitals drug file." BMJ 298 (1989): 1253[3] "Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.[4] Tenni P, Lalich DL, Byrne MJ "Life threatening interaction between tamoxifen and warfarin." BMJ 298 (1989): 93[5] Lodwick R, McConkey B, Brown AM, Beeley L "Life threatening interaction between tamoxifen and warfarin." Br Med J 295 (1987): 1141[6] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[7] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3[8] Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36[9] Kempin SJ "Warfarin resistance caused by broccoli." N Engl J Med 308 (1983): 1229-30[10] Lee M, Schwartz RN, Sharifi R "Warfarin resistance and vitamin K." Ann Intern Med 94 (1981): 140-1[11] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G "Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy." Eur J Clin Pharmacol 63 (2007): 565-70[12] Sullivan DM, Ford MA, Boyden TW "Grapefruit juice and the response to warfarin." Am J Health Syst Pharm 55 (1998): 1581-3[13] Harrell CC, Kline SS "Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin." Jama J Am Med Assn 282 (1999): 1133-4[14] Grant P "Warfarin and cranberry juice: an interaction?" J Heart Valve Dis 13 (2004): 25-6[15] Kazmier FJ, Spittell JA Jr "Coumarin drug interactions." Mayo Clin Proc 45 (1970): 249-55[16] Ge B, Zhang Z, Zuo Z "Updates on the clinical evidenced herb-warfarin interactions." Evid Based Complement Alternat Med 2014 (2014): 957362[17] Kuykendall JR, Houle MD, Rhodes RS "Possible warfarin failure due to interaction with smokeless tobacco." Ann Pharmacother 38 (2004): 595-7[18] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[19] Zallman JA, Lee DP, Jeffrey PL "Liquid nutrition as a cause of warfarin resistance." Am J Hosp Pharm 38 (1981): 1174[20] Watson AJ, Pegg M, Green JR "Enteral feeds may antagonise warfarin." Br Med J 288 (1984): 557[21] Monterrey-Rodriguez J "Interaction between warfarin and mango fruit." Ann Pharmacother 36 (2002): 940-1[22] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines "Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm." ([2003 Sept]):[23] Karlson B, Leijd B, Hellstrom K "On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment." Acta Med Scand 220 (1986): 347-50[24] Griffiths AP, Beddall A, Pegler S "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin." J R Soc Health 128 (2008): 324-6[25] Roberts D, Flanagan P "Case report: Cranberry juice and warfarin." Home Healthc Nurse 29 (2011): 92-7[26] O''Reilly RA, Rytand DA ""Resistance" to warfarin due to unrecognized vitamin K supplementation." N Engl J Med 303 (1980): 160-1[27] Parr MD, Record KE, Griffith GL, et al "Effect of enteral nutrition on warfarin therapy." Clin Pharm 1 (1982): 274-6[28] Andersen P, Godal HC "Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K." Acta Med Scand 198 (1975): 269-70[29] Cambria-Kiely JA "Effect of soy milk on warfarin efficacy." Ann Pharmacother 36 (2002): 1893-6[30] Howard PA, Hannaman KN "Warfarin resistance linked to enteral nutrition products." J Am Diet Assoc 85 (1985): 713-5[31] Rindone JP, Murphy TW "Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding." Am J Ther 13 (2006): 283-4[32] Suvarna R, Pirmohamed M, Henderson L "Possible interaction between warfarin and cranberry juice." BMJ 327 (2003): 1454[33] Beckey NP, Korman LB, Parra D "Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy." Pharmacotherapy 19 (1999): 1075-9[34] Westfall LK "An unrecognized cause of warfarin resistance." Drug Intell Clin Pharm 15 (1981): 131[35] Walker FB "Myocardial infarction after diet-induced warfarin resistance." Arch Intern Med 144 (1984): 2089-90[36] Pedersen FM, Hamberg O, Hess K, Ovesen L "The effect of dietary vitamin K on warfarin-induced anticoagulation." J Intern Med 229 (1991): 517-20[37] Griffith LD, Olvey SE, Triplett WC "Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus." Crit Care Med 10 (1982): 799-800[38] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[39] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[40] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT "Anticoagulation instability with life-threatening complication after dietary modification." Postgrad Med J 66 (1990): 855-7[41] Hamann GL, Campbell JD, George CM "Warfarin-cranberry juice interaction." Ann Pharmacother 45 (2011): e17[42] MacLeod SM, Sellers EM "Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants." Drugs 11 (1976): 461-70[43] Jarvis S, Li C, Bogle RG "Possible interaction between pomegranate juice and warfarin." Emerg Med J 27 (2010): 74-5', 'Darolutamide, Abarelix, Relugolix, Degarelix, Nilutamide, Abiraterone', 'Ticagrelor, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Desirudin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112206, 'Ziprasidone', 'Tamoxifen', 'Major', 'Ziprasidone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.', 'DDInter', 'Coadministration of ziprasidone with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of ziprasidone with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112337/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[4] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[8] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[10] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112207, 'Amoxapine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112338/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Phenelzine, Tranylcypromine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112208, 'Tiotropium', 'Azatadine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112339/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112209, 'Tiotropium', 'Belladonna', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112340/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112210, 'Chlorcyclizine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112341/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 'Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112211, 'Chlorpromazine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112342/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 'Mometasone, Mometasone furoate, Beclomethasone dipropionate, Cromoglicic acid, Ciclesonide, Mometasone furoate, Flunisolide, Cromoglicic acid, Betamethasone, Nedocromil, Triamcinolone, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112212, 'Cyclizine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112343/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112213, 'Cyproheptadine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112344/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112214, 'Demecarium (ophthalmic)', 'Tiotropium', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112345/', '[1] "Product Information. Pilopine HS (pilocarpine ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.[2] "Multum Information Services, Inc. Expert Review Panel"', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112215, 'Dexbrompheniramine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112346/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112216, 'Dimenhydrinate', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112347/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112217, 'Fesoterodine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112348/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Phenyl salicylate, Magnesium hydroxide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112218, 'Flavoxate', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112349/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Phenyl salicylate, Magnesium hydroxide, More', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112219, 'Fluphenazine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112350/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112220, 'Glycopyrronium (topical)', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112351/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112221, 'Haloperidol', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112352/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 'Mometasone, Mometasone furoate, Beclomethasone dipropionate, Cromoglicic acid, Ciclesonide, Mometasone furoate, Flunisolide, Cromoglicic acid, Betamethasone, Nedocromil, Triamcinolone, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112222, 'Hydroxyzine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112353/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Clobazam, Meprobamate, Halazepam, Clorazepic acid, Chlordiazepoxide', 'Mometasone furoate, Beclomethasone dipropionate, Mometasone, Ciclesonide, Mometasone furoate, Flunisolide, Nedocromil, Betamethasone, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112223, 'Imipramine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112354/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Phenelzine, Tranylcypromine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More', 'Mometasone, Mometasone furoate, Beclomethasone dipropionate, Cromoglicic acid, Ciclesonide, Mometasone furoate, Flunisolide, Cromoglicic acid, Betamethasone, Nedocromil, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112224, 'Insulin human (inhalation, rapid acting)', 'Tiotropium', 'Moderate', 'INTERVAL: Bronchodilators and other orally inhaled products may alter the absorption of inhaled human insulin. In nondiabetic subjects with mild asthma (n=36) and moderate asthma (n=31), administration of albuterol 30 minutes prior to inhaled human insulin resulted in a mean increase in insulin systemic exposure (AUC).', 'DDInter', 'Consistent timing of dosing of other inhaled products relative to inhaled human insulin administration is recommended. Blood glucose should be monitored closely, and the insulin dose adjusted accordingly.', 'Absorption', 'Consistent timing of dosing of other inhaled products relative to inhaled human insulin administration is recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112355/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[4] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[5] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 'Insulin lispro, Insulin degludec, Lixisenatide, Insulin detemir, Insulin human, Insulin glargine, Liraglutide, Insulin glulisine', 'Glycopyrronium, Revefenacin, Glycopyrronium', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112225, 'Ipratropium (nasal)', 'Tiotropium', 'Minor', 'Theoretically, the potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (new onset or exacerbation) when ipratropium nasal spray is used with other agents that possess anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide). However, due to the poor systemic absorption of ipratropium when administered nasally, the interaction would be unlikely at regularly recommended dosages.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112356/', '[1] "Product Information. Atrovent nasal spray (ipratropium nasal)." Boehringer-Ingelheim, Ridgefield, CT.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Mometasone furoate, Flunisolide, Nedocromil, Betamethasone, Tiotropium, Beclomethasone dipropionate, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Vitamin A, More', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112226, 'Isoflurophate (ophthalmic)', 'Tiotropium', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112357/', '[1] "Product Information. Pilopine HS (pilocarpine ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.[2] "Multum Information Services, Inc. Expert Review Panel"', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112227, 'Tiotropium', 'Loxapine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112358/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Olodaterol, Cromoglicic acid, Orciprenaline, Pirbuterol, Salmeterol, Bitolterol, Formoterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112228, 'Tiotropium', 'Maprotiline', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112359/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Phenelzine, Tranylcypromine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Epinephrine, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112229, 'Tiotropium', 'Meclizine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112360/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112230, 'Tiotropium', 'Mepenzolate', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112361/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 'Papaverine, Alosetron, Isometheptene', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112231, 'Tiotropium', 'Mesoridazine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112362/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112232, 'Tiotropium', 'Methdilazine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112363/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, Salmeterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112233, 'Tiotropium', 'Methotrimeprazine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112364/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Bitolterol, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112234, 'Tiotropium', 'Methscopolamine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112365/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 'Ephedrine, Tropicamide, Phenylephrine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112235, 'Tiotropium', 'Molindone', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112366/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, Salmeterol, More', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112236, 'Tiotropium', 'Nortriptyline', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112367/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Phenelzine, Tranylcypromine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More', 'Mometasone, Mometasone furoate, Beclomethasone dipropionate, Cromoglicic acid, Ciclesonide, Mometasone furoate, Flunisolide, Cromoglicic acid, Betamethasone, Nedocromil, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112237, 'Tiotropium', 'Olanzapine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112368/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 'Mometasone, Mometasone furoate, Beclomethasone dipropionate, Cromoglicic acid, Ciclesonide, Mometasone furoate, Flunisolide, Cromoglicic acid, Betamethasone, Nedocromil, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112238, 'Tiotropium', 'Oxybutynin', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112369/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Phenyl salicylate, Magnesium hydroxide, More', 'Mometasone furoate, Terbutaline, Mometasone, Epinephrine, Olodaterol, Cromoglicic acid, Orciprenaline, Vilanterol, Bitolterol, Formoterol, Isoprenaline, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112239, 'Tiotropium', 'Perphenazine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112370/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112240, 'Tiotropium', 'Phenindamine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112371/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 'Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112241, 'Tiotropium', 'Physostigmine (ophthalmic)', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112372/', '[1] "Product Information. Pilopine HS (pilocarpine ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.[2] "Multum Information Services, Inc. Expert Review Panel"', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112242, 'Tiotropium', 'Pimozide', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112373/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112243, 'Tiotropium', 'Procainamide', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112374/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Propafenone, Dronedarone, Tocainide, Bretylium, Moricizine, Ibutilide', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Epinephrine, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112244, 'Tiotropium', 'Procyclidine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112375/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112245, 'Tiotropium', 'Promazine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112376/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Bitolterol, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112246, 'Tiotropium', 'Propantheline', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112377/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Papaverine, Alosetron, Isometheptene', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112247, 'Tiotropium', 'Propiomazine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112378/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, More', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, Salmeterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112248, 'Tiotropium', 'Protriptyline', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112379/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Phenelzine, Tranylcypromine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112249, 'Tiotropium', 'Prucalopride', 'Moderate', 'Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.', 'DDInter', 'Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.', 'Absorption', 'Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112380/', '[1] "Product Information. Resotran (prucalopride)." Janssen Pharmaceuticals, Titusville, NJ.[2] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 'Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112250, 'Tiotropium', 'Quetiapine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112381/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 'Mometasone, Mometasone furoate, Beclomethasone dipropionate, Cromoglicic acid, Ciclesonide, Mometasone furoate, Cromoglicic acid, Nedocromil, Betamethasone, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112251, 'Tiotropium', 'Quinidine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112382/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Propafenone, Dronedarone, Tocainide, Bretylium, Moricizine, Ibutilide', 'Mometasone furoate, Mometasone, Cromoglicic acid, Epinephrine, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Cromoglicic acid, Nedocromil, Betamethasone, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112252, 'Tiotropium', 'Revefenacin', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112383/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 'Mometasone furoate, Flunisolide, Nedocromil, Betamethasone, Tiotropium, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112253, 'Tiotropium', 'Scopolamine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112384/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, More', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Cromoglicic acid, Orciprenaline, Pirbuterol, Salmeterol, Bitolterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112254, 'Tiotropium', 'Solifenacin', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112385/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Epinephrine, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, More', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Phenyl salicylate, Magnesium hydroxide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112255, 'Tiotropium', 'Thiethylperazine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112386/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, Salmeterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112256, 'Tiotropium', 'Thioridazine', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112387/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112257, 'Tiotropium', 'Thiothixene', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112388/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Olodaterol, Fluticasone, Cromoglicic acid, Orciprenaline, Pirbuterol, Salmeterol, Bitolterol, More', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112258, 'Tolterodine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112389/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Phenyl salicylate, Magnesium hydroxide, More', 'Mometasone furoate, Terbutaline, Mometasone, Epinephrine, Cromoglicic acid, Orciprenaline, Vilanterol, Bitolterol, Olodaterol, Isoprenaline, Beclomethasone dipropionate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112259, 'Trifluoperazine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112390/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112260, 'Triflupromazine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112391/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Bitolterol, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112261, 'Trihexyphenidyl', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112392/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Orciprenaline, Pirbuterol, Salmeterol, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112262, 'Alimemazine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112393/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Bitolterol, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112263, 'Trimipramine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112394/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Phenelzine, Tranylcypromine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More', 'Mometasone furoate, Budesonide, Mometasone, Cromoglicic acid, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Cromoglicic acid, Betamethasone, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112264, 'Tripelennamine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112395/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole, Tetracaine', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112265, 'Triprolidine', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112396/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Levocetirizine, Trimethobenzamide, Terfenadine, Astemizole', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112266, 'Umeclidinium', 'Tiotropium', 'Moderate', 'The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.', 'DDInter', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.', 'Synergism', 'Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112397/', '[1] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[2] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[4] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[5] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[6] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Formoterol, Cromoglicic acid, Isoprenaline, Beclomethasone dipropionate, Terbutaline, Budesonide, Mometasone, Fluticasone, Salbutamol, Orciprenaline, Pirbuterol, More', 'Mometasone furoate, Terbutaline, Mometasone, Bitolterol, Orciprenaline, Vilanterol, Isoprenaline, Olodaterol, Tiotropium, Beclomethasone dipropionate, Indacaterol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112267, 'Stavudine', 'Aurothioglucose', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112398/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Penicillamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112268, 'Stavudine', 'Bedaquiline', 'Moderate', 'Coadministration of bedaquiline with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'DDInter', 'The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; other antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; ketolide and macrolide antibiotics; interferons; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), especially in patients with diminished hepatic reserve. Patients treated with bedaquiline should have serum ALT, AST, alkaline phosphatase, and bilirubin monitored at baseline and monthly during treatment, or as often as needed. An increase of serum aminotransferases to greater than 3 times ULN should be followed by repeat testing within 48 hours. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Discontinue bedaquiline if aminotransferase elevations are accompanied by total bilirubin elevation greater than 2 times ULN, aminotransferase elevations are greater than 8 times ULN, or aminotransferase elevations persist beyond 2 weeks.', 'Synergism', 'The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112399/', '[1] "Product Information. Sirturo (bedaquiline)." Janssen Pharmaceuticals, Titusville, NJ.[2] "Product Information. Sirturo (bedaquiline)." Janssen Pharmaceuticals, Titusville, NJ.[3] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 'Paritaprevir, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More', 'Capreomycin, Rifamycin, Sulfamethoxazole, Rifapentine, Trimethoprim, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Aminosalicylic acid', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112269, 'Benznidazole', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112400/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 'Miltefosine, Pentamidine, Nifurtimox, Fexinidazole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112270, 'Cerivastatin', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112401/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Ezetimibe, Bempedoic acid, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112271, 'Dapsone', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112402/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Minocycline, Isotretinoin, Fluorometholone, Tretinoin, Methylprednisolone, Azelaic acid, Adapalene, Clofazimine', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112272, 'Doxorubicin (liposomal)', 'Stavudine', 'Moderate', 'Doxorubicin has been shown to inhibit the phosphorylation of stavudine to its active triphosphate form in vitro. The clinical significance is unknown. However, the potential for diminished antiretroviral activity of stavudine should be considered.', 'DDInter', 'Monitoring for altered antiretroviral efficacy and HIV-RNA levels is advisable during concomitant administration.', 'Antagonism', 'Monitoring for altered antiretroviral efficacy and HIV-RNA levels is advisable during concomitant administration.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112403/', '[1] "Product Information. Zerit (stavudine)." Bristol-Myers Squibb, Princeton, NJ.', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Idarubicin, Valrubicin, Plicamycin, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112273, 'Elotuzumab', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112404/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112274, 'Epirubicin', 'Stavudine', 'Moderate', 'The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury. Epirubicin undergoes elimination through the hepatobiliary system.', 'DDInter', 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', 'Synergism', 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112405/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Ellence (epirubicin)" Pharmacia and Upjohn, Kalamazoo, MI.[4] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 'Idarubicin, Valrubicin, Plicamycin, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Telaprevir, Velpatasvir, Etravirine, Dolutegravir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112275, 'Eribulin', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112406/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112276, 'Etanercept', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112407/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112277, 'Ethambutol', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112408/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Capreomycin, Rifamycin, Sulfamethoxazole, Rifapentine, Trimethoprim, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Aminosalicylic acid', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112278, 'Ethionamide', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112409/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Capreomycin, Rifamycin, Sulfamethoxazole, Rifapentine, Trimethoprim, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Aminosalicylic acid', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112279, 'Etoposide', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112410/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Velpatasvir, Rilpivirine, Dolutegravir, More', 'Topotecan, Irinotecan', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112280, 'Etravirine', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112411/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Etravirine, Oseltamivir, Acyclovir, Brincidofovir, Remdesivir, Elbasvir, Famciclovir, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112281, 'Fludarabine', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112412/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Fluorouracil, Pemetrexed, Mercaptopurine, Trifluridine, Floxuridine, Gemcitabine, Pralatrexate, Decitabine, Azacitidine, Capecitabine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112282, 'Fluvastatin', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112413/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Ezetimibe, Bempedoic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112283, 'Stavudine', 'Sodium aurothiomalate', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112414/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Penicillamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112284, 'Golimumab', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112415/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112285, 'Hydralazine', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112416/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112286, 'Hydroxychloroquine', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112417/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Dolutegravir, More', 'Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112287, 'Idelalisib', 'Stavudine', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', 'DDInter', 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112418/', '[1] "Product Information. Zydelig (idelalisib)." Gilead Sciences, Foster City, CA.[2] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 'Cabotegravir, Simeprevir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Famciclovir, Ribavirin, Tecovirimat, Maribavir, More', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112288, 'Indinavir', 'Stavudine', 'Minor', 'Indinavir has been shown to increase the area under the plasma concentration-time curves of the reverse transcriptase inhibitors zidovudine and stavudine by up to 36% and 25%, respectively. Concomitant use has inconsistently affected indinavir plasma concentrations, which have increased by up to 13% or have shown no change. The mechanism of the interaction is not clearly understood, but it may be related to the effects of these drugs on hepatic enzymes. Dosage adjustments are unlikely to be necessary, although it may be appropriate to monitor the patient for zidovudine and/or stavudine toxicity.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112419/', '[1] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[2] Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S "Single-dose pharmacokinetics of indinavir and the effect of food." Antimicrob Agents Chemother 42 (1998): 332-8[3] Shelton MJ, Wynn HE, Newitt RG, DiFrancesco R "Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects." J Clin Pharmacol 41 (2001): 435-42[4] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Glecaprevir, Cabotegravir, Zanamivir, Lenacapavir, Valaciclovir, Telaprevir, Velpatasvir, Rilpivirine, Oseltamivir, Remdesivir, Famciclovir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112289, 'Infliximab', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112420/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112290, 'Interferon alfa-2a, Recombinant', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112421/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112291, 'Interferon alfa-2b', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112422/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112292, 'Interferon alfa-n1', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112423/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112293, 'Interferon alfacon-1', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112424/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112294, 'Interferon beta-1a', 'Stavudine', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', 'DDInter', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112425/', '[1] "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA.[2] "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.[3] "Product Information. Rebif (interferon beta-1a)." Serono Laboratories Inc, Norwell, MA.[4] "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.', 'Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Etravirine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112295, 'Interferon beta-1b', 'Stavudine', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', 'DDInter', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112426/', '[1] "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA.[2] "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.[3] "Product Information. Rebif (interferon beta-1a)." Serono Laboratories Inc, Norwell, MA.[4] "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.', 'Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112296, 'Diiodohydroxyquinoline', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112427/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Ciclopirox, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112297, 'Ipilimumab', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112428/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112298, 'Isoniazid', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112429/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Oseltamivir, More', 'Capreomycin, Rifamycin, Sulfamethoxazole, Rifapentine, Trimethoprim, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Aminosalicylic acid', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112299, 'Stavudine', 'Ixabepilone', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112430/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 'Idarubicin, Valrubicin, Plicamycin, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112300, 'Stavudine', 'Ixazomib', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112431/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, More', 'Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112301, 'Stavudine', 'Leflunomide', 'Major', 'The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.', 'DDInter', 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide''s active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112432/', '[1] EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions. Available from URL: http://www.eudra.org/emea.html." ([1999 Sept 2]):[2] "Product Information. Arava (leflunomide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Dolutegravir, More', 'Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112302, 'Stavudine', 'Linezolid', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112433/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112303, 'Stavudine', 'Lomitapide', 'Major', 'Coadministration of lomitapide with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Lomitapide can cause elevations in serum transaminases and hepatic steatosis. Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with lomitapide, although the long-term consequences are unknown.', 'DDInter', 'Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with lomitapide should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking lomitapide not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112434/', '[1] "Product Information. Juxtapid (lomitapide)." Aegerion Pharmaceuticals Inc, Cambridge, MA.[2] "Product Information. Juxtapid (lomitapide)." Aegerion Pharmaceuticals Inc, Cambridge, MA.', 'Paritaprevir, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Etravirine, Oseltamivir, Acyclovir, Brincidofovir, More', 'Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Ezetimibe, Bempedoic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112304, 'Stavudine', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112435/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Ezetimibe, Bempedoic acid, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112305, 'Stavudine', 'Mipomersen', 'Major', 'Coadministration of mipomersen with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Mipomersen can cause elevations in serum transaminases and hepatic steatosis.', 'DDInter', 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, lomitapide, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Mipomersen has not been studied with other LDL-lowering agents that can also increase hepatic fat, thus concomitant use is not recommended. Patients treated with mipomersen should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112436/', '[1] "Product Information. Kynamro (mipomersen)." Genzyme Corporation, Cambridge, MA.[2] "Product Information. Kynamro (mipomersen)." Genzyme Corporation, Cambridge, MA.', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Etravirine, More', 'Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Ezetimibe, Bempedoic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112306, 'Stavudine', 'Naltrexone', 'Moderate', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.', 'DDInter', 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.', 'Synergism', 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112437/', '[1] "Product Information. ReVia (naltrexone)." DuPont Pharmaceuticals, Wilmington, DE.', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Etravirine, More', 'Codeine, Oliceridine, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Hydromorphone, Dezocine, Tramadol, Opium, Dextropropoxyphene, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112307, 'Stavudine', 'Naxitamab', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112438/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112308, 'Stavudine', 'Nelarabine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112439/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Fluorouracil, Pemetrexed, Mercaptopurine, Trifluridine, Floxuridine, Gemcitabine, Pralatrexate, Decitabine, Azacitidine, Capecitabine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112309, 'Stavudine', 'Nitrofurantoin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112440/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112310, 'Stavudine', 'Orlistat', 'Moderate', 'Orlistat may theoretically reduce the gastrointestinal absorption and therapeutic efficacy of antiretroviral agents. The mechanism may involve retention of lipophilic medicines in the gastrointestinal tract or reduced gastrointestinal tract transit time.', 'DDInter', 'The potential reduction in antiretroviral efficacy should be considered before initiating treatment with orlistat. Patients who take antiretroviral medications should be advised to consult their physician before using the non-prescription brand of orlistat.', 'Absorption', 'The potential reduction in antiretroviral efficacy should be considered before initiating treatment with orlistat.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112441/', '[1] MHRA. Medicines and Healthcare Products Regulatory Agency "Orlistat: theoretical interaction with antiretroviral HIV medicines. Available from: URL: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON392868" ([2014 Mar]):[2] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 'Paritaprevir, Glecaprevir, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Cobicistat, Brincidofovir, More', 'Dexfenfluramine, Ephedrine, Fenfluramine, Phentermine, Lorcaserin, Sibutramine, Diethylpropion, Mazindol', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112311, 'Stavudine', 'Oxaliplatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112442/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, More', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Dolutegravir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112312, 'Stavudine', 'Paclitaxel (protein-bound)', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112443/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112313, 'Stavudine', 'Pegaspargase', 'Moderate', 'Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.', 'DDInter', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112444/', '[1] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub[4] Cerner Multum, Inc "ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp." O 0 (2015):[5] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[6] Christ TN, Stock W, Knoebel RW "Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen." J Oncol Pharm Pract 24 (2018): 299-308[7] Lu G, Karur V, Herrington JD, Walker MG "Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine" Proc (Bayl Univ Med Cent) 29 (2016): 46-7[8] Jenkins R, Perlin E "Severe hepatotoxicity from Escherichia coli L-asparaginase." J Natl Med Assoc 79 (1987): 775-9[9] "Product Information. Asparlas (calaspargase pegol)." Servier, Boston, MA.[10] Burke PW, Aldoss I, Lunning MA, et.al "High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles." Blood 122 (2013): 2671[11] "Product Information. Erwinaze (asparaginase Erwinia chrysanthemi)." EUSA Pharma, Newtown, PA.[12] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[13] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4', 'Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, More', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Etravirine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112314, 'Stavudine', 'Peginterferon alfa-2a', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112445/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112315, 'Stavudine', 'Peginterferon alfa-2b', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112446/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112316, 'Stavudine', 'Peginterferon beta-1a', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', 'DDInter', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112447/', '[1] "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA.[2] "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.[3] "Product Information. Rebif (interferon beta-1a)." Serono Laboratories Inc, Norwell, MA.[4] "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Etravirine, More', 'Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112317, 'Stavudine', 'Pexidartinib', 'Major', 'Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases.', 'DDInter', 'The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The use of pexidartinib with other potentially hepatotoxic agents should be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112448/', '[1] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.[2] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.', 'Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Elbasvir, Famciclovir, Ribavirin, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112318, 'Stavudine', 'Pitavastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112449/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Ezetimibe, Bempedoic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112319, 'Stavudine', 'Polatuzumab vedotin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112450/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112320, 'Stavudine', 'Pomalidomide', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112451/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 'Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112321, 'Stavudine', 'Ponatinib', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112452/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112322, 'Stavudine', 'Pravastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112453/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Ezetimibe, Bempedoic acid, More', 'Tenofovir alafenamide, Cabotegravir, Maraviroc, Amprenavir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112323, 'Stavudine', 'Remdesivir', 'Moderate', 'Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from investigational use and clinical studies suggest that remdesivir may be associated with hepatotoxic effects.', 'DDInter', 'Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible. Liver function should be evaluated prior to starting remdesivir and monitored during treatment as clinically appropriate. Remdesivir should not be initiated in patients with ALT greater than or equal to 5 times the upper limit of normal (ULN) at baseline. Likewise, remdesivir should be discontinued immediately if ALT increases to 5 times ULN or greater during treatment (may be restarted when ALT falls below 5 times ULN), or if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.', 'Synergism', 'Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112454/', '[1] Gilead Sciences, Inc "About Remdesivir. Available from: URL: https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir." ([2020]):[2] US Food and Drug Administration "Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM) Available from: URL: https://www.fda.gov/media/137566/download." ([2020, May 1]]):[3] European Medicines Agency "Summary on compassionate use. Remdesivir Gilead. Available from: URL: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf." ([2020 Apr 03]):[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Etravirine, Dolutegravir, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112324, 'Stavudine', 'Rosuvastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112455/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Maraviroc, Zanamivir, Lenacapavir, Telaprevir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, More', 'Perindopril, Niacin, Ezetimibe, Bempedoic acid, Indapamide, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112325, 'Stavudine', 'Simvastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112456/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Maraviroc, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, Doravirine, Bictegravir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112326, 'Telbivudine', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112457/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112327, 'Teniposide', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112458/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Topotecan, Irinotecan', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112328, 'Teriflunomide', 'Stavudine', 'Major', 'The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.', 'DDInter', 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide''s active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112459/', '[1] EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions. Available from URL: http://www.eudra.org/emea.html." ([1999 Sept 2]):[2] "Product Information. Arava (leflunomide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 'Glecaprevir, Cabotegravir, Amprenavir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Velpatasvir, Dolutegravir, Oseltamivir, Cobicistat, More', 'Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112329, 'Thalidomide', 'Stavudine', 'Moderate', 'Thalidomide can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Peripheral neuropathy is a common, potentially severe side effect of thalidomide that may be irreversible.', 'DDInter', 'Caution is advised if thalidomide is used in combination with other neurotoxic agents. All patients treated with thalidomide should be examined at monthly intervals for the first three months of therapy and periodically thereafter to detect early signs of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Electrophysiological testing may be performed at baseline and every six months during therapy to detect asymptomatic neuropathy. Consideration should be given to immediate discontinuation of thalidomide in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Caution is advised if thalidomide is used in combination with other neurotoxic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112460/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6[3] "Product Information. Thalomid (thalidomide)." Celgene Corporation, Warren, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112330, 'Tioguanine', 'Stavudine', 'Moderate', 'The concomitant or sequential use of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with thioguanine. A high risk of liver toxicity characterized by vascular endothelial damage has been reported with long-term continuous use of thioguanine, particularly in children receiving the drug as part of maintenance therapy for acute lymphoblastic leukemia and in other conditions associated with continuous use.', 'DDInter', 'The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Baseline and regular monitoring of hepatic function is recommended. Thioguanine therapy should be discontinued if there is evidence of toxic hepatitis or biliary stasis, as reversal of signs and symptoms of liver toxicity have been reported upon withdrawal. Early indications of liver toxicity are signs associated with portal hypertension such as thrombocytopenia out of proportion with neutropenia and splenomegaly. Elevations of liver enzymes have also been reported, but do not always occur.', 'Synergism', 'The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112461/', '[1] "Product Information. Aubagio (teriflunomide)." Genzyme Corporation, Cambridge, MA.[2] "Product Information. Tabloid (thioguanine)." Prasco Laboratories, Cincinnati, OH.', 'Fluorouracil, Pemetrexed, Mercaptopurine, Trifluridine, Floxuridine, Gemcitabine, Pralatrexate, Decitabine, Azacitidine, Capecitabine', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Etravirine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112331, 'Tinidazole', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112462/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 'Tetracycline, Cefepime, Cefuroxime, Cefixime, Amikacin, Levofloxacin, Tetracycline, Levofloxacin, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112332, 'Tocilizumab', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112463/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112333, 'Trabectedin', 'Stavudine', 'Moderate', 'Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'DDInter', 'The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.', 'Synergism', 'The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112464/', '[1] "Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals, Titusville, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Paritaprevir, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More', 'Topotecan, Irinotecan', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112334, 'Vinblastine', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112465/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Topotecan, Irinotecan', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112335, 'Vincristine', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112466/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Topotecan, Irinotecan', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112336, 'Vincristine (liposome)', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112467/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Topotecan, Irinotecan', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112337, 'Vinorelbine', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112468/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Topotecan, Irinotecan', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112338, 'Zafirlukast', 'Stavudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112469/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 'Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Dolutegravir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112339, 'Zalcitabine', 'Stavudine', 'Moderate', 'Zalcitabine can cause peripheral neuropathy in up to one-third of patients with advanced HIV disease, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Zalcitabine-related peripheral neuropathy is a sensorimotor neuropathy characterized initially by numbness and burning dysesthesia involving the distal extremities. These symptoms may be followed by sharp shooting pains or severe continuous burning pain if the drug is not withdrawn, and progress to severe pain requiring narcotic analgesics. The neuropathy is potentially irreversible. However, with prompt discontinuation of zalcitabine, it is usually slowly reversible, although symptoms may initially progress following discontinuation.', 'DDInter', 'Use of zalcitabine with other drugs that have the potential to cause peripheral neuropathy should be avoided whenever possible. Otherwise, careful monitoring is recommended for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness in the extremities, particularly in patients with a low CD4 cell count or diabetes. Since the development of peripheral neuropathy appears to be dose-related, the recommended dosage of zalcitabine should not be exceeded. Patients should be advised to promptly discontinue zalcitabine therapy and contact their physician if neuropathy develops. Therapy may be reinstituted following resolution of neuropathy symptoms, but dosage should be reduced to one-half the initially recommended dosage. Zalcitabine should be permanently discontinued in patients who develop severe peripheral neuropathy during treatment.', 'Synergism', 'Use of zalcitabine with other drugs that have the potential to cause peripheral neuropathy should be avoided whenever possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112470/', '[1] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6[2] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.[3] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112340, 'Abarelix', 'Vardenafil', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112471/', '[1] "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] "Product Information. Zoladex (goserelin)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.[5] "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc, Deerfield, IL.[7] "Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals, New York, NY.[8] "Product Information. Plenaxis (abarelix)." Praecis Pharmaceuticals Inc, Waltham, MA.', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112341, 'Amoxapine', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112472/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Avanafil, Phenyl salicylate, Tadalafil, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112342, 'Amprenavir', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112473/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, More', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112343, 'Amyl Nitrite', 'Vardenafil', 'Major', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the hypotensive effect of organic nitrates. Severe hypotension, syncope, or myocardial ischemia may result from use of the combination. The mechanism involves peripheral vasodilation secondary to enhanced levels of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells, as PDE5 inhibitors prevent degradation of cGMP while nitrates promote its synthesis.', 'DDInter', 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated. A suitable time interval following sildenafil or vardenafil use for the safe administration of nitrates has not been determined. For patients treated with avanafil or tadalafil, at least 12 hours after the last dose of avanafil and 48 hours after the last dose of tadalafil are recommended before nitrate administration, should it be deemed medically necessary in a life-threatening situation. Even then, nitrates should only be administered under close medical supervision with appropriate hemodynamic monitoring. Patients should be advised to seek immediate medical attention if they experience anginal chest pain after taking a PDE5 inhibitor.', 'Synergism', 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112474/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[4] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[5] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation, Silver Spring, MD.', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Deferoxamine, Levoleucovorin, Methionine, Deferiprone, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112344, 'Vardenafil', 'Astemizole', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112475/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112345, 'Vardenafil', 'Bedaquiline', 'Major', 'Bedaquiline can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if bedaquiline is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting bedaquiline therapy and periodically during treatment in accordance with the product labeling. Hypokalemia, hypomagnesemia, and hypocalcemia must be corrected prior to bedaquiline administration.', 'Synergism', 'Caution is recommended if bedaquiline is used in combination with other drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112476/', '[1] "Product Information. Sirturo (bedaquiline)." Janssen Pharmaceuticals, Titusville, NJ.[2] "Product Information. Sirturo (bedaquiline)." Janssen Pharmaceuticals, Titusville, NJ.', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Rifampicin, Cycloserine, Rifabutin, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112346, 'Vardenafil', 'Bendroflumethiazide', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112477/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Tinidazole, Ascorbic acid, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Probenecid, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, Zonisamide, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112347, 'Vardenafil', 'Benzthiazide', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112478/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Tinidazole, Ascorbic acid, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Probenecid, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, Zonisamide, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112348, 'Vardenafil', 'Bepridil', 'Major', 'Vardenafil has been reported to cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, should avoid using vardenafil.', 'Synergism', 'Patients treated with class IA (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112479/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[3] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[6] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[7] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[8] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[9] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[10] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[13] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[14] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[15] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[16] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[17] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[24] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[25] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[26] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[27] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[28] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[29] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[30] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[31] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[32] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[33] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Fesoterodine, Pentosan polysulfate, Tolterodine, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112349, 'Vardenafil', 'Berotralstat', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112480/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112350, 'Boceprevir', 'Vardenafil', 'Major', 'Coadministration with boceprevir may significantly increase the plasma concentrations of vardenafil. The mechanism involves inhibition of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of vardenafil. The interaction has not been specifically studied with boceprevir, but has been reported with other potent CYP450 3A4 inhibitors such as HIV protease inhibitors, ketoconazole, and erythromycin.', 'DDInter', 'Patients treated with boceprevir should not receive more than a single 2.5 mg dose of vardenafil within a 24-hour period. Patients should be advised to promptly notify their physician if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).', 'Metabolism', 'Patients treated with boceprevir should not receive more than a single 2.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112481/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation, Kenilworth, NJ.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[35] "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation, Kenilworth, NJ.', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112351, 'Carteolol', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112482/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Epinephrine, Brimonidine, Levobunolol', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Papaverine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112352, 'Frangula purshiana bark', 'Vardenafil', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112483/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112353, 'Castor oil', 'Vardenafil', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112484/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 'Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112354, 'Chlorpromazine', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112485/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112355, 'Cisapride', 'Vardenafil', 'Major', 'Cisapride can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112486/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] "Product Information. Propulsid (cisapride)." Janssen Pharmaceutica, Titusville, NJ.[4] Trinkle R "Comment: syncopal episodes associated with cisapride." Ann Pharmacother 33 (1999): 251[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Michalets EL, Williams CR "Drug interactions with cisapride: clinical implications." Clin Pharmacokinet 39 (2000): 49-75[7] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[8] Lewin MB, Bryant RM, Fenrich AL, Grifka RG "Cisapride-induced long QT interval." J Pediatr 128 (1996): 279-81[9] Offman EM, Freeman DJ, Dresser GK, Munoz C, Bend JR, Bailey DG "Red wine-cisapride interaction: Comparison with grapefruit juice." Clin Pharmacol Ther 70 (2001): 17-23[10] Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI "Proarrhythmia associated with cisapride in children." Pediatrics 101 (1998): 1053-6[11] "Product Information. Propulsid (cisapride)." Janssen Pharmaceutica, Titusville, NJ.[12] Kivisto KT, Lilja TJ, Backman JT, Neuvonen PJ "Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride." Clin Pharmacol Ther 66 (1999): 448-53[13] Desta Z, Soukhova N, Mahal SK, Flockhart DA "Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies." Drug Metab Dispos 28 (2000): 789-800[14] Michalets EL, Williams CR "Drug interactions with cisapride: clinical implications." Clin Pharmacokinet 39 (2000): 49-75[15] Gross AS, Goh YD, Addison RS, Shenfield GM "Influence of grapefruit juice on cisapride pharmacokinetics." Clin Pharmacol Ther 65 (1999): 395-401[16] Bran S, Murray WA, Hirsch IB, Palmer JP "Long QT syndrome during high-dose cisapride." Arch Intern Med 155 (1995): 765-8', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112356, 'Clotrimazole', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112487/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Salicylic acid, Thiabendazole, Griseofulvin, Econazole, Flucytosine, Tioconazole, Chlorphenesin, Tetracycline, Minocycline, Amphotericin B, Prednisolone, More', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112357, 'Cyclandelate', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112488/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112358, 'Deserpidine', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112489/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112359, 'Doxorubicin (liposomal)', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112490/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112360, 'Echinacea', 'Vardenafil', 'Moderate', 'Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.', 'DDInter', 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.', 'Metabolism', 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112491/', '[1] Gorski JC, Huang SM, Pinto A, et al. "The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo." Clin Pharmacol Ther 75 (2004): 89-100[2] Cerner Multum, Inc. "Australian Product Information." O 0', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112361, 'Entrectinib', 'Vardenafil', 'Moderate', 'Entrectinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of entrectinib with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have electrocardiograms (ECGs) performed prior to initiation of entrectinib and periodically during treatment as appropriate based on individual risk factors.', 'Synergism', 'Coadministration of entrectinib with other drugs that can prolong the QT interval should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112492/', '[1] "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, Oxybutynin, More', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112362, 'Enzalutamide', 'Vardenafil', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112493/', '[1] "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] "Product Information. Zoladex (goserelin)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.[5] "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc, Deerfield, IL.[7] "Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals, New York, NY.[8] "Product Information. Plenaxis (abarelix)." Praecis Pharmaceuticals Inc, Waltham, MA.', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112363, 'Epirubicin', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112494/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112364, 'Eplerenone', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112495/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112365, 'Epoprostenol', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112496/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Magnesium hydroxide, More', 'Ticagrelor, Betrixaban, Apixaban, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112366, 'Eprosartan', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112497/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 'Sacubitril', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112367, 'Eribulin', 'Vardenafil', 'Moderate', 'Eribulin may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if eribulin is used in combination with other drugs that can prolong the QT interval. Baseline and periodic monitoring of electrocardiograms and serum electrolytes (potassium, magnesium) should be considered, and hypokalemia or hypomagnesemia corrected prior to initiating treatment with eribulin. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if eribulin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112498/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Halaven (eribulin)." Eisai Inc, Teaneck, NJ.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112368, 'Ertugliflozin', 'Vardenafil', 'Moderate', 'Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.', 'DDInter', 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.', 'Synergism', 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112499/', '[1] "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb, Princeton, NJ.[5] "Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals, Titusville, NJ.[6] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[9] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[10] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 'Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, Semaglutide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112369, 'Escitalopram', 'Vardenafil', 'Major', 'Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if escitalopram is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. When escitalopram is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Caution is recommended if escitalopram is used in combination with other drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112500/', '[1] Castro VM, Clements CC, Murphy SN, et al. "QT interval and antidepressant use: a cross sectional study of electronic health records." BMJ 346 (2013): f288[2] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[9] Health Canada "Antidepressant Cipralex (escitalopram): Updated information regarding dose-related heart risk. Available from: URL: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2012/2012_63-eng.php." ([2012 May 7]):[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[13] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Tadalafil, More', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112370, 'Esmolol', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112501/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112371, 'Etacrynic acid', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112502/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112372, 'Etravirine', 'Vardenafil', 'Moderate', 'Coadministration with etravirine may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by etravirine.', 'DDInter', 'Caution is advised if etravirine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever etravirine is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if etravirine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112503/', '[1] "Product Information. Intelence (etravirine)." Ortho Biotech Inc, Bridgewater, NJ.[2] "Product Information. Intelence (etravirine)." Ortho Biotech Inc, Bridgewater, NJ.', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112373, 'Ezogabine', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112504/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Acetohydroxamic acid, More', 'Brivaracetam, Cenobamate, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Paramethadione, Perampanel, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112374, 'Fedratinib', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112505/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Magnesium hydroxide, More', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112375, 'Felodipine', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112506/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Papaverine, Magnesium hydroxide, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112376, 'Fenoldopam', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112507/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112377, 'Fingolimod', 'Vardenafil', 'Major', 'Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of fingolimod treatment in patients receiving drugs that prolong the QT interval. Fingolimod can cause a decrease in heart rate during initiation of therapy that is apparent within an hour of the first dose and maximal at approximately 6 hours postdose in most cases, but occasionally up to 20 hours after the first dose.', 'DDInter', 'Fingolimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, close monitoring is recommended during initiation of fingolimod treatment in patients receiving concomitant drugs that can prolong the QT interval, patients with significant QT prolongation (QTc >470 msec in females or >450 msec in males), or patients with relevant risk factors for QT prolongation (e.g., hypokalemia, hypomagnesemia, congenital QT prolongation).', 'Synergism', 'Fingolimod has not been studied in patients receiving drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112508/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] "Product Information. Gilenya (fingolimod)." Novartis Pharmaceuticals, East Hanover, NJ.[4] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm#data." ([2012 May 14]):[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112378, 'Flecainide', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112509/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, Tadalafil, Oxybutynin, More', 'Lidocaine, Moricizine, Bretylium, Tocainide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112379, 'Fluconazole', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112510/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Caspofungin, Micafungin, Amphotericin B, Oteseconazole, More', 'Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112380, 'Fluoxetine', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112511/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Avanafil, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112381, 'Fluphenazine', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112512/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112382, 'Flutamide', 'Vardenafil', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112513/', '[1] "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] "Product Information. Zoladex (goserelin)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.[5] "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc, Deerfield, IL.[7] "Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals, New York, NY.[8] "Product Information. Plenaxis (abarelix)." Praecis Pharmaceuticals Inc, Waltham, MA.', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112383, 'Fluvoxamine', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112514/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Oxybutynin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112384, 'Fosamprenavir', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112515/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112385, 'Fosaprepitant', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112516/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112386, 'Foscarnet', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112517/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, More', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112387, 'Fosinopril', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112518/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112388, 'Fostamatinib', 'Vardenafil', 'Moderate', 'Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.', 'DDInter', 'Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112519/', '[1] "Product Information. Tavalisse (fostamatinib)." Rigel Pharmaceuticals, South San Francisco, CA.', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112389, 'Fostemsavir', 'Vardenafil', 'Moderate', 'Fostemsavir can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if fostemsavir is used in combination with other drugs that can prolong the QT interval. Consider obtaining electrocardiogram and serum electrolyte levels prior to initiating fostemsavir therapy and periodically thereafter, particularly in patients with risk factors for torsade de pointes and/or receiving one or more potent CYP450 3A4 inhibitors (e.g., azole antifungal agents; cobicistat; protease inhibitors; ketolide and certain macrolide antibiotics; ceritinib; idelalisib; nefazodone) or P-gp inhibitors (e.g., cyclosporine; diltiazem; quinidine; quinine; tacrolimus; verapamil). Correct hypokalemia and/or hypomagnesemia before starting treatment and as indicated during treatment, as they may be risk factors for ventricular arrhythmias.', 'Synergism', 'Caution is recommended if fostemsavir is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112520/', '[1] "Product Information. Rukobia (fostemsavir)." ViiV Healthcare, Research Triangle Park, NC.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112390, 'Furosemide', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112521/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Tinidazole, Ascorbic acid, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Probenecid, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, Zonisamide, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Papaverine, Ammonium chloride, Dimethyl sulfoxide, Solifenacin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112391, 'Galantamine', 'Vardenafil', 'Moderate', 'Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.', 'DDInter', 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.', 'Synergism', 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112522/', '[1] "Product Information. Razadyne (galantamine)." Johnson and Johnson Medical Inc, Arlington, TX.[2] "Product Information. Exelon (rivastigmine)" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Aricept (donepezil)." Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 'Ginkgo biloba, Aducanumab', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Phenyl salicylate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112392, 'Gatifloxacin', 'Vardenafil', 'Major', 'Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112523/', '[1] Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001): 23[2] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003): 292-303[5] Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002): 455-64[6] "Product Information. Tequin (gatifloxacin)" Bristol-Myers Squibb, Princeton, NJ.[7] Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004): 1091-124[8] Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72[9] Dale KM, Lertsburapa K, Kluger J, White CM "Moxifloxacin and torsade de pointes." Ann Pharmacother 41 (2007): 336-40[10] Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002): 861-3[11] Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003): 2317-20[12] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[13] Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001): 361-2[14] Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF "Effects of three fluoroquinolones on QT analysis after standard treatment courses." Ann Noninvasive Electrocardiol 11 (2006): 52-6[15] Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000): 658-66[16] Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19[17] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[18] Falagas ME, Rafailidis PI, Rosmarakis ES "Arrhythmias associated with fluoroquinolone therapy." Int J Antimicrob Agents 29 (2007): 374-9[19] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.[20] White CM, Grant EM, Quintiliani R "Moxifloxacin does increase the corrected QT interval." Clin Infect Dis 33 (2001): 1441-2[21] Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002): 269-77[22] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[23] Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001): 1468-72[24] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001): 46-7[25] Cerner Multum, Inc. "Australian Product Information." O 0[26] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6[27] "Product Information. Tequin (gatifloxacin)" Bristol-Myers Squibb, Princeton, NJ.[28] Wallace AW, Victory JM, Amsden GW "Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers." J Clin Pharmacol 43 (2003): 92-6', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', 'Rifamycin, Kanamycin, Ampicillin, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112393, 'Gemfibrozil', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112524/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Darifenacin, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 'Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, Colestipol, Bempedoic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112394, 'Gemifloxacin', 'Vardenafil', 'Moderate', 'Certain quinolones, including gemifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if gemifloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation may increase with increasing plasma concentrations of gemifloxacin, the recommended dosage should not be exceeded, especially in patients with renal or hepatic impairment.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if gemifloxacin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112525/', '[1] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001): 46-7[2] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[3] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[4] Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19[5] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Flavoxate, More', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112395, 'Gilteritinib', 'Vardenafil', 'Moderate', 'Gilteritinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution and clinical monitoring are recommended if gilteritinib is used in combination with other drugs that can prolong the QT interval. Patients should have electrocardiograms (ECGs) performed prior to initiation of treatment with gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended if gilteritinib is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112526/', '[1] "Product Information. Xospata (gilteritinib)." Astellas Pharma US, Inc, Deerfield, IL.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112396, 'Glasdegib', 'Vardenafil', 'Moderate', 'Glasdegib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of glasdegib with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have electrocardiograms (ECGs) performed prior to initiation of treatment with glasdegib, approximately one week after initiation, and then once monthly for the next two months, although patients with risk factors may require more frequent and ongoing ECG monitoring.', 'Synergism', 'Coadministration of glasdegib with other drugs that can prolong the QT interval should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112527/', '[1] "Product Information. Daurismo (glasdegib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Daurismo (glasdegib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112397, 'Glycerin', 'Vardenafil', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112528/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 'Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112398, 'Goldenseal', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112529/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112399, 'Goserelin', 'Vardenafil', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112530/', '[1] "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] "Product Information. Zoladex (goserelin)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.[5] "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc, Deerfield, IL.[7] "Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals, New York, NY.[8] "Product Information. Plenaxis (abarelix)." Praecis Pharmaceuticals Inc, Waltham, MA.', 'Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate', 'Fesoterodine, Pentosan polysulfate, Tolterodine, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112400, 'Granisetron', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112531/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Scopolamine, Nabilone, Rolapitant, Dronabinol', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112401, 'Grepafloxacin', 'Vardenafil', 'Major', 'Grepafloxacin can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112532/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[4] Thomas M, Maconochie JG, Fletcher E "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol 41 (1996): 77-81[5] Lode H, Vogel F, Elies W "Grepafloxacin: A review of its safety profile based on clinical trials and postmarketing surveillance." Clin Ther 21 (1999): 61-74[6] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[7] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 'Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Oxybutynin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112402, 'Guanabenz', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112533/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112403, 'Guanadrel', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112534/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112404, 'Guanethidine', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112535/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', 'Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Epinephrine, Brimonidine, Levobunolol', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112405, 'Guanfacine', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112536/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112406, 'Halofantrine', 'Vardenafil', 'Major', 'Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses. QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112537/', '[1] "Product Information. Lariam (mefloquine)." Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Halfan (halofantrine)." GlaxoSmithKline, Philadelphia, PA.[4] Nosten F, ter Kuile FO, Luxemburger C, et al "Cardiac effects of antimalarial treatment with halofantrine." Lancet 341 (1993): 1054-6[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] "Sudden death in a traveler following halofantrine administration--Togo, 2000." MMWR Morb Mortal Wkly Rep 50 (2001): 169-70, 179[7] Giao PT, de Vries PJ "Pharmacokinetic interactions of antimalarial agents." Clin Pharmacokinet 40 (2001): 343-73[8] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[9] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7[10] Giao PT, de Vries PJ "Pharmacokinetic interactions of antimalarial agents." Clin Pharmacokinet 40 (2001): 343-73[11] "Product Information. Halfan (halofantrine)." GlaxoSmithKline, Philadelphia, PA.[12] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7[13] Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C "Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine." Clin Pharmacol Ther 72 (2002): 514-23', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, More', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112407, 'Haloperidol', 'Vardenafil', 'Major', 'Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Haloperidol treatment alone has been associated with a number of reported cases of torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with haloperidol. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.', 'DDInter', 'Caution is recommended if haloperidol is used in combination with other drugs that can prolong the QT interval, particularly when administered intravenously or at higher than recommended dosages.', 'Synergism', 'Caution is recommended if haloperidol is used in combination with other drugs that can prolong the QT interval, particularly when administered intravenously or at higher than recommended dosages.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112538/', '[1] Huyse F, van Schijndel RS "Haloperidol and cardiac arrest." Lancet 2 (1988): 568-9[2] "Product Information. Haldol (haloperidol)." McNeil Pharmaceutical, Raritan, NJ.[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] O''Brien JM, Rockwood RP, Suh KI "Haloperidol-induced torsade de pointes." Ann Pharmacother 33 (1999): 1046-9[7] Wilt JL, Minnema AM, Johnson RF, Rosenblum AM "Torsade de pointes associated with the use of intravenous haloperidol." Ann Intern Med 119 (1993): 391-4[8] Hatta K, Takahashi T, Nakamura H, Yamashiro H, Asukai N, Matsuzaki I, Yonezawa Y "The association between intravenous haloperidol and prolonged QT interval." J Clin Psychopharmacol 21 (2001): 257-61[9] Metzger E, Friedman R "Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill." J Clin Psychopharmacol 13 (1993): 128-32[10] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[11] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[12] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112408, 'Halothane', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112539/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112409, 'Histrelin', 'Vardenafil', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112540/', '[1] "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] "Product Information. Zoladex (goserelin)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.[5] "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc, Deerfield, IL.[7] "Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals, New York, NY.[8] "Product Information. Plenaxis (abarelix)." Praecis Pharmaceuticals Inc, Waltham, MA.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112410, 'Hydralazine', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112541/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112411, 'Hydroflumethiazide', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112542/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Tinidazole, Ascorbic acid, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Probenecid, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, Zonisamide, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112412, 'Hydroxychloroquine', 'Vardenafil', 'Major', 'Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Because COVID-19 may disproportionately affect the elderly and individuals with preexisting heart disease, and cardiac complications such as myocarditis and cardiomyopathy as well as organ failure may occur in patients with severe COVID-19, it appears likely that hospitalized patients with COVID-19 may represent a particularly susceptible and high-risk population, and other, less critically ill patients may not have the same arrhythmic risk.', 'DDInter', 'Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.g., QTc >=500 msec) or congenital long QT syndrome. Close monitoring of QTc interval, electrolyte levels, and renal and hepatic function is recommended if concomitant use is required and benefits are anticipated to outweigh the risks. Electrolyte abnormalities should be corrected prior to initiating treatment with chloroquine or hydroxychloroquine. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Because chloroquine and hydroxychloroquine are eliminated slowly from the body, the potential for drug interactions should be observed for a prolonged period following their discontinuation.', 'Synergism', 'Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112543/', '[1] Mercuro NJ, Yen CF, Shim DJ, et.al "Risk of QT interval prolongation associated with the use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)" JAMA Cardiol May 1:e201834 (2020): epub ahead of print[2] "Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine)." Prasco Laboratories, Cincinnati, OH.[3] US Food and Drug Administration "FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF HYDROXYCHLOROQUINE SULFATE SUPPLIED FROM THE STRATEGIC NATIONAL STOCKPILE FOR TREATMENT OF COVID-19 IN CERTAIN HOSPITALIZED PATIENTS. Available from: URL: https://www.fda.gov/media/" ({2020, Apr 27]):[4] "Product Information. Plaquenil (R). (hydroxychloroquine)." Sanofi Winthrop Pharmaceuticals, New York, NY.[5] "Product Information. Chloroquine Phosphate (chloroquine)." West-Ward Pharmaceutical Corporation, Eatontown, NJ.[6] Bessiere F, Roccia H, Deliniere A, et.al "Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit." JAMA Cardiol May 1 (2020): epub ahead of print[7] National Institutes of Health (NIH) "Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available from: URL: https://covid19treatmentguidelines.nih.gov/" ([2020, Apr 21]):[8] Sacher F, Fauchier L, Boveda S, et.al "Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection." Arch Cardiovasc Dis Apr 24 (2020): epub ahead of print[9] Kapoor A, Pandurangi U, Arora V, et.al "Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society." Indian Pacing Electorphysiol J Apr 8 (2020): epub ahead of print[10] Borba MGS, Val FFA, Sampaio VS, et.al "Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 1 (SARS-CoV-2) infection: A randomized clinical trial." JAMA Netw Open Apr 1 (2020): epub ahead of print[11] Sapp JL, Alqarawi W, MacIntyre CJ, et.al "Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: A statement from the Canadian Heart Rhythm Society." Can J Cardiol Apr 8 (2020): epub ahead of print[12] Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ "Chloroquine for SARS-CoV-2: Implications of its unique pharmacokinetic and safety properties." Clin Pharmacokinet Ar 18 (2020): epub ahead of print[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] Javelot H, El-Hage W, Meyer G, Becker G, Michel B, Hingray C "COVID-19 and (hydroxy)chloroquine-azithromycin combination: should we take the risk for our patients?" Br J Clin Pharmacol Apr 29 (2020): epub ahead of print[15] US Food and Drug Administration "Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication - FDA Cautions Against Use Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems. Available from: URL: https://www.fda.gov/safety/medical-product-" ([2020, Apr 24]):[16] Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ "Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)" Mayo Clin Proc Apr 7 (2020): epub ahead of print[17] Roden DM, Harrington RA, Poppas A, Russo AM "Considerations for drug interactions on QTc in exploratory COVID-19 (Coroanvirus disease 2019) treatment." Heart Rhythm Apr 14 (2020): epub ahead of print[18] mitra RL, Greenstein SA, Epstein lm "An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin; Possible benefits of intravenous lidocaine." HeartRythm Case Rep Apr 1 (2020): epub ahead of print[19] US Food and Drug Administration "FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF CHLOROQUINE PHOSPHATE SUPPLIED FROM THE STRATEGIC NATIONAL STOCKPILE FOR TREATMENT OF COVID-19 IN CERTAIN HOSPITALIZED PATIENTS. Available from: URL: https://www.fda.gov/media/13653" ([2020, Apr 27]):[20] Saleh M, Gabriels J, ChangD, et.al "The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection." Circ Arrhythm Electrophysiol Apr 29 (2020): epub ahead of print[21] Bonow RO, Hernandez AF, Turakhia M "Hydroxychloroquine, coronavirus disease 2019, and QT prolongation." JAMA Cardiol May 1 (2020): epub ahead of print[22] Cerner Multum, Inc. "Australian Product Information." O 0', 'Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112413, 'Hydroxyzine', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112544/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Clobazam, Meprobamate, Chlordiazepoxide, Halazepam, Buspirone, Clorazepic acid, Oxazepam', 'Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112414, 'Ibutilide', 'Vardenafil', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112545/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Corvert (ibutilide)." Pharmacia and Upjohn, Kalamazoo, MI.[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 'Lidocaine, Moricizine, Bretylium, Tocainide', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112415, 'Idarubicin', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112546/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112416, 'Idelalisib', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112547/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Acetohydroxamic acid, Alprostadil, Trospium, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Magnesium hydroxide, More', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112417, 'Iloperidone', 'Vardenafil', 'Major', 'Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged. Persistent QTc measurements exceeding 500 msec will require suspension of iloperidone therapy and immediate action to correct any concomitant risk factors before resuming treatment.', 'Synergism', 'Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112548/', '[1] "Product Information. Exforge HCT (amlodipine/hydrochlorothiazide/valsartan)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, Ammonium chloride, Dimethyl sulfoxide', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112418, 'Iloprost', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112549/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Oxybutynin, Magnesium hydroxide, More', 'Ticagrelor, Betrixaban, Apixaban, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112419, 'Imatinib', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112550/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112420, 'Imipramine', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112551/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Avanafil, Tadalafil, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112421, 'Indacaterol', 'Vardenafil', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112552/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112422, 'Indapamide', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112553/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Tinidazole, Ascorbic acid, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Probenecid, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, Zonisamide, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Mirabegron, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112423, 'Indinavir', 'Vardenafil', 'Major', 'Coadministration with indinavir may significantly increase the plasma concentrations of vardenafil. The mechanism is indinavir inhibition of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of vardenafil.', 'DDInter', 'Patients treated with indinavir should not receive more than a single 2.5 mg dose of vardenafil within a 24-hour period. Patients should be advised to promptly notify their physician if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).', 'Metabolism', 'Patients treated with indinavir should not receive more than a single 2.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112554/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S "Single-dose pharmacokinetics of indinavir and the effect of food." Antimicrob Agents Chemother 42 (1998): 332-8[3] Shelton MJ, Wynn HE, Newitt RG, DiFrancesco R "Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects." J Clin Pharmacol 41 (2001): 435-42[4] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[5] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[8] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[23] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, More', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112424, 'Inotuzumab ozogamicin', 'Vardenafil', 'Moderate', 'Inotuzumab ozogamicin may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of inotuzumab ozogamicin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use cannot be avoided or if inotuzumab ozogamicin is used in patients with other risk factors for QT prolongation. The manufacturer suggests obtaining electrocardiograms and serum electrolytes at baseline and regularly during treatment.', 'Synergism', 'Coadministration of inotuzumab ozogamicin with other drugs that can prolong the QT interval should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112555/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Besponsa (inotuzumab ozogamicin)." Wyeth Laboratories, Philadelphia, PA.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112425, 'Irbesartan', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112556/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Magnesium hydroxide, More', 'Sacubitril', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112426, 'Isavuconazonium', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112557/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112427, 'Isocarboxazid', 'Vardenafil', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112558/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112428, 'Isoetharine', 'Vardenafil', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112559/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112429, 'Isoniazid', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112560/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Rifampicin, Cycloserine, Rifabutin, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112430, 'Isoprenaline', 'Vardenafil', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112561/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112431, 'Isosorbide', 'Vardenafil', 'Major', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the hypotensive effect of organic nitrates. Severe hypotension, syncope, or myocardial ischemia may result from use of the combination. The mechanism involves peripheral vasodilation secondary to enhanced levels of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells, as PDE5 inhibitors prevent degradation of cGMP while nitrates promote its synthesis.', 'DDInter', 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated. A suitable time interval following sildenafil or vardenafil use for the safe administration of nitrates has not been determined. For patients treated with avanafil or tadalafil, at least 12 hours after the last dose of avanafil and 48 hours after the last dose of tadalafil are recommended before nitrate administration, should it be deemed medically necessary in a life-threatening situation. Even then, nitrates should only be administered under close medical supervision with appropriate hemodynamic monitoring. Patients should be advised to seek immediate medical attention if they experience anginal chest pain after taking a PDE5 inhibitor.', 'Synergism', 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112562/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[4] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[5] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation, Silver Spring, MD.', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112432, 'Isosorbide dinitrate', 'Vardenafil', 'Major', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the hypotensive effect of organic nitrates. Severe hypotension, syncope, or myocardial ischemia may result from use of the combination. The mechanism involves peripheral vasodilation secondary to enhanced levels of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells, as PDE5 inhibitors prevent degradation of cGMP while nitrates promote its synthesis.', 'DDInter', 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated. A suitable time interval following sildenafil or vardenafil use for the safe administration of nitrates has not been determined. For patients treated with avanafil or tadalafil, at least 12 hours after the last dose of avanafil and 48 hours after the last dose of tadalafil are recommended before nitrate administration, should it be deemed medically necessary in a life-threatening situation. Even then, nitrates should only be administered under close medical supervision with appropriate hemodynamic monitoring. Patients should be advised to seek immediate medical attention if they experience anginal chest pain after taking a PDE5 inhibitor.', 'Synergism', 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112563/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[4] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[5] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation, Silver Spring, MD.', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Papaverine, More', 'Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Prednisolone, Betamethasone, Fluorometholone, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112433, 'Isosorbide mononitrate', 'Vardenafil', 'Major', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the hypotensive effect of organic nitrates. Severe hypotension, syncope, or myocardial ischemia may result from use of the combination. The mechanism involves peripheral vasodilation secondary to enhanced levels of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells, as PDE5 inhibitors prevent degradation of cGMP while nitrates promote its synthesis.', 'DDInter', 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated. A suitable time interval following sildenafil or vardenafil use for the safe administration of nitrates has not been determined. For patients treated with avanafil or tadalafil, at least 12 hours after the last dose of avanafil and 48 hours after the last dose of tadalafil are recommended before nitrate administration, should it be deemed medically necessary in a life-threatening situation. Even then, nitrates should only be administered under close medical supervision with appropriate hemodynamic monitoring. Patients should be advised to seek immediate medical attention if they experience anginal chest pain after taking a PDE5 inhibitor.', 'Synergism', 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112564/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[4] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[5] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation, Silver Spring, MD.', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Papaverine, Phenyl salicylate, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112434, 'Isoxsuprine', 'Vardenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112565/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112435, 'Itraconazole', 'Vardenafil', 'Major', 'Coadministration with the azole antifungal agents, ketoconazole and itraconazole, may significantly increase the plasma concentrations of vardenafil. The mechanism is azole inhibition of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of vardenafil.', 'DDInter', 'Patients treated with ketoconazole or itraconazole at a dosage of 200 mg/day should not receive more than a single 5 mg dose of vardenafil within a 24-hour period. Since higher dosages of the azole antifungal agents may result in higher increases in vardenafil plasma concentrations, a single 2.5 mg dose of vardenafil should not be exceeded within a 24-hour period when used in combination with ketoconazole or itraconazole 400 mg/day. Some authorities recommend avoiding concomitant use of vardenafil during and for 2 weeks after treatment with itraconazole. Patients should be advised to promptly notify their physician if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).', 'Metabolism', 'Patients treated with ketoconazole or itraconazole at a dosage of 200 mg/day should not receive more than a single 5 mg dose of vardenafil within a 24-hour period.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112566/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[7] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[8] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[12] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[15] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[17] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[19] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[21] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[22] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[24] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[26] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[27] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[28] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[29] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[30] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[31] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[32] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[33] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[34] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[35] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112436, 'Ivabradine', 'Vardenafil', 'Major', 'Due to its bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased when ivabradine is used with drugs that prolong the QT interval.', 'DDInter', 'Coadministration of ivabradine with drugs that can prolong the QT interval should generally be avoided. Caution and cardiac monitoring are recommended if concomitant use is required.', 'Synergism', 'Coadministration of ivabradine with drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112567/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Corlanor (ivabradine)." Amgen USA, Thousand Oaks, CA.[3] Mittal SR "Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine." J Assoc Physicians India 62 (2014): 426-7[4] "Product Information. Corlanor (ivabradine)." Amgen USA, Thousand Oaks, CA.[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Regadenoson, Ubidecarenone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112437, 'Vardenafil', 'Ivosidenib', 'Major', 'Ivosidenib can cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of ivosidenib with other drugs that can prolong the QT interval should generally be avoided. Otherwise, close monitoring of electrocardiograms and electrolytes is recommended. If QT prolongation occurs during treatment, withhold and/or reduce dose in accordance with the product labeling. Ivosidenib should be permanently discontinued in patients who develop QT prolongation with signs or symptoms of life-threatening arrhythmia.', 'Synergism', 'Coadministration of ivosidenib with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112568/', '[1] "Product Information. Tibsovo (ivosidenib)." Agios Pharmaceuticals, Cambridge, MA.[2] "Product Information. Tibsovo (ivosidenib)." Agios Pharmaceuticals, Cambridge, MA.[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Oxybutynin, More', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112438, 'Vardenafil', 'Ketoconazole', 'Major', 'Coadministration with the azole antifungal agents, ketoconazole and itraconazole, may significantly increase the plasma concentrations of vardenafil. The mechanism is azole inhibition of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of vardenafil.', 'DDInter', 'Patients treated with ketoconazole or itraconazole at a dosage of 200 mg/day should not receive more than a single 5 mg dose of vardenafil within a 24-hour period. Since higher dosages of the azole antifungal agents may result in higher increases in vardenafil plasma concentrations, a single 2.5 mg dose of vardenafil should not be exceeded within a 24-hour period when used in combination with ketoconazole or itraconazole 400 mg/day. Some authorities recommend avoiding concomitant use of vardenafil during and for 2 weeks after treatment with itraconazole. Patients should be advised to promptly notify their physician if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).', 'Metabolism', 'Patients treated with ketoconazole or itraconazole at a dosage of 200 mg/day should not receive more than a single 5 mg dose of vardenafil within a 24-hour period.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112569/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[7] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[8] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[12] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[15] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[17] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[19] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[21] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[22] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[24] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[26] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[27] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[28] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[29] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[30] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[31] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[32] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[33] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[34] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[35] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Pentosan polysulfate, Calcium chloride, Acetohydroxamic acid, Alprostadil, Yohimbine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Tinidazole, Ascorbic acid, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Probenecid, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, Zonisamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112439, 'Vardenafil', 'Labetalol', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112570/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Papaverine, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112440, 'Vardenafil', 'Lactitol', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112571/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 'Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112441, 'Vardenafil', 'Lactulose', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112572/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 'Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Avanafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112442, 'Vardenafil', 'Lapatinib', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112573/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112443, 'Vardenafil', 'Larotrectinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112574/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112444, 'Vardenafil', 'Lefamulin', 'Major', 'When administered orally, lefamulin may significantly increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Increased exposure to sensitive CYP450 3A4 substrates that can prolong the QT interval may increase the risk of ventricular arrhythmias including torsade de pointes and sudden death. Because lefamulin itself may cause prolongation of the QT interval, the potential for a pharmacodynamic interaction with other agents that can prolong the QT interval should also be considered.', 'DDInter', 'Concomitant use of oral (but not intravenous) lefamulin with sensitive CYP450 3A4 substrates that can prolong the QT interval is considered contraindicated. However, because lefamulin itself can also cause QT prolongation regardless of the route of administration, concomitant use with other drugs that can prolong the QT interval should generally be avoided even when lefamulin is administered intravenously.', 'Metabolism, Synergism', 'Concomitant use of oral (but not intravenous) lefamulin with sensitive CYP450 3A4 substrates that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112575/', '[1] "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] "Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.[3] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[4] "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112445, 'Vardenafil', 'Leflunomide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112576/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Acetohydroxamic acid, Alprostadil, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Avanafil, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112446, 'Vardenafil', 'Lemborexant', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112577/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Papaverine, Phenyl salicylate, Oxybutynin, More', 'Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112447, 'Vardenafil', 'Lenvatinib', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112578/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112448, 'Vardenafil', 'Letermovir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112579/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112449, 'Vardenafil', 'Levosalbutamol', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112580/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112450, 'Vardenafil', 'Levamlodipine', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112581/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Tolterodine, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112451, 'Vardenafil', 'Levofloxacin', 'Moderate', 'Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112582/', '[1] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002): 455-64[5] Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES "Arrhythmias associated with fluoroquinolone therapy." Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones." Br Med J 322 (2001): 46-7[12] "Product Information. Floxin (ofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B "Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?" South Med J 99 (2006): 52-6[14] Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG "QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine." Ann Pharmacother 39 (2005): 543-6[16] Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[20] Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[25] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Flavoxate, More', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin, Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112452, 'Vardenafil', 'Levacetylmethadol', 'Major', 'Levomethadyl acetate may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. High dosages of levomethadyl acetate alone have been associated with QT interval prolongation and torsade de pointes.', 'DDInter', 'Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112583/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.[3] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[4] Krantz MJ, Mehler PS "Synthetic opioids and QT prolongation." Arch Intern Med 163 (2003): 1615; author reply 1615[5] Deamer RL, Wilson DR, Clark DS, Prichard JG "Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM)." J Addict Dis 20 (2001): 7-14[6] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, Ammonium chloride, Dimethyl sulfoxide', 'Diamorphine, Acamprosate, Naltrexone, Nalmefene, Nicotine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112453, 'Vardenafil', 'Linezolid', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112584/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Flavoxate, Darifenacin, Phenyl salicylate, Magnesium hydroxide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112454, 'Vardenafil', 'Lisdexamfetamine', 'Moderate', 'Limited data suggests the lisdexamfetamine may rarely prolong the QT interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including ventricular tachycardia, torsade de pointes, and sudden death.', 'DDInter', 'Caution is recommended whenever lisdexamfetamine is used concomitantly with other agents known to cause QT prolongation. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended whenever lisdexamfetamine is used concomitantly with other agents known to cause QT prolongation.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112585/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[7] Jiao X, Velez S, Ringstad J, Eyma V, Miller D, Bleiberg M "Myocardial infarction associated with Adderall XR and alcohol use in a young man." J Am Board Fam Med 22 (2009): 197-201', 'Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Flavoxate, Darifenacin, More', 'Amphetamine, Pemoline, Metamfetamine, Solriamfetol, Caffeine, Dexmethylphenidate, Dextroamphetamine, Citicoline', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112455, 'Vardenafil', 'Lisinopril', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112586/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Bempedoic acid', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Papaverine, Ammonium chloride, Dimethyl sulfoxide, Solifenacin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112456, 'Vardenafil', 'Lithium carbonate', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112587/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Acetohydroxamic acid, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112457, 'Vardenafil', 'Lofexidine', 'Moderate', 'Lofexidine has been associated with asymptomatic prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Coadministration of lofexidine with other agents with hypotensive effects may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution is recommended if lofexidine is used in combination with other drugs that can prolong the QT interval. Periodic monitoring with on-treatment electrocardiograms and serum electrolytes (magnesium, potassium) should be considered. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if lofexidine is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112588/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Lucemyra (lofexidine)." US WorldMeds LLC, Louisville , KY.[4] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[7] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Darifenacin, More', 'Diamorphine, Acamprosate, Naltrexone, Nalmefene, Nicotine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112458, 'Vardenafil', 'Lomefloxacin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112589/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Flavoxate, More', 'Rifamycin, Kanamycin, Ampicillin, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112459, 'Vardenafil', 'Lomitapide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112590/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', 'Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, Colestipol, Bempedoic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112460, 'Vardenafil', 'Lonafarnib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112591/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112461, 'Vardenafil', 'Lorlatinib', 'Moderate', 'Coadministration with lorlatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The proposed mechanism is increased clearance due to lorlatinib-mediated induction of CYP450 3A4 metabolism.', 'DDInter', 'Caution is advised when lorlatinib is used concomitantly with drugs that are substrates of CYP450 3A4. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lorlatinib is added to or withdrawn from therapy. Avoid concomitant use with lorlatinib where minimal decreases in concentration of the CYP450 3A4 substrate may lead to serious therapeutic failure. If coadministration is required, the CYP450 3A4 substrate dosage should be increased in accordance with approved product labeling.', 'Metabolism', 'Caution is advised when lorlatinib is used concomitantly with drugs that are substrates of CYP450 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112592/', '[1] "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112462, 'Vardenafil', 'Losartan', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112593/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Sacubitril', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Papaverine, Magnesium hydroxide, Ammonium chloride, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112463, 'Vardenafil', 'Macimorelin', 'Major', 'Macimorelin can cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of macimorelin with other drugs that can prolong the QT interval should generally be avoided. A sufficient washout period following discontinuation of these drugs is recommended prior to macimorelin administration. Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of macimorelin with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112594/', '[1] "Product Information. Macrilen (macimorelin)." Aeterna Zentaris, Charleston, SC.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] "Product Information. Macrilen (macimorelin)." Aeterna Zentaris, Charleston, SC.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Methacholine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112464, 'Vardenafil', 'Magnesium citrate', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112595/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 'Sorbitol, Sodium citrate, Mannitol, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Magnesium gluconate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112465, 'Vardenafil', 'Magnesium hydroxide', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112596/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Vardenafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112466, 'Vardenafil', 'Maprotiline', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112597/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Alprostadil, Acetohydroxamic acid, Avanafil, Phenyl salicylate, Tadalafil, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112467, 'Vardenafil', 'Maraviroc', 'Moderate', 'Maraviroc may potentiate the hypotensive effect of some medications.', 'DDInter', 'Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112598/', '[1] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 'Darifenacin, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, Magnesium hydroxide, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112468, 'Vardenafil', 'Mecamylamine', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112599/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112469, 'Vardenafil', 'Mefloquine', 'Moderate', 'Mefloquine is a myocardial depressant and can cause ECG abnormalities. Theoretically, coadministration with other agents that can affect cardiac conduction (e.g., antiarrhythmic agents, beta blockers, calcium channel blockers, certain antihistamines, tricyclic antidepressants, phenothiazines, some neuroleptics) may result in additive effects and increased risk of ventricular arrhythmias including ventricular tachycardia and torsade de pointes.', 'DDInter', 'Caution and clinical monitoring are recommended if mefloquine is used in combination with other drugs that can prolong the QT interval or otherwise affect cardiac conduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes or other arrhythmia such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended if mefloquine is used in combination with other drugs that can prolong the QT interval or otherwise affect cardiac conduction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112600/', '[1] "Product Information. Lariam (mefloquine)." Roche Laboratories, Nutley, NJ.[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] "Product Information. Lariam (mefloquine)." Roche Laboratories, Nutley, NJ.[6] Schmidt LE, Dalhoff K "Food-drug interactions." Drugs 62 (2002): 1481-502[7] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[8] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[10] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112470, 'Vardenafil', 'Mesoridazine', 'Major', 'Mesoridazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Mesoridazine overdosage has been associated with ventricular arrhythmias and death. The extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s). In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with mesoridazine. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.', 'DDInter', 'Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112601/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Serentil (mesoridazine)" Boehringer-Ingelheim, Ridgefield, CT.[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, More', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112471, 'Vardenafil', 'Orciprenaline', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112602/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate, Ephedrine', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112472, 'Vardenafil', 'Methazolamide', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112603/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Tinidazole, Ascorbic acid, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Probenecid, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, Zonisamide, More', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112473, 'Vardenafil', 'Methotrimeprazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112604/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, Ammonium chloride, Dimethyl sulfoxide', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112474, 'Vardenafil', 'Metolazone', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112605/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Tinidazole, Ascorbic acid, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Probenecid, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, Zonisamide, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112475, 'Vardenafil', 'Metoprolol', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112606/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, Solifenacin', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112476, 'Vardenafil', 'Miconazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112607/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More', 'Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112477, 'Vardenafil', 'Midostaurin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112608/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112478, 'Vardenafil', 'Mifepristone', 'Major', 'Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing''s syndrome, coadministration with other drugs that can prolong the QT interval should generally be avoided. Caution is recommended if no alternatives exist and concomitant use is required. Serum potassium should be assessed prior to starting mifepristone and 1 to 2 weeks following initiation of therapy or an increase in dosage, and periodically as needed. Hypokalemia must be corrected prior to initiation of mifepristone. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heart rhythm.', 'Synergism', 'When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing''s syndrome, coadministration with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112609/', '[1] "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated, Menlo Park, CA.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated, Menlo Park, CA.[6] "Product Information. Mifeprex (mifepristone)" Danco Laboratories, New York, NY.[7] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[8] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[10] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Ulipristal, Ospemifene, Raloxifene, Bazedoxifene, Prasterone', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112479, 'Vardenafil', 'Mineral oil', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112610/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 'Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112480, 'Vardenafil', 'Minoxidil (topical)', 'Moderate', 'Theoretically, topical administration of minoxidil may potentiate the hypotensive effects of systemic minoxidil and other vasodilators. Increased systemic absorption may occur when topical minoxidil is used in excess of normally recommended dosages or applied to compromised skin.', 'DDInter', 'Patients prescribed topical minoxidil in combination with systemic vasodilators or peripherally-acting antiadrenergic agents should be monitored for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.', 'Synergism', 'Patients prescribed topical minoxidil in combination with systemic vasodilators or peripherally-acting antiadrenergic agents should be monitored for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112611/', '[1] Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988): 481-5[2] "Product Information. Rogaine (minoxidil topical)." Johnson and Johnson/McNeil Consumer, Fort Washington, PA.', 'Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, Dupilumab, More', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112481, 'Vardenafil', 'Mirtazapine', 'Moderate', 'Available data suggest that mirtazapine may cause mild prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if mirtazapine is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if mirtazapine is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112612/', '[1] "Product Information. Remeron (mirtazapine)." Organon, West Orange, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112482, 'Vardenafil', 'Modafinil', 'Minor', 'Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Modafinil and armodafinil are modest inducers of CYP450 3A4, and pharmacokinetic studies suggest that their effects may be primarily intestinal rather than hepatic. Thus, clinically significant interactions would most likely be expected with drugs that have low oral bioavailability due to significant intestinal CYP450 3A4-mediated first-pass metabolism (e.g., buspirone, cyclosporine, lovastatin, midazolam, saquinavir, simvastatin, sirolimus, tacrolimus, triazolam, calcium channel blockers). However, the potential for interaction should be considered with any drug metabolized by CYP450 3A4, especially given the high degree of interpatient variability with respect to CYP450-mediated metabolism. Pharmacologic response to these drugs may be altered and should be monitored more closely whenever modafinil or armodafinil is added to or withdrawn from therapy. Dosage adjustments may be required if an interaction is suspected.', 'DDInter', '-', 'Metabolism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112613/', '[1] Robertson P Jr, Hellriegel ET, Arora S, Nelson M "Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers." Clin Pharmacol Ther 71 (2002): 46-56[2] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53[3] "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.[4] Robertson P, Decory HH, Madan A, Parkinson A "In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil." Drug Metab Dispos 28 (2000): 664-71[5] "Product Information. Nuvigil (armodafinil)." Cephalon Inc, West Chester, PA.[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.[11] "Product Information. Nuvigil (armodafinil)." Cephalon Inc, West Chester, PA.', 'Amphetamine, Pemoline, Metamfetamine, Solriamfetol, Caffeine, Dexmethylphenidate, Dextroamphetamine, Citicoline', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Magnesium hydroxide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112483, 'Vardenafil', 'Moexipril', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112614/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112484, 'Vardenafil', 'Moxifloxacin', 'Major', 'Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112615/', '[1] Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001): 23[2] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003): 292-303[5] Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002): 455-64[6] "Product Information. Tequin (gatifloxacin)" Bristol-Myers Squibb, Princeton, NJ.[7] Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004): 1091-124[8] Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72[9] Dale KM, Lertsburapa K, Kluger J, White CM "Moxifloxacin and torsade de pointes." Ann Pharmacother 41 (2007): 336-40[10] Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002): 861-3[11] Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003): 2317-20[12] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[13] Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001): 361-2[14] Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF "Effects of three fluoroquinolones on QT analysis after standard treatment courses." Ann Noninvasive Electrocardiol 11 (2006): 52-6[15] Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000): 658-66[16] Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19[17] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[18] Falagas ME, Rafailidis PI, Rosmarakis ES "Arrhythmias associated with fluoroquinolone therapy." Int J Antimicrob Agents 29 (2007): 374-9[19] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.[20] White CM, Grant EM, Quintiliani R "Moxifloxacin does increase the corrected QT interval." Clin Infect Dis 33 (2001): 1441-2[21] Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002): 269-77[22] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[23] Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001): 1468-72[24] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001): 46-7[25] Cerner Multum, Inc. "Australian Product Information." O 0[26] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6[27] "Product Information. Tequin (gatifloxacin)" Bristol-Myers Squibb, Princeton, NJ.[28] Wallace AW, Victory JM, Amsden GW "Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers." J Clin Pharmacol 43 (2003): 92-6', 'Rifamycin, Kanamycin, Ampicillin, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112485, 'Vardenafil', 'Nadolol', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112616/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Papaverine, Phenyl salicylate, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112486, 'Vardenafil', 'Nateglinide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112617/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, Semaglutide, More', 'Darifenacin, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112487, 'Vardenafil', 'Nebivolol', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112618/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Papaverine, Phenyl salicylate, More', 'Sacubitril', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112488, 'Vardenafil', 'Nefazodone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112619/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112489, 'Vardenafil', 'Nelfinavir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112620/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, More', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112490, 'Vardenafil', 'Nesiritide', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112621/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112491, 'Vardenafil', 'Nicardipine', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112622/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Tolterodine, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112492, 'Vardenafil', 'Nilotinib', 'Major', 'Nilotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of nilotinib with other drugs that can prolong the QT interval should generally be avoided. Should treatment with other QT-prolonging drugs be required, the manufacturer recommends that nilotinib therapy be withheld temporarily. Caution and clinical monitoring are recommended if concomitant use is unavoidable. Patients should have frequent ECGs and be monitored for arrhythmias when QT interval is prolonged.', 'Synergism', 'Coadministration of nilotinib with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112623/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals, East Hanover, NJ.[5] "Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals, East Hanover, NJ.[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112493, 'Vardenafil', 'Nilutamide', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112624/', '[1] "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] "Product Information. Zoladex (goserelin)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.[5] "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc, Deerfield, IL.[7] "Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals, New York, NY.[8] "Product Information. Plenaxis (abarelix)." Praecis Pharmaceuticals Inc, Waltham, MA.', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112494, 'Vardenafil', 'Nimodipine', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112625/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Tolterodine, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112495, 'Vardenafil', 'Nisoldipine', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112626/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Oxybutynin, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112496, 'Vardenafil', 'Nitisinone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112627/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More', 'Darifenacin, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112497, 'Vardenafil', 'Nitroglycerin', 'Major', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the hypotensive effect of organic nitrates. Severe hypotension, syncope, or myocardial ischemia may result from use of the combination. The mechanism involves peripheral vasodilation secondary to enhanced levels of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells, as PDE5 inhibitors prevent degradation of cGMP while nitrates promote its synthesis.', 'DDInter', 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated. A suitable time interval following sildenafil or vardenafil use for the safe administration of nitrates has not been determined. For patients treated with avanafil or tadalafil, at least 12 hours after the last dose of avanafil and 48 hours after the last dose of tadalafil are recommended before nitrate administration, should it be deemed medically necessary in a life-threatening situation. Even then, nitrates should only be administered under close medical supervision with appropriate hemodynamic monitoring. Patients should be advised to seek immediate medical attention if they experience anginal chest pain after taking a PDE5 inhibitor.', 'Synergism', 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112628/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[4] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[5] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation, Silver Spring, MD.', 'Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Prednisolone, Betamethasone, Fluorometholone, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Mirabegron, Yohimbine, Papaverine, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112498, 'Vardenafil', 'Norfloxacin', 'Moderate', 'Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112629/', '[1] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002): 455-64[5] Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES "Arrhythmias associated with fluoroquinolone therapy." Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones." Br Med J 322 (2001): 46-7[12] "Product Information. Floxin (ofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B "Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?" South Med J 99 (2006): 52-6[14] Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG "QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine." Ann Pharmacother 39 (2005): 543-6[16] Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[20] Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[25] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Flavoxate, More', 'Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Netilmicin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112499, 'Vardenafil', 'Nortriptyline', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112630/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Avanafil, Phenyl salicylate, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112500, 'Vardenafil', 'Ofloxacin', 'Moderate', 'Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112631/', '[1] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002): 455-64[5] Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES "Arrhythmias associated with fluoroquinolone therapy." Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones." Br Med J 322 (2001): 46-7[12] "Product Information. Floxin (ofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B "Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?" South Med J 99 (2006): 52-6[14] Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG "QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine." Ann Pharmacother 39 (2005): 543-6[16] Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[20] Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[25] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Ammonium chloride, Dimethyl sulfoxide', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin, Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112501, 'Vardenafil', 'Olanzapine', 'Moderate', 'It is uncertain whether olanzapine causes clinically significant prolongation of the QT interval.', 'DDInter', 'Some authorities recommend caution when olanzapine is used with drugs that are known to cause QT prolongation.', 'Synergism', 'Some authorities recommend caution when olanzapine is used with drugs that are known to cause QT prolongation.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112632/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[4] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[5] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[6] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[7] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[8] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[9] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[10] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[11] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[12] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[16] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[17] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[19] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112502, 'Vardenafil', 'Oliceridine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112633/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, Ammonium chloride, Dimethyl sulfoxide', 'Codeine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Dezocine, Opium, Pentazocine, Dihydrocodeine, Naloxone, Nalbuphine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112503, 'Vardenafil', 'Olmesartan', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112634/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Sacubitril', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112504, 'Vardenafil', 'Olodaterol', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112635/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112505, 'Vardenafil', 'Ondansetron', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112636/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, More', 'Scopolamine, Nabilone, Rolapitant, Dronabinol', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112506, 'Vardenafil', 'Osilodrostat', 'Moderate', 'Osilodrostat can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if osilodrostat is used in combination with other drugs that can prolong the QT interval. An electrocardiogram and serum electrolyte levels should be obtained prior to initiating osilodrostat therapy and periodically thereafter. Correct hypokalemia and/or hypomagnesemia before starting treatment and as indicated during treatment, as they may be risk factors for ventricular arrhythmias.', 'Synergism', 'Caution is recommended if osilodrostat is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112637/', '[1] "Product Information. Isturisa (osilodrostat)." Recordati Rare Diseases Inc, Lebanon, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112507, 'Vardenafil', 'Osimertinib', 'Major', 'Osimertinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if osimertinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting osimertinib therapy and periodically during treatment.', 'Synergism', 'Caution is recommended if osimertinib is used in combination with other drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112638/', '[1] "Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112508, 'Vardenafil', 'Oxaliplatin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112639/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112509, 'Vardenafil', 'Oxytocin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112640/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Methylergometrine, Misoprostol, Ergometrine, Dinoprostone, Terlipressin, Desmopressin', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112510, 'Vardenafil', 'Ozanimod', 'Major', 'Due to the risk of bradycardia and atrioventricular (AV) block, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of ozanimod treatment in patients receiving drugs that prolong the QT interval.', 'DDInter', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.', 'Synergism', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112641/', '[1] "Product Information. Zeposia (ozanimod)." Celgene Corporation, Summit, NJ.[2] "Product Information. Zeposia (ozanimod)." Celgene Corporation, Summit, NJ.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112511, 'Vardenafil', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112642/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112512, 'Vardenafil', 'Paliperidone', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112643/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, Ammonium chloride, Dimethyl sulfoxide', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112513, 'Vardenafil', 'Panobinostat', 'Major', 'Panobinostat can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Concomitant use of panobinostat with other drugs that can prolong the QT interval should generally be avoided. Anti-emetic drugs with known QT prolonging risk such as dolasetron, granisetron, ondansetron, palonosetron, and tropisetron may be used with frequent ECG monitoring. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting panobinostat therapy and periodically during treatment as clinically indicated.', 'Synergism', 'Concomitant use of panobinostat with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112644/', '[1] "Product Information. Farydak (panobinostat)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Farydak (panobinostat)." Novartis Pharmaceuticals, East Hanover, NJ.', 'Fesoterodine, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, More', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112514, 'Vardenafil', 'Papaverine', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112645/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Vardenafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112515, 'Vardenafil', 'Pasireotide', 'Major', 'Pasireotide can cause bradycardia and QT prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if pasireotide is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting pasireotide therapy and periodically during treatment in accordance with the product labeling. Hypokalemia and hypomagnesemia must be corrected prior to pasireotide administration.', 'Synergism', 'Caution is recommended if pasireotide is used in combination with other drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112646/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals, East Hanover, NJ.[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[6] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112516, 'Vardenafil', 'Pazopanib', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112647/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, Oxybutynin, More', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112517, 'Vardenafil', 'Penbutolol', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112648/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Papaverine, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112518, 'Vardenafil', 'Pentoxifylline', 'Moderate', 'Pentoxifylline may potentiate the action of hypotensive agents. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril. The mechanism of interaction has not been described.', 'DDInter', 'Caution is advised if pentoxifylline is used in combination with hypotensive agents. Periodic systemic blood pressure monitoring is recommended.', 'Synergism', 'Caution is advised if pentoxifylline is used in combination with hypotensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112649/', '[1] "Product Information. Trental (pentoxifylline)." Hoechst Marion-Roussel Inc, Kansas City, MO.', 'Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, More', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112519, 'Vardenafil', 'Perflutren', 'Moderate', 'Perflutren lipid microsphere suspension (Definity) has been reported to cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if perflutren lipid microsphere suspension is used in combination with other drugs that can prolong the QT interval. Please refer to the prescribing information for these drugs for more information. No data are available regarding the effect of perflutren protein-type A microsphere suspension (Optison) on the QT interval of the electrocardiogram.', 'Synergism', 'Caution is recommended if perflutren lipid microsphere suspension is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112650/', '[1] "Product Information. Definity (perflutren)." Lantheus Medical Imaging Inc, North Billerica, MA.[2] "Product Information. Optison (perflutren)." Mallinckrodt Medical Inc, St. Louis, MO.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112520, 'Vardenafil', 'Perindopril', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112651/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Bempedoic acid', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112521, 'Vardenafil', 'Perphenazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112652/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112522, 'Vardenafil', 'Phenelzine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112653/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112523, 'Vardenafil', 'Phenolphthalein', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112654/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 'Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112524, 'Vardenafil', 'Phenoxybenzamine', 'Moderate', 'Vardenafil may potentiate the hypotensive effect of alpha blockers, resulting in symptomatic hypotension in some patients. Vardenafil inhibits phosphodiesterase-5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation that may be additive with that induced by alpha blockers.', 'DDInter', 'Caution is advised if vardenafil is used in combination with alpha blockers. Patients who demonstrate hemodynamic instability on alpha blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of vardenafil. Therefore, patients should be stable on alpha blocker therapy prior to initiating vardenafil, and vardenafil should be initiated at the lowest recommended dosage (i.e., 5 mg). In those patients already on an optimized dosage of vardenafil, alpha blocker therapy should be initiated at the lowest dosage. The safety of vardenafil in combination with alpha blockers may be affected by other variables such as intravascular volume depletion and use of other antihypertensive medications.', 'Synergism', 'Caution is advised if vardenafil is used in combination with alpha blockers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112655/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[3] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[6] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[7] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[8] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[9] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[10] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[13] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[14] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[15] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[16] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[17] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[24] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[25] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[26] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[27] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[28] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[29] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[30] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[31] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[32] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[33] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112525, 'Vardenafil', 'Phenylbutazone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112656/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Fenoprofen, Meclofenamic acid, Ketorolac, Mefenamic acid, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, Flurbiprofen, Esomeprazole, More', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112526, 'Vardenafil', 'Pimavanserin', 'Moderate', 'Pimavanserin may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of pimavanserin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged.', 'Synergism', 'Coadministration of pimavanserin with other drugs that can prolong the QT interval should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112657/', '[1] "Product Information. Nuplazid (pimavanserin)." Accelis Pharma, East Windsor, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112527, 'Vardenafil', 'Pimozide', 'Major', 'Pimozide can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with pimozide. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.', 'DDInter', 'Coadministration of pimozide with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of pimozide with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112658/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Orap Tablets (pimozide)." Gate Pharmaceuticals, Sellersville, PA.[3] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[4] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[5] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[6] "Product Information. Orap Tablets (pimozide)." Gate Pharmaceuticals, Sellersville, PA.[7] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[8] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[10] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Phenyl salicylate, Tadalafil, More', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112528, 'Vardenafil', 'Pindolol', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112659/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Ammonium chloride, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112529, 'Vardenafil', 'Pitolisant', 'Moderate', 'Limited data suggest that pitolisant may produce mild to moderate QT interval prolongation (10 to 13 milliseconds) at doses 3 to 6 times the standard therapeutic dose. Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Coadministration with pitolisant may decrease the plasma concentrations and therapeutic effects of drugs that are primarily metabolized by CYP450 3A4. Pitolisant is a borderline/weak inducer of CYP450 3A4. When studied with midazolam, a probe substrate for CYP450 3A4, pitolisant was found to reduce midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) by less than 25%.', 'DDInter', 'Concomitant use of pitolisant with other agents associated with QT interval prolongation should generally be avoided. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. In addition, it may be advisable to avoid concomitant use of pitolisant with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index, if possible (e.g., ergot alkaloids, alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, macrolide immunosuppressants, oral midazolam, pimozide, quinidine, sufentanil, triazolam, vinca alkaloids). Caution is advised if pitolisant is used in combination with these drugs. Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary.', 'Metabolism', 'Concomitant use of pitolisant with other agents associated with QT interval prolongation should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112660/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Wakix (pitolisant)." Harmony Biosciences, LLC, Plymouth Meeting, PA.[3] Hooks MA "Tacrolimus, a new immunosuppressant--a review of the literature." Ann Pharmacother 28 (1994): 501-11[4] "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 'Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112530, 'Vardenafil', 'Polyethylene glycol (3350)', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112661/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112531, 'Vardenafil', 'Polythiazide', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112662/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Tinidazole, Ascorbic acid, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Probenecid, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, Zonisamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112532, 'Vardenafil', 'Posaconazole', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112663/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Tadalafil, More', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112533, 'Vardenafil', 'Prazosin', 'Moderate', 'Vardenafil may potentiate the hypotensive effect of alpha blockers, resulting in symptomatic hypotension in some patients. Vardenafil inhibits phosphodiesterase-5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation that may be additive with that induced by alpha blockers.', 'DDInter', 'Caution is advised if vardenafil is used in combination with alpha blockers. Patients who demonstrate hemodynamic instability on alpha blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of vardenafil. Therefore, patients should be stable on alpha blocker therapy prior to initiating vardenafil, and vardenafil should be initiated at the lowest recommended dosage (i.e., 5 mg). In those patients already on an optimized dosage of vardenafil, alpha blocker therapy should be initiated at the lowest dosage. The safety of vardenafil in combination with alpha blockers may be affected by other variables such as intravascular volume depletion and use of other antihypertensive medications.', 'Synergism', 'Caution is advised if vardenafil is used in combination with alpha blockers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112664/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[3] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[6] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[7] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[8] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[9] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[10] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[13] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[14] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[15] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[16] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[17] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[24] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[25] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[26] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[27] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[28] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[29] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[30] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[31] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[32] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[33] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112534, 'Vardenafil', 'Primaquine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112665/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, More', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112535, 'Vardenafil', 'Probucol', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112666/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, Colestipol, Bempedoic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112536, 'Vardenafil', 'Procainamide', 'Major', 'Vardenafil has been reported to cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, should avoid using vardenafil.', 'Synergism', 'Patients treated with class IA (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112667/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[3] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[6] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[7] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[8] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[9] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[10] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[13] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[14] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[15] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[16] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[17] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[24] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[25] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[26] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[27] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[28] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[29] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[30] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[31] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[32] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[33] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 'Lidocaine, Moricizine, Bretylium, Tocainide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112537, 'Vardenafil', 'Procarbazine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112668/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Flavoxate, More', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112538, 'Vardenafil', 'Promazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112669/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112539, 'Vardenafil', 'Propafenone', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112670/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, Tadalafil, More', 'Lidocaine, Moricizine, Bretylium, Tocainide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112540, 'Vardenafil', 'Propranolol', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112671/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, Solifenacin', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112541, 'Vardenafil', 'Protriptyline', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112672/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Alprostadil, Avanafil, Phenyl salicylate, Tadalafil, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112542, 'Vardenafil', 'Quetiapine', 'Moderate', 'There is some concern that quetiapine may have additive cardiovascular effects in combination with other drugs that are known to prolong the QT interval of the electrocardiogram.', 'DDInter', 'Coadministration of quetiapine with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. In addition, if combination therapy with agents with anticholinergic properties is required, caution is advised, particularly in the elderly and those with underlying organic brain disease.', 'Synergism', 'Coadministration of quetiapine with other drugs that can prolong the QT interval should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112673/', '[1] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[2] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] Vieweg WV "New generation antipsychotic drugs and QTc interval prolongation." Prim Care Companion J Clin Psychiatry 5 (2003): 205-15[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Vieweg WV, Schneider RK, Wood MA "Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine." Acta Psychiatr Scand 112 (2005): 318-22[9] Sala M, Vicentini A, Brambilla P, et al. "QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy." Ann Gen Psychiatry 4 (2005): 1[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[13] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112543, 'Vardenafil', 'Quinapril', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112674/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Papaverine, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112544, 'Vardenafil', 'Quinidine', 'Major', 'Vardenafil has been reported to cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, should avoid using vardenafil.', 'Synergism', 'Patients treated with class IA (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112675/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[3] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[6] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[7] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[8] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[9] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[10] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[13] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[14] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[15] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[16] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[17] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[24] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[25] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[26] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[27] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[28] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[29] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[30] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[31] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[32] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[33] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Lidocaine, Moricizine, Bretylium, Tocainide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112545, 'Vardenafil', 'Quinine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112676/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112546, 'Vardenafil', 'Ramipril', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112677/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Bempedoic acid', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Papaverine, Ammonium chloride, Dimethyl sulfoxide, Solifenacin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112547, 'Vardenafil', 'Ranolazine', 'Moderate', 'Ranolazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if ranolazine is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of ranolazine, the maximum recommended dosage of 1000 mg twice daily should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Ranolazine is contraindicated in patients with liver cirrhosis because of the profound effect on QT prolongation in this population.', 'Synergism', 'Caution is recommended if ranolazine is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112678/', '[1] European Medicines Agency "CHMP Assessment Report for Latixa. International nonproprietary name: ranolazine. Procedure No. EMEA/H/C/805. Available from: URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/latixa/H-805-en6.pdf." ([cited 2008]):[2] "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.[3] "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Regadenoson, Ubidecarenone', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, Tadalafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112548, 'Vardenafil', 'Rasagiline', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112679/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Darifenacin, More', 'Opicapone, Cabergoline, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Amantadine, Levodopa', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112549, 'Vardenafil', 'Relugolix', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112680/', '[1] "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] "Product Information. Zoladex (goserelin)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.[5] "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc, Deerfield, IL.[7] "Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals, New York, NY.[8] "Product Information. Plenaxis (abarelix)." Praecis Pharmaceuticals Inc, Waltham, MA.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Fulvestrant, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112550, 'Vardenafil', 'Reserpine', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112681/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112551, 'Vardenafil', 'Ribociclib', 'Major', 'Ribociclib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Coadministration with ribociclib may increase the plasma concentrations and pharmacologic effects of drugs that are substrates of CYP450 3A4. The proposed mechanism is decreased clearance due to ribociclib-mediated inhibition of CYP450 3A4 metabolism.', 'DDInter', 'Coadministration of ribociclib with other drugs that can prolong the QT interval and are substrates of CYP450 3A4, particularly those with a narrow therapeutic range, should generally be avoided. Since the magnitude of QT prolongation may increase with increasing plasma concentrations of these drugs, caution and close clinical monitoring are recommended if concomitant use with these drugs is unavoidable. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ribociclib is added to or withdrawn from therapy.', 'Metabolism, Synergism', 'Coadministration of ribociclib with other drugs that can prolong the QT interval and are substrates of CYP450 3A4, particularly those with a narrow therapeutic range, should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112682/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[4] Abbas R, Hug BA, Leister C, Sonnichsen D "A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects." Int J Cancer 131 (2012): Epub[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] "Product Information. Uroxatral (alfuzosin)." sanofi-aventis , Bridgewater, NJ.[7] "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.[8] "Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.[9] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[10] "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112552, 'Vardenafil', 'Rifapentine', 'Moderate', 'Coadministration with rifapentine may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C8, 2C9, and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of these isoenzymes by rifapentine. Enzyme activities may be induced within 4 days of the first dose and return to normal 14 days after discontinuation of rifapentine.', 'DDInter', 'The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever rifapentine is added to or withdrawn from therapy.', 'Metabolism', 'The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112683/', '[1] Thijssen HH, Flin ois JP, Beaune PH "Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes." Drug Metab Dispos 28 (2000): 1284-90[2] "Product Information. Priftin (rifapentine)." Hoechst Marion-Roussel Inc, Kansas City, MO.', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Rifampicin, Cycloserine, Rifabutin, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112553, 'Vardenafil', 'Riociguat', 'Major', 'Coadministration of riociguat with phosphodiesterase (PDE) inhibitors may cause significant hypotension. The mechanism involves peripheral vasodilation secondary to enhanced levels of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells, as PDE inhibitors prevent degradation of cGMP while riociguat promotes its synthesis by stimulating soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system that binds with nitric oxide (NO) to catalyze the synthesis of cGMP. Riociguat does not affect the pharmacokinetics of sildenafil.', 'DDInter', 'Concomitant use of riociguat with PDE inhibitors, including specific PDE-5 inhibitors (e.g., avanafil, sildenafil, tadalafil, vardenafil) or nonspecific PDE inhibitors (e.g., dipyridamole, theophylline), is considered contraindicated. Riociguat should be discontinued at least 24 hours before administering a PDE-5 inhibitor, and avoidance of riociguat administration within 24 hours after sildenafil or within 48 hours after tadalafil is recommended. Limited data exists for other PDE inhibitors.', 'Others', 'Concomitant use of riociguat with PDE inhibitors, including specific PDE-5 inhibitors (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112684/', '[1] "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc, West Haven, CT.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc, West Haven, CT.', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 'Bosentan, Macitentan, Metyrosine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112554, 'Vardenafil', 'Ritodrine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112685/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 'Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112555, 'Vardenafil', 'Rivastigmine', 'Moderate', 'Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.', 'DDInter', 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.', 'Synergism', 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112686/', '[1] "Product Information. Razadyne (galantamine)." Johnson and Johnson Medical Inc, Arlington, TX.[2] "Product Information. Exelon (rivastigmine)" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Aricept (donepezil)." Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Phenyl salicylate, More', 'Ginkgo biloba, Aducanumab', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112556, 'Vardenafil', 'Romidepsin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112687/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112557, 'Vardenafil', 'Rucaparib', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112688/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112558, 'Vardenafil', 'Rufinamide', 'Moderate', 'Rufinamide may modestly or moderately decrease the plasma concentrations and therapeutic effects of drugs that are CYP450 3A4 substrates. The mechanism is enhanced metabolism by CYP450 3A4 enzyme induction.', 'DDInter', 'During concomitant treatment with rufinamide and drugs that are CYP450 3A4 substrates, it is recommended that patients should be monitored for 2 weeks when rufinamide is added to or withdrawn from therapy, or after increases of the dose. Dose adjustments of the coadministered drug may be required if an interaction is suspected.', 'Metabolism', 'During concomitant treatment with rufinamide and drugs that are CYP450 3A4 substrates, it is recommended that patients should be monitored for 2 weeks when rufinamide is added to or withdrawn from therapy, or after increases of the dose.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112689/', '[1] "Product Information. Banzel (rufinamide)." Eisai Inc, Teaneck, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] "Product Information. Banzel (rufinamide)." Eisai Inc, Teaneck, NJ.', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Darifenacin, Papaverine, Phenyl salicylate, More', 'Brivaracetam, Cenobamate, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Paramethadione, Perampanel, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112559, 'Vardenafil', 'Safinamide', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112690/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, More', 'Opicapone, Cabergoline, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Amantadine, Levodopa', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112560, 'Vardenafil', 'Salmeterol', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112691/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112561, 'Vardenafil', 'Saquinavir', 'Major', 'Coadministration with saquinavir may significantly increase the plasma concentrations of vardenafil. The mechanism is inhibition of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of vardenafil. The risk of vardenafil-associated adverse effects may be increased, such as hypotension, syncope, visual disturbances, and priapism. Theoretically, coadministration of agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution and dose reductions of vardenafil are recommended. If vardenafil is to be used in patients taking ritonavir-boosted saquinavir therapy, the dose should not exceed 2.5 mg every 72 hours. Patients should be monitored for adverse events during concomitant use, and advised to promptly notify their doctor if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).', 'Metabolism, Synergism', 'Caution and dose reductions of vardenafil are recommended.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112692/', '[1] Bertics PJ, Wiepz GJ "New Developments with Vancomycin-Resistant Enterococci: E. faecium-Friend or Foe?" J Infect Dis (2009):[2] "Product Information. Invirase (saquinavir)." Roche Laboratories, Nutley, NJ.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[7] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[9] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[10] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[14] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[16] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[17] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[19] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[21] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[22] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[23] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[24] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[25] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[26] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[29] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[30] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[31] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[32] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[33] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[34] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[35] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[36] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[37] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[38] Cerner Multum, Inc. "Australian Product Information." O 0[39] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[40] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[41] Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, Krahenbuhl S "Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man." Br J Clin Pharmacol 45 (1998): 355-9[42] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[43] "Product Information. Invirase (saquinavir)." Roche Laboratories, Nutley, NJ.', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Oxybutynin, Ammonium chloride, Dimethyl sulfoxide', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112562, 'Vardenafil', 'Selegiline', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112693/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Darifenacin, More', 'Opicapone, Cabergoline, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Amantadine, Levodopa', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112563, 'Vardenafil', 'Selpercatinib', 'Major', 'Selpercatinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if selpercatinib is used in combination with other drugs that can prolong the QT interval. An electrocardiogram and serum electrolyte levels should be obtained prior to initiating selpercatinib therapy and periodically during treatment as appropriate based on individual risk factors including diarrhea. Correct hypokalemia, hypomagnesemia, and/or hypocalcemia before starting treatment and during treatment, as they may be risk factors for ventricular arrhythmias.', 'Synergism', 'Caution is recommended if selpercatinib is used in combination with other drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112694/', '[1] "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company, Indianapolis, IN.[2] "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company, Indianapolis, IN.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112564, 'Vardenafil', 'Sertraline', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112695/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Avanafil, Ammonium chloride, Dimethyl sulfoxide', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112565, 'Vardenafil', 'Sevoflurane', 'Moderate', 'Sevoflurane may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if sevoflurane is used in combination with other drugs that can prolong the QT interval. The patient''s cardiovascular status and serum electrolytes should be closely monitored.', 'Synergism', 'Caution is recommended if sevoflurane is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112696/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Ultane (sevoflurane)." Abbott Pharmaceutical, Abbott Park, IL.[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[6] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Fesoterodine, Pentosan polysulfate, Tolterodine, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Avanafil, More', 'Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112566, 'Vardenafil', 'Silodosin', 'Moderate', 'Vardenafil may potentiate the hypotensive effect of alpha blockers, resulting in symptomatic hypotension in some patients. Vardenafil inhibits phosphodiesterase-5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation that may be additive with that induced by alpha blockers.', 'DDInter', 'Caution is advised if vardenafil is used in combination with alpha blockers. Patients who demonstrate hemodynamic instability on alpha blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of vardenafil. Therefore, patients should be stable on alpha blocker therapy prior to initiating vardenafil, and vardenafil should be initiated at the lowest recommended dosage (i.e., 5 mg). In those patients already on an optimized dosage of vardenafil, alpha blocker therapy should be initiated at the lowest dosage. The safety of vardenafil in combination with alpha blockers may be affected by other variables such as intravascular volume depletion and use of other antihypertensive medications.', 'Synergism', 'Caution is advised if vardenafil is used in combination with alpha blockers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112697/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[3] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[6] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[7] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[8] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[9] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[10] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[13] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[14] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[15] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[16] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[17] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[24] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[25] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[26] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[27] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[28] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[29] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[30] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[31] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[32] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[33] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Darifenacin, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112567, 'Vardenafil', 'Simeprevir', 'Moderate', 'Coadministration with simeprevir may result in mild increases in plasma concentrations of phosphodiesterase-5 (PDE5) inhibitors, which are primarily metabolized by CYP450 3A4. In vivo, simeprevir mildly inhibits intestinal CYP450 3A4, but does not affect hepatic CYP450 3A4 activity. Therefore, a major pharmacokinetic interaction is not expected under normal circumstances.', 'DDInter', 'When prescribed with simeprevir, no empiric dosage adjustment is required for PDE5 inhibitors in the treatment of erectile dysfunction. However, dosage adjustment of sildenafil or tadalafil may be needed when these agents are administered chronically for the treatment of pulmonary arterial hypertension. Consider starting with the lowest effective dose and increase as needed, with clinical monitoring as appropriate.', 'Metabolism', 'When prescribed with simeprevir, no empiric dosage adjustment is required for PDE5 inhibitors in the treatment of erectile dysfunction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112698/', '[1] "Product Information. Olysio (simeprevir)." Janssen Pharmaceuticals, Titusville, NJ.[2] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation, Silver Spring, MD.[4] "Product Information. Olysio (simeprevir)." Janssen Pharmaceuticals, Titusville, NJ.', 'Darifenacin, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 'Tinidazole, Ascorbic acid, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Probenecid, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, Zonisamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112568, 'Vardenafil', 'Siponimod', 'Major', 'Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of siponimod treatment in patients receiving drugs that prolong the QT interval.', 'DDInter', 'Siponimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with siponimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.', 'Synergism', 'Siponimod has not been studied in patients receiving drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112699/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Mayzent (siponimod)." Novartis Pharmaceuticals, East Hanover, NJ.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112569, 'Vardenafil', 'Solifenacin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112700/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, Ammonium chloride, More', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Vardenafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112570, 'Vardenafil', 'Somapacitan', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112701/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN.', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112571, 'Vardenafil', 'Somatrem', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112702/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN.', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112572, 'Vardenafil', 'Somatotropin', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112703/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN.', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112573, 'Vardenafil', 'Sorafenib', 'Moderate', 'Sorafenib has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if sorafenib is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting sorafenib therapy and periodically during treatment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if sorafenib is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112704/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] "Product Information. Nexavar (sorafenib)." Bayer Pharmaceutical Inc, West Haven, CT.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[6] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[7] "Product Information. Nexavar (sorafenib)." Bayer Pharmaceutical Inc, West Haven, CT.', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112574, 'Vardenafil', 'Sotalol', 'Major', 'Vardenafil has been reported to cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, should avoid using vardenafil.', 'Synergism', 'Patients treated with class IA (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112705/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[3] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[6] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[7] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[8] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[9] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[10] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[13] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[14] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[15] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[16] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[17] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[24] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[25] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[26] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[27] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[28] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[29] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[30] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[31] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[32] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[33] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Phenyl salicylate, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112575, 'Vardenafil', 'Sparfloxacin', 'Major', 'Sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112706/', '[1] Thomas M, Maconochie JG, Fletcher E "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol 41 (1996): 77-81[2] Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996): 161-7[3] Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996): 350-1[4] Lipsky BA, Dorr MB, Magner DJ, Talbot GH "Safety profile of sparfloxacin, a new fluoroquinolone antibiotic." Clin Ther 21 (1999): 148-59[5] Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72[6] Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004): 1091-124[7] Zix JA, GeerdesFenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[8] Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002): 455-64[9] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[10] Falagas ME, Rafailidis PI, Rosmarakis ES "Arrhythmias associated with fluoroquinolone therapy." Int J Antimicrob Agents 29 (2007): 374-9[11] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[12] Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003): 2317-20[13] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9[14] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001): 46-7[15] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6[16] Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996): 499-503[17] Cerner Multum, Inc. "Australian Product Information." O 0[18] Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19[19] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[20] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[21] Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002): 269-77', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Flavoxate, More', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112576, 'Vardenafil', 'Stiripentol', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112707/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Papaverine, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide', 'Brivaracetam, Cenobamate, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Paramethadione, Perampanel, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112577, 'Vardenafil', 'Sulfadiazine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112708/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Sulfisoxazole, Tinidazole, Ascorbic acid, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Probenecid, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, More', 'Darifenacin, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112578, 'Vardenafil', 'Sulfamethizole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112709/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Sulfisoxazole, Sorbitol, Sodium citrate, Mannitol, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Tinidazole, Ascorbic acid, Lactic acid, More', 'Darifenacin, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112579, 'Vardenafil', 'Sulfamethoxazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112710/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Rifampicin, Cycloserine, Rifabutin, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112580, 'Vardenafil', 'Sulfinpyrazone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112711/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Lesinurad, Febuxostat, Pegloticase, Colchicine, Rasburicase, Probenecid', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112581, 'Vardenafil', 'Sunitinib', 'Moderate', 'Sunitinib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if sunitinib is used in combination with other drugs that can prolong the QT interval. Periodic monitoring with on-treatment electrocardiograms and serum electrolytes (magnesium, potassium) should be considered. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if sunitinib is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112712/', '[1] "Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] "Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112582, 'Vardenafil', 'Suvorexant', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112713/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Darifenacin, Avanafil, More', 'Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112583, 'Vardenafil', 'Tacrine', 'Moderate', 'Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.', 'DDInter', 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.', 'Synergism', 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112714/', '[1] "Product Information. Razadyne (galantamine)." Johnson and Johnson Medical Inc, Arlington, TX.[2] "Product Information. Exelon (rivastigmine)" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Aricept (donepezil)." Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 'Ginkgo biloba, Aducanumab', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112584, 'Vardenafil', 'Tacrolimus', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112715/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Avanafil, Phenyl salicylate, More', 'Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, Dupilumab, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112585, 'Vardenafil', 'Telaprevir', 'Major', 'Coadministration with telaprevir may significantly increase the plasma concentrations of vardenafil. The mechanism involves inhibition of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of vardenafil. The interaction has not been specifically studied with telaprevir, but has been reported with other potent CYP450 3A4 inhibitors such as HIV protease inhibitors, ketoconazole, and erythromycin.', 'DDInter', 'Patients treated with telaprevir should not receive more than a single 2.5 mg dose of vardenafil within a 72-hour period. Patients should be advised to promptly notify their physician if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).', 'Metabolism', 'Patients treated with telaprevir should not receive more than a single 2.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112716/', '[1] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.[2] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[35] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112586, 'Vardenafil', 'Telavancin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112717/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112587, 'Vardenafil', 'Telithromycin', 'Moderate', 'Telithromycin has the potential to prolong the QT interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if telithromycin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation may increase with increasing plasma concentrations of telithromycin, the recommended dosage should not be exceeded, particularly in patients with renal or hepatic impairment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if telithromycin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112718/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] "Product Information. Ketek (telithromycin)." Aventis Pharmaceuticals, Bridgewater, NJ.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Demolis JL, Vacheron F, Cardus S, Funck-Brentano C "Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects." Clin Pharmacol Ther 73 (2003): 242-52[5] European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products "European Public Assessment Report Ketek (telithromycin) (Rev. 2) Available from: URL: http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm." ([2001]):[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[8] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Dirithromycin, Lincomycin, Clindamycin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112588, 'Vardenafil', 'Telmisartan', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112719/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Papaverine, More', 'Sacubitril', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112589, 'Vardenafil', 'Terazosin', 'Moderate', 'Vardenafil may potentiate the hypotensive effect of alpha blockers, resulting in symptomatic hypotension in some patients. Vardenafil inhibits phosphodiesterase-5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation that may be additive with that induced by alpha blockers.', 'DDInter', 'Caution is advised if vardenafil is used in combination with alpha blockers. Patients who demonstrate hemodynamic instability on alpha blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of vardenafil. Therefore, patients should be stable on alpha blocker therapy prior to initiating vardenafil, and vardenafil should be initiated at the lowest recommended dosage (i.e., 5 mg). In those patients already on an optimized dosage of vardenafil, alpha blocker therapy should be initiated at the lowest dosage. The safety of vardenafil in combination with alpha blockers may be affected by other variables such as intravascular volume depletion and use of other antihypertensive medications.', 'Synergism', 'Caution is advised if vardenafil is used in combination with alpha blockers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112720/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[3] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[6] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[7] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[8] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[9] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[10] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[13] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[14] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[15] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[16] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[17] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[24] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[25] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[26] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[27] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[28] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[29] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[30] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[31] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[32] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[33] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112590, 'Vardenafil', 'Terbutaline', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112721/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Ephedrine, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112591, 'Vardenafil', 'Terfenadine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112722/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112592, 'Vardenafil', 'Tetrabenazine', 'Moderate', 'Tetrabenazine may cause modest prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of tetrabenazine with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of tetrabenazine with other drugs that can prolong the QT interval should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112723/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] "Product Information. Xenazine (tetrabenazine)." Prestwick Pharmaceuticals Inc, Washington DC, VA.[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[11] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Alprostadil, Acetohydroxamic acid, Yohimbine, Darifenacin, More', 'Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112593, 'Vardenafil', 'Thalidomide', 'Moderate', 'Thalidomide can cause bradycardia and may have additive effects with other drugs that decrease heart rate. Cases of bradycardia have been associated with thalidomide use, some requiring medical interventions. The clinical significance and underlying etiology of the bradycardia observed with thalidomide treatment have not been established. However, the potential for additive bradycardic effects should be considered when used with other drugs that slow cardiac conduction such as beta-blockers, calcium channel blockers, digitalis, flecainide, moricizine, and propafenone. Non-cardiac drugs that may also cause bradycardia include atazanavir, lacosamide, lithium, mefloquine, succinylcholine, H2-receptor antagonists, tricyclic antidepressants, and anticholinesterase or cholinergic agents. Because bradycardia is a risk factor for torsade de pointes arrhythmia, concerns also exist when thalidomide is used with drugs that prolong the QT interval or cause torsade de pointes.', 'DDInter', 'Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat. A dose reduction of thalidomide or discontinuation may be required.', 'Synergism', 'Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112724/', '[1] "Product Information. Thalomid (thalidomide)." Celgene Corporation, Warren, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[9] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Darifenacin, Avanafil, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112594, 'Vardenafil', 'Thioridazine', 'Major', 'Thioridazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with thioridazine. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.', 'DDInter', 'Coadministration of thioridazine with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of thioridazine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112725/', '[1] "Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Liberatore MA, Robinson DS "Torsade de pointes: a mechanism for sudden death associated with neuroleptic drug therapy?" J Clin Psychopharmacol 4 (1984): 143-6[4] Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969): 135-8[5] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[8] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[9] Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SHL "Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans." Clin Pharmacol Ther 60 (1996): 543-53[10] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[13] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[14] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[15] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[16] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[17] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[18] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[19] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[20] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[21] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[22] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[23] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[24] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[25] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[26] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112595, 'Vardenafil', 'Timolol', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112726/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Epinephrine, Brimonidine, Levobunolol', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Ammonium chloride, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112596, 'Vardenafil', 'Tizanidine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112727/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Baclofen, Chlorzoxazone, Orphenadrine, Chlormezanone', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112597, 'Vardenafil', 'Tolazoline', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112728/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Ketoprofen, Flurbiprofen, Tolmetin, Meclofenamic acid, Dimethyl sulfoxide', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112598, 'Vardenafil', 'Toremifene', 'Major', 'Toremifene has the potential to prolong the QT interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of toremifene with other drugs that can prolong the QT interval should generally be avoided. If treatment with other QT-prolonging drugs is required, interruption of toremifene therapy should be considered. Caution and clinical monitoring are recommended if concomitant use is unavoidable. In patients at increased risk, electrocardiograms (ECGs) are recommended at baseline and as clinically indicated. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of toremifene with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112729/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] "Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.[10] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112599, 'Vardenafil', 'Torasemide', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112730/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Tinidazole, Ascorbic acid, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Probenecid, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, Zonisamide, More', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112600, 'Vardenafil', 'Trandolapril', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112731/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112601, 'Vardenafil', 'Tranylcypromine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112732/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112602, 'Vardenafil', 'Treprostinil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112733/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Ticagrelor, Betrixaban, Apixaban, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, More', 'Fesoterodine, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Oxybutynin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112603, 'Vardenafil', 'Triamterene', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112734/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Calcium chloride, Tolterodine, Phenazopyridine, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Papaverine, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112604, 'Vardenafil', 'Trichlormethiazide', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112735/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Tinidazole, Ascorbic acid, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Probenecid, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, Zonisamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112605, 'Vardenafil', 'Triclabendazole', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112736/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Praziquantel, Oxamniquine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112606, 'Vardenafil', 'Trifluoperazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112737/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112607, 'Vardenafil', 'Triflupromazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112738/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112608, 'Alimemazine', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112739/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, More', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112609, 'Vardenafil', 'Trimethaphan', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112740/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112610, 'Vardenafil', 'Trimethoprim', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112741/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Sulfisoxazole, Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Rifampicin, Cycloserine, Rifabutin, Ethambutol, Pyridoxine, Ethionamide, More', 'Darifenacin, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112611, 'Vardenafil', 'Trimipramine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112742/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Alprostadil, Avanafil, Phenyl salicylate, Tadalafil, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112612, 'Vardenafil', 'Triptorelin', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112743/', '[1] "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] "Product Information. Zoladex (goserelin)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.[5] "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc, Deerfield, IL.[7] "Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals, New York, NY.[8] "Product Information. Plenaxis (abarelix)." Praecis Pharmaceuticals Inc, Waltham, MA.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112613, 'Vardenafil', 'Troleandomycin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112744/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, More', 'Dirithromycin, Lincomycin, Clindamycin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112614, 'Vardenafil', 'Tucatinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112745/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112615, 'Vardenafil', 'Valbenazine', 'Moderate', 'Valbenazine may cause modest prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Central nervous system (CNS)-depressant effects may be additively or synergistically increased in patients taking valbenazine with certain other drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'Caution and clinical monitoring are recommended if concomitant use of valbenazine with other drugs that can prolong the QT interval is required. Valbenazine is not recommended for use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. In patients with other risk factors for QT prolongation, the QT interval should be assessed before increasing the dose of valbenazine. The manufacturer recommends that valbenazine dosage be reduced to 40 mg once daily in patients on concomitant therapy with a strong CYP450 3A4 inhibitor (e.g., itraconazole, ketoconazole, clarithromycin). Valbenazine dose reduction should also be considered in patients on concurrent therapy with a strong CYP450 2D6 inhibitor (e.g., paroxetine, fluoxetine, quinidine), or in patients who are poor metabolizers of CYP450 2D6.', 'Synergism', 'Caution and clinical monitoring are recommended if concomitant use of valbenazine with other drugs that can prolong the QT interval is required.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112746/', '[1] "Product Information. Ingrezza (valbenazine)." Neurocrine Biosciences, Inc., San Diego, CA.[2] "Product Information. Ingrezza (valbenazine)." Neurocrine Biosciences, Inc., San Diego, CA.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Acetohydroxamic acid, More', 'Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112616, 'Vardenafil', 'Valproic acid', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112747/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Brivaracetam, Cenobamate, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Paramethadione, Perampanel, More', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Darifenacin, Avanafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112617, 'Vardenafil', 'Vandetanib', 'Major', 'Vandetanib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of vandetanib with other drugs that can prolong the QT interval should generally be avoided. Should treatment with other QT-prolonging drugs be required, the manufacturer recommends more frequent monitoring of the ECG as well as serum potassium, magnesium, and calcium levels.', 'Synergism', 'Coadministration of vandetanib with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112748/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[6] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112618, 'Vardenafil', 'Vasopressin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112749/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112619, 'Vardenafil', 'Vemurafenib', 'Major', 'Vemurafenib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of vemurafenib with other drugs that can prolong the QT interval is not recommended. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting vemurafenib therapy and after dose modification.', 'Synergism', 'Coadministration of vemurafenib with other drugs that can prolong the QT interval is not recommended.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112750/', '[1] "Product Information. Zelboraf (vemurafenib)." Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[6] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Oxybutynin, Ammonium chloride, Dimethyl sulfoxide', 'Tinidazole, Ascorbic acid, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Probenecid, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, Zonisamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112620, 'Venlafaxine', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112751/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Avanafil, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112621, 'Vardenafil', 'Verteporfin', 'Moderate', 'Drugs that decrease clotting, vasoconstriction, or platelet aggregation may interfere with the therapeutic effect of verteporfin. These agents may antagonize the physiologic responses to local damage of neovascular endothelium induced by activated verteporfin, which include the release of procoagulant and vasoactive factors that result in vessel occlusion. However, the clinical significance is unknown.', 'DDInter', 'If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy. Otherwise, the potential for diminished efficacy of verteporfin should be considered.', 'Antagonism', 'If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112752/', '[1] "Product Information. Visudyne (verteporfin)" Valeant Pharmaceuticals, Costa Mesa, CA.[2] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.', 'Aflibercept, Bevacizumab', 'Apomorphine, Fesoterodine, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112622, 'Voriconazole', 'Vardenafil', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112753/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Honig PK, Wortham DC, Zamani K, et al "Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences." JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P "Torsades de pointes after terfenadine-itraconazole interaction." BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL "Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram." Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG "Drug interactions associated with terfenadine and related nonsedating antihistamines." West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. "Drug-induced torsades de pointes in one patient with congenital long QT syndrome." Int J Cardiol 54 (1996): 85-8[16] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP "Torsades-de-pointes induced by erythromycin and terfenadine." Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al "Torsades de Pointes after treatment with terfenadine and ketoconazole." Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG "Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance." Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR "Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine." J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr "Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin." Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al "Torsades de pointes occurring in association with terfenadine use." JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC "Potential interaction between terfenadine and macrolide antibiotics." Clin Pharm 11 (1992): 675', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Phenyl salicylate, Oxybutynin, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112623, 'Voxelotor', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112754/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112624, 'Zafirlukast', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112755/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 'Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, More', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112625, 'Ziprasidone', 'Vardenafil', 'Major', 'Ziprasidone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.', 'DDInter', 'Coadministration of ziprasidone with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', 'Coadministration of ziprasidone with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112756/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[4] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[7] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[8] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[10] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Phenyl salicylate, Tadalafil, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112626, 'Iron sucrose', 'Demeclocycline', 'Moderate', 'INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of tetracyclines. The proposed mechanism is chelation of tetracyclines to the ferric ion component of sucroferric oxyhydroxide, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'Doxycycline should be administered at least 1 hour before sucroferric oxyhydroxide. Omadacycline administration with sucroferric oxyhydroxide should be separated by 4 hours. No dosing recommendations are available for use with other tetracyclines, although patients should consider following the same precaution.', 'Absorption', 'Doxycycline should be administered at least 1 hour before sucroferric oxyhydroxide.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112757/', '[1] Neuvonen PJ "Interactions with the absorption of tetracyclines." Drugs 11 (1976): 45-54[2] "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc., Boston, MA.[3] "Product Information. Velphoro (sucroferric oxyhydroxide)." Fresenius Medical Care North America, Lexington, MA.[4] Campbell NR, Hasinoff BB "Iron supplements: a common cause of drug interactions." Br J Clin Pharmacol 31 (1991): 251-5[5] Greenberger NJ "Absorption of tetracyclines: interference by iron." Ann Intern Med 74 (1971): 792-3[6] Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K "Interference of iron with the absorption of tetracyclines in man." Br Med J 4 (1970): 532-4[7] Gothoni G, Neuvonen PJ, Mattila M, Hackman R "Iron-tetracycline interaction: effect of time interval between the drugs." Acta Med Scand 191 (1972): 409-11[8] Venho VM, Salonen RO, Mattila MJ "Modification of the pharmacokinetics of doxycycline in man by ferrous sulphate or charcoal." Eur J Clin Pharmacol 14 (1978): 277-80[9] Neuvonen PJ, Penttila O "Effect of oral ferrous sulphate on the half-life of doxycycline in man." Eur J Clin Pharmacol 7 (1974): 361-3[10] "Product Information. Seysara (sarecycline)." Allergan Inc, Irvine, CA.[11] "Product Information. Achromycin (tetracycline)." Lederle Laboratories, Wayne, NJ.[12] "Product Information. Declomycin (demeclocycline)." Lederle Laboratories, Wayne, NJ.', 'Tigecycline, Eravacycline, Mupirocin, Rifamycin, Bacitracin, Rifaximin, Gentamicin, Amikacin, Neomycin', 'Cyanocobalamin, Folic acid, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Difelikefalin, Cobicistat, Deferoxamine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112627, 'Iron sucrose', 'Dihydrotachysterol', 'Moderate', 'Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption to the ferric ion component of sucroferric oxyhydroxide, resulting in an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'Oral formulations of vitamin D analogs should not be prescribed with sucroferric oxyhydroxide.', 'Absorption', 'Oral formulations of vitamin D analogs should not be prescribed with sucroferric oxyhydroxide.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112758/', '[1] "Product Information. Velphoro (sucroferric oxyhydroxide)." Fresenius Medical Care North America, Lexington, MA.', 'Vitamin A, Beta carotene, Calcitriol', 'Cyanocobalamin, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112628, 'Iron sucrose', 'Erdafitinib', 'Major', 'Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be related to the pharmacodynamic effects of fibroblast growth factor receptor (FGFR) inhibition by erdafitinib. Inhibition of the FGFR receptor has been shown to lead to an increase in serum phosphate levels.', 'DDInter', 'The manufacturer recommends that concomitant use of erdafitinib with agents that may alter serum phosphate levels be avoided before its initial dose increase period, which is between days 14 to 21 of starting erdafitinib therapy and is based on serum phosphate levels. After the initial dose increase period, an oral phosphate binder may be appropriate in the management of patients with serum phosphate levels greater than 7 mg/dL. If concomitant use with agents known to increase serum phosphate levels is required after this initial dose increase period, close monitoring of patient tolerability and serum phosphate levels is recommended.', 'Others', 'The manufacturer recommends that concomitant use of erdafitinib with agents that may alter serum phosphate levels be avoided before its initial dose increase period, which is between days 14 to 21 of starting erdafitinib therapy and is based on serum phosphate levels.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112759/', '[1] "Product Information. Balversa (erdafitinib)." Janssen Products, LP, Horsham, PA.', 'Cyanocobalamin, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, More', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112629, 'Iron sucrose', 'Ergocalciferol', 'Moderate', 'Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption to the ferric ion component of sucroferric oxyhydroxide, resulting in an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'Oral formulations of vitamin D analogs should not be prescribed with sucroferric oxyhydroxide.', 'Absorption', 'Oral formulations of vitamin D analogs should not be prescribed with sucroferric oxyhydroxide.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112760/', '[1] "Product Information. Velphoro (sucroferric oxyhydroxide)." Fresenius Medical Care North America, Lexington, MA.', 'Vitamin A, Beta carotene, Calcitriol', 'Cyanocobalamin, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112630, 'Iron sucrose', 'Etidronic acid', 'Moderate', 'INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of bisphosphonates. The proposed mechanism is chelation of bisphosphonates to the ferric ion component of sucroferric oxyhydroxide, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'Alendronate should be administered at least 1 hour before sucroferric oxyhydroxide. No dosing recommendations are available for use with other bisphosphonates. Patients may follow the manufacturers'' suggestion provided in the individual bisphosphonate label regarding use with mineral supplements and other polyvalent cation-containing products (i.e., administer sucroferric oxyhydroxide at least 30 minutes after risedronate, 1 hour after ibandronate, and at least 2 hours before or 2 hours after clodronate, etidronate, or tiludronate).', 'Absorption', 'Alendronate should be administered at least 1 hour before sucroferric oxyhydroxide.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112761/', '[1] "Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] "Product Information. Bonefos (clodronate)." Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] "Product Information. Boniva (ibandronate)." Roche Laboratories, Nutley, NJ.[4] "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.[5] "Product Information. Velphoro (sucroferric oxyhydroxide)." Fresenius Medical Care North America, Lexington, MA.[6] "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.', 'Vosoritide, Denosumab, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Promethazine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112631, 'Iron sucrose', 'Oxytetracycline', 'Moderate', 'INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of tetracyclines. The proposed mechanism is chelation of tetracyclines to the ferric ion component of sucroferric oxyhydroxide, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'Doxycycline should be administered at least 1 hour before sucroferric oxyhydroxide. Omadacycline administration with sucroferric oxyhydroxide should be separated by 4 hours. No dosing recommendations are available for use with other tetracyclines, although patients should consider following the same precaution.', 'Absorption', 'Doxycycline should be administered at least 1 hour before sucroferric oxyhydroxide.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112762/', '[1] Neuvonen PJ "Interactions with the absorption of tetracyclines." Drugs 11 (1976): 45-54[2] "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc., Boston, MA.[3] "Product Information. Velphoro (sucroferric oxyhydroxide)." Fresenius Medical Care North America, Lexington, MA.[4] Campbell NR, Hasinoff BB "Iron supplements: a common cause of drug interactions." Br J Clin Pharmacol 31 (1991): 251-5[5] Greenberger NJ "Absorption of tetracyclines: interference by iron." Ann Intern Med 74 (1971): 792-3[6] Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K "Interference of iron with the absorption of tetracyclines in man." Br Med J 4 (1970): 532-4[7] Gothoni G, Neuvonen PJ, Mattila M, Hackman R "Iron-tetracycline interaction: effect of time interval between the drugs." Acta Med Scand 191 (1972): 409-11[8] Venho VM, Salonen RO, Mattila MJ "Modification of the pharmacokinetics of doxycycline in man by ferrous sulphate or charcoal." Eur J Clin Pharmacol 14 (1978): 277-80[9] Neuvonen PJ, Penttila O "Effect of oral ferrous sulphate on the half-life of doxycycline in man." Eur J Clin Pharmacol 7 (1974): 361-3[10] "Product Information. Seysara (sarecycline)." Allergan Inc, Irvine, CA.[11] "Product Information. Achromycin (tetracycline)." Lederle Laboratories, Wayne, NJ.[12] "Product Information. Declomycin (demeclocycline)." Lederle Laboratories, Wayne, NJ.', 'Tigecycline, Eravacycline, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Netilmicin, More', 'Cyanocobalamin, Folic acid, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Difelikefalin, Cobicistat, Deferoxamine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112632, 'Iron sucrose', 'Paricalcitol', 'Moderate', 'Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption to the ferric ion component of sucroferric oxyhydroxide, resulting in an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'Oral formulations of vitamin D analogs should not be prescribed with sucroferric oxyhydroxide.', 'Absorption', 'Oral formulations of vitamin D analogs should not be prescribed with sucroferric oxyhydroxide.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112763/', '[1] "Product Information. Velphoro (sucroferric oxyhydroxide)." Fresenius Medical Care North America, Lexington, MA.', 'Etelcalcetide, Cinacalcet, Salmon calcitonin', 'Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112633, 'Iron sucrose', 'Sarecycline', 'Moderate', 'INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of tetracyclines. The proposed mechanism is chelation of tetracyclines to the ferric ion component of sucroferric oxyhydroxide, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'Doxycycline should be administered at least 1 hour before sucroferric oxyhydroxide. Omadacycline administration with sucroferric oxyhydroxide should be separated by 4 hours. No dosing recommendations are available for use with other tetracyclines, although patients should consider following the same precaution.', 'Absorption', 'Doxycycline should be administered at least 1 hour before sucroferric oxyhydroxide.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112764/', '[1] Neuvonen PJ "Interactions with the absorption of tetracyclines." Drugs 11 (1976): 45-54[2] "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc., Boston, MA.[3] "Product Information. Velphoro (sucroferric oxyhydroxide)." Fresenius Medical Care North America, Lexington, MA.[4] Campbell NR, Hasinoff BB "Iron supplements: a common cause of drug interactions." Br J Clin Pharmacol 31 (1991): 251-5[5] Greenberger NJ "Absorption of tetracyclines: interference by iron." Ann Intern Med 74 (1971): 792-3[6] Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K "Interference of iron with the absorption of tetracyclines in man." Br Med J 4 (1970): 532-4[7] Gothoni G, Neuvonen PJ, Mattila M, Hackman R "Iron-tetracycline interaction: effect of time interval between the drugs." Acta Med Scand 191 (1972): 409-11[8] Venho VM, Salonen RO, Mattila MJ "Modification of the pharmacokinetics of doxycycline in man by ferrous sulphate or charcoal." Eur J Clin Pharmacol 14 (1978): 277-80[9] Neuvonen PJ, Penttila O "Effect of oral ferrous sulphate on the half-life of doxycycline in man." Eur J Clin Pharmacol 7 (1974): 361-3[10] "Product Information. Seysara (sarecycline)." Allergan Inc, Irvine, CA.[11] "Product Information. Achromycin (tetracycline)." Lederle Laboratories, Wayne, NJ.[12] "Product Information. Declomycin (demeclocycline)." Lederle Laboratories, Wayne, NJ.', 'Cyanocobalamin, Folic acid, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Difelikefalin, Cobicistat, Deferoxamine, More', 'Tigecycline, Eravacycline', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112634, 'Iron sucrose', 'Tetracycline', 'Moderate', 'INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of tetracyclines. The proposed mechanism is chelation of tetracyclines to the ferric ion component of sucroferric oxyhydroxide, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'Doxycycline should be administered at least 1 hour before sucroferric oxyhydroxide. Omadacycline administration with sucroferric oxyhydroxide should be separated by 4 hours. No dosing recommendations are available for use with other tetracyclines, although patients should consider following the same precaution.', 'Absorption', 'Doxycycline should be administered at least 1 hour before sucroferric oxyhydroxide.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112765/', '[1] Neuvonen PJ "Interactions with the absorption of tetracyclines." Drugs 11 (1976): 45-54[2] "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc., Boston, MA.[3] "Product Information. Velphoro (sucroferric oxyhydroxide)." Fresenius Medical Care North America, Lexington, MA.[4] Campbell NR, Hasinoff BB "Iron supplements: a common cause of drug interactions." Br J Clin Pharmacol 31 (1991): 251-5[5] Greenberger NJ "Absorption of tetracyclines: interference by iron." Ann Intern Med 74 (1971): 792-3[6] Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K "Interference of iron with the absorption of tetracyclines in man." Br Med J 4 (1970): 532-4[7] Gothoni G, Neuvonen PJ, Mattila M, Hackman R "Iron-tetracycline interaction: effect of time interval between the drugs." Acta Med Scand 191 (1972): 409-11[8] Venho VM, Salonen RO, Mattila MJ "Modification of the pharmacokinetics of doxycycline in man by ferrous sulphate or charcoal." Eur J Clin Pharmacol 14 (1978): 277-80[9] Neuvonen PJ, Penttila O "Effect of oral ferrous sulphate on the half-life of doxycycline in man." Eur J Clin Pharmacol 7 (1974): 361-3[10] "Product Information. Seysara (sarecycline)." Allergan Inc, Irvine, CA.[11] "Product Information. Achromycin (tetracycline)." Lederle Laboratories, Wayne, NJ.[12] "Product Information. Declomycin (demeclocycline)." Lederle Laboratories, Wayne, NJ.', 'Rifamycin, Miconazole, Polymyxin B, Ciprofloxacin, Gentamicin, Chlorhexidine, Neomycin, Ofloxacin, Tinidazole, Dexlansoprazole, Rabeprazole, More', 'Cyanocobalamin, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112635, 'Iron sucrose', 'Tiludronic acid', 'Moderate', 'INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of bisphosphonates. The proposed mechanism is chelation of bisphosphonates to the ferric ion component of sucroferric oxyhydroxide, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'Alendronate should be administered at least 1 hour before sucroferric oxyhydroxide. No dosing recommendations are available for use with other bisphosphonates. Patients may follow the manufacturers'' suggestion provided in the individual bisphosphonate label regarding use with mineral supplements and other polyvalent cation-containing products (i.e., administer sucroferric oxyhydroxide at least 30 minutes after risedronate, 1 hour after ibandronate, and at least 2 hours before or 2 hours after clodronate, etidronate, or tiludronate).', 'Absorption', 'Alendronate should be administered at least 1 hour before sucroferric oxyhydroxide.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112766/', '[1] "Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] "Product Information. Bonefos (clodronate)." Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] "Product Information. Boniva (ibandronate)." Roche Laboratories, Nutley, NJ.[4] "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.[5] "Product Information. Velphoro (sucroferric oxyhydroxide)." Fresenius Medical Care North America, Lexington, MA.[6] "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.', 'Vosoritide, Denosumab, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid', 'Cyanocobalamin, Folic acid, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Difelikefalin, Cobicistat, Deferoxamine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112636, 'Amoxapine', 'Sufentanil', 'Moderate', 'Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.', 'DDInter', 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John''s wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.', 'Synergism', 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112767/', '[1] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919[2] Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5[3] Mittino D, Mula M, Monaco F "Serotonin syndrome associated with tramadol-sertraline coadministration." Clin Neuropharmacol 27 (2004): 150-1[4] Gillman PK "Possible serotonin syndrome with moclobemide and pethidine." Med J Aust 162 (1995): 554[5] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[6] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[7] Kesavan S, Sobala GM "Serotonin syndrome with fluoxetine plus tramadol." J R Soc Med 92 (1999): 474-5[8] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[9] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[10] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[11] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[12] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[13] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[14] Meyer D, Halfin V "Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review." J Clin Psychopharmacol 1 (1981): 319-21[15] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[16] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[17] US Food and Drug Administration (FDA) "FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf." ([2016, Mar 22]):[18] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K "Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology." J Clin Psychopharmacol 22 (2002): 440-1[19] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA "Mania and tramadol-fluoxetine combination." Am J Psychiatry 158 (2001): 964-5[20] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[21] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F "Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database." J Clin Psychopharmacol (2015):[22] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[23] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[24] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE "Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil." J Clin Anesth 25 (2013): 52-4[25] Shakoor M, Ayub S, Ahad A, Ayub Z "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor." Am J Case Rep 15 (2014): 562-4[26] Lantz MS, Buchalter EN, Giambanco V "Serotonin syndrome following the administration of tramadol with paroxetine." Int J Geriatr Psychiatry 13 (1998): 343-5[27] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[28] "Venlafaxine + tramadol: serotonin syndrome." Prescrire Int 13 (2004): 57[29] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB "Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?" J Am Med Dir Assoc 6 (2005): 265-9[30] Houlihan DJ "Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine." Ann Pharmacother 38 (2004): 411-3[31] Hillman AD, Witenko CJ, Sultan SM, Gala G "Serotonin syndrome caused by fentanyl and methadone in a burn injury." Pharmacotherapy 35 (2015): 112-7[32] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[33] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[34] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL "Meperidine-induced serotonin syndrome in a susceptible patient." Br J Anaesth (2009):[35] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H "Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction." Pharmacotherapy (2015):[36] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[37] Kitson R, Carr B "Tramadol and severe serotonin syndrome." Anaesthesia 60 (2005): 934-5[38] Zornberg GL, Bodkin JA, Cohen BM "Severe adverse interaction between pethidine and selegiline." Lancet 337 (1991): 246[39] Mahlberg R, Kunz D, Sasse J, Kirchheiner J "Serotonin syndrome with tramadol and citalopram." Am J Psychiatry 161 (2004): 1129[40] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J "Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy." J Clin Anesth 27 (2015): 247-51[41] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Viloxazine', 'Desflurane, Enflurane, Etomidate, Nitrous oxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112637, 'Amprenavir', 'Sufentanil', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112768/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112638, 'Sufentanil', 'Atracurium', 'Minor', 'Sufentanil, when combined with neuromuscular blocking agents during surgical procedures, may adversely effect cardiovascular function. Tachycardia, bradycardia, and/or hypotension may result. However, muscle relaxants and sufentanil frequently are used together during surgery. Patients should be closely monitored for clinically significant alterations in hemodynamics.', 'DDInter', '-', 'Others', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112769/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Clotz MA, Nahata MC "Clinical uses of fentanyl, sufentanil, and alfentanil." Clin Pharm 10 (1991): 581-93', 'Thiopental, Remifentanil, Sodium oxybate, Methohexital, Propofol, Esketamine, Etomidate', 'Botulinum toxin type A', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112639, 'Sufentanil', 'Azatadine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112770/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112640, 'Belladonna', 'Sufentanil', 'Moderate', 'Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.', 'DDInter', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112771/', '[1] "Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc, Coralville, IA.[2] "Product Information. Lortab (acetaminophen-hydrocodone)." Akorn Inc, Buffalo Grove, IL.[3] "Product Information. Exalgo (hydromorphone)." Covidien, Mansfield, MA.[4] "Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine)." Actavis U.S. (Amide Pharmaceutical Inc), Little Falls, NJ.[5] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[6] "Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC, Chadds Ford, PA.[7] "Product Information. Kadian (morphine)." Zeneca Pharmaceuticals, Wilmington, DE.[8] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[9] "Product Information. Opana (oxymorphone)." Endo Laboratories LLC, Chadds Ford, PA.[10] "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.[11] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[12] "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.[13] "Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals, New York, NY.[14] "Product Information. Levorphanol Tartrate (levorphanol)." Sentynl Therapeutics, Solana Beach, CA.[15] "Product Information. Belbuca (buprenorphine)." Endo Pharmaceuticals Solutions Inc, Malvern, PA.[16] "Product Information. SUFentanil Citrate (SUFentanil)." Akorn Inc, Buffalo Grove, IL.[17] "Product Information. Dolophine (methadone)." Lilly, Eli and Company, Indianapolis, IN.[18] "Product Information. Alfentanil Hydrochloride (alfentanil)." Akorn Inc, Buffalo Grove, IL.[19] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112641, 'Bepridil', 'Sufentanil', 'Moderate', 'In patients receiving chronic therapy with calcium channel blockers, the use of sufentanil during induction may lead to a higher degree of bradycardia and hypotension.', 'DDInter', 'These patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'These patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112772/', '[1] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[2] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[3] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[4] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[7] "Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.[8] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[9] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[10] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[11] "Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.[12] Fuhr U, Muller-Peltzer H, Kern R, et al. "Effects of grapefruit juice and smoking on verapamil concentrations in steady state." Eur J Clin Pharmacol 58 (2002): 45-53[13] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[14] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[15] "Product Information. Sular (nisoldipine)." Zeneca Pharmaceuticals, Wilmington, DE.[16] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[17] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[18] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[19] Ho PC, Ghose K, Saville D, Wanwimolruk S "Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers." Eur J Clin Pharmacol 56 (2000): 693-8[20] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94', 'Thiopental, Nitrous oxide, Methohexital, Esketamine, Etomidate, Ketamine', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112642, 'Berotralstat', 'Sufentanil', 'Moderate', 'Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6. The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.', 'DDInter', 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.', 'Metabolism', 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112773/', '[1] "Product Information. Orladeyo (berotralstat)." BioCryst Pharmaceuticals Inc, Durham, NC.', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', 'Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112643, 'Boceprevir', 'Sufentanil', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112774/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112644, 'Butabarbital', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112775/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Nitrazepam, Zopiclone', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112645, 'Sufentanil', 'Pentoxyverine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112776/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Benzonatate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112646, 'Carteolol', 'Sufentanil', 'Moderate', 'In patients receiving chronic beta-blocker therapy, the use of sufentanil may lead to a higher degree of bradycardia and hypotension. One study has shown that induction and maintenance of anesthesia requires lower doses of sufentanil in patients receiving beta-blockers.', 'DDInter', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112777/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Propofol, Enflurane, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112647, 'Clofedanol', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112778/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Benzonatate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112648, 'Chloral hydrate', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112779/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112649, 'Chlorcyclizine', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112780/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Ketamine', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112650, 'Chlormezanone', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112781/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112651, 'Chlorphenesin', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112782/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Salicylic acid, Selenium Sulfide, Thiabendazole, Nystatin, Ciclopirox, Griseofulvin, Terbinafine, Econazole, Flucytosine, Tioconazole, Clotrimazole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112652, 'Chlorpromazine', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112783/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Amisulpride', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112653, 'Clidinium', 'Sufentanil', 'Moderate', 'Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.', 'DDInter', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112784/', '[1] "Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc, Coralville, IA.[2] "Product Information. Lortab (acetaminophen-hydrocodone)." Akorn Inc, Buffalo Grove, IL.[3] "Product Information. Exalgo (hydromorphone)." Covidien, Mansfield, MA.[4] "Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine)." Actavis U.S. (Amide Pharmaceutical Inc), Little Falls, NJ.[5] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[6] "Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC, Chadds Ford, PA.[7] "Product Information. Kadian (morphine)." Zeneca Pharmaceuticals, Wilmington, DE.[8] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[9] "Product Information. Opana (oxymorphone)." Endo Laboratories LLC, Chadds Ford, PA.[10] "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.[11] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[12] "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.[13] "Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals, New York, NY.[14] "Product Information. Levorphanol Tartrate (levorphanol)." Sentynl Therapeutics, Solana Beach, CA.[15] "Product Information. Belbuca (buprenorphine)." Endo Pharmaceuticals Solutions Inc, Malvern, PA.[16] "Product Information. SUFentanil Citrate (SUFentanil)." Akorn Inc, Buffalo Grove, IL.[17] "Product Information. Dolophine (methadone)." Lilly, Eli and Company, Indianapolis, IN.[18] "Product Information. Alfentanil Hydrochloride (alfentanil)." Akorn Inc, Buffalo Grove, IL.[19] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112654, 'Cyclizine', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112785/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112655, 'Cyproheptadine', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112786/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112656, 'Desflurane', 'Sufentanil', 'Moderate', 'Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.', 'DDInter', 'In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.', 'Synergism', 'In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112787/', '[1] "Product Information. Ultane (sevoflurane)." Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A "Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses." Anesth Analg 84 (1997): 100-5[3] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.', 'Thiopental, Isoflurane, Methohexital, Desflurane, Enflurane, Halothane, Etomidate, Ketamine', 'Sufentanil', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112657, 'Dexbrompheniramine', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112788/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112658, 'Dexfenfluramine', 'Sufentanil', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112789/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Ephedrine, Orlistat, Diethylpropion', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112659, 'Dezocine', 'Sufentanil', 'Moderate', 'Potent narcotics, when used as an adjuvant in patients receiving alfentanil, remifentanil, or sufentanil for anesthesia or conscious sedation, may further decrease cardiac output and respiratory drive.', 'DDInter', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Synergism', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112790/', '[1] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Etomidate', 'Acetylsalicylic acid, Ibuprofen, Celecoxib', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112660, 'Dimenhydrinate', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112791/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112661, 'Doxacurium', 'Sufentanil', 'Minor', 'Sufentanil, when combined with neuromuscular blocking agents during surgical procedures, may adversely effect cardiovascular function. Tachycardia, bradycardia, and/or hypotension may result. However, muscle relaxants and sufentanil frequently are used together during surgery. Patients should be closely monitored for clinically significant alterations in hemodynamics.', 'DDInter', '-', 'Others', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112792/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Clotz MA, Nahata MC "Clinical uses of fentanyl, sufentanil, and alfentanil." Clin Pharm 10 (1991): 581-93', 'Thiopental, Remifentanil, Sodium oxybate, Methohexital, Propofol, Esketamine, Etomidate', 'Botulinum toxin type A', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112662, 'Echinacea', 'Sufentanil', 'Moderate', 'Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.', 'DDInter', 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.', 'Metabolism', 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112793/', '[1] Gorski JC, Huang SM, Pinto A, et al. "The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo." Clin Pharmacol Ther 75 (2004): 89-100[2] Cerner Multum, Inc. "Australian Product Information." O 0', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112663, 'Enflurane', 'Sufentanil', 'Moderate', 'Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.', 'DDInter', 'In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.', 'Synergism', 'In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112794/', '[1] "Product Information. Ultane (sevoflurane)." Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A "Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses." Anesth Analg 84 (1997): 100-5[3] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.', 'Sufentanil', 'Halothane, Thiopental, Isoflurane, Methohexital, Desflurane, Enflurane, Sevoflurane, Etomidate, Ketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112664, 'Erdafitinib', 'Sufentanil', 'Moderate', 'Coadministration with erdafitinib may alter the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme, resulting in increased toxicity or decreased efficacy of these drugs.', 'DDInter', 'Concomitant use of erdafitinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.', 'Metabolism', 'Concomitant use of erdafitinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112795/', '[1] "Product Information. Balversa (erdafitinib)." Janssen Products, LP, Horsham, PA.[2] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[32] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', 'Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112665, 'Escitalopram', 'Sufentanil', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112796/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate', 'Viloxazine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112666, 'Esketamine', 'Sufentanil', 'Moderate', 'Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.', 'DDInter', 'Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants. Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting. Patients should be instructed not to engage in potentially hazardous activities, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.', 'Synergism', 'Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112797/', '[1] "Product Information. Spravato (esketamine)." Janssen Pharmaceuticals, Titusville, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Esketamine', 'Viloxazine, Sufentanil', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112667, 'Eslicarbazepine', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112798/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112668, 'Esmolol', 'Sufentanil', 'Moderate', 'In patients receiving chronic beta-blocker therapy, the use of sufentanil may lead to a higher degree of bradycardia and hypotension. One study has shown that induction and maintenance of anesthesia requires lower doses of sufentanil in patients receiving beta-blockers.', 'DDInter', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112799/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Halothane, Thiopental, Remifentanil, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112669, 'Estazolam', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines may result in profound sedation, respiratory depression, coma, and death. The use of benzodiazepines with sufentanil during induction has been reported to decrease mean arterial pressure and systemic vascular resistance. The mechanism appears to be an indirect effect on the autonomic nervous system.', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect. Patients receiving sufentanil with benzodiazepines should be monitored closely for signs and symptoms of respiratory depression, altered hemodynamics, and hypotension.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112800/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] West JM, Estrada S, Heerdt M "Sudden hypotension associated with midazolam and sufentanil." Anesth Analg 66 (1987): 693-4[5] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[6] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8[7] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[8] "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.[9] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[10] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.', 'Etomidate, Nitrous oxide', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112670, 'Eszopiclone', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112801/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Nitrazepam, Zopiclone', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112671, 'Etanercept', 'Sufentanil', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112802/', '[1] "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, North Chicago, IL.[2] "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Gamifant (emapalumab)." Sobi Inc, Ardmore, PA.[5] "Product Information. Kevzara (sarilumab)." sanofi-aventis, Bridgewater, NJ.[6] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc., Horsham, PA, PA.[9] "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.[10] "Product Information. Ilumya (tildrakizumab)." Merck & Company Inc, Whitehouse Station, NJ.[11] "Product Information. Actemra (tocilizumab)." Genentech, South San Francisco, CA.[12] "Product Information. Amevive (alefacept)." Biogen, Cambridge, MA.[13] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[14] "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company, Indianapolis, IN.[15] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112672, 'Ethchlorvynol', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112803/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Nitrazepam, Zopiclone', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate, Ketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112673, 'Ethosuximide', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112804/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Lacosamide', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112674, 'Ethotoin', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112805/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112675, 'Ezogabine', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112806/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112676, 'Felbamate', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112807/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112677, 'Felodipine', 'Sufentanil', 'Moderate', 'In patients receiving chronic therapy with calcium channel blockers, the use of sufentanil during induction may lead to a higher degree of bradycardia and hypotension.', 'DDInter', 'These patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'These patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112808/', '[1] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[2] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[3] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[4] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[7] "Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.[8] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[9] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[10] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[11] "Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.[12] Fuhr U, Muller-Peltzer H, Kern R, et al. "Effects of grapefruit juice and smoking on verapamil concentrations in steady state." Eur J Clin Pharmacol 58 (2002): 45-53[13] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[14] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[15] "Product Information. Sular (nisoldipine)." Zeneca Pharmaceuticals, Wilmington, DE.[16] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[17] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[18] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[19] Ho PC, Ghose K, Saville D, Wanwimolruk S "Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers." Eur J Clin Pharmacol 56 (2000): 693-8[20] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94', 'Thiopental, Remifentanil, Nitrous oxide, Methohexital, Esketamine, Etomidate, Ketamine', 'Acetylsalicylic acid, Ivabradine, Celecoxib, Indapamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112678, 'Fenfluramine', 'Sufentanil', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112809/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Ephedrine, Orlistat, Diethylpropion, Lacosamide', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112679, 'Fesoterodine', 'Sufentanil', 'Moderate', 'Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.', 'DDInter', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112810/', '[1] "Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc, Coralville, IA.[2] "Product Information. Lortab (acetaminophen-hydrocodone)." Akorn Inc, Buffalo Grove, IL.[3] "Product Information. Exalgo (hydromorphone)." Covidien, Mansfield, MA.[4] "Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine)." Actavis U.S. (Amide Pharmaceutical Inc), Little Falls, NJ.[5] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[6] "Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC, Chadds Ford, PA.[7] "Product Information. Kadian (morphine)." Zeneca Pharmaceuticals, Wilmington, DE.[8] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[9] "Product Information. Opana (oxymorphone)." Endo Laboratories LLC, Chadds Ford, PA.[10] "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.[11] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[12] "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.[13] "Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals, New York, NY.[14] "Product Information. Levorphanol Tartrate (levorphanol)." Sentynl Therapeutics, Solana Beach, CA.[15] "Product Information. Belbuca (buprenorphine)." Endo Pharmaceuticals Solutions Inc, Malvern, PA.[16] "Product Information. SUFentanil Citrate (SUFentanil)." Akorn Inc, Buffalo Grove, IL.[17] "Product Information. Dolophine (methadone)." Lilly, Eli and Company, Indianapolis, IN.[18] "Product Information. Alfentanil Hydrochloride (alfentanil)." Akorn Inc, Buffalo Grove, IL.[19] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112680, 'Flavoxate', 'Sufentanil', 'Moderate', 'Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.', 'DDInter', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112811/', '[1] "Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc, Coralville, IA.[2] "Product Information. Lortab (acetaminophen-hydrocodone)." Akorn Inc, Buffalo Grove, IL.[3] "Product Information. Exalgo (hydromorphone)." Covidien, Mansfield, MA.[4] "Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine)." Actavis U.S. (Amide Pharmaceutical Inc), Little Falls, NJ.[5] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[6] "Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC, Chadds Ford, PA.[7] "Product Information. Kadian (morphine)." Zeneca Pharmaceuticals, Wilmington, DE.[8] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[9] "Product Information. Opana (oxymorphone)." Endo Laboratories LLC, Chadds Ford, PA.[10] "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.[11] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[12] "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.[13] "Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals, New York, NY.[14] "Product Information. Levorphanol Tartrate (levorphanol)." Sentynl Therapeutics, Solana Beach, CA.[15] "Product Information. Belbuca (buprenorphine)." Endo Pharmaceuticals Solutions Inc, Malvern, PA.[16] "Product Information. SUFentanil Citrate (SUFentanil)." Akorn Inc, Buffalo Grove, IL.[17] "Product Information. Dolophine (methadone)." Lilly, Eli and Company, Indianapolis, IN.[18] "Product Information. Alfentanil Hydrochloride (alfentanil)." Akorn Inc, Buffalo Grove, IL.[19] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112681, 'Flibanserin', 'Sufentanil', 'Moderate', 'The central nervous system (CNS) effects of flibanserin such as somnolence and fatigue may be potentiated by concomitant use of other agents with CNS depressant effects. The risk of CNS depression is increased if flibanserin is taken during waking hours or with alcohol or other CNS depressants.', 'DDInter', 'Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue. Patients should not drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking flibanserin.', 'Synergism', 'Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112812/', '[1] "Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals, Raleigh, NC.[2] "Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals, Raleigh, NC.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Halothane, Isoflurane, Nitrous oxide, Methohexital, Desflurane, Enflurane, Sevoflurane', 'Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112682, 'Fluconazole', 'Sufentanil', 'Moderate', 'Coadministration with fluconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4-mediated metabolism by fluconazole, a moderate inhibitor of the isoenzyme.', 'DDInter', 'Caution is advised when fluconazole is used with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fluconazole is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when fluconazole is used with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112813/', '[1] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[2] Assan R, Fredj G, Larger E, Feutren G, Bismuth H "FK 506/fluconazole interaction enhances FK 506 nephrotoxicity." Diabete Metab 20 (1994): 49-52[3] Ulivelli M, Rubegni P, Nuti D, Bartalini S, Giannini F, Rossi S "Clinical evidence of fluconazole-induced carbamazepine toxicity." J Neurol 251 (2004): 622-3[4] "Product Information. Diflucan (fluconazole)." Roerig Division, New York, NY.[5] Michalets EL, Williams CR "Drug interactions with cisapride: clinical implications." Clin Pharmacokinet 39 (2000): 49-75[6] Canafax DM, Graves NM, Hilligoss DM, et al "Interaction between cyclosporine and fluconazole in renal allograft recipients." Transplantation 51 (1991): 1014-8[7] Hilbert J, Messig M, Kuye O, Friedman H "Evaluation of interaction between fluconazole and an oral contraceptive in healthy women." Obstet Gynecol 98 (2001): 218-23[8] Finch CK, Green CA, Self TH "Fluconazole-carbamazepine interaction." South Med J 95 (2002): 1099-100[9] Torregrosa V, De la Torre M, Campistol JM, et al "Interaction of fluconazole with ciclosporin A." Nephron 60 (1992): 125-6[10] Tsouli S, Maranis S, Kyritsis AP "Fluconazole-carbamazepine interaction in a patient with bipolar disorder." Psychiatry Clin Neurosci 65 (2011): 112[11] Barbara JA, Clarkson AR, LaBrooy J, et al "Candida albicans arthritis in a renal allograft recipient with an interaction between cyclosporin and fluconazole." Nephrol Dial Transplant 8 (1993): 263-6[12] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[13] Sugar AM, Saunders C, Idelson BA, Bernard DB "Interaction of fluconazole and cyclosporine." Ann Intern Med 110 (1989): 844[14] Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR "Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients." Transplantation 61 (1996): 1268-72[15] Baciewicz AM, Baciewicz FA, Jr "Ketoconazole and fluconazole drug interactions." Arch Intern Med 153 (1993): 1970-6[16] Bedford TA, Rowbotham DJ "Cisapride: drug interactions of clinical significance." Drug Saf 15 (1996): 167-75[17] Lopez-Gil JA "Fluconazole-cyclosporin interaction: a dose-dependent effect?" Ann Pharmacother 27 (1993): 427-30[18] Nair DR, Morris HH "Potential fluconazole-induced carbamazepine toxicity." Ann Pharmacother 33 (1999): 790-2', 'Tinidazole, Tetracycline, Cefepime, Norfloxacin, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, Caspofungin, Micafungin, More', 'Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Ketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112683, 'Fluphenazine', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112814/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Amisulpride', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112684, 'Flurazepam', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines may result in profound sedation, respiratory depression, coma, and death. The use of benzodiazepines with sufentanil during induction has been reported to decrease mean arterial pressure and systemic vascular resistance. The mechanism appears to be an indirect effect on the autonomic nervous system.', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect. Patients receiving sufentanil with benzodiazepines should be monitored closely for signs and symptoms of respiratory depression, altered hemodynamics, and hypotension.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112815/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] West JM, Estrada S, Heerdt M "Sudden hypotension associated with midazolam and sufentanil." Anesth Analg 66 (1987): 693-4[5] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[6] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8[7] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[8] "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.[9] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[10] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.', 'Nitrazepam, Zopiclone', 'Etomidate, Thiopental, Nitrous oxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112685, 'Fluvoxamine', 'Sufentanil', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112816/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Viloxazine', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112686, 'Fosamprenavir', 'Sufentanil', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112817/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112687, 'Fosaprepitant', 'Sufentanil', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', 'DDInter', 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112818/', '[1] "Product Information. Emend for Injection (fosaprepitant)." Merck & Company Inc, West Point, PA.[2] "Product Information. Emend (aprepitant)." Merck & Company Inc, West Point, PA.', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112688, 'Fosphenytoin', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112819/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 'Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112689, 'Fospropofol', 'Sufentanil', 'Moderate', 'Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.', 'DDInter', 'Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly. Supportive therapy should be provided if needed.', 'Synergism', 'Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112820/', '[1] McClune S, McKay AC, Wright PM, et al "Synergistic interaction between midazolam and propofol." Br J Anaesth 69 (1992): 240-5[2] "Product Information. Lusedra (fospropofol)." Eisai Inc, Teaneck, NJ.[3] "Product Information. Diprivan (propofol)." Zeneca Pharmaceuticals, Wilmington, DE.[4] Pavlin DJ, Coda B, Shen DD, et al "Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers." Anesthesiology 84 (1996): 23-37[5] Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5[6] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A "Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study." Clin Pharmacol Ther 66 (1999): 110-7', 'Propofol', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112690, 'Fostamatinib', 'Sufentanil', 'Moderate', 'Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.', 'DDInter', 'Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112821/', '[1] "Product Information. Tavalisse (fostamatinib)." Rigel Pharmaceuticals, South San Francisco, CA.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate', 'Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112691, 'Gabapentin', 'Sufentanil', 'Major', 'Concomitant use of opioids with gabapentinoids (e.g., gabapentin, pregabalin) may increase the risk of opioid overdose and serious adverse effects such as profound sedation, respiratory depression, syncope, and death due to potentially additive depressant effects on the central nervous system. Coadministration with opioids may increase the oral bioavailability of gabapentin.', 'DDInter', 'Caution is advised when opioids and gabapentinoids are coadministered, particularly in patients with additional risk factors for respiratory depression such as advanced age, renal insufficiency, or chronic lung disease. The dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Use of additional central nervous system depressants should be avoided if possible. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them. For patients who have been receiving extended therapy with both an opioid and a gabapentinoid (either for analgesia or seizure control) and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms and increased seizure risk.', 'Absorption', 'Caution is advised when opioids and gabapentinoids are coadministered, particularly in patients with additional risk factors for respiratory depression such as advanced age, renal insufficiency, or chronic lung disease.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112822/', '[1] Eipe N, Penning J "Postoperative respiratory depression associated with pregabalin: a case series and a preoperative decision algorithm." Pain Res Manag 16 (2011): 353-6[2] Smith RV, Havens JR, Walsh SL "Gabapentin misuse, abuse and diversion: a systematic review." Addiction 111 (2016): 1160-74[3] Government of Canada "Summary Safety Review - Gabapentin - Assessing the Potential Risk of Serious Breathing Problems. Available from: URL: https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-gabapentin-as" ([2016, Sep 16]):[4] US Food and Drug Administration "FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) When used with CNS depressants or in patients with lung problems. Available from: URL: https://ww" ([2019, Dec 19]):[5] "Product Information. Neurontin (gabapentin)." Parke-Davis, Morris Plains, NJ.[6] Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91[7] "Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[8] Peckham AM, Evoy KE, Covvey JR, Ochs L, Fairman KA, Sclar DA "Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured U.S. population." Pharmacotherapy 38 (2018): 436-43[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Nitrous oxide, Desflurane, Enflurane, Halothane, Etomidate', 'Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112692, 'Ginkgo biloba', 'Sufentanil', 'Moderate', 'Certain preparations of ginkgo biloba have been reported to induce seizures. There may be a theoretical risk of increased seizure potential when used with other agents that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Ginkgo products may contain varying amounts of 4''-O-methylpyridoxine (ginkgotoxin), a known neurotoxin found primarily in ginkgo biloba seeds but also detected in lesser amounts in the leaves. In vivo, 4''-O-methylpyridoxine competes with vitamin B6, which causes an indirect inhibition of glutamate decarboxylase and subsequent decrease in the formation of gamma-aminobutyric acid (GABA) in the brain. There have been published case reports of generalized convulsions and vomiting within several hours after ingestion of large amounts of ginkgo nuts/seeds, including in young children and healthy individuals with no known personal or family history of epilepsy.', 'DDInter', 'Patients should consult a healthcare provider before taking any herbal or alternative medicine. Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4''-O-methylpyridoxine may be present in a given ginkgo preparation. Patients treated with agents that can lower the seizure threshold should preferably avoid the use of products containing ginkgo biloba.', 'Synergism', 'Patients should consult a healthcare provider before taking any herbal or alternative medicine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112823/', '[1] Kajiyama Y, Fujii K, Takeuchi H, Manabe Y "Ginkgo seed poisoning." Pediatrics 109 (2002): 325-7[2] Granger AS "Ginkgo biloba precipitating epileptic seizures." Age Ageing 30 (2001): 523-5[3] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[4] Gregory PJ "Seizure associated with Ginkgo biloba?." Ann Intern Med 134 (2001): 344[5] Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE "Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder." Epilepsia 47 (2006): 323-9[6] Spinella M "Herbal medicines and epilepsy: the potential for benefit and adverse effects." Epilepsy Behav 2 (2001): 524-32[7] Miwa H, Iijima M, Tanaka S, Mizuno Y "Generalized convulsions after consuming a large amount of Gingko nuts." Epilepsia 42 (2001): 280-1[8] Kupiec T, Raj V "Fatal seizures due to potential herb-drug interactions with Ginkgo biloba." J Anal Toxicol 29 (2005): 755-8', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Rivastigmine, Galantamine, Donepezil, Tacrine, Memantine, Aducanumab', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112693, 'Glycerol phenylbutyrate', 'Sufentanil', 'Moderate', 'Coadministration with glycerol phenylbutyrate may decrease the systemic exposure to and therapeutic efficacy of drugs that are substrates of CYP450 3A4. Glycerol phenylbutyrate, its active moiety phenylbutyrate, and active metabolite phenylacetic acid are considered weak CYP450 3A4 inducers in vivo.', 'DDInter', 'Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.g., oral midazolam) or CYP450 3A4 substrates with a narrow therapeutic index (e.g., alfentanil, oral contraceptives, quinidine, and cyclosporine) should be done with caution and monitoring for reduced efficacy. Dosage adjustment as well as clinical and laboratory monitoring may be appropriate whenever glycerol phenylbutyrate is added to or withdrawn from therapy.', 'Metabolism', 'Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112824/', '[1] "Product Information. Ravicti (glycerol phenylbutyrate)." Hyperion Therapeutics Inc, South San Francisco, CA.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112694, 'Golimumab', 'Sufentanil', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112825/', '[1] "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, North Chicago, IL.[2] "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Gamifant (emapalumab)." Sobi Inc, Ardmore, PA.[5] "Product Information. Kevzara (sarilumab)." sanofi-aventis, Bridgewater, NJ.[6] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc., Horsham, PA, PA.[9] "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.[10] "Product Information. Ilumya (tildrakizumab)." Merck & Company Inc, Whitehouse Station, NJ.[11] "Product Information. Actemra (tocilizumab)." Genentech, South San Francisco, CA.[12] "Product Information. Amevive (alefacept)." Biogen, Cambridge, MA.[13] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[14] "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company, Indianapolis, IN.[15] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112695, 'Granisetron', 'Sufentanil', 'Major', 'Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), 5-HT1 receptor agonists (triptans), ergot alkaloids, phenylpiperidine opioids, bupropion, dextromethorphan, linezolid, lithium, St. John''s wort, tramadol, and tryptophan may potentiate the risk of serotonin syndrome.', 'DDInter', 'Caution is advised if 5-HT3 receptor antagonists are prescribed with other agents that affect the serotonergic neurotransmitter system. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is warranted when initiating or increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life. For example, a 5-week washout period is typically recommended following use of fluoxetine and 2 weeks following use of MAOIs before administering another serotonergic agent. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.', 'Synergism', 'Caution is advised if 5-HT3 receptor antagonists are prescribed with other agents that affect the serotonergic neurotransmitter system.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112826/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] "Product Information. Sancuso (granisetron)." ProStrakan Group, Bedminster, NJ.[6] "Product Information. Aloxi (palonosetron)." MGI Pharma Inc, Minnetonka, MN.[7] "Product Information. Anzemet (dolasetron)." Hoechst Marion-Roussel Inc, Kansas City, MO.', 'Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine', 'Rolapitant', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112696, 'Grepafloxacin', 'Sufentanil', 'Moderate', 'Based on in vitro inhibition data, coadministration with grepafloxacin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by grepafloxacin.', 'DDInter', 'Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever grepafloxacin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112827/', '[1] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.', 'Enoxacin, Gatifloxacin, Norfloxacin, Levofloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112697, 'Guselkumab', 'Sufentanil', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112828/', '[1] "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, North Chicago, IL.[2] "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Gamifant (emapalumab)." Sobi Inc, Ardmore, PA.[5] "Product Information. Kevzara (sarilumab)." sanofi-aventis, Bridgewater, NJ.[6] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc., Horsham, PA, PA.[9] "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.[10] "Product Information. Ilumya (tildrakizumab)." Merck & Company Inc, Whitehouse Station, NJ.[11] "Product Information. Actemra (tocilizumab)." Genentech, South San Francisco, CA.[12] "Product Information. Amevive (alefacept)." Biogen, Cambridge, MA.[13] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[14] "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company, Indianapolis, IN.[15] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112698, 'Halazepam', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines may result in profound sedation, respiratory depression, coma, and death. The use of benzodiazepines with sufentanil during induction has been reported to decrease mean arterial pressure and systemic vascular resistance. The mechanism appears to be an indirect effect on the autonomic nervous system.', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect. Patients receiving sufentanil with benzodiazepines should be monitored closely for signs and symptoms of respiratory depression, altered hemodynamics, and hypotension.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112829/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] West JM, Estrada S, Heerdt M "Sudden hypotension associated with midazolam and sufentanil." Anesth Analg 66 (1987): 693-4[5] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[6] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8[7] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[8] "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.[9] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[10] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.', 'Etomidate, Nitrous oxide', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112699, 'Haloperidol', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112830/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Amisulpride', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112700, 'Halothane', 'Sufentanil', 'Moderate', 'Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.', 'DDInter', 'In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.', 'Synergism', 'In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112831/', '[1] "Product Information. Ultane (sevoflurane)." Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A "Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses." Anesth Analg 84 (1997): 100-5[3] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.', 'Thiopental, Isoflurane, Methohexital, Desflurane, Enflurane, Halothane, Etomidate, Ketamine', 'Sufentanil', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112701, 'Diamorphine', 'Sufentanil', 'Moderate', 'Potent narcotics, when used as an adjuvant in patients receiving alfentanil, remifentanil, or sufentanil for anesthesia or conscious sedation, may further decrease cardiac output and respiratory drive.', 'DDInter', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Synergism', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112832/', '[1] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Etomidate', 'Varenicline, Nalmefene, Disulfiram, Acamprosate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112702, 'Hydromorphone', 'Sufentanil', 'Moderate', 'Potent narcotics, when used as an adjuvant in patients receiving alfentanil, remifentanil, or sufentanil for anesthesia or conscious sedation, may further decrease cardiac output and respiratory drive.', 'DDInter', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Synergism', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112833/', '[1] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Acetylsalicylic acid, Ibuprofen, Celecoxib', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112703, 'Hydroxyzine', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112834/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Thiopental, Nitrous oxide, Desflurane, Enflurane, Etomidate', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112704, 'Idelalisib', 'Sufentanil', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112835/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate', 'Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112705, 'Ifosfamide', 'Sufentanil', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', 'DDInter', 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112836/', '[1] Simonian NA, Gilliam FG, Chiappa KH "Ifosfamide causes a diazepam-sensitive encephalopathy." Neurology 43 (1993): 2700-2[2] "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Halothane, Isoflurane, Nitrous oxide, Methohexital, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Ketamine', 'Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112706, 'Iloperidone', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112837/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Amisulpride', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112707, 'Imatinib', 'Sufentanil', 'Moderate', 'Coadministration with imatinib may increase the plasma concentrations of drugs that are substrates of CYP450 2C9, 2D6 and/or 3A4. The mechanism is decreased clearance due to inhibition of these isoenzymes by imatinib.', 'DDInter', 'Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever imatinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112838/', '[1] "Product Information. Gleevec (imatinib mesylate)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Gleevec (imatinib mesylate)." Novartis Pharmaceuticals, East Hanover, NJ.', 'Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, More', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112708, 'Imipramine', 'Sufentanil', 'Moderate', 'Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.', 'DDInter', 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John''s wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.', 'Synergism', 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112839/', '[1] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919[2] Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5[3] Mittino D, Mula M, Monaco F "Serotonin syndrome associated with tramadol-sertraline coadministration." Clin Neuropharmacol 27 (2004): 150-1[4] Gillman PK "Possible serotonin syndrome with moclobemide and pethidine." Med J Aust 162 (1995): 554[5] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[6] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[7] Kesavan S, Sobala GM "Serotonin syndrome with fluoxetine plus tramadol." J R Soc Med 92 (1999): 474-5[8] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[9] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[10] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[11] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[12] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[13] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[14] Meyer D, Halfin V "Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review." J Clin Psychopharmacol 1 (1981): 319-21[15] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[16] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[17] US Food and Drug Administration (FDA) "FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf." ([2016, Mar 22]):[18] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K "Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology." J Clin Psychopharmacol 22 (2002): 440-1[19] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA "Mania and tramadol-fluoxetine combination." Am J Psychiatry 158 (2001): 964-5[20] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[21] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F "Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database." J Clin Psychopharmacol (2015):[22] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[23] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[24] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE "Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil." J Clin Anesth 25 (2013): 52-4[25] Shakoor M, Ayub S, Ahad A, Ayub Z "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor." Am J Case Rep 15 (2014): 562-4[26] Lantz MS, Buchalter EN, Giambanco V "Serotonin syndrome following the administration of tramadol with paroxetine." Int J Geriatr Psychiatry 13 (1998): 343-5[27] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[28] "Venlafaxine + tramadol: serotonin syndrome." Prescrire Int 13 (2004): 57[29] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB "Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?" J Am Med Dir Assoc 6 (2005): 265-9[30] Houlihan DJ "Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine." Ann Pharmacother 38 (2004): 411-3[31] Hillman AD, Witenko CJ, Sultan SM, Gala G "Serotonin syndrome caused by fentanyl and methadone in a burn injury." Pharmacotherapy 35 (2015): 112-7[32] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[33] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[34] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL "Meperidine-induced serotonin syndrome in a susceptible patient." Br J Anaesth (2009):[35] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H "Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction." Pharmacotherapy (2015):[36] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[37] Kitson R, Carr B "Tramadol and severe serotonin syndrome." Anaesthesia 60 (2005): 934-5[38] Zornberg GL, Bodkin JA, Cohen BM "Severe adverse interaction between pethidine and selegiline." Lancet 337 (1991): 246[39] Mahlberg R, Kunz D, Sasse J, Kirchheiner J "Serotonin syndrome with tramadol and citalopram." Am J Psychiatry 161 (2004): 1129[40] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J "Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy." J Clin Anesth 27 (2015): 247-51[41] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Viloxazine', 'Desflurane, Enflurane, Etomidate, Nitrous oxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112709, 'Indinavir', 'Sufentanil', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112840/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112710, 'Infliximab', 'Sufentanil', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112841/', '[1] "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, North Chicago, IL.[2] "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Gamifant (emapalumab)." Sobi Inc, Ardmore, PA.[5] "Product Information. Kevzara (sarilumab)." sanofi-aventis, Bridgewater, NJ.[6] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc., Horsham, PA, PA.[9] "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.[10] "Product Information. Ilumya (tildrakizumab)." Merck & Company Inc, Whitehouse Station, NJ.[11] "Product Information. Actemra (tocilizumab)." Genentech, South San Francisco, CA.[12] "Product Information. Amevive (alefacept)." Biogen, Cambridge, MA.[13] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[14] "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company, Indianapolis, IN.[15] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112711, 'Iohexol', 'Sufentanil', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', 'DDInter', 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112842/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112712, 'Iopamidol', 'Sufentanil', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', 'DDInter', 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112843/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112713, 'Isavuconazonium', 'Sufentanil', 'Moderate', 'Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.', 'DDInter', 'Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112844/', '[1] "Product Information. Cresemba (isavuconazonium)." Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112714, 'Isocarboxazid', 'Sufentanil', 'Major', 'Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.', 'DDInter', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.', 'Others', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112845/', '[1] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[2] Zornberg GL, Hegarty JD "Adverse interaction between propoxyphene and phenelzine." Am J Psychiatry 150 (1993): 1270-1[3] "Product Information. Emsam (selegiline)." Bristol-Myers Squibb, Princeton, NJ.[4] Michaels I, Serrins M, Shier NQ, Barash PG "Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors." Anesth Analg 63 (1984): 1041-4[5] Evans-Prosser CD "The use of pethidine and morphine in the presence of monoamine oxidase inhibitors." Br J Anaesth 40 (1968): 279-82[6] "Product Information. Talacen (acetaminophen-pentazocine)." Sanofi-Synthelabo Inc, New York, NY.[7] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[8] "Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceutical, Richmond, VA.[9] "Product Information. Nubain (nalbuphine)." Endo Laboratories, Texarkana, TX.[10] "Product Information. Roxicodone (oxycodone)." Roxane Laboratories Inc, Columbus, OH.[11] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[12] "Product Information. MS Contin (morphine)." Purdue Frederick Company, Norwalk, CT.[13] Garbutt JC "Potentiation of propoxyphene by phenelzine." Am J Psychiatry 144 (1987): 251-2[14] "Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[16] Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2[17] "Product Information. Xadago (safinamide)." US WorldMeds LLC, Louisville , KY.', 'Viloxazine', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112715, 'Isoflurane', 'Sufentanil', 'Moderate', 'Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.', 'DDInter', 'In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.', 'Synergism', 'In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112846/', '[1] "Product Information. Ultane (sevoflurane)." Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A "Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses." Anesth Analg 84 (1997): 100-5[3] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.', 'Thiopental, Isoflurane, Methohexital, Desflurane, Enflurane, Halothane, Ketamine', 'Sufentanil', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112716, 'Itraconazole', 'Sufentanil', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112847/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Halothane, Etomidate, Ketamine', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112717, 'Sufentanil', 'Ivosidenib', 'Moderate', 'Coadministration with ivosidenib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Ivosidenib induces its own metabolism via CYP450 3A4.', 'DDInter', 'Concomitant use of ivosidenib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. If coadministration is required, patients should be monitored carefully for potential loss of therapeutic effects.', 'Metabolism', 'Concomitant use of ivosidenib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112848/', '[1] "Product Information. Tibsovo (ivosidenib)." Agios Pharmaceuticals, Cambridge, MA.[2] "Product Information. Tibsovo (ivosidenib)." Agios Pharmaceuticals, Cambridge, MA.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112718, 'Sufentanil', 'Ixekizumab', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112849/', '[1] "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, North Chicago, IL.[2] "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Gamifant (emapalumab)." Sobi Inc, Ardmore, PA.[5] "Product Information. Kevzara (sarilumab)." sanofi-aventis, Bridgewater, NJ.[6] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc., Horsham, PA, PA.[9] "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.[10] "Product Information. Ilumya (tildrakizumab)." Merck & Company Inc, Whitehouse Station, NJ.[11] "Product Information. Actemra (tocilizumab)." Genentech, South San Francisco, CA.[12] "Product Information. Amevive (alefacept)." Biogen, Cambridge, MA.[13] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[14] "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company, Indianapolis, IN.[15] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112719, 'Sufentanil', 'Kava', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112850/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112720, 'Sufentanil', 'Ketamine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112851/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Methohexital, Desflurane, Enflurane, Sevoflurane, Etomidate, Ketamine', 'Sufentanil', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112721, 'Sufentanil', 'Ketoconazole', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112852/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112722, 'Sufentanil', 'Labetalol', 'Moderate', 'In patients receiving chronic beta-blocker therapy, the use of sufentanil may lead to a higher degree of bradycardia and hypotension. One study has shown that induction and maintenance of anesthesia requires lower doses of sufentanil in patients receiving beta-blockers.', 'DDInter', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112853/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112723, 'Sufentanil', 'Lamotrigine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112854/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Lacosamide', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112724, 'Sufentanil', 'Lapatinib', 'Moderate', 'Coadministration with lapatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these routes due to inhibition by lapatinib.', 'DDInter', 'Caution is advised if lapatinib must be used concurrently with medications that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or P-gp efflux transporter, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lapatinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if lapatinib must be used concurrently with medications that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or P-gp efflux transporter, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112855/', '[1] "Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] "Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals, East Hanover, NJ.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine', 'Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112725, 'Sufentanil', 'Larotrectinib', 'Moderate', 'Coadministration with larotrectinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.', 'DDInter', 'Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever larotrectinib is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects. Some authorities recommend avoiding concomitant use of larotrectinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.', 'Metabolism', 'Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112856/', '[1] "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate', 'Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112726, 'Sufentanil', 'Lasmiditan', 'Major', 'Coadministration of lasmiditan and serotonergic agents may increase the risk of serotonin syndrome. Lasmiditan binds to the 5-HT(1F) receptor, where it presumably exerts therapeutic effects via agonist actions.', 'DDInter', 'Caution is advised during coadministration of lasmiditan and agents that increase serotonin. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Extra caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'Caution is advised during coadministration of lasmiditan and agents that increase serotonin.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112857/', '[1] "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company, Indianapolis, IN.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Ketamine', 'Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112727, 'Sufentanil', 'Lefamulin', 'Moderate', 'When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor. When oral midazolam was administered concomitantly with and at 2 or 4 hours after administration of lefamulin tablets, mean midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 100% and 200%, respectively.', 'DDInter', 'Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever oral lefamulin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112858/', '[1] "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112728, 'Sufentanil', 'Lemborexant', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112859/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112729, 'Sufentanil', 'Letermovir', 'Moderate', 'Coadministration with letermovir may increase the plasma concentrations of drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or organic anion transporting polypeptide protein (OATP) 1B1 and 1B3. Letermovir has been shown to be a reversible inhibitor of CYP450 2C8 in vitro, although its effect on CYP450 2C8 substrates has not been evaluated clinically. Letermovir is also a time-dependent inhibitor and inducer of CYP450 3A4 in vitro.', 'DDInter', 'Caution is advised when letermovir is used concurrently with drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or OATP 1B1 and 1B3, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever letermovir is added to or withdrawn from therapy. Moreover, clinicians should be aware that the magnitude of CYP450 3A- and OATP1B1/3-mediated drug interactions with coadministered drugs may be different when letermovir is used with cyclosporine. The combined effect of the two drugs on CYP450 3A4 may be similar to that of a strong CYP450 3A4 inhibitor, hence clinicians should refer to the prescribing information for dosing recommendations of the CYP450 3A4 substrate with a strong CYP450 3A4 inhibitor. Similarly, letermovir and cyclosporine may demonstrate some additive effects on OATP1B1 inhibition, although cyclosporine by itself is already a strong OATP1B1/3 inhibitor.', 'Metabolism', 'Caution is advised when letermovir is used concurrently with drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or OATP 1B1 and 1B3, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112860/', '[1] "Product Information. Prevymis (letermovir)." Merck & Company Inc, Whitehouse Station, NJ.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112730, 'Sufentanil', 'Levamlodipine', 'Moderate', 'In patients receiving chronic therapy with calcium channel blockers, the use of sufentanil during induction may lead to a higher degree of bradycardia and hypotension.', 'DDInter', 'These patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'These patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112861/', '[1] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[2] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[3] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[4] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[7] "Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.[8] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[9] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[10] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[11] "Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.[12] Fuhr U, Muller-Peltzer H, Kern R, et al. "Effects of grapefruit juice and smoking on verapamil concentrations in steady state." Eur J Clin Pharmacol 58 (2002): 45-53[13] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[14] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[15] "Product Information. Sular (nisoldipine)." Zeneca Pharmaceuticals, Wilmington, DE.[16] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[17] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[18] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[19] Ho PC, Ghose K, Saville D, Wanwimolruk S "Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers." Eur J Clin Pharmacol 56 (2000): 693-8[20] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94', 'Nitrous oxide, Propofol, Esketamine, Etomidate, Ketamine', 'Celecoxib', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112731, 'Sufentanil', 'Levobetaxolol (ophthalmic)', 'Moderate', 'In patients receiving chronic beta-blocker therapy, the use of sufentanil may lead to a higher degree of bradycardia and hypotension. One study has shown that induction and maintenance of anesthesia requires lower doses of sufentanil in patients receiving beta-blockers.', 'DDInter', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112862/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Propofol, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112732, 'Sufentanil', 'Levobunolol (ophthalmic)', 'Moderate', 'In patients receiving chronic beta-blocker therapy, the use of sufentanil may lead to a higher degree of bradycardia and hypotension. One study has shown that induction and maintenance of anesthesia requires lower doses of sufentanil in patients receiving beta-blockers.', 'DDInter', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112863/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Propofol, More', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112733, 'Sufentanil', 'Levocetirizine', 'Moderate', 'Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.', 'DDInter', 'Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112864/', '[1] "Product Information. Zyrtec (cetirizine)." Pfizer US Pharmaceuticals, New York, NY.[2] "Product Information. Xyzal (levocetirizine)." UCB Pharma Inc, Smyrna, GA.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[8] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[10] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Halothane, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112734, 'Sufentanil', 'Levacetylmethadol', 'Moderate', 'Potent narcotics, when used as an adjuvant in patients receiving alfentanil, remifentanil, or sufentanil for anesthesia or conscious sedation, may further decrease cardiac output and respiratory drive.', 'DDInter', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Synergism', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112865/', '[1] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Etomidate', 'Varenicline, Nalmefene, Disulfiram, Acamprosate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112735, 'Sufentanil', 'Levomilnacipran', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112866/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate', 'Viloxazine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112736, 'Sufentanil', 'Levorphanol', 'Moderate', 'Potent narcotics, when used as an adjuvant in patients receiving alfentanil, remifentanil, or sufentanil for anesthesia or conscious sedation, may further decrease cardiac output and respiratory drive.', 'DDInter', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Synergism', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112867/', '[1] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Etomidate', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112737, 'Sufentanil', 'Lindane', 'Moderate', 'Lindane penetrates human skin and has the potential to cause central nervous system toxicity. Seizures have been reported after excessive use or oral ingestion of lindane. There may be a theoretical risk of increased seizure potential when lindane is used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, theophylline).', 'DDInter', 'Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Lindane should be used according to recommended dosage and directions for application.', 'Synergism', 'Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112868/', '[1] Cox R, Krupnick J, Bush N, Houpt A "Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder." J Miss State Med Assoc 41 (2000): 690-2[2] Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9[3] "Product Information. Kwell (lindane)." Reed and Carnrick, Jersey City, NJ.[4] Telch J, Jarvis DA "Acute intoxication with lindane (gamma benzene hexachloride)." Can Med Assoc J 126 (1982): 662-3[5] Pramanik AK, Hansen RC "Transcutaneous gamma benzene hexachloride absorption and toxicity in infants and children." Arch Dermatol 115 (1979): 1224-5[6] Ramchander V, Cameron ES, Reid HF "Lindane toxicity in an infant." West Indian Med J 40 (1991): 41-3[7] Tenenbein M "Seizures after lindane therapy." J Am Geriatr Soc 39 (1991): 394-5[8] Solomon BA, Haut SR, Carr EM, Shalita AR "Neurotoxic reaction to lindane in an HIV-seropositive patient: an old medication''s new problem." J Fam Pract 40 (1995): 291-6[9] Munk ZM, Nantel A "Acute lindane poisoning with development of muscle necrosis." Can Med Assoc J 117 (1977): 1050-4', 'Disulfiram', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112738, 'Sufentanil', 'Linezolid', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112869/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin', 'Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Halothane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112739, 'Sufentanil', 'Lisdexamfetamine', 'Moderate', 'Coadministration of amphetamines and amphetamine-like drugs with certain opioids or the synthetic opioid derivative, dextromethorphan, may increase the risk of serotonin syndrome. Dextromethorphan and some opioids, particularly those in the phenylpiperidine class, are weak serotonin reuptake inhibitors whose effects may be potentiated by amphetamines.', 'DDInter', 'Caution is recommended when amphetamines and amphetamine-like drugs are used with dextromethorphan or opioids with serotonergic effects such as fentanyl, meperidine, methadone, propoxyphene, and tramadol. Patients should be monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.', 'Synergism', 'Caution is recommended when amphetamines and amphetamine-like drugs are used with dextromethorphan or opioids with serotonergic effects such as fentanyl, meperidine, methadone, propoxyphene, and tramadol.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112870/', '[1] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[2] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[3] "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.[5] "Product Information. Nuedexta (dextromethorphan-quinidine)." Avanir Pharmaceuticals, Inc, Aliso Viejo, CA.[6] "Product Information. Adipex-P (phentermine)." Teva Pharmaceuticals (formerly Gate Pharmaceuticals), Sellersville, PA.[7] "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.[8] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE "Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil." J Clin Anesth 25 (2013): 52-4[9] "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc, Florence, KY.[10] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[11] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[12] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[13] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[14] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 'Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Pemoline, Atomoxetine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Citicoline', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112740, 'Sufentanil', 'Lithium carbonate', 'Moderate', 'Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.', 'DDInter', 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John''s wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.', 'Synergism', 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112871/', '[1] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919[2] Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5[3] Mittino D, Mula M, Monaco F "Serotonin syndrome associated with tramadol-sertraline coadministration." Clin Neuropharmacol 27 (2004): 150-1[4] Gillman PK "Possible serotonin syndrome with moclobemide and pethidine." Med J Aust 162 (1995): 554[5] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[6] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[7] Kesavan S, Sobala GM "Serotonin syndrome with fluoxetine plus tramadol." J R Soc Med 92 (1999): 474-5[8] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[9] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[10] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[11] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[12] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[13] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[14] Meyer D, Halfin V "Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review." J Clin Psychopharmacol 1 (1981): 319-21[15] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[16] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[17] US Food and Drug Administration (FDA) "FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf." ([2016, Mar 22]):[18] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K "Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology." J Clin Psychopharmacol 22 (2002): 440-1[19] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA "Mania and tramadol-fluoxetine combination." Am J Psychiatry 158 (2001): 964-5[20] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[21] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F "Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database." J Clin Psychopharmacol (2015):[22] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[23] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[24] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE "Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil." J Clin Anesth 25 (2013): 52-4[25] Shakoor M, Ayub S, Ahad A, Ayub Z "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor." Am J Case Rep 15 (2014): 562-4[26] Lantz MS, Buchalter EN, Giambanco V "Serotonin syndrome following the administration of tramadol with paroxetine." Int J Geriatr Psychiatry 13 (1998): 343-5[27] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[28] "Venlafaxine + tramadol: serotonin syndrome." Prescrire Int 13 (2004): 57[29] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB "Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?" J Am Med Dir Assoc 6 (2005): 265-9[30] Houlihan DJ "Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine." Ann Pharmacother 38 (2004): 411-3[31] Hillman AD, Witenko CJ, Sultan SM, Gala G "Serotonin syndrome caused by fentanyl and methadone in a burn injury." Pharmacotherapy 35 (2015): 112-7[32] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[33] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[34] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL "Meperidine-induced serotonin syndrome in a susceptible patient." Br J Anaesth (2009):[35] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H "Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction." Pharmacotherapy (2015):[36] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[37] Kitson R, Carr B "Tramadol and severe serotonin syndrome." Anaesthesia 60 (2005): 934-5[38] Zornberg GL, Bodkin JA, Cohen BM "Severe adverse interaction between pethidine and selegiline." Lancet 337 (1991): 246[39] Mahlberg R, Kunz D, Sasse J, Kirchheiner J "Serotonin syndrome with tramadol and citalopram." Am J Psychiatry 161 (2004): 1129[40] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J "Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy." J Clin Anesth 27 (2015): 247-51[41] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112741, 'Sufentanil', 'Lofexidine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112872/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Varenicline, Nalmefene, Disulfiram, Acamprosate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112742, 'Sufentanil', 'Lonafarnib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112873/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112743, 'Sufentanil', 'Lorazepam', 'Major', 'Concomitant use of opioids with benzodiazepines may result in profound sedation, respiratory depression, coma, and death. The use of benzodiazepines with sufentanil during induction has been reported to decrease mean arterial pressure and systemic vascular resistance. The mechanism appears to be an indirect effect on the autonomic nervous system.', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect. Patients receiving sufentanil with benzodiazepines should be monitored closely for signs and symptoms of respiratory depression, altered hemodynamics, and hypotension.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112874/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] West JM, Estrada S, Heerdt M "Sudden hypotension associated with midazolam and sufentanil." Anesth Analg 66 (1987): 693-4[5] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[6] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8[7] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[8] "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.[9] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[10] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.', 'Thiopental, Nitrous oxide', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112744, 'Sufentanil', 'Lorlatinib', 'Moderate', 'Coadministration with lorlatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The proposed mechanism is increased clearance due to lorlatinib-mediated induction of CYP450 3A4 metabolism.', 'DDInter', 'Caution is advised when lorlatinib is used concomitantly with drugs that are substrates of CYP450 3A4. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lorlatinib is added to or withdrawn from therapy. Avoid concomitant use with lorlatinib where minimal decreases in concentration of the CYP450 3A4 substrate may lead to serious therapeutic failure. If coadministration is required, the CYP450 3A4 substrate dosage should be increased in accordance with approved product labeling.', 'Metabolism', 'Caution is advised when lorlatinib is used concomitantly with drugs that are substrates of CYP450 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112875/', '[1] "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Sevoflurane, Etomidate', 'Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112745, 'Sufentanil', 'Loxapine', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112876/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Amisulpride', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112746, 'Sufentanil', 'Lumateperone', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112877/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Amisulpride', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112747, 'Sufentanil', 'Lurasidone', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112878/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Amisulpride', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112748, 'Sufentanil', 'Maprotiline', 'Moderate', 'Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.', 'DDInter', 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John''s wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.', 'Synergism', 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112879/', '[1] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919[2] Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5[3] Mittino D, Mula M, Monaco F "Serotonin syndrome associated with tramadol-sertraline coadministration." Clin Neuropharmacol 27 (2004): 150-1[4] Gillman PK "Possible serotonin syndrome with moclobemide and pethidine." Med J Aust 162 (1995): 554[5] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[6] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[7] Kesavan S, Sobala GM "Serotonin syndrome with fluoxetine plus tramadol." J R Soc Med 92 (1999): 474-5[8] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[9] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[10] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[11] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[12] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[13] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[14] Meyer D, Halfin V "Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review." J Clin Psychopharmacol 1 (1981): 319-21[15] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[16] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[17] US Food and Drug Administration (FDA) "FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf." ([2016, Mar 22]):[18] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K "Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology." J Clin Psychopharmacol 22 (2002): 440-1[19] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA "Mania and tramadol-fluoxetine combination." Am J Psychiatry 158 (2001): 964-5[20] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[21] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F "Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database." J Clin Psychopharmacol (2015):[22] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[23] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[24] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE "Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil." J Clin Anesth 25 (2013): 52-4[25] Shakoor M, Ayub S, Ahad A, Ayub Z "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor." Am J Case Rep 15 (2014): 562-4[26] Lantz MS, Buchalter EN, Giambanco V "Serotonin syndrome following the administration of tramadol with paroxetine." Int J Geriatr Psychiatry 13 (1998): 343-5[27] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[28] "Venlafaxine + tramadol: serotonin syndrome." Prescrire Int 13 (2004): 57[29] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB "Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?" J Am Med Dir Assoc 6 (2005): 265-9[30] Houlihan DJ "Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine." Ann Pharmacother 38 (2004): 411-3[31] Hillman AD, Witenko CJ, Sultan SM, Gala G "Serotonin syndrome caused by fentanyl and methadone in a burn injury." Pharmacotherapy 35 (2015): 112-7[32] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[33] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[34] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL "Meperidine-induced serotonin syndrome in a susceptible patient." Br J Anaesth (2009):[35] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H "Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction." Pharmacotherapy (2015):[36] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[37] Kitson R, Carr B "Tramadol and severe serotonin syndrome." Anaesthesia 60 (2005): 934-5[38] Zornberg GL, Bodkin JA, Cohen BM "Severe adverse interaction between pethidine and selegiline." Lancet 337 (1991): 246[39] Mahlberg R, Kunz D, Sasse J, Kirchheiner J "Serotonin syndrome with tramadol and citalopram." Am J Psychiatry 161 (2004): 1129[40] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J "Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy." J Clin Anesth 27 (2015): 247-51[41] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Viloxazine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112749, 'Sufentanil', 'Mazindol', 'Moderate', 'Coadministration of amphetamines and amphetamine-like drugs with certain opioids or the synthetic opioid derivative, dextromethorphan, may increase the risk of serotonin syndrome. Dextromethorphan and some opioids, particularly those in the phenylpiperidine class, are weak serotonin reuptake inhibitors whose effects may be potentiated by amphetamines.', 'DDInter', 'Caution is recommended when amphetamines and amphetamine-like drugs are used with dextromethorphan or opioids with serotonergic effects such as fentanyl, meperidine, methadone, propoxyphene, and tramadol. Patients should be monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.', 'Synergism', 'Caution is recommended when amphetamines and amphetamine-like drugs are used with dextromethorphan or opioids with serotonergic effects such as fentanyl, meperidine, methadone, propoxyphene, and tramadol.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112880/', '[1] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[2] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[3] "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.[5] "Product Information. Nuedexta (dextromethorphan-quinidine)." Avanir Pharmaceuticals, Inc, Aliso Viejo, CA.[6] "Product Information. Adipex-P (phentermine)." Teva Pharmaceuticals (formerly Gate Pharmaceuticals), Sellersville, PA.[7] "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.[8] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE "Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil." J Clin Anesth 25 (2013): 52-4[9] "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc, Florence, KY.[10] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[11] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[12] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[13] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[14] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 'Ephedrine, Orlistat, Diethylpropion', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112750, 'Sufentanil', 'Meclizine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112881/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112751, 'Sufentanil', 'Mepenzolate', 'Moderate', 'Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.', 'DDInter', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112882/', '[1] "Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc, Coralville, IA.[2] "Product Information. Lortab (acetaminophen-hydrocodone)." Akorn Inc, Buffalo Grove, IL.[3] "Product Information. Exalgo (hydromorphone)." Covidien, Mansfield, MA.[4] "Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine)." Actavis U.S. (Amide Pharmaceutical Inc), Little Falls, NJ.[5] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[6] "Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC, Chadds Ford, PA.[7] "Product Information. Kadian (morphine)." Zeneca Pharmaceuticals, Wilmington, DE.[8] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[9] "Product Information. Opana (oxymorphone)." Endo Laboratories LLC, Chadds Ford, PA.[10] "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.[11] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[12] "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.[13] "Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals, New York, NY.[14] "Product Information. Levorphanol Tartrate (levorphanol)." Sentynl Therapeutics, Solana Beach, CA.[15] "Product Information. Belbuca (buprenorphine)." Endo Pharmaceuticals Solutions Inc, Malvern, PA.[16] "Product Information. SUFentanil Citrate (SUFentanil)." Akorn Inc, Buffalo Grove, IL.[17] "Product Information. Dolophine (methadone)." Lilly, Eli and Company, Indianapolis, IN.[18] "Product Information. Alfentanil Hydrochloride (alfentanil)." Akorn Inc, Buffalo Grove, IL.[19] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Papaverine, Alosetron, Isometheptene', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112752, 'Sufentanil', 'Meperidine', 'Moderate', 'Potent narcotics, when used as an adjuvant in patients receiving alfentanil, remifentanil, or sufentanil for anesthesia or conscious sedation, may further decrease cardiac output and respiratory drive.', 'DDInter', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Synergism', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112883/', '[1] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Acetylsalicylic acid, Ibuprofen, Celecoxib', 'Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112753, 'Sufentanil', 'Mephenytoin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112884/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Lacosamide', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112754, 'Sufentanil', 'Methylphenobarbital', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112885/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 'Lacosamide, Nitrazepam, Zopiclone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112755, 'Sufentanil', 'Meprobamate', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112886/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Nitrazepam, Zopiclone', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112756, 'Sufentanil', 'Mesoridazine', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112887/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Amisulpride', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112757, 'Sufentanil', 'Metaxalone', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112888/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112758, 'Sufentanil', 'Metamfetamine', 'Moderate', 'Coadministration of amphetamines and amphetamine-like drugs with certain opioids or the synthetic opioid derivative, dextromethorphan, may increase the risk of serotonin syndrome. Dextromethorphan and some opioids, particularly those in the phenylpiperidine class, are weak serotonin reuptake inhibitors whose effects may be potentiated by amphetamines.', 'DDInter', 'Caution is recommended when amphetamines and amphetamine-like drugs are used with dextromethorphan or opioids with serotonergic effects such as fentanyl, meperidine, methadone, propoxyphene, and tramadol. Patients should be monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.', 'Synergism', 'Caution is recommended when amphetamines and amphetamine-like drugs are used with dextromethorphan or opioids with serotonergic effects such as fentanyl, meperidine, methadone, propoxyphene, and tramadol.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112889/', '[1] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[2] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[3] "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.[5] "Product Information. Nuedexta (dextromethorphan-quinidine)." Avanir Pharmaceuticals, Inc, Aliso Viejo, CA.[6] "Product Information. Adipex-P (phentermine)." Teva Pharmaceuticals (formerly Gate Pharmaceuticals), Sellersville, PA.[7] "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.[8] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE "Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil." J Clin Anesth 25 (2013): 52-4[9] "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc, Florence, KY.[10] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[11] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[12] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[13] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[14] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Pemoline, Atomoxetine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Citicoline', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112759, 'Sufentanil', 'Methdilazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112890/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112760, 'Sufentanil', 'Methocarbamol', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112891/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112761, 'Sufentanil', 'Methohexital', 'Moderate', 'Narcotic analgesics may reduce the dosage of barbiturate anesthetics needed to induce anesthesia by as much as 40%. Additionally, apnea is more common with this combination.', 'DDInter', 'Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.', 'Others', 'Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112892/', '[1] Stambaugh JE, Wainer IW, Schwartz I "The effect of phenobarbital on the metabolism of meperidine in normal volunteers." J Clin Pharmacol 18 (1978): 482-90[2] DeLapa RJ "Influence of alphaprodine hydrochloride on intravenous barbiturate induction dosage." J Oral Surg 18 (1960): 163-8[3] Stambaugh JE, Hemphill DM, Wainer IW, Schwartz I "A potentially toxic drug interaction between pethidine (meperidine) and phenobarbitone." Lancet 1 (1977): 398-9[4] Dundee JW, Halliday NJ, McMurray TJ, Harper KW "Pretreatment with opioids: the effect on thiopentone induction requirements and on the onset of action of midazolam." Anaesthesia 41 (1986): 159-61[5] Levine B, Saady J, Fierro M, Valentour J "A hydromorphone and ethanol fatality." J Forensic Sci 29 (1984): 655-9[6] FDA. U.S. Food and Drug Administration "Healthcare Professional Sheet. FDA Alert [07/2005]: alcohol-palladone interaction. Available from: URL: http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#Palladone." ([2005 July 13]):[7] "Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company, Whippany, NJ.', 'Nitrazepam, Zopiclone, Sufentanil', 'Halothane, Isoflurane, Nitrous oxide, Methohexital, Desflurane, Enflurane, Sevoflurane, Etomidate, Ketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112762, 'Sufentanil', 'Methotrimeprazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112893/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Amisulpride', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112763, 'Sufentanil', 'Methoxyflurane', 'Moderate', 'Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.', 'DDInter', 'In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.', 'Synergism', 'In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112894/', '[1] "Product Information. Ultane (sevoflurane)." Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A "Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses." Anesth Analg 84 (1997): 100-5[3] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.', 'Halothane, Isoflurane, Desflurane, Enflurane, Sevoflurane, Etomidate, Ketamine', 'Salicylic acid, Choline salicylate, Diflunisal, Salsalate, Acetylsalicylic acid', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112764, 'Sufentanil', 'Methscopolamine', 'Moderate', 'Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.', 'DDInter', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112895/', '[1] "Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc, Coralville, IA.[2] "Product Information. Lortab (acetaminophen-hydrocodone)." Akorn Inc, Buffalo Grove, IL.[3] "Product Information. Exalgo (hydromorphone)." Covidien, Mansfield, MA.[4] "Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine)." Actavis U.S. (Amide Pharmaceutical Inc), Little Falls, NJ.[5] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[6] "Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC, Chadds Ford, PA.[7] "Product Information. Kadian (morphine)." Zeneca Pharmaceuticals, Wilmington, DE.[8] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[9] "Product Information. Opana (oxymorphone)." Endo Laboratories LLC, Chadds Ford, PA.[10] "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.[11] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[12] "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.[13] "Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals, New York, NY.[14] "Product Information. Levorphanol Tartrate (levorphanol)." Sentynl Therapeutics, Solana Beach, CA.[15] "Product Information. Belbuca (buprenorphine)." Endo Pharmaceuticals Solutions Inc, Malvern, PA.[16] "Product Information. SUFentanil Citrate (SUFentanil)." Akorn Inc, Buffalo Grove, IL.[17] "Product Information. Dolophine (methadone)." Lilly, Eli and Company, Indianapolis, IN.[18] "Product Information. Alfentanil Hydrochloride (alfentanil)." Akorn Inc, Buffalo Grove, IL.[19] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Ephedrine, Tropicamide, Phenylephrine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112765, 'Sufentanil', 'Methsuximide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112896/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112766, 'Sufentanil', 'Metipranolol (ophthalmic)', 'Moderate', 'In patients receiving chronic beta-blocker therapy, the use of sufentanil may lead to a higher degree of bradycardia and hypotension. One study has shown that induction and maintenance of anesthesia requires lower doses of sufentanil in patients receiving beta-blockers.', 'DDInter', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112897/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Propofol, More', 'Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112767, 'Sufentanil', 'Metoclopramide', 'Moderate', 'By diminishing gastrointestinal motility, narcotic analgesics may antagonize the pharmacologic effects of gastrointestinal prokinetic agents. In addition, concomitant use may increase central nervous system effects such as sedation, dizziness, confusion, and mental depression. Gastrointestinal prokinetic agents may alter the absorption characteristics of some controlled release narcotic analgesic preparations.', 'DDInter', 'The potential for reduced efficacy of gastrokinetic agents should be considered during coadministration with opioid analgesics. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Antagonism, Absorption', 'The potential for reduced efficacy of gastrokinetic agents should be considered during coadministration with opioid analgesics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112898/', '[1] Manara AR, Shelly MP, Quinn K, Park GR "The effect of metoclopramide on the absorption of oral controlled release morphine." Br J Clin Pharmacol 25 (1988): 518-21[2] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[3] "Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Thiopental, Nitrous oxide, Desflurane, Enflurane, Halothane', 'Cisapride', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112768, 'Sufentanil', 'Metocurine', 'Minor', 'Sufentanil, when combined with neuromuscular blocking agents during surgical procedures, may adversely effect cardiovascular function. Tachycardia, bradycardia, and/or hypotension may result. However, muscle relaxants and sufentanil frequently are used together during surgery. Patients should be closely monitored for clinically significant alterations in hemodynamics.', 'DDInter', '-', 'Others', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112899/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Clotz MA, Nahata MC "Clinical uses of fentanyl, sufentanil, and alfentanil." Clin Pharm 10 (1991): 581-93', 'Thiopental, Remifentanil, Sodium oxybate, Methohexital, Propofol, Esketamine, Etomidate', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112769, 'Sufentanil', 'Metoprolol', 'Moderate', 'In patients receiving chronic beta-blocker therapy, the use of sufentanil may lead to a higher degree of bradycardia and hypotension. One study has shown that induction and maintenance of anesthesia requires lower doses of sufentanil in patients receiving beta-blockers.', 'DDInter', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112900/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Acetylsalicylic acid, Ivabradine', 'Thiopental, Nitrous oxide, Methohexital, Desflurane, Enflurane, Esketamine, Halothane, Ketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112770, 'Sufentanil', 'Metyrosine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112901/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112771, 'Sufentanil', 'Miconazole', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112902/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Sevoflurane, More', 'Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112772, 'Sufentanil', 'Midazolam', 'Major', 'Concomitant use of opioids with benzodiazepines may result in profound sedation, respiratory depression, coma, and death. The use of benzodiazepines with sufentanil during induction has been reported to decrease mean arterial pressure and systemic vascular resistance. The mechanism appears to be an indirect effect on the autonomic nervous system.', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect. Patients receiving sufentanil with benzodiazepines should be monitored closely for signs and symptoms of respiratory depression, altered hemodynamics, and hypotension.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112903/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] West JM, Estrada S, Heerdt M "Sudden hypotension associated with midazolam and sufentanil." Anesth Analg 66 (1987): 693-4[5] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[6] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8[7] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[8] "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.[9] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[10] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.', 'Nitrazepam, Zopiclone', 'Nitrous oxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112773, 'Sufentanil', 'Mifepristone', 'Moderate', 'Based on in vitro inhibition data, coadministration with mifepristone may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by mifepristone.', 'DDInter', 'Caution is advised if mifepristone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever mifepristone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if mifepristone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112904/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7[3] "Product Information. Mifeprex (mifepristone)" Danco Laboratories, New York, NY.[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated, Menlo Park, CA.[10] "Product Information. Mifeprex (mifepristone)" Danco Laboratories, New York, NY.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate', 'Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112774, 'Sufentanil', 'Milnacipran', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', 'DDInter', 'In general, the use of milnacipran in combination with other serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the use of milnacipran in combination with other serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112905/', '[1] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[2] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[3] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[4] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[5] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[6] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[7] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[8] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[10] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[11] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[12] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[13] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[14] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[15] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[16] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[17] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[18] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[19] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[22] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[23] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[24] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[25] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[26] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[27] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[28] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[29] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[30] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[31] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[32] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[33] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[34] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[35] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[36] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[37] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[38] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[40] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[41] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[42] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[43] Cerner Multum, Inc. "Australian Product Information." O 0[44] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[45] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[46] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[47] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[48] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[49] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[50] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[51] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[52] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[53] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[54] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[55] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[56] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[57] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[58] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[59] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[60] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[61] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[62] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[63] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[64] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[65] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[66] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[67] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[68] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[69] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[70] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[71] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[72] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[73] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[74] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[75] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[76] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[77] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[78] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[79] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[80] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[81] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[82] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[83] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[84] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[85] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[86] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[87] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[88] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[89] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[90] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[91] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[92] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[93] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[94] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[95] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[97] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[98] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[99] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[100] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[101] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[102] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate', 'Viloxazine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112775, 'Sufentanil', 'Mirtazapine', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112906/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Viloxazine', 'Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112776, 'Sufentanil', 'Mivacurium', 'Minor', 'Sufentanil, when combined with neuromuscular blocking agents during surgical procedures, may adversely effect cardiovascular function. Tachycardia, bradycardia, and/or hypotension may result. However, muscle relaxants and sufentanil frequently are used together during surgery. Patients should be closely monitored for clinically significant alterations in hemodynamics.', 'DDInter', '-', 'Others', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112907/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Clotz MA, Nahata MC "Clinical uses of fentanyl, sufentanil, and alfentanil." Clin Pharm 10 (1991): 581-93', 'Thiopental, Remifentanil, Sodium oxybate, Methohexital, Propofol, Esketamine, Etomidate', 'Botulinum toxin type A', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112777, 'Sufentanil', 'Modafinil', 'Minor', 'Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Modafinil and armodafinil are modest inducers of CYP450 3A4, and pharmacokinetic studies suggest that their effects may be primarily intestinal rather than hepatic. Thus, clinically significant interactions would most likely be expected with drugs that have low oral bioavailability due to significant intestinal CYP450 3A4-mediated first-pass metabolism (e.g., buspirone, cyclosporine, lovastatin, midazolam, saquinavir, simvastatin, sirolimus, tacrolimus, triazolam, calcium channel blockers). However, the potential for interaction should be considered with any drug metabolized by CYP450 3A4, especially given the high degree of interpatient variability with respect to CYP450-mediated metabolism. Pharmacologic response to these drugs may be altered and should be monitored more closely whenever modafinil or armodafinil is added to or withdrawn from therapy. Dosage adjustments may be required if an interaction is suspected.', 'DDInter', '-', 'Metabolism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112908/', '[1] Robertson P Jr, Hellriegel ET, Arora S, Nelson M "Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers." Clin Pharmacol Ther 71 (2002): 46-56[2] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53[3] "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.[4] Robertson P, Decory HH, Madan A, Parkinson A "In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil." Drug Metab Dispos 28 (2000): 664-71[5] "Product Information. Nuvigil (armodafinil)." Cephalon Inc, West Chester, PA.[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.[11] "Product Information. Nuvigil (armodafinil)." Cephalon Inc, West Chester, PA.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Pemoline, Atomoxetine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Citicoline', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112778, 'Sufentanil', 'Molindone', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112909/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Amisulpride', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112779, 'Sufentanil', 'Morphine (liposomal)', 'Moderate', 'Potent narcotics, when used as an adjuvant in patients receiving alfentanil, remifentanil, or sufentanil for anesthesia or conscious sedation, may further decrease cardiac output and respiratory drive.', 'DDInter', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Synergism', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112910/', '[1] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Loperamide, Acetylsalicylic acid, Ibuprofen, Celecoxib', 'Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112780, 'Sufentanil', 'Nabilone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112911/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Rolapitant', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112781, 'Sufentanil', 'Nalbuphine', 'Moderate', 'Potent narcotics, when used as an adjuvant in patients receiving alfentanil, remifentanil, or sufentanil for anesthesia or conscious sedation, may further decrease cardiac output and respiratory drive.', 'DDInter', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Synergism', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112912/', '[1] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Etomidate', 'Acetylsalicylic acid, Ibuprofen, Celecoxib', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112782, 'Sufentanil', 'Nefazodone', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112913/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Thiopental, Propofol', 'Viloxazine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112783, 'Sufentanil', 'Nelfinavir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112914/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112784, 'Sufentanil', 'Nicardipine', 'Moderate', 'In patients receiving chronic therapy with calcium channel blockers, the use of sufentanil during induction may lead to a higher degree of bradycardia and hypotension.', 'DDInter', 'These patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'These patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112915/', '[1] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[2] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[3] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[4] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[7] "Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.[8] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[9] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[10] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[11] "Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.[12] Fuhr U, Muller-Peltzer H, Kern R, et al. "Effects of grapefruit juice and smoking on verapamil concentrations in steady state." Eur J Clin Pharmacol 58 (2002): 45-53[13] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[14] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[15] "Product Information. Sular (nisoldipine)." Zeneca Pharmaceuticals, Wilmington, DE.[16] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[17] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[18] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[19] Ho PC, Ghose K, Saville D, Wanwimolruk S "Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers." Eur J Clin Pharmacol 56 (2000): 693-8[20] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94', 'Celecoxib', 'Remifentanil, Nitrous oxide, Esketamine, Etomidate, Ketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112785, 'Sufentanil', 'Nimodipine', 'Moderate', 'In patients receiving chronic therapy with calcium channel blockers, the use of sufentanil during induction may lead to a higher degree of bradycardia and hypotension.', 'DDInter', 'These patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'These patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112916/', '[1] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[2] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[3] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[4] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[7] "Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.[8] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[9] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[10] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[11] "Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.[12] Fuhr U, Muller-Peltzer H, Kern R, et al. "Effects of grapefruit juice and smoking on verapamil concentrations in steady state." Eur J Clin Pharmacol 58 (2002): 45-53[13] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[14] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[15] "Product Information. Sular (nisoldipine)." Zeneca Pharmaceuticals, Wilmington, DE.[16] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[17] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[18] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[19] Ho PC, Ghose K, Saville D, Wanwimolruk S "Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers." Eur J Clin Pharmacol 56 (2000): 693-8[20] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94', 'Celecoxib', 'Esketamine, Etomidate, Ketamine, Nitrous oxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112786, 'Sufentanil', 'Nisoldipine', 'Moderate', 'In patients receiving chronic therapy with calcium channel blockers, the use of sufentanil during induction may lead to a higher degree of bradycardia and hypotension.', 'DDInter', 'These patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'These patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112917/', '[1] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[2] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[3] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[4] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[7] "Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.[8] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[9] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[10] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[11] "Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.[12] Fuhr U, Muller-Peltzer H, Kern R, et al. "Effects of grapefruit juice and smoking on verapamil concentrations in steady state." Eur J Clin Pharmacol 58 (2002): 45-53[13] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[14] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[15] "Product Information. Sular (nisoldipine)." Zeneca Pharmaceuticals, Wilmington, DE.[16] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[17] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[18] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[19] Ho PC, Ghose K, Saville D, Wanwimolruk S "Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers." Eur J Clin Pharmacol 56 (2000): 693-8[20] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94', 'Celecoxib', 'Remifentanil, Nitrous oxide, Propofol, Esketamine, Etomidate, Ketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112787, 'Sufentanil', 'Nitrous oxide', 'Minor', 'Although the combination of nitrous oxide and high doses of sufentanil may lead to cardiovascular depression, these agents are frequently administered together during surgery. Caution should be exercised if nitrous oxide and sufentanil are used concomitantly.', 'DDInter', '-', 'Others', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112918/', '[1] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.', 'Thiopental, Nitrous oxide, Methohexital, Etomidate, Ketamine', 'Sufentanil', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112788, 'Sufentanil', 'Nortriptyline', 'Moderate', 'Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.', 'DDInter', 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John''s wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.', 'Synergism', 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112919/', '[1] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919[2] Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5[3] Mittino D, Mula M, Monaco F "Serotonin syndrome associated with tramadol-sertraline coadministration." Clin Neuropharmacol 27 (2004): 150-1[4] Gillman PK "Possible serotonin syndrome with moclobemide and pethidine." Med J Aust 162 (1995): 554[5] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[6] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[7] Kesavan S, Sobala GM "Serotonin syndrome with fluoxetine plus tramadol." J R Soc Med 92 (1999): 474-5[8] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[9] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[10] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[11] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[12] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[13] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[14] Meyer D, Halfin V "Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review." J Clin Psychopharmacol 1 (1981): 319-21[15] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[16] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[17] US Food and Drug Administration (FDA) "FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf." ([2016, Mar 22]):[18] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K "Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology." J Clin Psychopharmacol 22 (2002): 440-1[19] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA "Mania and tramadol-fluoxetine combination." Am J Psychiatry 158 (2001): 964-5[20] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[21] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F "Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database." J Clin Psychopharmacol (2015):[22] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[23] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[24] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE "Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil." J Clin Anesth 25 (2013): 52-4[25] Shakoor M, Ayub S, Ahad A, Ayub Z "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor." Am J Case Rep 15 (2014): 562-4[26] Lantz MS, Buchalter EN, Giambanco V "Serotonin syndrome following the administration of tramadol with paroxetine." Int J Geriatr Psychiatry 13 (1998): 343-5[27] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[28] "Venlafaxine + tramadol: serotonin syndrome." Prescrire Int 13 (2004): 57[29] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB "Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?" J Am Med Dir Assoc 6 (2005): 265-9[30] Houlihan DJ "Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine." Ann Pharmacother 38 (2004): 411-3[31] Hillman AD, Witenko CJ, Sultan SM, Gala G "Serotonin syndrome caused by fentanyl and methadone in a burn injury." Pharmacotherapy 35 (2015): 112-7[32] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[33] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[34] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL "Meperidine-induced serotonin syndrome in a susceptible patient." Br J Anaesth (2009):[35] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H "Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction." Pharmacotherapy (2015):[36] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[37] Kitson R, Carr B "Tramadol and severe serotonin syndrome." Anaesthesia 60 (2005): 934-5[38] Zornberg GL, Bodkin JA, Cohen BM "Severe adverse interaction between pethidine and selegiline." Lancet 337 (1991): 246[39] Mahlberg R, Kunz D, Sasse J, Kirchheiner J "Serotonin syndrome with tramadol and citalopram." Am J Psychiatry 161 (2004): 1129[40] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J "Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy." J Clin Anesth 27 (2015): 247-51[41] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Viloxazine', 'Desflurane, Enflurane, Etomidate, Nitrous oxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112789, 'Sufentanil', 'Olanzapine', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112920/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Amisulpride', 'Desflurane, Enflurane, Etomidate, Nitrous oxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112790, 'Sufentanil', 'Olaparib', 'Moderate', 'Based on in vitro inhibition data, coadministration with olaparib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 (e.g., cisapride, ergot alkaloids, fentanyl, lovastatin, oral midazolam, pimozide, quetiapine, simvastatin, triazolam, vinca alkaloids), P-gp (e.g., colchicine, dabigatran, digoxin), breast cancer resistance protein (BCRP) (e.g., rosuvastatin), OATP1B1 (e.g., eluxadoline, glyburide, repaglinide, statins, valsartan), or organic cation transporter 1 or 2 (OCT1, OCT2) (e.g., metformin). The proposed mechanism is decreased clearance due to inhibition of the corresponding metabolizing enzyme and/or efflux/uptake transporter by olaparib.', 'DDInter', 'Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever olaparib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112921/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[7] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[9] "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.[10] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[11] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[12] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Sevoflurane, Etomidate', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112791, 'Sufentanil', 'Oliceridine', 'Moderate', 'Potent narcotics, when used as an adjuvant in patients receiving alfentanil, remifentanil, or sufentanil for anesthesia or conscious sedation, may further decrease cardiac output and respiratory drive.', 'DDInter', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Synergism', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112922/', '[1] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Etomidate', 'Acetylsalicylic acid, Ibuprofen, Celecoxib', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112792, 'Sufentanil', 'Olopatadine (nasal)', 'Moderate', 'Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance. Somnolence has been reported in some patients using olopatadine nasal spray in clinical trials.', 'DDInter', 'Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112923/', '[1] "Product Information. Patanase (olopatadine nasal)." Alcon Laboratories Inc, Fort Worth, TX.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Halothane, Isoflurane, Nitrous oxide, Methohexital, Desflurane, Enflurane, Sevoflurane, Etomidate', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112793, 'Sufentanil', 'Ondansetron', 'Major', 'Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), 5-HT1 receptor agonists (triptans), ergot alkaloids, phenylpiperidine opioids, bupropion, dextromethorphan, linezolid, lithium, St. John''s wort, tramadol, and tryptophan may potentiate the risk of serotonin syndrome.', 'DDInter', 'Caution is advised if 5-HT3 receptor antagonists are prescribed with other agents that affect the serotonergic neurotransmitter system. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is warranted when initiating or increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life. For example, a 5-week washout period is typically recommended following use of fluoxetine and 2 weeks following use of MAOIs before administering another serotonergic agent. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.', 'Synergism', 'Caution is advised if 5-HT3 receptor antagonists are prescribed with other agents that affect the serotonergic neurotransmitter system.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112924/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] "Product Information. Sancuso (granisetron)." ProStrakan Group, Bedminster, NJ.[6] "Product Information. Aloxi (palonosetron)." MGI Pharma Inc, Minnetonka, MN.[7] "Product Information. Anzemet (dolasetron)." Hoechst Marion-Roussel Inc, Kansas City, MO.', 'Thiopental, Sodium oxybate, Nitrous oxide, Methohexital, Enflurane, Esketamine', 'Rolapitant', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112794, 'Sufentanil', 'Opicapone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112925/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Amantadine, Cabergoline', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112795, 'Sufentanil', 'Opium', 'Moderate', 'Potent narcotics, when used as an adjuvant in patients receiving alfentanil, remifentanil, or sufentanil for anesthesia or conscious sedation, may further decrease cardiac output and respiratory drive.', 'DDInter', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Synergism', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112926/', '[1] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Etomidate, Thiopental, Methohexital', 'Loperamide, Acetylsalicylic acid, Ibuprofen, Celecoxib', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112796, 'Sufentanil', 'Osimertinib', 'Moderate', 'Coadministration with osimertinib may alter the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. In vitro, osimertinib has been shown to be a competitive inhibitor as well as inducer of CYP450 3A4.', 'DDInter', 'Concomitant use of osimertinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.', 'Metabolism', 'Concomitant use of osimertinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112927/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine', 'Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112797, 'Sufentanil', 'Oxazepam', 'Major', 'Concomitant use of opioids with benzodiazepines may result in profound sedation, respiratory depression, coma, and death. The use of benzodiazepines with sufentanil during induction has been reported to decrease mean arterial pressure and systemic vascular resistance. The mechanism appears to be an indirect effect on the autonomic nervous system.', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect. Patients receiving sufentanil with benzodiazepines should be monitored closely for signs and symptoms of respiratory depression, altered hemodynamics, and hypotension.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112928/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] West JM, Estrada S, Heerdt M "Sudden hypotension associated with midazolam and sufentanil." Anesth Analg 66 (1987): 693-4[5] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[6] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8[7] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[8] "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.[9] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[10] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.', 'Etomidate, Thiopental, Nitrous oxide', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112798, 'Sufentanil', 'Oxcarbazepine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112929/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 'Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112799, 'Sufentanil', 'Oxybutynin', 'Moderate', 'Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.', 'DDInter', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112930/', '[1] "Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc, Coralville, IA.[2] "Product Information. Lortab (acetaminophen-hydrocodone)." Akorn Inc, Buffalo Grove, IL.[3] "Product Information. Exalgo (hydromorphone)." Covidien, Mansfield, MA.[4] "Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine)." Actavis U.S. (Amide Pharmaceutical Inc), Little Falls, NJ.[5] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[6] "Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC, Chadds Ford, PA.[7] "Product Information. Kadian (morphine)." Zeneca Pharmaceuticals, Wilmington, DE.[8] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[9] "Product Information. Opana (oxymorphone)." Endo Laboratories LLC, Chadds Ford, PA.[10] "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.[11] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[12] "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.[13] "Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals, New York, NY.[14] "Product Information. Levorphanol Tartrate (levorphanol)." Sentynl Therapeutics, Solana Beach, CA.[15] "Product Information. Belbuca (buprenorphine)." Endo Pharmaceuticals Solutions Inc, Malvern, PA.[16] "Product Information. SUFentanil Citrate (SUFentanil)." Akorn Inc, Buffalo Grove, IL.[17] "Product Information. Dolophine (methadone)." Lilly, Eli and Company, Indianapolis, IN.[18] "Product Information. Alfentanil Hydrochloride (alfentanil)." Akorn Inc, Buffalo Grove, IL.[19] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112800, 'Sufentanil', 'Oxymorphone', 'Moderate', 'Potent narcotics, when used as an adjuvant in patients receiving alfentanil, remifentanil, or sufentanil for anesthesia or conscious sedation, may further decrease cardiac output and respiratory drive.', 'DDInter', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Synergism', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112931/', '[1] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Etomidate', 'Acetylsalicylic acid, Ibuprofen, Celecoxib', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112801, 'Sufentanil', 'Ozanimod', 'Major', 'Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.', 'DDInter', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.', 'Others', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112932/', '[1] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[2] Zornberg GL, Hegarty JD "Adverse interaction between propoxyphene and phenelzine." Am J Psychiatry 150 (1993): 1270-1[3] "Product Information. Emsam (selegiline)." Bristol-Myers Squibb, Princeton, NJ.[4] Michaels I, Serrins M, Shier NQ, Barash PG "Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors." Anesth Analg 63 (1984): 1041-4[5] Evans-Prosser CD "The use of pethidine and morphine in the presence of monoamine oxidase inhibitors." Br J Anaesth 40 (1968): 279-82[6] "Product Information. Talacen (acetaminophen-pentazocine)." Sanofi-Synthelabo Inc, New York, NY.[7] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[8] "Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceutical, Richmond, VA.[9] "Product Information. Nubain (nalbuphine)." Endo Laboratories, Texarkana, TX.[10] "Product Information. Roxicodone (oxycodone)." Roxane Laboratories Inc, Columbus, OH.[11] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[12] "Product Information. MS Contin (morphine)." Purdue Frederick Company, Norwalk, CT.[13] Garbutt JC "Potentiation of propoxyphene by phenelzine." Am J Psychiatry 144 (1987): 251-2[14] "Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[16] Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2[17] "Product Information. Xadago (safinamide)." US WorldMeds LLC, Louisville , KY.', 'Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112802, 'Sufentanil', 'Palbociclib', 'Moderate', 'Coadministration with palbociclib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.', 'DDInter', 'Caution is advised when palbociclib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, macrolide immunosuppressants, oral midazolam, pimozide, quinidine, sufentanil, triazolam, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever palbociclib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when palbociclib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112933/', '[1] "Product Information. Ibrance (palbociclib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Ibrance (palbociclib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', 'Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112803, 'Sufentanil', 'Paliperidone', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112934/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Amisulpride', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112804, 'Sufentanil', 'Pancuronium', 'Minor', 'Sufentanil, when combined with neuromuscular blocking agents during surgical procedures, may adversely effect cardiovascular function. Tachycardia, bradycardia, and/or hypotension may result. However, muscle relaxants and sufentanil frequently are used together during surgery. Patients should be closely monitored for clinically significant alterations in hemodynamics.', 'DDInter', '-', 'Others', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112935/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Clotz MA, Nahata MC "Clinical uses of fentanyl, sufentanil, and alfentanil." Clin Pharm 10 (1991): 581-93', 'Esketamine, Sodium oxybate, Thiopental, Methohexital', 'Botulinum toxin type A', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112805, 'Sufentanil', 'Paraldehyde', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112936/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112806, 'Sufentanil', 'Paramethadione', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112937/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Lacosamide', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112807, 'Sufentanil', 'Paroxetine', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112938/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Nitrous oxide, Desflurane, Enflurane, Esketamine, Halothane, Etomidate', 'Viloxazine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112808, 'Sufentanil', 'Penbutolol', 'Moderate', 'In patients receiving chronic beta-blocker therapy, the use of sufentanil may lead to a higher degree of bradycardia and hypotension. One study has shown that induction and maintenance of anesthesia requires lower doses of sufentanil in patients receiving beta-blockers.', 'DDInter', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112939/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Propofol, Enflurane, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112809, 'Sufentanil', 'Pentobarbital', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112940/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Nitrazepam, Zopiclone', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112810, 'Sufentanil', 'Perampanel', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112941/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112811, 'Sufentanil', 'Pergolide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112942/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Amantadine, Cabergoline', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112812, 'Sufentanil', 'Perphenazine', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112943/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Amisulpride', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112813, 'Sufentanil', 'Phenacemide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112944/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112814, 'Sufentanil', 'Phenelzine', 'Major', 'Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs. Concomitant use of pentazocine with MAOIs may also cause CNS excitation and hypertension through their respective effects on catecholamines.', 'DDInter', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids. However, morphine has been safely used in MAOI-treated patients who previously had an adverse reaction with meperidine and is generally suggested as an alternative to meperidine in anesthesia. A sensitivity test should be performed in which repeated, small, incremental doses of morphine are administered over the course of several hours while overall clinical status and vital signs are carefully monitored.', 'Others', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112945/', '[1] "Product Information. MS Contin (morphine)." Purdue Frederick Company, Norwalk, CT.[2] "Product Information. Nubain (nalbuphine)." Endo Laboratories, Texarkana, TX.[3] "Product Information. Emsam (selegiline)." Bristol-Myers Squibb, Princeton, NJ.[4] "Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories, Nutley, NJ.[5] "Product Information. Talacen (acetaminophen-pentazocine)." Sanofi-Synthelabo Inc, New York, NY.[6] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[7] "Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceutical, Richmond, VA.[8] Michaels I, Serrins M, Shier NQ, Barash PG "Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors." Anesth Analg 63 (1984): 1041-4[9] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[10] Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2[11] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[12] Evans-Prosser CD "The use of pethidine and morphine in the presence of monoamine oxidase inhibitors." Br J Anaesth 40 (1968): 279-82[13] "Product Information. Roxicodone (oxycodone)." Roxane Laboratories Inc, Columbus, OH.[14] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[15] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[16] Cerner Multum, Inc. "Australian Product Information." O 0[17] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[18] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[19] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[20] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[21] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[22] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[23] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[24] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[25] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[26] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[27] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[28] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[29] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[30] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[31] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[32] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[33] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[34] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[35] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 'Viloxazine', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112815, 'Sufentanil', 'Phenindamine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112946/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112816, 'Sufentanil', 'Phensuximide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112947/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112817, 'Sufentanil', 'Phenytoin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112948/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Lacosamide', 'Thiopental, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112818, 'Sufentanil', 'Pimavanserin', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112949/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Etomidate, Ketamine', 'Amisulpride', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112819, 'Sufentanil', 'Pimozide', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112950/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Amisulpride', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112820, 'Sufentanil', 'Pindolol', 'Moderate', 'In patients receiving chronic beta-blocker therapy, the use of sufentanil may lead to a higher degree of bradycardia and hypotension. One study has shown that induction and maintenance of anesthesia requires lower doses of sufentanil in patients receiving beta-blockers.', 'DDInter', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112951/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Halothane, Thiopental, Remifentanil, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112821, 'Sufentanil', 'Pipecuronium', 'Minor', 'Sufentanil, when combined with neuromuscular blocking agents during surgical procedures, may adversely effect cardiovascular function. Tachycardia, bradycardia, and/or hypotension may result. However, muscle relaxants and sufentanil frequently are used together during surgery. Patients should be closely monitored for clinically significant alterations in hemodynamics.', 'DDInter', '-', 'Others', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112952/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Clotz MA, Nahata MC "Clinical uses of fentanyl, sufentanil, and alfentanil." Clin Pharm 10 (1991): 581-93', 'Thiopental, Remifentanil, Sodium oxybate, Methohexital, Propofol, Esketamine, Etomidate', 'Botulinum toxin type A', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112822, 'Sufentanil', 'Posaconazole', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112953/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112823, 'Sufentanil', 'Pramipexole', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112954/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Amantadine, Cabergoline', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112824, 'Sufentanil', 'Prasugrel', 'Moderate', 'Coadministration with opioid agonists may delay and reduce the absorption of orally administered P2Y12 inhibitors (e.g., clopidogrel, prasugrel, ticagrelor). The proposed mechanism may involve opioid-mediated slowed gastric emptying.', 'DDInter', 'Although data are limited, caution is recommended when orally administered P2Y12 inhibitors are given concomitantly with opioid agonists. In acute coronary syndrome patients who require an opioid agonist, the use of a parenteral antiplatelet agent, such as cangrelor, should be considered.', 'Absorption', 'Although data are limited, caution is recommended when orally administered P2Y12 inhibitors are given concomitantly with opioid agonists.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112955/', '[1] Hobl EL, Reiter B, Schoergenhofer C, et al. "Morphine Decreases Ticagrelor Concentrations but not its Antiplatelet Effects: A Randomized Trial in Healthy Volunteers." Eur J Clin Invest 46 (2015): 7-14[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Kubica J, Adamski P, Ostrowska M, et al. "Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial." Eur Heart J (2015):[5] Hobl EL, Stimpfl T, Ebner J, et al. "Morphine Decreases Clopidogrel Concentrations and Effects: A Randomized, Double Blind, Placebo-Controlled Trial." J Am Coll Cardiol (2013):[6] Kubica J, Kubica A, Jilma B, et al. "Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors." Int J Cardiol 215 (2016): 201-208[7] "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[8] "Product Information. Plavix (clopidogrel)." Bristol-Myers Squibb, Princeton, NJ.[9] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[11] "Product Information. Effient (prasugrel)." Lilly, Eli and Company, Indianapolis, IN.[12] Hobl EL, Reiter B, Schoergenhofer C, et al. "Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers." Clin Res Cardiol 105 (2015): 349-55', 'Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine', 'Betrixaban, Apixaban, Cilostazol, Iloprost, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112825, 'Sufentanil', 'Primidone', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112956/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Nitrazepam, Zopiclone, Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112826, 'Sufentanil', 'Procarbazine', 'Major', 'Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.', 'DDInter', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.', 'Others', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112957/', '[1] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[2] Zornberg GL, Hegarty JD "Adverse interaction between propoxyphene and phenelzine." Am J Psychiatry 150 (1993): 1270-1[3] "Product Information. Emsam (selegiline)." Bristol-Myers Squibb, Princeton, NJ.[4] Michaels I, Serrins M, Shier NQ, Barash PG "Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors." Anesth Analg 63 (1984): 1041-4[5] Evans-Prosser CD "The use of pethidine and morphine in the presence of monoamine oxidase inhibitors." Br J Anaesth 40 (1968): 279-82[6] "Product Information. Talacen (acetaminophen-pentazocine)." Sanofi-Synthelabo Inc, New York, NY.[7] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[8] "Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceutical, Richmond, VA.[9] "Product Information. Nubain (nalbuphine)." Endo Laboratories, Texarkana, TX.[10] "Product Information. Roxicodone (oxycodone)." Roxane Laboratories Inc, Columbus, OH.[11] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[12] "Product Information. MS Contin (morphine)." Purdue Frederick Company, Norwalk, CT.[13] Garbutt JC "Potentiation of propoxyphene by phenelzine." Am J Psychiatry 144 (1987): 251-2[14] "Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[16] Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2[17] "Product Information. Xadago (safinamide)." US WorldMeds LLC, Louisville , KY.', 'Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112827, 'Sufentanil', 'Procyclidine', 'Moderate', 'Central anticholinergic agents may have additive central nervous system (CNS) effects with cannabinoids, barbiturates, opiates, and alcohol. These agents individually can cause cognitive and psychomotor impairment, drowsiness, and dizziness, thus concomitant use may result in more potent effects. In addition, the potential for abuse may be increased when central anticholinergic agents are combined with these drugs.', 'DDInter', 'Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated. Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness.', 'Synergism', 'Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112958/', '[1] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.', 'Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112828, 'Sufentanil', 'Promazine', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112959/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Amisulpride', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112829, 'Sufentanil', 'Propantheline', 'Moderate', 'Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.', 'DDInter', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112960/', '[1] "Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc, Coralville, IA.[2] "Product Information. Lortab (acetaminophen-hydrocodone)." Akorn Inc, Buffalo Grove, IL.[3] "Product Information. Exalgo (hydromorphone)." Covidien, Mansfield, MA.[4] "Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine)." Actavis U.S. (Amide Pharmaceutical Inc), Little Falls, NJ.[5] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[6] "Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC, Chadds Ford, PA.[7] "Product Information. Kadian (morphine)." Zeneca Pharmaceuticals, Wilmington, DE.[8] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[9] "Product Information. Opana (oxymorphone)." Endo Laboratories LLC, Chadds Ford, PA.[10] "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.[11] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[12] "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.[13] "Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals, New York, NY.[14] "Product Information. Levorphanol Tartrate (levorphanol)." Sentynl Therapeutics, Solana Beach, CA.[15] "Product Information. Belbuca (buprenorphine)." Endo Pharmaceuticals Solutions Inc, Malvern, PA.[16] "Product Information. SUFentanil Citrate (SUFentanil)." Akorn Inc, Buffalo Grove, IL.[17] "Product Information. Dolophine (methadone)." Lilly, Eli and Company, Indianapolis, IN.[18] "Product Information. Alfentanil Hydrochloride (alfentanil)." Akorn Inc, Buffalo Grove, IL.[19] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Papaverine, Alosetron, Isometheptene', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112830, 'Sufentanil', 'Propiomazine', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112961/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112831, 'Sufentanil', 'Propranolol', 'Moderate', 'In patients receiving chronic beta-blocker therapy, the use of sufentanil may lead to a higher degree of bradycardia and hypotension. One study has shown that induction and maintenance of anesthesia requires lower doses of sufentanil in patients receiving beta-blockers.', 'DDInter', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112962/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Acetylsalicylic acid, Ivabradine', 'Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Halothane, Etomidate, Ketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112832, 'Sufentanil', 'Protriptyline', 'Moderate', 'Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.', 'DDInter', 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John''s wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.', 'Synergism', 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112963/', '[1] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919[2] Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5[3] Mittino D, Mula M, Monaco F "Serotonin syndrome associated with tramadol-sertraline coadministration." Clin Neuropharmacol 27 (2004): 150-1[4] Gillman PK "Possible serotonin syndrome with moclobemide and pethidine." Med J Aust 162 (1995): 554[5] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[6] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[7] Kesavan S, Sobala GM "Serotonin syndrome with fluoxetine plus tramadol." J R Soc Med 92 (1999): 474-5[8] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[9] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[10] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[11] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[12] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[13] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[14] Meyer D, Halfin V "Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review." J Clin Psychopharmacol 1 (1981): 319-21[15] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[16] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[17] US Food and Drug Administration (FDA) "FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf." ([2016, Mar 22]):[18] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K "Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology." J Clin Psychopharmacol 22 (2002): 440-1[19] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA "Mania and tramadol-fluoxetine combination." Am J Psychiatry 158 (2001): 964-5[20] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[21] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F "Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database." J Clin Psychopharmacol (2015):[22] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[23] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[24] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE "Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil." J Clin Anesth 25 (2013): 52-4[25] Shakoor M, Ayub S, Ahad A, Ayub Z "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor." Am J Case Rep 15 (2014): 562-4[26] Lantz MS, Buchalter EN, Giambanco V "Serotonin syndrome following the administration of tramadol with paroxetine." Int J Geriatr Psychiatry 13 (1998): 343-5[27] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[28] "Venlafaxine + tramadol: serotonin syndrome." Prescrire Int 13 (2004): 57[29] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB "Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?" J Am Med Dir Assoc 6 (2005): 265-9[30] Houlihan DJ "Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine." Ann Pharmacother 38 (2004): 411-3[31] Hillman AD, Witenko CJ, Sultan SM, Gala G "Serotonin syndrome caused by fentanyl and methadone in a burn injury." Pharmacotherapy 35 (2015): 112-7[32] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[33] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[34] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL "Meperidine-induced serotonin syndrome in a susceptible patient." Br J Anaesth (2009):[35] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H "Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction." Pharmacotherapy (2015):[36] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[37] Kitson R, Carr B "Tramadol and severe serotonin syndrome." Anaesthesia 60 (2005): 934-5[38] Zornberg GL, Bodkin JA, Cohen BM "Severe adverse interaction between pethidine and selegiline." Lancet 337 (1991): 246[39] Mahlberg R, Kunz D, Sasse J, Kirchheiner J "Serotonin syndrome with tramadol and citalopram." Am J Psychiatry 161 (2004): 1129[40] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J "Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy." J Clin Anesth 27 (2015): 247-51[41] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Viloxazine', 'Desflurane, Enflurane, Etomidate, Nitrous oxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112833, 'Sufentanil', 'Quazepam', 'Major', 'Concomitant use of opioids with benzodiazepines may result in profound sedation, respiratory depression, coma, and death. The use of benzodiazepines with sufentanil during induction has been reported to decrease mean arterial pressure and systemic vascular resistance. The mechanism appears to be an indirect effect on the autonomic nervous system.', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect. Patients receiving sufentanil with benzodiazepines should be monitored closely for signs and symptoms of respiratory depression, altered hemodynamics, and hypotension.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112964/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] West JM, Estrada S, Heerdt M "Sudden hypotension associated with midazolam and sufentanil." Anesth Analg 66 (1987): 693-4[5] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[6] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8[7] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[8] "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.[9] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[10] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.', 'Etomidate, Nitrous oxide', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112834, 'Sufentanil', 'Quetiapine', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112965/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Amisulpride', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112835, 'Sufentanil', 'Ramelteon', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112966/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112836, 'Sufentanil', 'Ranolazine', 'Moderate', 'Coadministration with ranolazine may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by ranolazine. The interaction may be significant for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index.', 'DDInter', 'Caution is advised if ranolazine is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever ranolazine is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if ranolazine is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112967/', '[1] Pierce DA, Reeves-Daniel AM "Ranolazine-tacrolimus interaction." Ann Pharmacother 44 (2010): 1844-9[2] "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.[3] "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.', 'Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Ivabradine, Adenosine, Regadenoson', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112837, 'Sufentanil', 'Rapacuronium', 'Minor', 'Sufentanil, when combined with neuromuscular blocking agents during surgical procedures, may adversely effect cardiovascular function. Tachycardia, bradycardia, and/or hypotension may result. However, muscle relaxants and sufentanil frequently are used together during surgery. Patients should be closely monitored for clinically significant alterations in hemodynamics.', 'DDInter', '-', 'Others', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112968/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Clotz MA, Nahata MC "Clinical uses of fentanyl, sufentanil, and alfentanil." Clin Pharm 10 (1991): 581-93', 'Thiopental, Remifentanil, Sodium oxybate, Methohexital, Propofol, Esketamine, Etomidate', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112838, 'Sufentanil', 'Rasagiline', 'Major', 'Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.', 'DDInter', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.', 'Others', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112969/', '[1] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[2] Zornberg GL, Hegarty JD "Adverse interaction between propoxyphene and phenelzine." Am J Psychiatry 150 (1993): 1270-1[3] "Product Information. Emsam (selegiline)." Bristol-Myers Squibb, Princeton, NJ.[4] Michaels I, Serrins M, Shier NQ, Barash PG "Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors." Anesth Analg 63 (1984): 1041-4[5] Evans-Prosser CD "The use of pethidine and morphine in the presence of monoamine oxidase inhibitors." Br J Anaesth 40 (1968): 279-82[6] "Product Information. Talacen (acetaminophen-pentazocine)." Sanofi-Synthelabo Inc, New York, NY.[7] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[8] "Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceutical, Richmond, VA.[9] "Product Information. Nubain (nalbuphine)." Endo Laboratories, Texarkana, TX.[10] "Product Information. Roxicodone (oxycodone)." Roxane Laboratories Inc, Columbus, OH.[11] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[12] "Product Information. MS Contin (morphine)." Purdue Frederick Company, Norwalk, CT.[13] Garbutt JC "Potentiation of propoxyphene by phenelzine." Am J Psychiatry 144 (1987): 251-2[14] "Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[16] Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2[17] "Product Information. Xadago (safinamide)." US WorldMeds LLC, Louisville , KY.', 'Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Amantadine, Cabergoline', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112839, 'Sufentanil', 'Remifentanil', 'Moderate', 'Potent narcotics, when used as an adjuvant in patients receiving alfentanil, remifentanil, or sufentanil for anesthesia or conscious sedation, may further decrease cardiac output and respiratory drive.', 'DDInter', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Synergism', 'The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112970/', '[1] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Remifentanil, Etomidate', 'Sufentanil', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112840, 'Sufentanil', 'Remimazolam', 'Major', 'Concomitant use of opioids with benzodiazepines may result in profound sedation, respiratory depression, coma, and death. The use of benzodiazepines with sufentanil during induction has been reported to decrease mean arterial pressure and systemic vascular resistance. The mechanism appears to be an indirect effect on the autonomic nervous system.', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect. Patients receiving sufentanil with benzodiazepines should be monitored closely for signs and symptoms of respiratory depression, altered hemodynamics, and hypotension.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112971/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] West JM, Estrada S, Heerdt M "Sudden hypotension associated with midazolam and sufentanil." Anesth Analg 66 (1987): 693-4[5] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[6] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8[7] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[8] "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.[9] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[10] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.', 'Etomidate, Nitrous oxide', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112841, 'Sufentanil', 'Ribociclib', 'Moderate', 'Coadministration with ribociclib may increase the plasma concentrations and pharmacologic effects of drugs that are substrates of CYP450 3A4. The proposed mechanism is decreased clearance due to ribociclib-mediated inhibition of CYP450 3A4 metabolism.', 'DDInter', 'Caution is advised when ribociclib is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ribociclib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when ribociclib is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112972/', '[1] Rawden HC, Kokwaro GO, Ward SA, Edwards G "Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes." Br J Clin Pharmacol 49 (2000): 313-22[2] Trivier JM, Libersa C, Belloc C, Lhermitte M "Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report)." Life Sci 52 (1993): pl91-6[3] Kane GC, Lipsky JJ "Drug-grapefruit juice interactions." Mayo Clin Proc 75 (2000): 933-42[4] Katoh M, Nakajima M, Yamazaki H, Yokoi T "Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport." Eur J Pharm Sci 12 (2001): 505-13[5] DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4[6] "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.[7] Yu DK "The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions." J Clin Pharmacol 39 (1999): 1203-11[8] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R "Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions." Biochem Pharmacol 45 (1993): 853-61[9] Nagy J, Schipper HG, Koopmans RP, Butter JJ, van Boxtel CJ, Kager PA "Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability." Am J Trop Med Hyg 66 (2002): 260-3[10] "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate', 'Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112842, 'Sufentanil', 'Rilonacept', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112973/', '[1] "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, North Chicago, IL.[2] "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Gamifant (emapalumab)." Sobi Inc, Ardmore, PA.[5] "Product Information. Kevzara (sarilumab)." sanofi-aventis, Bridgewater, NJ.[6] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc., Horsham, PA, PA.[9] "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.[10] "Product Information. Ilumya (tildrakizumab)." Merck & Company Inc, Whitehouse Station, NJ.[11] "Product Information. Actemra (tocilizumab)." Genentech, South San Francisco, CA.[12] "Product Information. Amevive (alefacept)." Biogen, Cambridge, MA.[13] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[14] "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company, Indianapolis, IN.[15] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112843, 'Sufentanil', 'Rocuronium', 'Minor', 'Sufentanil, when combined with neuromuscular blocking agents during surgical procedures, may adversely effect cardiovascular function. Tachycardia, bradycardia, and/or hypotension may result. However, muscle relaxants and sufentanil frequently are used together during surgery. Patients should be closely monitored for clinically significant alterations in hemodynamics.', 'DDInter', '-', 'Others', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112974/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Clotz MA, Nahata MC "Clinical uses of fentanyl, sufentanil, and alfentanil." Clin Pharm 10 (1991): 581-93', 'Esketamine, Sodium oxybate, Thiopental, Methohexital', 'Botulinum toxin type A', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112844, 'Sufentanil', 'Rotigotine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112975/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Amantadine, Cabergoline', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112845, 'Sufentanil', 'Rucaparib', 'Moderate', 'Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 3A4. The proposed mechanism is decreased clearance due to rucaparib-mediated inhibition of CYP450 3A4.', 'DDInter', 'Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112976/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112846, 'Sufentanil', 'Rufinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112977/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112847, 'Sufentanil', 'Safinamide', 'Major', 'Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.', 'DDInter', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.', 'Others', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112978/', '[1] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[2] Zornberg GL, Hegarty JD "Adverse interaction between propoxyphene and phenelzine." Am J Psychiatry 150 (1993): 1270-1[3] "Product Information. Emsam (selegiline)." Bristol-Myers Squibb, Princeton, NJ.[4] Michaels I, Serrins M, Shier NQ, Barash PG "Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors." Anesth Analg 63 (1984): 1041-4[5] Evans-Prosser CD "The use of pethidine and morphine in the presence of monoamine oxidase inhibitors." Br J Anaesth 40 (1968): 279-82[6] "Product Information. Talacen (acetaminophen-pentazocine)." Sanofi-Synthelabo Inc, New York, NY.[7] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[8] "Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceutical, Richmond, VA.[9] "Product Information. Nubain (nalbuphine)." Endo Laboratories, Texarkana, TX.[10] "Product Information. Roxicodone (oxycodone)." Roxane Laboratories Inc, Columbus, OH.[11] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[12] "Product Information. MS Contin (morphine)." Purdue Frederick Company, Norwalk, CT.[13] Garbutt JC "Potentiation of propoxyphene by phenelzine." Am J Psychiatry 144 (1987): 251-2[14] "Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[16] Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2[17] "Product Information. Xadago (safinamide)." US WorldMeds LLC, Louisville , KY.', 'Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Amantadine, Cabergoline', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112848, 'Sufentanil', 'Saquinavir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112979/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112849, 'Sufentanil', 'Sarilumab', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112980/', '[1] "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, North Chicago, IL.[2] "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Gamifant (emapalumab)." Sobi Inc, Ardmore, PA.[5] "Product Information. Kevzara (sarilumab)." sanofi-aventis, Bridgewater, NJ.[6] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc., Horsham, PA, PA.[9] "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.[10] "Product Information. Ilumya (tildrakizumab)." Merck & Company Inc, Whitehouse Station, NJ.[11] "Product Information. Actemra (tocilizumab)." Genentech, South San Francisco, CA.[12] "Product Information. Amevive (alefacept)." Biogen, Cambridge, MA.[13] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[14] "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company, Indianapolis, IN.[15] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112850, 'Sufentanil', 'Satralizumab', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112981/', '[1] "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, North Chicago, IL.[2] "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Gamifant (emapalumab)." Sobi Inc, Ardmore, PA.[5] "Product Information. Kevzara (sarilumab)." sanofi-aventis, Bridgewater, NJ.[6] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc., Horsham, PA, PA.[9] "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.[10] "Product Information. Ilumya (tildrakizumab)." Merck & Company Inc, Whitehouse Station, NJ.[11] "Product Information. Actemra (tocilizumab)." Genentech, South San Francisco, CA.[12] "Product Information. Amevive (alefacept)." Biogen, Cambridge, MA.[13] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[14] "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company, Indianapolis, IN.[15] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112851, 'Sufentanil', 'Scopolamine', 'Moderate', 'Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.', 'DDInter', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112982/', '[1] "Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc, Coralville, IA.[2] "Product Information. Lortab (acetaminophen-hydrocodone)." Akorn Inc, Buffalo Grove, IL.[3] "Product Information. Exalgo (hydromorphone)." Covidien, Mansfield, MA.[4] "Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine)." Actavis U.S. (Amide Pharmaceutical Inc), Little Falls, NJ.[5] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[6] "Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC, Chadds Ford, PA.[7] "Product Information. Kadian (morphine)." Zeneca Pharmaceuticals, Wilmington, DE.[8] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[9] "Product Information. Opana (oxymorphone)." Endo Laboratories LLC, Chadds Ford, PA.[10] "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.[11] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[12] "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.[13] "Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals, New York, NY.[14] "Product Information. Levorphanol Tartrate (levorphanol)." Sentynl Therapeutics, Solana Beach, CA.[15] "Product Information. Belbuca (buprenorphine)." Endo Pharmaceuticals Solutions Inc, Malvern, PA.[16] "Product Information. SUFentanil Citrate (SUFentanil)." Akorn Inc, Buffalo Grove, IL.[17] "Product Information. Dolophine (methadone)." Lilly, Eli and Company, Indianapolis, IN.[18] "Product Information. Alfentanil Hydrochloride (alfentanil)." Akorn Inc, Buffalo Grove, IL.[19] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 'Nitrazepam, Zopiclone, Ephedrine, Tropicamide, Phenylephrine, Rolapitant', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112852, 'Sufentanil', 'Secobarbital', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112983/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Nitrazepam, Zopiclone', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112853, 'Sufentanil', 'Secukinumab', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112984/', '[1] "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, North Chicago, IL.[2] "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Gamifant (emapalumab)." Sobi Inc, Ardmore, PA.[5] "Product Information. Kevzara (sarilumab)." sanofi-aventis, Bridgewater, NJ.[6] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc., Horsham, PA, PA.[9] "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.[10] "Product Information. Ilumya (tildrakizumab)." Merck & Company Inc, Whitehouse Station, NJ.[11] "Product Information. Actemra (tocilizumab)." Genentech, South San Francisco, CA.[12] "Product Information. Amevive (alefacept)." Biogen, Cambridge, MA.[13] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[14] "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company, Indianapolis, IN.[15] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112854, 'Sufentanil', 'Selegiline', 'Major', 'Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs. Concomitant use of pentazocine with MAOIs may also cause CNS excitation and hypertension through their respective effects on catecholamines.', 'DDInter', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids. However, morphine has been safely used in MAOI-treated patients who previously had an adverse reaction with meperidine and is generally suggested as an alternative to meperidine in anesthesia. A sensitivity test should be performed in which repeated, small, incremental doses of morphine are administered over the course of several hours while overall clinical status and vital signs are carefully monitored.', 'Others', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112985/', '[1] "Product Information. MS Contin (morphine)." Purdue Frederick Company, Norwalk, CT.[2] "Product Information. Nubain (nalbuphine)." Endo Laboratories, Texarkana, TX.[3] "Product Information. Emsam (selegiline)." Bristol-Myers Squibb, Princeton, NJ.[4] "Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories, Nutley, NJ.[5] "Product Information. Talacen (acetaminophen-pentazocine)." Sanofi-Synthelabo Inc, New York, NY.[6] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[7] "Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceutical, Richmond, VA.[8] Michaels I, Serrins M, Shier NQ, Barash PG "Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors." Anesth Analg 63 (1984): 1041-4[9] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[10] Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2[11] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[12] Evans-Prosser CD "The use of pethidine and morphine in the presence of monoamine oxidase inhibitors." Br J Anaesth 40 (1968): 279-82[13] "Product Information. Roxicodone (oxycodone)." Roxane Laboratories Inc, Columbus, OH.[14] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[15] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[16] Cerner Multum, Inc. "Australian Product Information." O 0[17] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[18] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[19] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[20] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[21] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[22] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[23] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[24] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[25] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[26] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[27] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[28] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[29] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[30] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[31] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[32] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[33] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[34] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[35] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 'Sodium oxybate', 'Amantadine, Cabergoline', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112855, 'Sufentanil', 'Selpercatinib', 'Moderate', 'Coadministration with selpercatinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by selpercatinib. The interaction may be particularly important for sensitive substrates or those that demonstrate a narrow therapeutic index.', 'DDInter', 'Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever selpercatinib is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112986/', '[1] "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company, Indianapolis, IN.[2] "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company, Indianapolis, IN.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate', 'Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112856, 'Sufentanil', 'Sertraline', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112987/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate', 'Viloxazine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112857, 'Sufentanil', 'Sevoflurane', 'Moderate', 'Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.', 'DDInter', 'In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.', 'Synergism', 'In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112988/', '[1] "Product Information. Ultane (sevoflurane)." Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A "Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses." Anesth Analg 84 (1997): 100-5[3] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.', 'Thiopental, Methohexital, Enflurane, Sevoflurane, Ketamine', 'Sufentanil', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112858, 'Sufentanil', 'Sibutramine', 'Major', 'Concomitant use of sibutramine with other serotonin reuptake inhibitors or other agents that possess or enhance serotonergic activity such as monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, phenylpiperidine opioids, bupropion, dextromethorphan, linezolid, lithium, St. John''s wort, tramadol, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', 'DDInter', 'In general, the concomitant use of sibutramine with other agents that affect the serotonergic neurotransmitter system should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when initiating or increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life. For example, a 5-week washout period is recommended following use of fluoxetine and 3 weeks following use of vortioxetine before administering another serotonergic agent such as sibutramine. At least 14 days should elapse between discontinuation of other serotonergic agents and initiation of treatment with sibutramine. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.', 'Synergism', 'In general, the concomitant use of sibutramine with other agents that affect the serotonergic neurotransmitter system should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112989/', '[1] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[2] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[3] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[6] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[7] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[8] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[10] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[11] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[12] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate', 'Ephedrine, Orlistat, Diethylpropion', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112859, 'Sufentanil', 'Silodosin', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112990/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine', 'Finasteride, Dutasteride, Terazosin, Tadalafil', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112860, 'Sufentanil', 'Siltuximab', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112991/', '[1] "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, North Chicago, IL.[2] "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Gamifant (emapalumab)." Sobi Inc, Ardmore, PA.[5] "Product Information. Kevzara (sarilumab)." sanofi-aventis, Bridgewater, NJ.[6] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc., Horsham, PA, PA.[9] "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.[10] "Product Information. Ilumya (tildrakizumab)." Merck & Company Inc, Whitehouse Station, NJ.[11] "Product Information. Actemra (tocilizumab)." Genentech, South San Francisco, CA.[12] "Product Information. Amevive (alefacept)." Biogen, Cambridge, MA.[13] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[14] "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company, Indianapolis, IN.[15] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112861, 'Sufentanil', 'Sirolimus', 'Moderate', 'Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.', 'DDInter', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112992/', '[1] "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.[2] "Product Information. Rapamune (sirolimus)" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Cyclosporine, Nandrolone, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112862, 'Sufentanil', 'Solifenacin', 'Moderate', 'Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.', 'DDInter', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112993/', '[1] "Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc, Coralville, IA.[2] "Product Information. Lortab (acetaminophen-hydrocodone)." Akorn Inc, Buffalo Grove, IL.[3] "Product Information. Exalgo (hydromorphone)." Covidien, Mansfield, MA.[4] "Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine)." Actavis U.S. (Amide Pharmaceutical Inc), Little Falls, NJ.[5] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[6] "Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC, Chadds Ford, PA.[7] "Product Information. Kadian (morphine)." Zeneca Pharmaceuticals, Wilmington, DE.[8] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[9] "Product Information. Opana (oxymorphone)." Endo Laboratories LLC, Chadds Ford, PA.[10] "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.[11] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[12] "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.[13] "Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals, New York, NY.[14] "Product Information. Levorphanol Tartrate (levorphanol)." Sentynl Therapeutics, Solana Beach, CA.[15] "Product Information. Belbuca (buprenorphine)." Endo Pharmaceuticals Solutions Inc, Malvern, PA.[16] "Product Information. SUFentanil Citrate (SUFentanil)." Akorn Inc, Buffalo Grove, IL.[17] "Product Information. Dolophine (methadone)." Lilly, Eli and Company, Indianapolis, IN.[18] "Product Information. Alfentanil Hydrochloride (alfentanil)." Akorn Inc, Buffalo Grove, IL.[19] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112863, 'Sufentanil', 'Somapacitan', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112994/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112864, 'Sufentanil', 'Somatrem', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112995/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112865, 'Sufentanil', 'Somatotropin', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112996/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN.', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112866, 'Sufentanil', 'Sotalol', 'Moderate', 'In patients receiving chronic beta-blocker therapy, the use of sufentanil may lead to a higher degree of bradycardia and hypotension. One study has shown that induction and maintenance of anesthesia requires lower doses of sufentanil in patients receiving beta-blockers.', 'DDInter', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112997/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Acetylsalicylic acid, Ivabradine', 'Thiopental, Remifentanil, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112867, 'Sufentanil', 'Stiripentol', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112998/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112868, 'Suvorexant', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/112999/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112869, 'Tacrolimus', 'Sufentanil', 'Moderate', 'Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.', 'DDInter', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113000/', '[1] "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.[2] "Product Information. Rapamune (sirolimus)" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine', 'Minoxidil, Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112870, 'Tapentadol', 'Sufentanil', 'Major', 'Concomitant use of opioids with other central nervous system (CNS) depressants (e.g., benzodiazepines, sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. Concomitant use of phenylpiperidine opioids, tapentadol, or tramadol with each other or with other serotonergic agents may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', 'DDInter', 'The use of opioids in conjunction with other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them. In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.', 'Synergism', 'The use of opioids in conjunction with other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113001/', '[1] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[2] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[3] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[4] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[5] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[6] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[7] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):[8] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[9] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[10] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[11] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[12] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[13] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[14] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[15] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[16] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[17] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[19] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Acetylsalicylic acid, Ibuprofen, Celecoxib', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112871, 'Tasimelteon', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113002/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112872, 'Telaprevir', 'Sufentanil', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113003/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112873, 'Telithromycin', 'Sufentanil', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113004/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine', 'Lincomycin, Azithromycin, Dirithromycin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112874, 'Telmisartan', 'Sufentanil', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113005/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine', 'Sacubitril, Aliskiren', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112875, 'Telotristat ethyl', 'Sufentanil', 'Moderate', 'Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.', 'DDInter', 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113006/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Sevoflurane, Etomidate', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112876, 'Temazepam', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines may result in profound sedation, respiratory depression, coma, and death. The use of benzodiazepines with sufentanil during induction has been reported to decrease mean arterial pressure and systemic vascular resistance. The mechanism appears to be an indirect effect on the autonomic nervous system.', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect. Patients receiving sufentanil with benzodiazepines should be monitored closely for signs and symptoms of respiratory depression, altered hemodynamics, and hypotension.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113007/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] West JM, Estrada S, Heerdt M "Sudden hypotension associated with midazolam and sufentanil." Anesth Analg 66 (1987): 693-4[5] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[6] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8[7] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[8] "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.[9] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[10] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.', 'Nitrazepam, Zopiclone', 'Thiopental, Nitrous oxide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112877, 'Temsirolimus', 'Sufentanil', 'Moderate', 'Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.', 'DDInter', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113008/', '[1] "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.[2] "Product Information. Rapamune (sirolimus)" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112878, 'Tetrabenazine', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113009/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Dalfampridine, Riluzole, Inotersen, Pitolisant, Tafamidis', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112879, 'Thalidomide', 'Sufentanil', 'Moderate', 'Thalidomide can commonly cause drowsiness/sedation and may have additive effects with other drugs that cause central nervous system (CNS) depression.', 'DDInter', 'Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics. Patients should be advised to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Dosage reductions may be necessary. Thalidomide should preferably be administered at bedtime to reduce the impact of somnolence. Alcohol use is not recommended.', 'Synergism', 'Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113010/', '[1] "Product Information. Thalomid (thalidomide)." Celgene Corporation, Warren, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 'Isoflurane, Nitrous oxide, Methohexital, Desflurane, Enflurane, Etomidate', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112880, 'Thiethylperazine', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113011/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112881, 'Thiopental', 'Sufentanil', 'Moderate', 'Narcotic analgesics may reduce the dosage of barbiturate anesthetics needed to induce anesthesia by as much as 40%. Additionally, apnea is more common with this combination.', 'DDInter', 'Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.', 'Others', 'Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113012/', '[1] Stambaugh JE, Wainer IW, Schwartz I "The effect of phenobarbital on the metabolism of meperidine in normal volunteers." J Clin Pharmacol 18 (1978): 482-90[2] DeLapa RJ "Influence of alphaprodine hydrochloride on intravenous barbiturate induction dosage." J Oral Surg 18 (1960): 163-8[3] Stambaugh JE, Hemphill DM, Wainer IW, Schwartz I "A potentially toxic drug interaction between pethidine (meperidine) and phenobarbitone." Lancet 1 (1977): 398-9[4] Dundee JW, Halliday NJ, McMurray TJ, Harper KW "Pretreatment with opioids: the effect on thiopentone induction requirements and on the onset of action of midazolam." Anaesthesia 41 (1986): 159-61[5] Levine B, Saady J, Fierro M, Valentour J "A hydromorphone and ethanol fatality." J Forensic Sci 29 (1984): 655-9[6] FDA. U.S. Food and Drug Administration "Healthcare Professional Sheet. FDA Alert [07/2005]: alcohol-palladone interaction. Available from: URL: http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#Palladone." ([2005 July 13]):[7] "Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company, Whippany, NJ.', 'Sufentanil, Nitrazepam, Zopiclone', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112882, 'Thioridazine', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113013/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Amisulpride', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112883, 'Thiothixene', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113014/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Amisulpride', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112884, 'Tiagabine', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113015/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112885, 'Ticagrelor', 'Sufentanil', 'Moderate', 'Coadministration with ticagrelor may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by ticagrelor, which is a mild inhibitor. The interaction may be significant for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index.', 'DDInter', 'Concomitant use of ticagrelor with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., cisapride, ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, pimozide, triazolam, vinca alkaloids) is not recommended.', 'Metabolism', 'Concomitant use of ticagrelor with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113016/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Betrixaban, Apixaban, Cilostazol, Iloprost, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112886, 'Timolol', 'Sufentanil', 'Moderate', 'In patients receiving chronic beta-blocker therapy, the use of sufentanil may lead to a higher degree of bradycardia and hypotension. One study has shown that induction and maintenance of anesthesia requires lower doses of sufentanil in patients receiving beta-blockers.', 'DDInter', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113017/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More', 'Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112887, 'Tizanidine', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113018/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Isoflurane, Nitrous oxide, Methohexital, Desflurane, Enflurane, Etomidate, Ketamine', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112888, 'Tocilizumab', 'Sufentanil', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113019/', '[1] "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, North Chicago, IL.[2] "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Gamifant (emapalumab)." Sobi Inc, Ardmore, PA.[5] "Product Information. Kevzara (sarilumab)." sanofi-aventis, Bridgewater, NJ.[6] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc., Horsham, PA, PA.[9] "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.[10] "Product Information. Ilumya (tildrakizumab)." Merck & Company Inc, Whitehouse Station, NJ.[11] "Product Information. Actemra (tocilizumab)." Genentech, South San Francisco, CA.[12] "Product Information. Amevive (alefacept)." Biogen, Cambridge, MA.[13] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[14] "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company, Indianapolis, IN.[15] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112889, 'Tofacitinib', 'Sufentanil', 'Moderate', 'Baricitinib and tofacitinib, both Janus kinase (JAK) inhibitors, have been associated with an increased risk of diverticulitis (DV) and gastrointestinal (GI) perforation, particularly in patients with risk factors (e.g., history of diverticulosis or diverticulitis, concomitant use of other agents associated with DV).', 'DDInter', 'Caution is recommended when using baricitinib or tofacitinib in patients with a history of diverticular disease and in patients receiving long-term concomitant treatment with drugs associated with an increased risk of DV and/or GI perforation, such as aspirin, NSAIDs, corticosteroids, and opioids. Patients should be advised to contact their healthcare provider if they experience signs of DV or GI perforation, such as severe abdominal pain, fever, nausea, or vomiting.', 'Synergism', 'Caution is recommended when using baricitinib or tofacitinib in patients with a history of diverticular disease and in patients receiving long-term concomitant treatment with drugs associated with an increased risk of DV and/or GI perforation, such as aspirin, NSAIDs, corticosteroids, and opioids.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113020/', '[1] Medicines and Healthcare products Regulatory Agency "Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors. Available from: URL: https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-fac" ([2020, Aug 26]):[2] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT "Use of Aspirin or Nonsteroidal Anti-inflammatory Drugs Increases Risk for Diverticulitis and Diverticular Bleeding." Gastroenterology 140 (2011): 1427-33', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112890, 'Tolcapone', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113021/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Amantadine, Cabergoline', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112891, 'Tolterodine', 'Sufentanil', 'Moderate', 'Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.', 'DDInter', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113022/', '[1] "Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc, Coralville, IA.[2] "Product Information. Lortab (acetaminophen-hydrocodone)." Akorn Inc, Buffalo Grove, IL.[3] "Product Information. Exalgo (hydromorphone)." Covidien, Mansfield, MA.[4] "Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine)." Actavis U.S. (Amide Pharmaceutical Inc), Little Falls, NJ.[5] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[6] "Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC, Chadds Ford, PA.[7] "Product Information. Kadian (morphine)." Zeneca Pharmaceuticals, Wilmington, DE.[8] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[9] "Product Information. Opana (oxymorphone)." Endo Laboratories LLC, Chadds Ford, PA.[10] "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.[11] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[12] "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.[13] "Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals, New York, NY.[14] "Product Information. Levorphanol Tartrate (levorphanol)." Sentynl Therapeutics, Solana Beach, CA.[15] "Product Information. Belbuca (buprenorphine)." Endo Pharmaceuticals Solutions Inc, Malvern, PA.[16] "Product Information. SUFentanil Citrate (SUFentanil)." Akorn Inc, Buffalo Grove, IL.[17] "Product Information. Dolophine (methadone)." Lilly, Eli and Company, Indianapolis, IN.[18] "Product Information. Alfentanil Hydrochloride (alfentanil)." Akorn Inc, Buffalo Grove, IL.[19] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112892, 'Topiramate', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113023/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Lacosamide', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112893, 'Tranylcypromine', 'Sufentanil', 'Major', 'Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs. Concomitant use of pentazocine with MAOIs may also cause CNS excitation and hypertension through their respective effects on catecholamines.', 'DDInter', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids. However, morphine has been safely used in MAOI-treated patients who previously had an adverse reaction with meperidine and is generally suggested as an alternative to meperidine in anesthesia. A sensitivity test should be performed in which repeated, small, incremental doses of morphine are administered over the course of several hours while overall clinical status and vital signs are carefully monitored.', 'Others', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113024/', '[1] "Product Information. MS Contin (morphine)." Purdue Frederick Company, Norwalk, CT.[2] "Product Information. Nubain (nalbuphine)." Endo Laboratories, Texarkana, TX.[3] "Product Information. Emsam (selegiline)." Bristol-Myers Squibb, Princeton, NJ.[4] "Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories, Nutley, NJ.[5] "Product Information. Talacen (acetaminophen-pentazocine)." Sanofi-Synthelabo Inc, New York, NY.[6] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[7] "Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceutical, Richmond, VA.[8] Michaels I, Serrins M, Shier NQ, Barash PG "Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors." Anesth Analg 63 (1984): 1041-4[9] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[10] Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2[11] "Product Information. Tylenol with Codeine (acetaminophen-codeine)." Janssen Pharmaceuticals, Raritan, NJ.[12] Evans-Prosser CD "The use of pethidine and morphine in the presence of monoamine oxidase inhibitors." Br J Anaesth 40 (1968): 279-82[13] "Product Information. Roxicodone (oxycodone)." Roxane Laboratories Inc, Columbus, OH.[14] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[15] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[16] Cerner Multum, Inc. "Australian Product Information." O 0[17] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[18] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[19] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[20] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[21] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[22] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[23] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[24] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[25] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[26] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[27] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[28] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[29] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[30] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[31] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[32] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[33] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[34] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[35] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 'Viloxazine', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112894, 'Triazolam', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines may result in profound sedation, respiratory depression, coma, and death. The use of benzodiazepines with sufentanil during induction has been reported to decrease mean arterial pressure and systemic vascular resistance. The mechanism appears to be an indirect effect on the autonomic nervous system.', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect. Patients receiving sufentanil with benzodiazepines should be monitored closely for signs and symptoms of respiratory depression, altered hemodynamics, and hypotension.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113025/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] West JM, Estrada S, Heerdt M "Sudden hypotension associated with midazolam and sufentanil." Anesth Analg 66 (1987): 693-4[5] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[6] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8[7] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[8] "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.[9] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[10] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.', 'Etomidate, Nitrous oxide', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112895, 'Trifluoperazine', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113026/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Amisulpride', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112896, 'Triflupromazine', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113027/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Amisulpride', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112897, 'Trihexyphenidyl', 'Sufentanil', 'Moderate', 'Central anticholinergic agents may have additive central nervous system (CNS) effects with cannabinoids, barbiturates, opiates, and alcohol. These agents individually can cause cognitive and psychomotor impairment, drowsiness, and dizziness, thus concomitant use may result in more potent effects. In addition, the potential for abuse may be increased when central anticholinergic agents are combined with these drugs.', 'DDInter', 'Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated. Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness.', 'Synergism', 'Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113028/', '[1] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.', 'Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112898, 'Alimemazine', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113029/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112899, 'Trimethadione', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113030/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Lacosamide', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112900, 'Trimethobenzamide', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113031/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112901, 'Trimipramine', 'Sufentanil', 'Moderate', 'Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.', 'DDInter', 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John''s wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.', 'Synergism', 'Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113032/', '[1] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919[2] Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5[3] Mittino D, Mula M, Monaco F "Serotonin syndrome associated with tramadol-sertraline coadministration." Clin Neuropharmacol 27 (2004): 150-1[4] Gillman PK "Possible serotonin syndrome with moclobemide and pethidine." Med J Aust 162 (1995): 554[5] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[6] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[7] Kesavan S, Sobala GM "Serotonin syndrome with fluoxetine plus tramadol." J R Soc Med 92 (1999): 474-5[8] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[9] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[10] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[11] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[12] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[13] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[14] Meyer D, Halfin V "Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review." J Clin Psychopharmacol 1 (1981): 319-21[15] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[16] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[17] US Food and Drug Administration (FDA) "FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf." ([2016, Mar 22]):[18] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K "Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology." J Clin Psychopharmacol 22 (2002): 440-1[19] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA "Mania and tramadol-fluoxetine combination." Am J Psychiatry 158 (2001): 964-5[20] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[21] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F "Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database." J Clin Psychopharmacol (2015):[22] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[23] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[24] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE "Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil." J Clin Anesth 25 (2013): 52-4[25] Shakoor M, Ayub S, Ahad A, Ayub Z "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor." Am J Case Rep 15 (2014): 562-4[26] Lantz MS, Buchalter EN, Giambanco V "Serotonin syndrome following the administration of tramadol with paroxetine." Int J Geriatr Psychiatry 13 (1998): 343-5[27] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[28] "Venlafaxine + tramadol: serotonin syndrome." Prescrire Int 13 (2004): 57[29] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB "Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?" J Am Med Dir Assoc 6 (2005): 265-9[30] Houlihan DJ "Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine." Ann Pharmacother 38 (2004): 411-3[31] Hillman AD, Witenko CJ, Sultan SM, Gala G "Serotonin syndrome caused by fentanyl and methadone in a burn injury." Pharmacotherapy 35 (2015): 112-7[32] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[33] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[34] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL "Meperidine-induced serotonin syndrome in a susceptible patient." Br J Anaesth (2009):[35] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H "Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction." Pharmacotherapy (2015):[36] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[37] Kitson R, Carr B "Tramadol and severe serotonin syndrome." Anaesthesia 60 (2005): 934-5[38] Zornberg GL, Bodkin JA, Cohen BM "Severe adverse interaction between pethidine and selegiline." Lancet 337 (1991): 246[39] Mahlberg R, Kunz D, Sasse J, Kirchheiner J "Serotonin syndrome with tramadol and citalopram." Am J Psychiatry 161 (2004): 1129[40] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J "Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy." J Clin Anesth 27 (2015): 247-51[41] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Desflurane, Enflurane, Etomidate, Nitrous oxide', 'Viloxazine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112902, 'Tripelennamine', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113033/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole, Tetracaine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112903, 'Triprolidine', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113034/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112904, 'Troleandomycin', 'Sufentanil', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113035/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', 'Lincomycin, Azithromycin, Dirithromycin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112905, 'Tubocurarine', 'Sufentanil', 'Minor', 'Sufentanil, when combined with neuromuscular blocking agents during surgical procedures, may adversely effect cardiovascular function. Tachycardia, bradycardia, and/or hypotension may result. However, muscle relaxants and sufentanil frequently are used together during surgery. Patients should be closely monitored for clinically significant alterations in hemodynamics.', 'DDInter', '-', 'Others', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113036/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Clotz MA, Nahata MC "Clinical uses of fentanyl, sufentanil, and alfentanil." Clin Pharm 10 (1991): 581-93', 'Thiopental, Remifentanil, Sodium oxybate, Methohexital, Propofol, Esketamine, Etomidate', 'Botulinum toxin type A', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112906, 'Tucatinib', 'Sufentanil', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113037/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', 'Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112907, 'Ustekinumab', 'Sufentanil', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113038/', '[1] "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, North Chicago, IL.[2] "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Gamifant (emapalumab)." Sobi Inc, Ardmore, PA.[5] "Product Information. Kevzara (sarilumab)." sanofi-aventis, Bridgewater, NJ.[6] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc., Horsham, PA, PA.[9] "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.[10] "Product Information. Ilumya (tildrakizumab)." Merck & Company Inc, Whitehouse Station, NJ.[11] "Product Information. Actemra (tocilizumab)." Genentech, South San Francisco, CA.[12] "Product Information. Amevive (alefacept)." Biogen, Cambridge, MA.[13] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[14] "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company, Indianapolis, IN.[15] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112908, 'Valbenazine', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113039/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Dalfampridine, Riluzole, Inotersen, Pitolisant, Tafamidis', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112909, 'Valerian', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113040/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112910, 'Vecuronium', 'Sufentanil', 'Minor', 'Sufentanil, when combined with neuromuscular blocking agents during surgical procedures, may adversely effect cardiovascular function. Tachycardia, bradycardia, and/or hypotension may result. However, muscle relaxants and sufentanil frequently are used together during surgery. Patients should be closely monitored for clinically significant alterations in hemodynamics.', 'DDInter', '-', 'Others', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113041/', '[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M "Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants." Anesthesiology 76 (1992): 922-9[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Clotz MA, Nahata MC "Clinical uses of fentanyl, sufentanil, and alfentanil." Clin Pharm 10 (1991): 581-93', 'Esketamine, Sodium oxybate, Thiopental, Methohexital', 'Botulinum toxin type A', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112911, 'Venlafaxine', 'Sufentanil', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113042/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Viloxazine', 'Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112912, 'Vigabatrin', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113043/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Lacosamide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112913, 'Vilazodone', 'Sufentanil', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113044/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine', 'Viloxazine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112914, 'Voriconazole', 'Sufentanil', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.', 'DDInter', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Metabolism', 'Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113045/', '[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5[2] "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112915, 'Vortioxetine', 'Sufentanil', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113046/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Viloxazine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112916, 'Zaleplon', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113047/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Halothane, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112917, 'Ziconotide', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113048/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Salicylic acid, Choline salicylate, Diflunisal, Salsalate, Acetylsalicylic acid', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112918, 'Ziprasidone', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113049/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Amisulpride', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112919, 'Zolpidem', 'Sufentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113050/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 'Nitrazepam, Zopiclone', 'Thiopental, Nitrous oxide, Desflurane, Enflurane, Halothane', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112920, 'Zonisamide', 'Sufentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113051/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Halothane, Etomidate', 'Lacosamide, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112921, 'Sulfacetamide (ophthalmic)', 'Silver nitrate (ophthalmic)', 'Moderate', 'Sulfacetamide preparations are incompatible with silver preparations. Sulfacetamide will precipitate as its silver salt in the presence of silver nitrate.', 'DDInter', 'Concurrent use of sulfacetamide preparations with silver preparations should be avoided.', 'Antagonism', 'Concurrent use of sulfacetamide preparations with silver preparations should be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113052/', '[1] "Product Information. FML-S Liquifilm Sterile Ophthalmic Suspension (fluorometholone-sodium sulfacetamide ophthalmic)." Allergan Inc, Irvine, CA.', NULL, NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112922, 'Abarelix', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113053/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112923, 'Sulfamethoxazole', 'Acetohexamide', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113054/', '[1] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A "Potentiation of acetohexamide hypoglycemia by phenylbutazone." N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J "Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole." Diabet Med 4 (1987): 245-7[7] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT "Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride." Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P "Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs." Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[11] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP "Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function." Diabetes 51 (2002): 1772-8[13] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[14] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[16] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[20] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA "Effect of pirprofen on glibenclamide kinetics and response." Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[23] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[25] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D "Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors." Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO "Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition." Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH "A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide." Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS "Phenylbutazone-tolbutamide drug interaction." N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB "Aspirin-induced hypoglycaemia in a patient on haemodialysis." Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC "Lack of interaction between glipizide and co-trimoxazole." J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[41] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[46] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA "Drug interactions with fibric acids." Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS "Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone." Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK "Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia." Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[54] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[56] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[59] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[74] "Product Information. Micronase (glyburide)." Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al "Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy." Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN "Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole." Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N "Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea." Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM "Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism." Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV "Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans." Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[98] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[100] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[101] Harris EL "Adverse reactions to oral antidiabetic agents." Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK "Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide." Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[104] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[105] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[109] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[110] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[111] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Pretomanid, Aminosalicylic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112924, 'Aminolevulinic acid', 'Sulfamethoxazole', 'Major', 'Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid.', 'DDInter', 'Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John''s wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid.', 'Synergism', 'Photosensitizing agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113055/', '[1] "Product Information. Gleolan (aminolevulinic acid)." NX Development Corp, Lexington, KY.[2] "Product Information. Nulibry (fosdenopterin)." Origin Biosciences Inc, Boston, MA.', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, Enasidenib, More', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112925, 'Amoxapine', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113056/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112926, 'Anisindione', 'Sulfamethoxazole', 'Major', 'Coadministration with a sulfonamide may increase the plasma concentrations and hypoprothrombinemic effects of coumarin anticoagulants. The proposed mechanism is sulfonamide inhibition of coumarin metabolism via CYP450 2C9 and possibly also displacement of coumarin derivatives from plasma protein binding sites.', 'DDInter', 'Patients receiving coumarin anticoagulants should be closely monitored during concomitant therapy with sulfonamides. The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of sulfonamide therapy in patients who are stabilized on their anticoagulant regimen. The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Metabolism, Distribution', 'Patients receiving coumarin anticoagulants should be closely monitored during concomitant therapy with sulfonamides.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113057/', '[1] Hermida J, Zarza J, Alberca I, et al. "Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol." Blood 99 (2002): 4237-9[2] Venkatakrishnan K, vonMoltke LL, Greenblatt DJ "Effects of the antifungal agents on oxidative drug metabolism - Clinical relevance." Clin Pharmacokinet 38 (2000): 111-80[3] O''Reilly RA, Motley CH "Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans." Ann Intern Med 91 (1979): 34-6[4] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R "Main comedications associated with major bleeding during anticoagulant therapy with coumarins." Eur J Clin Pharmacol 61 (2005): 439-44[5] Glasheen JJ, Fugit RV, Prochazka AV "The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens." J Gen Intern Med 20 (2005): 653-6[6] Visser LE, Penning-Van Bees FJ, Harrie Kasbergen AA, et al. "Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants." Thromb Haemost 88 (2002): 705-10[7] Sioris LJ, Weibert RT, Pentel PR "Potentiation of warfarin anaticoagulation by sulfisoxazole." Arch Intern Med 140 (1980): 546-7[8] Serlin MJ, Breckenridge AM "Drug interactions with warfarin." Drugs 25 (1983): 610-20[9] Self TH, Evans W, Ferguson T "Interaction of sulfisoxizole and warfarin." Circulation 52 (1975): 528[10] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[11] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM "Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism." Clin Pharmacol Ther 17 (1975): 731-4[12] Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A "Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study." Arch Intern Med 170 (2010): 617-21[13] Cook DE, Ponte CD "Suspected trimethoprim sulfamethoxazole induced hypoprothrombinemia." J Fam Pract 39 (1994): 589-91[14] O''Donnell D "Antibiotic-induced potentiation of oral anticoagulant agents." Med J Aust 150 (1989): 163-4[15] Miners JO, Birkett DJ "Cytochrome P4502C9: an enzyme of major importance in human drug metabolism." Br J Clin Pharmacol 45 (1998): 525-38[16] O''Reilly RA "Stereoselective interaction of trimethoprim-sulfamethaxazole with the separated enantiomorphs of racemic warfarin in man." N Engl J Med 302 (1980): 33-5[17] Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH "Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs." Clin Pharmacol Ther 69 (2001): 451-7[18] Thijssen HH, Flinois JP, Beaune PH "Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes." Drug Metab Disposition 28 (2000): 1284-90[19] Hermans JJ, Thijssen HH "Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics." Br J Pharmacol 110 (1993): 482-90[20] Takahashi H, Wilkinson GR, Caraco Y, et al. "Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients." Clin Pharmacol Ther 73 (2003): 253-63[21] Kelly JG, O''Malley K "Clinical pharmacokinetics of oral anticoagulants." Clin Pharmacokinet 4 (1979): 1-15[22] Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36[23] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3[24] Suvarna R, Pirmohamed M, Henderson L "Possible interaction between warfarin and cranberry juice." BMJ 327 (2003): 1454[25] Lee M, Schwartz RN, Sharifi R "Warfarin resistance and vitamin K." Ann Intern Med 94 (1981): 140-1[26] Beckey NP, Korman LB, Parra D "Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy." Pharmacotherapy 19 (1999): 1075-9[27] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G "Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy." Eur J Clin Pharmacol 63 (2007): 565-70[28] Kempin SJ "Warfarin resistance caused by broccoli." N Engl J Med 308 (1983): 1229-30[29] Westfall LK "An unrecognized cause of warfarin resistance." Drug Intell Clin Pharm 15 (1981): 131[30] Kuykendall JR, Houle MD, Rhodes RS "Possible warfarin failure due to interaction with smokeless tobacco." Ann Pharmacother 38 (2004): 595-7[31] Walker FB "Myocardial infarction after diet-induced warfarin resistance." Arch Intern Med 144 (1984): 2089-90[32] Pedersen FM, Hamberg O, Hess K, Ovesen L "The effect of dietary vitamin K on warfarin-induced anticoagulation." J Intern Med 229 (1991): 517-20[33] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[34] Griffith LD, Olvey SE, Triplett WC "Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus." Crit Care Med 10 (1982): 799-800[35] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[36] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines "Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm." ([2003 Sept]):[37] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[38] Karlson B, Leijd B, Hellstrom K "On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment." Acta Med Scand 220 (1986): 347-50[39] O''Reilly RA, Rytand DA ""Resistance" to warfarin due to unrecognized vitamin K supplementation." N Engl J Med 303 (1980): 160-1[40] Kazmier FJ, Spittell JA Jr "Coumarin drug interactions." Mayo Clin Proc 45 (1970): 249-55[41] Cambria-Kiely JA "Effect of soy milk on warfarin efficacy." Ann Pharmacother 36 (2002): 1893-6[42] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT "Anticoagulation instability with life-threatening complication after dietary modification." Postgrad Med J 66 (1990): 855-7[43] Hamann GL, Campbell JD, George CM "Warfarin-cranberry juice interaction." Ann Pharmacother 45 (2011): e17[44] Monterrey-Rodriguez J "Interaction between warfarin and mango fruit." Ann Pharmacother 36 (2002): 940-1[45] Griffiths AP, Beddall A, Pegler S "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin." J R Soc Health 128 (2008): 324-6[46] Roberts D, Flanagan P "Case report: Cranberry juice and warfarin." Home Healthc Nurse 29 (2011): 92-7[47] MacLeod SM, Sellers EM "Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants." Drugs 11 (1976): 461-70[48] Jarvis S, Li C, Bogle RG "Possible interaction between pomegranate juice and warfarin." Emerg Med J 27 (2010): 74-5[49] Parr MD, Record KE, Griffith GL, et al "Effect of enteral nutrition on warfarin therapy." Clin Pharm 1 (1982): 274-6[50] Sullivan DM, Ford MA, Boyden TW "Grapefruit juice and the response to warfarin." Am J Health Syst Pharm 55 (1998): 1581-3[51] Howard PA, Hannaman KN "Warfarin resistance linked to enteral nutrition products." J Am Diet Assoc 85 (1985): 713-5[52] Rindone JP, Murphy TW "Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding." Am J Ther 13 (2006): 283-4[53] Harrell CC, Kline SS "Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin." Jama J Am Med Assn 282 (1999): 1133-4[54] Grant P "Warfarin and cranberry juice: an interaction?" J Heart Valve Dis 13 (2004): 25-6[55] Ge B, Zhang Z, Zuo Z "Updates on the clinical evidenced herb-warfarin interactions." Evid Based Complement Alternat Med 2014 (2014): 957362[56] Zallman JA, Lee DP, Jeffrey PL "Liquid nutrition as a cause of warfarin resistance." Am J Hosp Pharm 38 (1981): 1174[57] Watson AJ, Pegg M, Green JR "Enteral feeds may antagonise warfarin." Br Med J 288 (1984): 557[58] Andersen P, Godal HC "Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K." Acta Med Scand 198 (1975): 269-70', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112927, 'Sulfamethoxazole', 'Astemizole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113058/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112928, 'Sulfamethoxazole', 'Bedaquiline', 'Moderate', 'Coadministration of bedaquiline with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'DDInter', 'The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; other antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; ketolide and macrolide antibiotics; interferons; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), especially in patients with diminished hepatic reserve. Patients treated with bedaquiline should have serum ALT, AST, alkaline phosphatase, and bilirubin monitored at baseline and monthly during treatment, or as often as needed. An increase of serum aminotransferases to greater than 3 times ULN should be followed by repeat testing within 48 hours. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Discontinue bedaquiline if aminotransferase elevations are accompanied by total bilirubin elevation greater than 2 times ULN, aminotransferase elevations are greater than 8 times ULN, or aminotransferase elevations persist beyond 2 weeks.', 'Synergism', 'The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113059/', '[1] "Product Information. Sirturo (bedaquiline)." Janssen Pharmaceuticals, Titusville, NJ.[2] "Product Information. Sirturo (bedaquiline)." Janssen Pharmaceuticals, Titusville, NJ.[3] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 'Capreomycin, Rifamycin, Bedaquiline, Streptomycin, Cycloserine, Pyridoxine, Pretomanid, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, More', 'Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112929, 'Bepridil', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113060/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112930, 'Bifidobacterium longum infantis', 'Sulfamethoxazole', 'Moderate', 'INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.', 'DDInter', 'Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.', 'Others', 'Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113061/', '[1] Clarion Brands, Inc. "Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women." ([2018]):', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112931, 'Chlorpromazine', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113062/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, Pyridoxine, Ethionamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112932, 'Cisapride', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113063/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Metoclopramide', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112933, 'Creatine', 'Trimethoprim', 'Minor', 'Cimetidine, trimethoprim, and probenecid are all known to interfere with the kidney''s secretion of creatinine. Administration of creatine supplements to patients on these medications may lead to an increase in the serum level of these drugs and/or of creatinine. The physician should be aware that these increased serum levels may occur, and dosages may need to be adjusted or creatine supplementation may need to be discontinued as necessary.', 'DDInter', '-', 'Excretion', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113064/', '[1] Vandenberghe K, Gosris M, Van Hecke PV, Van Leemputte M, Vangerven L, Hespel P "Long-term creatine intake is beneficial to muscle performance during resistance training." J Appl Physiol 83 (1997): 2055-63[2] Goldbart A, Press J, Sofer S, Kapelushnik J "Near fatal acute colchicine intoxication in a child. A case report." Eur J Pediatr 159 (2000): 895-7[3] "Colchicine: serious interactions." Prescrire Int 17 (2008): 151-3[4] Wilbur K, Makowsky M "Colchicine myotoxicity: case reports and literature review." Pharmacotherapy 24 (2004): 1784-92[5] Schiff D, Drislane FW "Rapid-onset colchicine myoneuropathy." Arthritis Rheum 35 (1992): 1535-6[6] Putterman C, Ben-Chetrit E, Caraco Y, Levy M "Colchicine intoxication: clinical pharmacology, risk factors, features, and management." Semin Arthritis Rheum 21 (1991): 143-55[7] "Product Information. Colcrys (colchicine)." AR Scientific Inc, Philadelphia, PA.[8] Hung IF, Wu AK, Cheng VC, et al. "Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study." Clin Infect Dis 41 (2005): 291-300[9] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P "Acute colchicine intoxication during clarithromycin administration." Ann Pharmacother 38 (2004): 2074-7[10] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7[11] "Severe colchicine-macrolide interactions." Prescrire Int 12 (2003): 18-9[12] Boomershine KH "Colchicine-induced rhabdomyolysis." Ann Pharmacother 36 (2002): 824-6[13] van der Velden W, Huussen J, Ter Laak H, de Sevaux R "Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin." Neth J Med 66 (2008): 204-6[14] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C "Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration." Clin Nephrol 55 (2001): 181-2[15] Pettinger WA "Clonidine, a new antihypertensive drug." N Engl J Med 293 (1975): 1179-80[16] Dahan A, Amidon GL "Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein." Pharm Res 26 (2009): 883-92[17] McKinnell J, Tayek JA "Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis." J Clin Rheumatol 15 (2009): 303-5[18] Cheng VC, Ho PL, Yuen KY "Two probable cases of serious drug interaction between clarithromycin and colchicine." South Med J 98 (2005): 811-3[19] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E "Acute colchicine intoxication: possible role of erythromycin administration." J Rheumatol 19 (1992): 494-6[20] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ "Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation." Biochem Pharmacol 53 (1996): 111-6', 'Sulfadiazine, Sulfamethoxazole, Sulfamethizole, Sulfisoxazole, Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112934, 'Dapsone', 'Trimethoprim', 'Moderate', 'Serum levels of both trimethoprim and dapsone may be increased during coadministration. The mechanism is unknown. Steady state levels are reached within approximately one week.', 'DDInter', 'When these agents are coadministered, monitoring for methemoglobinemia may be important, especially in patients with respiratory insufficiency, anemia, or cardiovascular disease.', 'Others', 'When these agents are coadministered, monitoring for methemoglobinemia may be important, especially in patients with respiratory insufficiency, anemia, or cardiovascular disease.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113065/', '[1] Lee B, Medina I, Benowitz N, et al "Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 110 (1989): 606-11[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] McKinsey D, Durfee D, Kurtin P "Megaloblastic pancytopenia associated with dapsone and trimethorprim treatment of pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome." Arch Intern Med 149 (1989): 965[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Fluorometholone, Azelaic acid, Adapalene, Clofazimine', 'Sulfamethoxazole, Capreomycin, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Cycloserine, Pyridoxine, Pretomanid, Aminosalicylic acid', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112935, 'Daunorubicin (liposomal)', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113066/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, More', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112936, 'Dicoumarol', 'Sulfamethoxazole', 'Major', 'Coadministration with a sulfonamide may increase the plasma concentrations and hypoprothrombinemic effects of coumarin anticoagulants. The proposed mechanism is sulfonamide inhibition of coumarin metabolism via CYP450 2C9 and possibly also displacement of coumarin derivatives from plasma protein binding sites.', 'DDInter', 'Patients receiving coumarin anticoagulants should be closely monitored during concomitant therapy with sulfonamides. The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of sulfonamide therapy in patients who are stabilized on their anticoagulant regimen. The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Metabolism, Distribution', 'Patients receiving coumarin anticoagulants should be closely monitored during concomitant therapy with sulfonamides.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113067/', '[1] Hermida J, Zarza J, Alberca I, et al. "Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol." Blood 99 (2002): 4237-9[2] Venkatakrishnan K, vonMoltke LL, Greenblatt DJ "Effects of the antifungal agents on oxidative drug metabolism - Clinical relevance." Clin Pharmacokinet 38 (2000): 111-80[3] O''Reilly RA, Motley CH "Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans." Ann Intern Med 91 (1979): 34-6[4] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R "Main comedications associated with major bleeding during anticoagulant therapy with coumarins." Eur J Clin Pharmacol 61 (2005): 439-44[5] Glasheen JJ, Fugit RV, Prochazka AV "The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens." J Gen Intern Med 20 (2005): 653-6[6] Visser LE, Penning-Van Bees FJ, Harrie Kasbergen AA, et al. "Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants." Thromb Haemost 88 (2002): 705-10[7] Sioris LJ, Weibert RT, Pentel PR "Potentiation of warfarin anaticoagulation by sulfisoxazole." Arch Intern Med 140 (1980): 546-7[8] Serlin MJ, Breckenridge AM "Drug interactions with warfarin." Drugs 25 (1983): 610-20[9] Self TH, Evans W, Ferguson T "Interaction of sulfisoxizole and warfarin." Circulation 52 (1975): 528[10] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[11] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM "Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism." Clin Pharmacol Ther 17 (1975): 731-4[12] Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A "Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study." Arch Intern Med 170 (2010): 617-21[13] Cook DE, Ponte CD "Suspected trimethoprim sulfamethoxazole induced hypoprothrombinemia." J Fam Pract 39 (1994): 589-91[14] O''Donnell D "Antibiotic-induced potentiation of oral anticoagulant agents." Med J Aust 150 (1989): 163-4[15] Miners JO, Birkett DJ "Cytochrome P4502C9: an enzyme of major importance in human drug metabolism." Br J Clin Pharmacol 45 (1998): 525-38[16] O''Reilly RA "Stereoselective interaction of trimethoprim-sulfamethaxazole with the separated enantiomorphs of racemic warfarin in man." N Engl J Med 302 (1980): 33-5[17] Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH "Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs." Clin Pharmacol Ther 69 (2001): 451-7[18] Thijssen HH, Flinois JP, Beaune PH "Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes." Drug Metab Disposition 28 (2000): 1284-90[19] Hermans JJ, Thijssen HH "Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics." Br J Pharmacol 110 (1993): 482-90[20] Takahashi H, Wilkinson GR, Caraco Y, et al. "Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients." Clin Pharmacol Ther 73 (2003): 253-63[21] Kelly JG, O''Malley K "Clinical pharmacokinetics of oral anticoagulants." Clin Pharmacokinet 4 (1979): 1-15[22] Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36[23] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3[24] Suvarna R, Pirmohamed M, Henderson L "Possible interaction between warfarin and cranberry juice." BMJ 327 (2003): 1454[25] Lee M, Schwartz RN, Sharifi R "Warfarin resistance and vitamin K." Ann Intern Med 94 (1981): 140-1[26] Beckey NP, Korman LB, Parra D "Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy." Pharmacotherapy 19 (1999): 1075-9[27] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G "Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy." Eur J Clin Pharmacol 63 (2007): 565-70[28] Kempin SJ "Warfarin resistance caused by broccoli." N Engl J Med 308 (1983): 1229-30[29] Westfall LK "An unrecognized cause of warfarin resistance." Drug Intell Clin Pharm 15 (1981): 131[30] Kuykendall JR, Houle MD, Rhodes RS "Possible warfarin failure due to interaction with smokeless tobacco." Ann Pharmacother 38 (2004): 595-7[31] Walker FB "Myocardial infarction after diet-induced warfarin resistance." Arch Intern Med 144 (1984): 2089-90[32] Pedersen FM, Hamberg O, Hess K, Ovesen L "The effect of dietary vitamin K on warfarin-induced anticoagulation." J Intern Med 229 (1991): 517-20[33] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[34] Griffith LD, Olvey SE, Triplett WC "Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus." Crit Care Med 10 (1982): 799-800[35] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[36] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines "Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm." ([2003 Sept]):[37] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[38] Karlson B, Leijd B, Hellstrom K "On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment." Acta Med Scand 220 (1986): 347-50[39] O''Reilly RA, Rytand DA ""Resistance" to warfarin due to unrecognized vitamin K supplementation." N Engl J Med 303 (1980): 160-1[40] Kazmier FJ, Spittell JA Jr "Coumarin drug interactions." Mayo Clin Proc 45 (1970): 249-55[41] Cambria-Kiely JA "Effect of soy milk on warfarin efficacy." Ann Pharmacother 36 (2002): 1893-6[42] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT "Anticoagulation instability with life-threatening complication after dietary modification." Postgrad Med J 66 (1990): 855-7[43] Hamann GL, Campbell JD, George CM "Warfarin-cranberry juice interaction." Ann Pharmacother 45 (2011): e17[44] Monterrey-Rodriguez J "Interaction between warfarin and mango fruit." Ann Pharmacother 36 (2002): 940-1[45] Griffiths AP, Beddall A, Pegler S "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin." J R Soc Health 128 (2008): 324-6[46] Roberts D, Flanagan P "Case report: Cranberry juice and warfarin." Home Healthc Nurse 29 (2011): 92-7[47] MacLeod SM, Sellers EM "Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants." Drugs 11 (1976): 461-70[48] Jarvis S, Li C, Bogle RG "Possible interaction between pomegranate juice and warfarin." Emerg Med J 27 (2010): 74-5[49] Parr MD, Record KE, Griffith GL, et al "Effect of enteral nutrition on warfarin therapy." Clin Pharm 1 (1982): 274-6[50] Sullivan DM, Ford MA, Boyden TW "Grapefruit juice and the response to warfarin." Am J Health Syst Pharm 55 (1998): 1581-3[51] Howard PA, Hannaman KN "Warfarin resistance linked to enteral nutrition products." J Am Diet Assoc 85 (1985): 713-5[52] Rindone JP, Murphy TW "Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding." Am J Ther 13 (2006): 283-4[53] Harrell CC, Kline SS "Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin." Jama J Am Med Assn 282 (1999): 1133-4[54] Grant P "Warfarin and cranberry juice: an interaction?" J Heart Valve Dis 13 (2004): 25-6[55] Ge B, Zhang Z, Zuo Z "Updates on the clinical evidenced herb-warfarin interactions." Evid Based Complement Alternat Med 2014 (2014): 957362[56] Zallman JA, Lee DP, Jeffrey PL "Liquid nutrition as a cause of warfarin resistance." Am J Hosp Pharm 38 (1981): 1174[57] Watson AJ, Pegg M, Green JR "Enteral feeds may antagonise warfarin." Br Med J 288 (1984): 557[58] Andersen P, Godal HC "Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K." Acta Med Scand 198 (1975): 269-70', 'Ticagrelor, Betrixaban, Clopidogrel, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112937, 'Doxorubicin (liposomal)', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113068/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112938, 'Entrectinib', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113069/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, More', 'Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112939, 'Enzalutamide', 'Trimethoprim', 'Moderate', 'Coadministration with potent inducers of CYP450 2C9 and 3A4 may decrease the plasma concentrations of sulfamethoxazole and trimethoprim. A small amount of sulfamethoxazole is metabolized by CYP450 2C9, while trimethoprim is partially metabolized by both CYP450 2C9 and 3A4.', 'DDInter', 'The potential for diminished pharmacologic effects of sulfamethoxazole-trimethoprim should be considered during coadministration with potent CYP450 2C9 ad 3A4 inducers, particularly when sulfamethoxazole-trimethoprim is used for prevention of toxoplasmic encephalitis in HIV patients because adequate drug levels are required in the central nervous system. It may be advisable to refrain from low-dose prophylactic regimens (less than 4 DS tablets per week). Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of sulfamethoxazole-trimethoprim should be considered during coadministration with potent CYP450 2C9 ad 3A4 inducers, particularly when sulfamethoxazole-trimethoprim is used for prevention of toxoplasmic encephalitis in HIV patients because adequate drug levels are required in the central nervous system.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113070/', '[1] Ribera E, Pou L, Fernandez-Sola A, et al. "Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients." Antimicrob Agents Chemother 45 (2001): 3238-41[2] Ribera E, FernandezSola A, Juste C, Rovira A, Romero FJ, ArmadansGil L, Ruiz I, Ocana I, Pahissa A "Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients." Clin Infect Dis 29 (1999): 1461-6[3] Bhatia RS, Uppal R, Malhi R, Behera D, Jindal SK "Drug interaction between rifampicin and cotrimazole in patients with tuberculosis." Hum Exp Toxicol 10 (1991): 419-21[4] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 'Sulfadiazine, Sulfamethizole, Sulfisoxazole, Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More', 'Darolutamide, Tamoxifen, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112940, 'Epirubicin', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113071/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin', 'Capreomycin, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Sulfamethizole, Sulfisoxazole, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112941, 'Eplerenone', 'Trimethoprim', 'Major', 'The use of trimethoprim in combination with other potassium-sparing drugs or potassium salts may increase the risk of hyperkalemia. Trimethoprim inhibits sodium reabsorption and potassium excretion by blocking sodium channels in the renal distal tubules.', 'DDInter', 'Serum potassium and sodium levels as well as renal function should be closely monitored during coadministration of trimethoprim with other potassium-sparing drugs or potassium salts, particularly in patients receiving high-dose or long-term trimethoprim treatment and in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. A dosage reduction of trimethoprim is recommended in renal dysfunction (50% reduction for CrCl between 15 and 30 mL/min). Patients should be given dietary counseling to avoid excessive intake of potassium-rich foods and salt substitutes, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat. Trimethoprim should be discontinued if hyperkalemia occurs.', 'Excretion', 'Serum potassium and sodium levels as well as renal function should be closely monitored during coadministration of trimethoprim with other potassium-sparing drugs or potassium salts, particularly in patients receiving high-dose or long-term trimethoprim treatment and in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113072/', '[1] Witt JM, Koo JM, Danielson BD "Effect of standard-dose trimethoprim/sulfamethoxazole on the serum potassium concentration in elderly men." Ann Pharmacother 30 (1996): 347-50[2] Canaday DH, Johnson JR "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 438[3] Noto H, Kaneko Y, Takano T, Kurokawa K "Severe hyponatremia and hyperkalemia induced by trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia." Intern Med 34 (1995): 96-9[4] Perazella MA, Mahnensmith RL "Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose." Clin Nephrol 46 (1996): 187-92[5] Velazquez H, Perazella MA, Wright FS, Ellison DH "Renal mechanism of trimethoprim-induced hyperkalemia." Ann Intern Med 119 (1993): 296-301[6] Marinella MA "Reversible hyperkalemia associated with trimethoprim-sulfamethoxazole." Am J Med Sci 310 (1995): 115-7[7] Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006): 49-58[8] Koc M, Bihorac A, Ozener CI, Kantarci G, Akoglu E "Severe hyperkalemia in two renal transplant recipients treated with standard dose of trimethoprim-sulfamethoxazole." Am J Kidney Dis 36 (2000): u59-64[9] Bugge JF "Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs." J Intern Med 240 (1996): 249-51[10] Choi MJ, Fernandez PC, Patnaik A, Coupaye-Gerard B, D''Andrea D, Szerlip H, Kleyman TR "Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS." N Engl J Med 328 (1993): 703-6[11] Thomas RJ "Severe hyperkalemia with trimethoprim-quinapril." Ann Pharmacother 30 (1996): 413-4[12] Marinella MA "Severe hyperkalemia associated with trimethoprim-sulfamethoxazole and spironolactone." Infect Dis Clin Pract 6 (1997): 256-8[13] Smith GW, Cohen SB "Hyperkalaemia and non-oliguric renal failure associated with trimethoprim." Br Med J 308 (1994): 454[14] Eiam-Ong S, Kurtzman NA, Sabatini S "Studies on the mechanism of trimethoprim-induced hyperkalemia." Kidney Int 49 (1996): 1372-8[15] Fouche R, Bernardin G, Roger PM, Corcelle P, Simler JM, Mattei M "Hyperkaliemia in a patient given high-dose trimethoprim-sulfamethoxazole." Presse Med 25 (1996): 2044[16] "Prevent-ERR: sulfamethoxazole and trimethoprim-induced hyperkalemia." ISMP Medication Safety Alert! 13(Dec 4) (2008): 3[17] Pennypacker LC, Mintzer J, Pitner J "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 437[18] Modest GA, Price B, Mascoli N "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 437[19] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[20] Martin J, Mourton S, Nicholls G "Severe hyperkalaemia with prescription of potassium-retaining agents in an elderly patient." N Z Med J 116 (2003): U542[21] Greenberg S, Reiser IW, Chou SY "Hyperkalemia with high-dose trimethoprim-sulfamethoxazole therapy." Am J Kidney Dis 22 (1993): 603-6[22] Mori H, Kuroda Y, Imamura S, et al "Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole." Intern Med 42 (2003): 665-9[23] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[24] Alappan R, Perazella MA, Buller GK "Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole." Ann Intern Med 124 (1996): 316-20[25] Perlmutter EP, Sweeney D, Herskovits G, Kleiner M "Case report: severe hyperkalemia in a geriatric patient receiving standard doses of trimethoprim-sulfamethoxazole." Am J Med Sci 311 (1996): 84-5[26] Marinella MA "Trimethoprim-sulfamethoxazole associated with hyperkalemia." West J Med 167 (1997): 356-8[27] Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM "Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study." Arch Intern Med 170 (2010): 1045-9[28] Hsu I, Wordell CJ "Hyperkalemia and high-dose trimethoprim/sulfamethoxazole." Ann Pharmacother 29 (1995): 427-9[29] Lin SH, Kuo AA, Yu FC, Lin YF "Reversible voltage-dependent distal renal tubular acidosis in a patient receiving standaard doses of trimethoprim-sulphamethoxazole." Nephrol Dial Transplant 12 (1997): 1031-33[30] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[31] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[32] Perazella MA, Alappan R, Buller GK "Hyperkalemia and trimethoprim-sulfamethoxazole." Ann Intern Med 125 (1996): 1015[33] "Product Information. Bactrim (trimethoprim-sulfamethoxazole)." Roche Laboratories, Nutley, NJ.[34] Mihm LB, Rathbun RC, Resmantargoff BH "Hyperkalemia associated with high-dose trimethoprim-sulfamethoxazole in a patient with the acquired immunodeficiency syndrome." Pharmacotherapy 15 (1995): 793-7[35] Lee SW, Park SW, Kang JM "Intraoperative hyperkalemia induced by administration of trimethoprim-sulfamethoxazole in a patient receiving angiotensin receptor blockers." J Clin Anesth 26 (2014): 427-8', 'Sulfadiazine, Sulfamethoxazole, Sulfamethizole, Sulfisoxazole, Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Cycloserine, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112942, 'Eprosartan', 'Trimethoprim', 'Major', 'The use of trimethoprim in combination with other potassium-sparing drugs or potassium salts may increase the risk of hyperkalemia. Trimethoprim inhibits sodium reabsorption and potassium excretion by blocking sodium channels in the renal distal tubules.', 'DDInter', 'Serum potassium and sodium levels as well as renal function should be closely monitored during coadministration of trimethoprim with other potassium-sparing drugs or potassium salts, particularly in patients receiving high-dose or long-term trimethoprim treatment and in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. A dosage reduction of trimethoprim is recommended in renal dysfunction (50% reduction for CrCl between 15 and 30 mL/min). Patients should be given dietary counseling to avoid excessive intake of potassium-rich foods and salt substitutes, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat. Trimethoprim should be discontinued if hyperkalemia occurs.', 'Excretion', 'Serum potassium and sodium levels as well as renal function should be closely monitored during coadministration of trimethoprim with other potassium-sparing drugs or potassium salts, particularly in patients receiving high-dose or long-term trimethoprim treatment and in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113073/', '[1] Witt JM, Koo JM, Danielson BD "Effect of standard-dose trimethoprim/sulfamethoxazole on the serum potassium concentration in elderly men." Ann Pharmacother 30 (1996): 347-50[2] Canaday DH, Johnson JR "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 438[3] Noto H, Kaneko Y, Takano T, Kurokawa K "Severe hyponatremia and hyperkalemia induced by trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia." Intern Med 34 (1995): 96-9[4] Perazella MA, Mahnensmith RL "Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose." Clin Nephrol 46 (1996): 187-92[5] Velazquez H, Perazella MA, Wright FS, Ellison DH "Renal mechanism of trimethoprim-induced hyperkalemia." Ann Intern Med 119 (1993): 296-301[6] Marinella MA "Reversible hyperkalemia associated with trimethoprim-sulfamethoxazole." Am J Med Sci 310 (1995): 115-7[7] Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006): 49-58[8] Koc M, Bihorac A, Ozener CI, Kantarci G, Akoglu E "Severe hyperkalemia in two renal transplant recipients treated with standard dose of trimethoprim-sulfamethoxazole." Am J Kidney Dis 36 (2000): u59-64[9] Bugge JF "Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs." J Intern Med 240 (1996): 249-51[10] Choi MJ, Fernandez PC, Patnaik A, Coupaye-Gerard B, D''Andrea D, Szerlip H, Kleyman TR "Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS." N Engl J Med 328 (1993): 703-6[11] Thomas RJ "Severe hyperkalemia with trimethoprim-quinapril." Ann Pharmacother 30 (1996): 413-4[12] Marinella MA "Severe hyperkalemia associated with trimethoprim-sulfamethoxazole and spironolactone." Infect Dis Clin Pract 6 (1997): 256-8[13] Smith GW, Cohen SB "Hyperkalaemia and non-oliguric renal failure associated with trimethoprim." Br Med J 308 (1994): 454[14] Eiam-Ong S, Kurtzman NA, Sabatini S "Studies on the mechanism of trimethoprim-induced hyperkalemia." Kidney Int 49 (1996): 1372-8[15] Fouche R, Bernardin G, Roger PM, Corcelle P, Simler JM, Mattei M "Hyperkaliemia in a patient given high-dose trimethoprim-sulfamethoxazole." Presse Med 25 (1996): 2044[16] "Prevent-ERR: sulfamethoxazole and trimethoprim-induced hyperkalemia." ISMP Medication Safety Alert! 13(Dec 4) (2008): 3[17] Pennypacker LC, Mintzer J, Pitner J "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 437[18] Modest GA, Price B, Mascoli N "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 437[19] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[20] Martin J, Mourton S, Nicholls G "Severe hyperkalaemia with prescription of potassium-retaining agents in an elderly patient." N Z Med J 116 (2003): U542[21] Greenberg S, Reiser IW, Chou SY "Hyperkalemia with high-dose trimethoprim-sulfamethoxazole therapy." Am J Kidney Dis 22 (1993): 603-6[22] Mori H, Kuroda Y, Imamura S, et al "Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole." Intern Med 42 (2003): 665-9[23] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[24] Alappan R, Perazella MA, Buller GK "Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole." Ann Intern Med 124 (1996): 316-20[25] Perlmutter EP, Sweeney D, Herskovits G, Kleiner M "Case report: severe hyperkalemia in a geriatric patient receiving standard doses of trimethoprim-sulfamethoxazole." Am J Med Sci 311 (1996): 84-5[26] Marinella MA "Trimethoprim-sulfamethoxazole associated with hyperkalemia." West J Med 167 (1997): 356-8[27] Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM "Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study." Arch Intern Med 170 (2010): 1045-9[28] Hsu I, Wordell CJ "Hyperkalemia and high-dose trimethoprim/sulfamethoxazole." Ann Pharmacother 29 (1995): 427-9[29] Lin SH, Kuo AA, Yu FC, Lin YF "Reversible voltage-dependent distal renal tubular acidosis in a patient receiving standaard doses of trimethoprim-sulphamethoxazole." Nephrol Dial Transplant 12 (1997): 1031-33[30] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[31] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[32] Perazella MA, Alappan R, Buller GK "Hyperkalemia and trimethoprim-sulfamethoxazole." Ann Intern Med 125 (1996): 1015[33] "Product Information. Bactrim (trimethoprim-sulfamethoxazole)." Roche Laboratories, Nutley, NJ.[34] Mihm LB, Rathbun RC, Resmantargoff BH "Hyperkalemia associated with high-dose trimethoprim-sulfamethoxazole in a patient with the acquired immunodeficiency syndrome." Pharmacotherapy 15 (1995): 793-7[35] Lee SW, Park SW, Kang JM "Intraoperative hyperkalemia induced by administration of trimethoprim-sulfamethoxazole in a patient receiving angiotensin receptor blockers." J Clin Anesth 26 (2014): 427-8', 'Sulfadiazine, Sulfamethoxazole, Sulfamethizole, Sulfisoxazole, Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, More', 'Sacubitril, Aliskiren, Nebivolol', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112943, 'Eribulin', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113074/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, More', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, Enasidenib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112944, 'Escitalopram', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113075/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Ethambutol, Pyridoxine, Ethionamide, More', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112945, 'Ethotoin', 'Sulfamethoxazole', 'Moderate', 'Some sulfonamides may inhibit the hepatic metabolism of hydantoins. Serum hydantoin levels and risk of toxicity may be increased. Data are available for sulfadiazine, sulfaphenazole, and sulfamethizole.', 'DDInter', 'Monitoring for clinical and laboratory evidence of altered efficacy and safety is recommended. Hydantoin dosage adjustments or an alternate antimicrobial may be required if an interaction is suspected. Patients should be advised to notify their physician if they experience symptoms of hydantoin toxicity (e.g., drowsiness, visual disturbances, change in mental status, seizures, nausea, or ataxia).', 'Others', 'Monitoring for clinical and laboratory evidence of altered efficacy and safety is recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113076/', '[1] Hansen JM, Kampmann JP, Siersback-Nielsen K, et al. "The effect of different sulfonamides on phenytoin metabolism in man." Acta Med Scand Suppl 624 (1979): 106-10[2] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM "Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism." Clin Pharmacol Ther 17 (1975): 731-4[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Fleisher D, Sheth N, Kou JH "Phenytoin interaction with enteral feedings administered through nasogastric tubes." JPEN J Parenter Enteral Nutr 14 (1990): 513-6[6] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM "Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability." Epilepsia 28 (1987): 706-12[7] Haley CJ, Nelson J "Phenytoin-enteral feeding interaction." DICP 23 (1989): 796-8[8] Faraji B, Yu PP "Serum phenytoin levels of patients on gastrostomy tube feeding." J Neurosci Nurs 30 (1998): 55-9[9] Au Yeung SC, Ensom MH "Phenytoin and enteral feedings: does evidence support an interaction?" Ann Pharmacother 34 (2000): 896-905[10] Sandor P, Sellers EM, Dumbrell M, Khouw V "Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics." Clin Pharmacol Ther 30 (1981): 390-7[11] Ozuna J, Friel P "Effect of enteral tube feeding on serum phenytoin levels." J Neurosurg Nurs 16 (1984): 289-91[12] Guidry JR, Eastwood TF, Curry SC "Phenytoin absorption in volunteers receiving selected enteral feedings." West J Med 150 (1989): 659-61[13] Marvel ME, Bertino JS "Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension." JPEN J Parenter Enteral Nutr 15 (1991): 316-8[14] "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.[15] Doak KK, Haas CE, Dunnigan KJ, et al. "Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings." Pharmacotherapy 18 (1998): 637-45[16] Rodman DP, Stevenson TL, Ray TR "Phenytoin malabsorption after jejunostomy tube delivery." Pharmacotherapy 15 (1995): 801-5[17] Sellers EM, Holloway MR "Drug kinetics and alcohol ingestion." Clin Pharmacokinet 3 (1978): 440-52[18] Holtz L, Milton J, Sturek JK "Compatibility of medications with enteral feedings." JPEN J Parenter Enteral Nutr 11 (1987): 183-6', 'Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112946, 'Etravirine', 'Sulfamethoxazole', 'Moderate', 'Coadministration with inhibitors of CYP450 2C19, 2C9, and/or 3A4 may increase the plasma concentrations of etravirine, which is a substrate of these isoenzymes.', 'DDInter', 'Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with CYP450 2C19, 2C9, and/or 3A4 inhibitors.', 'Metabolism', 'Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with CYP450 2C19, 2C9, and/or 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113077/', '[1] "Product Information. Intelence (etravirine)." Ortho Biotech Inc, Bridgewater, NJ.[2] "Product Information. Intelence (etravirine)." Ortho Biotech Inc, Bridgewater, NJ.', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Pyridoxine, Aminosalicylic acid, Sulfisoxazole, Trimethoprim, Tamsulosin, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112947, 'Ezogabine', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113078/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More', 'Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112948, 'Fingolimod', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113079/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Abatacept, Upadacitinib, Anakinra, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112949, 'Flecainide', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113080/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More', 'Moricizine, Tocainide, Bretylium, Mexiletine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112950, 'Fluconazole', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113081/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Caspofungin, Micafungin, Amphotericin B, Itraconazole, More', 'Capreomycin, Rifamycin, Rifapentine, Streptomycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, Sulfamethizole, Sulfisoxazole, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112951, 'Fluoxetine', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113082/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Cycloserine, Rifabutin, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112952, 'Fluphenazine', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113083/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Rifabutin, Isoniazid, Ethambutol, Ethionamide, Pyridoxine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112953, 'Flutamide', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113084/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112954, 'Foscarnet', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113085/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Pyridoxine, Ethionamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112955, 'Fosinopril', 'Trimethoprim', 'Major', 'The use of trimethoprim in combination with other potassium-sparing drugs or potassium salts may increase the risk of hyperkalemia. Trimethoprim inhibits sodium reabsorption and potassium excretion by blocking sodium channels in the renal distal tubules.', 'DDInter', 'Serum potassium and sodium levels as well as renal function should be closely monitored during coadministration of trimethoprim with other potassium-sparing drugs or potassium salts, particularly in patients receiving high-dose or long-term trimethoprim treatment and in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. A dosage reduction of trimethoprim is recommended in renal dysfunction (50% reduction for CrCl between 15 and 30 mL/min). Patients should be given dietary counseling to avoid excessive intake of potassium-rich foods and salt substitutes, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat. Trimethoprim should be discontinued if hyperkalemia occurs.', 'Excretion', 'Serum potassium and sodium levels as well as renal function should be closely monitored during coadministration of trimethoprim with other potassium-sparing drugs or potassium salts, particularly in patients receiving high-dose or long-term trimethoprim treatment and in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113086/', '[1] Witt JM, Koo JM, Danielson BD "Effect of standard-dose trimethoprim/sulfamethoxazole on the serum potassium concentration in elderly men." Ann Pharmacother 30 (1996): 347-50[2] Canaday DH, Johnson JR "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 438[3] Noto H, Kaneko Y, Takano T, Kurokawa K "Severe hyponatremia and hyperkalemia induced by trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia." Intern Med 34 (1995): 96-9[4] Perazella MA, Mahnensmith RL "Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose." Clin Nephrol 46 (1996): 187-92[5] Velazquez H, Perazella MA, Wright FS, Ellison DH "Renal mechanism of trimethoprim-induced hyperkalemia." Ann Intern Med 119 (1993): 296-301[6] Marinella MA "Reversible hyperkalemia associated with trimethoprim-sulfamethoxazole." Am J Med Sci 310 (1995): 115-7[7] Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006): 49-58[8] Koc M, Bihorac A, Ozener CI, Kantarci G, Akoglu E "Severe hyperkalemia in two renal transplant recipients treated with standard dose of trimethoprim-sulfamethoxazole." Am J Kidney Dis 36 (2000): u59-64[9] Bugge JF "Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs." J Intern Med 240 (1996): 249-51[10] Choi MJ, Fernandez PC, Patnaik A, Coupaye-Gerard B, D''Andrea D, Szerlip H, Kleyman TR "Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS." N Engl J Med 328 (1993): 703-6[11] Thomas RJ "Severe hyperkalemia with trimethoprim-quinapril." Ann Pharmacother 30 (1996): 413-4[12] Marinella MA "Severe hyperkalemia associated with trimethoprim-sulfamethoxazole and spironolactone." Infect Dis Clin Pract 6 (1997): 256-8[13] Smith GW, Cohen SB "Hyperkalaemia and non-oliguric renal failure associated with trimethoprim." Br Med J 308 (1994): 454[14] Eiam-Ong S, Kurtzman NA, Sabatini S "Studies on the mechanism of trimethoprim-induced hyperkalemia." Kidney Int 49 (1996): 1372-8[15] Fouche R, Bernardin G, Roger PM, Corcelle P, Simler JM, Mattei M "Hyperkaliemia in a patient given high-dose trimethoprim-sulfamethoxazole." Presse Med 25 (1996): 2044[16] "Prevent-ERR: sulfamethoxazole and trimethoprim-induced hyperkalemia." ISMP Medication Safety Alert! 13(Dec 4) (2008): 3[17] Pennypacker LC, Mintzer J, Pitner J "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 437[18] Modest GA, Price B, Mascoli N "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 437[19] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[20] Martin J, Mourton S, Nicholls G "Severe hyperkalaemia with prescription of potassium-retaining agents in an elderly patient." N Z Med J 116 (2003): U542[21] Greenberg S, Reiser IW, Chou SY "Hyperkalemia with high-dose trimethoprim-sulfamethoxazole therapy." Am J Kidney Dis 22 (1993): 603-6[22] Mori H, Kuroda Y, Imamura S, et al "Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole." Intern Med 42 (2003): 665-9[23] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[24] Alappan R, Perazella MA, Buller GK "Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole." Ann Intern Med 124 (1996): 316-20[25] Perlmutter EP, Sweeney D, Herskovits G, Kleiner M "Case report: severe hyperkalemia in a geriatric patient receiving standard doses of trimethoprim-sulfamethoxazole." Am J Med Sci 311 (1996): 84-5[26] Marinella MA "Trimethoprim-sulfamethoxazole associated with hyperkalemia." West J Med 167 (1997): 356-8[27] Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM "Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study." Arch Intern Med 170 (2010): 1045-9[28] Hsu I, Wordell CJ "Hyperkalemia and high-dose trimethoprim/sulfamethoxazole." Ann Pharmacother 29 (1995): 427-9[29] Lin SH, Kuo AA, Yu FC, Lin YF "Reversible voltage-dependent distal renal tubular acidosis in a patient receiving standaard doses of trimethoprim-sulphamethoxazole." Nephrol Dial Transplant 12 (1997): 1031-33[30] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[31] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[32] Perazella MA, Alappan R, Buller GK "Hyperkalemia and trimethoprim-sulfamethoxazole." Ann Intern Med 125 (1996): 1015[33] "Product Information. Bactrim (trimethoprim-sulfamethoxazole)." Roche Laboratories, Nutley, NJ.[34] Mihm LB, Rathbun RC, Resmantargoff BH "Hyperkalemia associated with high-dose trimethoprim-sulfamethoxazole in a patient with the acquired immunodeficiency syndrome." Pharmacotherapy 15 (1995): 793-7[35] Lee SW, Park SW, Kang JM "Intraoperative hyperkalemia induced by administration of trimethoprim-sulfamethoxazole in a patient receiving angiotensin receptor blockers." J Clin Anesth 26 (2014): 427-8', 'Sulfadiazine, Sulfamethoxazole, Sulfamethizole, Sulfisoxazole, Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Rifampicin, More', 'Felodipine, Bisoprolol', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112956, 'Fosphenytoin', 'Sulfamethoxazole', 'Moderate', 'Some sulfonamides may inhibit the hepatic metabolism of hydantoins. Serum hydantoin levels and risk of toxicity may be increased. Data are available for sulfadiazine, sulfaphenazole, and sulfamethizole.', 'DDInter', 'Monitoring for clinical and laboratory evidence of altered efficacy and safety is recommended. Hydantoin dosage adjustments or an alternate antimicrobial may be required if an interaction is suspected. Patients should be advised to notify their physician if they experience symptoms of hydantoin toxicity (e.g., drowsiness, visual disturbances, change in mental status, seizures, nausea, or ataxia).', 'Others', 'Monitoring for clinical and laboratory evidence of altered efficacy and safety is recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113087/', '[1] Hansen JM, Kampmann JP, Siersback-Nielsen K, et al. "The effect of different sulfonamides on phenytoin metabolism in man." Acta Med Scand Suppl 624 (1979): 106-10[2] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM "Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism." Clin Pharmacol Ther 17 (1975): 731-4[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Fleisher D, Sheth N, Kou JH "Phenytoin interaction with enteral feedings administered through nasogastric tubes." JPEN J Parenter Enteral Nutr 14 (1990): 513-6[6] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM "Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability." Epilepsia 28 (1987): 706-12[7] Haley CJ, Nelson J "Phenytoin-enteral feeding interaction." DICP 23 (1989): 796-8[8] Faraji B, Yu PP "Serum phenytoin levels of patients on gastrostomy tube feeding." J Neurosci Nurs 30 (1998): 55-9[9] Au Yeung SC, Ensom MH "Phenytoin and enteral feedings: does evidence support an interaction?" Ann Pharmacother 34 (2000): 896-905[10] Sandor P, Sellers EM, Dumbrell M, Khouw V "Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics." Clin Pharmacol Ther 30 (1981): 390-7[11] Ozuna J, Friel P "Effect of enteral tube feeding on serum phenytoin levels." J Neurosurg Nurs 16 (1984): 289-91[12] Guidry JR, Eastwood TF, Curry SC "Phenytoin absorption in volunteers receiving selected enteral feedings." West J Med 150 (1989): 659-61[13] Marvel ME, Bertino JS "Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension." JPEN J Parenter Enteral Nutr 15 (1991): 316-8[14] "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.[15] Doak KK, Haas CE, Dunnigan KJ, et al. "Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings." Pharmacotherapy 18 (1998): 637-45[16] Rodman DP, Stevenson TL, Ray TR "Phenytoin malabsorption after jejunostomy tube delivery." Pharmacotherapy 15 (1995): 801-5[17] Sellers EM, Holloway MR "Drug kinetics and alcohol ingestion." Clin Pharmacokinet 3 (1978): 440-52[18] Holtz L, Milton J, Sturek JK "Compatibility of medications with enteral feedings." JPEN J Parenter Enteral Nutr 11 (1987): 183-6', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Ethambutol, Pyridoxine, Ethionamide, Aminosalicylic acid, Tamsulosin, Ascorbic acid, Hydroflumethiazide, More', 'Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112957, 'Fostemsavir', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113088/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112958, 'Ganciclovir', 'Trimethoprim', 'Minor', 'The coadministration of ganciclovir or its prodrug, valganciclovir, with trimethoprim may result in elevated plasma concentrations of ganciclovir. The mechanism is unknown but may involve the competitive inhibition of ganciclovir renal tubular secretion by trimethoprim. Ganciclovir had minimal effect on the pharmacokinetics of trimethoprim. This interaction is unlikely to be of clinical significance. However, the use of ganciclovir with other potentially myelotoxic drugs such as trimethoprim may increase the risk and severity of these adverse events due to additive pharmacodynamic effects. The potential for this effect should be kept in consideration and the patient monitored for hematologic adverse effects.', 'DDInter', '-', 'Synergism, Excretion', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113089/', '[1] "Product Information. Valcyte (valganciclovir)" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Cytovene (ganciclovir)." Genentech, South San Francisco, CA.[5] Brown F, Banken L, Saywell K, Arum I "Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositiv volunteers." Clin Pharmacokinet 37 (1999): 167-76[6] "Product Information. Valcyte (valganciclovir)" Roche Laboratories, Nutley, NJ.', 'Sulfamethoxazole, Sulfamethizole, Sulfisoxazole, Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Rifampicin, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112959, 'Gatifloxacin', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113090/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More', 'Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112960, 'Gemifloxacin', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113091/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112961, 'Gilteritinib', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113092/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, More', 'Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112962, 'Givosiran', 'Sulfamethoxazole', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.', 'DDInter', 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113093/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Pyrazinamide, Rifamycin, Rifapentine, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, Pyridoxine, Pretomanid, More', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112963, 'Glasdegib', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113094/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, More', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, Enasidenib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112964, 'Glipizide', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113095/', '[1] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A "Potentiation of acetohexamide hypoglycemia by phenylbutazone." N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J "Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole." Diabet Med 4 (1987): 245-7[7] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT "Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride." Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P "Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs." Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[11] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP "Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function." Diabetes 51 (2002): 1772-8[13] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[14] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[16] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[20] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA "Effect of pirprofen on glibenclamide kinetics and response." Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[23] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[25] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D "Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors." Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO "Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition." Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH "A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide." Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS "Phenylbutazone-tolbutamide drug interaction." N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB "Aspirin-induced hypoglycaemia in a patient on haemodialysis." Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC "Lack of interaction between glipizide and co-trimoxazole." J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[41] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[46] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA "Drug interactions with fibric acids." Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS "Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone." Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK "Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia." Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[54] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[56] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[59] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[74] "Product Information. Micronase (glyburide)." Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al "Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy." Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN "Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole." Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N "Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea." Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM "Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism." Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV "Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans." Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[98] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[100] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[101] Harris EL "Adverse reactions to oral antidiabetic agents." Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK "Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide." Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[104] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[105] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[109] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[110] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[111] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Pretomanid, Aminosalicylic acid, More', 'Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112965, 'Glucarpidase', 'Trimethoprim', 'Moderate', 'Concomitant administration of glucarpidase may decrease the plasma concentrations and effects of reduced folates and folate antimetabolites, which are potential exogenous substrates of glucarpidase. Conversely, potential substrates of glucarpidase may interfere with its action in the treatment of toxic plasma methotrexate concentrations in patients with impaired renal function by reducing the availability of glucarpidase, a recombinant bacterial enzyme that provides an alternate nonrenal pathway for methotrexate elimination by converting methotrexate to an inactive metabolite and glutamate.', 'DDInter', 'On theoretical grounds, caution is advised if glucarpidase is administered in combination with potential substrates such as folate antimetabolites other than methotrexate. With leucovorin, experts recommend administering it two to four hours before or after a dose of glucarpidase. The same precaution may be appropriate with other potential substrates of glucarpidase, although clinical data are currently lacking.', 'Antagonism', 'On theoretical grounds, caution is advised if glucarpidase is administered in combination with potential substrates such as folate antimetabolites other than methotrexate.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113096/', '[1] "Product Information. Voraxaze (glucarpidase)." BTG International Inc, West Conshohocken, PA.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Sulfadiazine, Sulfamethoxazole, Sulfamethizole, Sulfisoxazole, Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Arginine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112966, 'Glyburide', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113097/', '[1] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A "Potentiation of acetohexamide hypoglycemia by phenylbutazone." N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J "Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole." Diabet Med 4 (1987): 245-7[7] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT "Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride." Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P "Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs." Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[11] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP "Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function." Diabetes 51 (2002): 1772-8[13] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[14] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[16] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[20] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA "Effect of pirprofen on glibenclamide kinetics and response." Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[23] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[25] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D "Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors." Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO "Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition." Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH "A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide." Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS "Phenylbutazone-tolbutamide drug interaction." N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB "Aspirin-induced hypoglycaemia in a patient on haemodialysis." Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC "Lack of interaction between glipizide and co-trimoxazole." J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[41] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[46] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA "Drug interactions with fibric acids." Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS "Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone." Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK "Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia." Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[54] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[56] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[59] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[74] "Product Information. Micronase (glyburide)." Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al "Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy." Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN "Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole." Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N "Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea." Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM "Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism." Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV "Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans." Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[98] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[100] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[101] Harris EL "Adverse reactions to oral antidiabetic agents." Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK "Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide." Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[104] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[105] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[109] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[110] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[111] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Capreomycin, Rifamycin, Bedaquiline, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Pretomanid, Aminosalicylic acid, Trimethoprim, More', 'Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112967, 'Goserelin', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113098/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Megestrol acetate, Diethylstilbestrol, Medroxyprogesterone acetate', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112968, 'Granisetron', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113099/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Nabilone, Scopolamine, Rolapitant, Aprepitant, Dronabinol', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112969, 'Grepafloxacin', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113100/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112970, 'Halofantrine', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113101/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, Pyridoxine, Ethionamide, More', 'Artesunate, Artemether, Tafenoquine, Proguanil, Sulfadoxine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112971, 'Haloperidol', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113102/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, Sulfadiazine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112972, 'Halothane', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113103/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, More', 'Alfentanil, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, Enflurane, Esketamine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112973, 'Histrelin', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113104/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More', 'Megestrol acetate, Diethylstilbestrol, Medroxyprogesterone acetate', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112974, 'Hydroxychloroquine', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113105/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Pyridoxine, Pretomanid, Aminosalicylic acid, Sulfamethizole, Sulfisoxazole, More', 'Artesunate, Artemether, Tafenoquine, Proguanil, Sulfadoxine', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112975, 'Hydroxyzine', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113106/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Clobazam, Meprobamate, Alprazolam, Lorazepam, Chlordiazepoxide, Halazepam, Clorazepic acid, Buspirone, Diazepam, Oxazepam', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Pyridoxine, Ethionamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112976, 'Ibutilide', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113107/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Moricizine, Tocainide, Bretylium, Mexiletine', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112977, 'Idarubicin', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113108/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More', 'Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112978, 'Idelalisib', 'Sulfamethoxazole', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', 'DDInter', 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113109/', '[1] "Product Information. Zydelig (idelalisib)." Gilead Sciences, Foster City, CA.[2] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 'Capreomycin, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Pyridoxine, Pretomanid, Trimethoprim, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, More', 'Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112979, 'Iloperidone', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113110/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112980, 'Imipramine', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113111/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112981, 'Indinavir', 'Trimethoprim', 'Minor', 'When indinavir was given concomitantly with trimethoprim/sulfamethoxazole DS (TMP/SMX 160/800 mg) for one week, a 19% increase was observed in the area under the plasma concentration-time curve of trimethoprim. The plasma concentrations of sulfamethoxazole and indinavir were not affected. This interaction is unlikely to be of clinical importance, although it may be appropriate to monitor the patient for trimethoprim-related toxicities.', 'DDInter', '-', 'Others', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113112/', '[1] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[2] Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S "Single-dose pharmacokinetics of indinavir and the effect of food." Antimicrob Agents Chemother 42 (1998): 332-8[3] Shelton MJ, Wynn HE, Newitt RG, DiFrancesco R "Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects." J Clin Pharmacol 41 (2001): 435-42[4] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Sulfadiazine, Sulfamethoxazole, Sulfamethizole, Sulfisoxazole, Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Cycloserine, Pyridoxine, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112982, 'Indium In-111 oxyquinoline', 'Sulfamethoxazole', 'Moderate', 'Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.', 'DDInter', 'Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.', 'Others', 'Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113113/', '[1] "Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111)." GE Healthcare, Princeton, NJ.', 'Pyridoxine, Rifamycin, Bedaquiline, Pretomanid, Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Lactic acid, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112983, 'Inotuzumab ozogamicin', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'DDInter', '-', 'Synergism', '-', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113114/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112984, 'Insulin human', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113115/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Liraglutide, Lixisenatide', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112985, 'Insulin aspart (aspart)', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113116/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112986, 'Insulin aspart (aspart protamine)', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113117/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112987, 'Insulin degludec', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113118/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, More', 'Liraglutide, Lixisenatide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112988, 'Insulin detemir', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113119/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, More', 'Liraglutide, Lixisenatide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112989, 'Insulin glargine', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113120/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Liraglutide, Lixisenatide', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112990, 'Insulin glulisine', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113121/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, More', 'Liraglutide, Lixisenatide', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112991, 'Insulin human (inhalation, rapid acting)', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113122/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Liraglutide, Lixisenatide', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112992, 'Insulin human (isophane)', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113123/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Liraglutide, Lixisenatide', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112993, 'Insulin lispro', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113124/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Liraglutide, Lixisenatide', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112994, 'Insulin lispro (protamine)', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113125/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, More', NULL, 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112995, 'Insulin human (regular)', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113126/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Liraglutide, Lixisenatide', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112996, 'Insulin human (zinc)', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113127/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Liraglutide, Lixisenatide', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112997, 'Insulin human (zinc extended)', 'Sulfamethoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113128/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 'Liraglutide, Lixisenatide', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Ethambutol, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112998, 'Interferon beta-1a', 'Sulfamethoxazole', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', 'DDInter', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113129/', '[1] "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA.[2] "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.[3] "Product Information. Rebif (interferon beta-1a)." Serono Laboratories Inc, Norwell, MA.[4] "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.', 'Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Sargramostim, Histamine, Aldesleukin, Pegademase, More', 'Capreomycin, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Trimethoprim, Tamsulosin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (112999, 'Interferon beta-1b', 'Sulfamethoxazole', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', 'DDInter', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113130/', '[1] "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA.[2] "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.[3] "Product Information. Rebif (interferon beta-1a)." Serono Laboratories Inc, Norwell, MA.[4] "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.', 'Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Sargramostim, Histamine, Aldesleukin, Pegademase, More', 'Capreomycin, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Trimethoprim, Tamsulosin, More', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (113000, 'Irbesartan', 'Trimethoprim', 'Major', 'The use of trimethoprim in combination with other potassium-sparing drugs or potassium salts may increase the risk of hyperkalemia. Trimethoprim inhibits sodium reabsorption and potassium excretion by blocking sodium channels in the renal distal tubules.', 'DDInter', 'Serum potassium and sodium levels as well as renal function should be closely monitored during coadministration of trimethoprim with other potassium-sparing drugs or potassium salts, particularly in patients receiving high-dose or long-term trimethoprim treatment and in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. A dosage reduction of trimethoprim is recommended in renal dysfunction (50% reduction for CrCl between 15 and 30 mL/min). Patients should be given dietary counseling to avoid excessive intake of potassium-rich foods and salt substitutes, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat. Trimethoprim should be discontinued if hyperkalemia occurs.', 'Excretion', 'Serum potassium and sodium levels as well as renal function should be closely monitored during coadministration of trimethoprim with other potassium-sparing drugs or potassium salts, particularly in patients receiving high-dose or long-term trimethoprim treatment and in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/113131/', '[1] Witt JM, Koo JM, Danielson BD "Effect of standard-dose trimethoprim/sulfamethoxazole on the serum potassium concentration in elderly men." Ann Pharmacother 30 (1996): 347-50[2] Canaday DH, Johnson JR "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 438[3] Noto H, Kaneko Y, Takano T, Kurokawa K "Severe hyponatremia and hyperkalemia induced by trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia." Intern Med 34 (1995): 96-9[4] Perazella MA, Mahnensmith RL "Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose." Clin Nephrol 46 (1996): 187-92[5] Velazquez H, Perazella MA, Wright FS, Ellison DH "Renal mechanism of trimethoprim-induced hyperkalemia." Ann Intern Med 119 (1993): 296-301[6] Marinella MA "Reversible hyperkalemia associated with trimethoprim-sulfamethoxazole." Am J Med Sci 310 (1995): 115-7[7] Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006): 49-58[8] Koc M, Bihorac A, Ozener CI, Kantarci G, Akoglu E "Severe hyperkalemia in two renal transplant recipients treated with standard dose of trimethoprim-sulfamethoxazole." Am J Kidney Dis 36 (2000): u59-64[9] Bugge JF "Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs." J Intern Med 240 (1996): 249-51[10] Choi MJ, Fernandez PC, Patnaik A, Coupaye-Gerard B, D''Andrea D, Szerlip H, Kleyman TR "Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS." N Engl J Med 328 (1993): 703-6[11] Thomas RJ "Severe hyperkalemia with trimethoprim-quinapril." Ann Pharmacother 30 (1996): 413-4[12] Marinella MA "Severe hyperkalemia associated with trimethoprim-sulfamethoxazole and spironolactone." Infect Dis Clin Pract 6 (1997): 256-8[13] Smith GW, Cohen SB "Hyperkalaemia and non-oliguric renal failure associated with trimethoprim." Br Med J 308 (1994): 454[14] Eiam-Ong S, Kurtzman NA, Sabatini S "Studies on the mechanism of trimethoprim-induced hyperkalemia." Kidney Int 49 (1996): 1372-8[15] Fouche R, Bernardin G, Roger PM, Corcelle P, Simler JM, Mattei M "Hyperkaliemia in a patient given high-dose trimethoprim-sulfamethoxazole." Presse Med 25 (1996): 2044[16] "Prevent-ERR: sulfamethoxazole and trimethoprim-induced hyperkalemia." ISMP Medication Safety Alert! 13(Dec 4) (2008): 3[17] Pennypacker LC, Mintzer J, Pitner J "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 437[18] Modest GA, Price B, Mascoli N "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 437[19] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[20] Martin J, Mourton S, Nicholls G "Severe hyperkalaemia with prescription of potassium-retaining agents in an elderly patient." N Z Med J 116 (2003): U542[21] Greenberg S, Reiser IW, Chou SY "Hyperkalemia with high-dose trimethoprim-sulfamethoxazole therapy." Am J Kidney Dis 22 (1993): 603-6[22] Mori H, Kuroda Y, Imamura S, et al "Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole." Intern Med 42 (2003): 665-9[23] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[24] Alappan R, Perazella MA, Buller GK "Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole." Ann Intern Med 124 (1996): 316-20[25] Perlmutter EP, Sweeney D, Herskovits G, Kleiner M "Case report: severe hyperkalemia in a geriatric patient receiving standard doses of trimethoprim-sulfamethoxazole." Am J Med Sci 311 (1996): 84-5[26] Marinella MA "Trimethoprim-sulfamethoxazole associated with hyperkalemia." West J Med 167 (1997): 356-8[27] Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM "Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study." Arch Intern Med 170 (2010): 1045-9[28] Hsu I, Wordell CJ "Hyperkalemia and high-dose trimethoprim/sulfamethoxazole." Ann Pharmacother 29 (1995): 427-9[29] Lin SH, Kuo AA, Yu FC, Lin YF "Reversible voltage-dependent distal renal tubular acidosis in a patient receiving standaard doses of trimethoprim-sulphamethoxazole." Nephrol Dial Transplant 12 (1997): 1031-33[30] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[31] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[32] Perazella MA, Alappan R, Buller GK "Hyperkalemia and trimethoprim-sulfamethoxazole." Ann Intern Med 125 (1996): 1015[33] "Product Information. Bactrim (trimethoprim-sulfamethoxazole)." Roche Laboratories, Nutley, NJ.[34] Mihm LB, Rathbun RC, Resmantargoff BH "Hyperkalemia associated with high-dose trimethoprim-sulfamethoxazole in a patient with the acquired immunodeficiency syndrome." Pharmacotherapy 15 (1995): 793-7[35] Lee SW, Park SW, Kang JM "Intraoperative hyperkalemia induced by administration of trimethoprim-sulfamethoxazole in a patient receiving angiotensin receptor blockers." J Clin Anesth 26 (2014): 427-8', 'Sulfadiazine, Sulfamethoxazole, Sulfamethizole, Sulfisoxazole, Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Cycloserine, More', 'Sacubitril, Aliskiren, Nebivolol', 1767369485);